西田 直生志 (ニシダ ナオシ)

  • 医学科 臨床教授
Last Updated :2024/04/23

コミュニケーション情報 byコメンテータガイド

  • コメント

    ウィルス感染や環境因子がDNAに与える影響と、消化器癌の発癌予防に関する研究をしています。特にゲノムやエピゲノムの変化と、肝発癌との関わりを解析しています。
  • 報道関連出演・掲載一覧

    <報道関連出演・掲載一覧> ●2018/9/18  読売テレビ「情報ライブミヤネ屋」  元モーニング娘の吉澤ひとみさんが飲酒運転で逮捕された件について

研究者情報

学位

  • 博士(医学)(京都大学)

ホームページURL

J-Global ID

研究キーワード

  • データベース   人工知能   分子生物学   肝臓病学   消化器内科   エピジェネティクス   染色体   癌抑制遺伝子   肝細胞癌   

現在の研究分野(キーワード)

    ウィルス感染や環境因子がDNAに与える影響と、消化器癌の発癌予防に関する研究をしています。特にゲノムやエピゲノムの変化と、肝発癌との関わりを解析しています。

研究分野

  • 情報通信 / 生命、健康、医療情報学
  • ライフサイエンス / ゲノム生物学
  • ライフサイエンス / 消化器内科学

経歴

  • 2021年04月 - 現在  近畿大学医学部 消化器内科教授
  • 2011年08月 - 2021年03月  近畿大学医学部消化器内科准教授
  • 2006年08月 - 2011年07月  京都大学医学部消化器内科助教/講師
  • 2004年02月 - 2006年07月  ベイラー大学メディカルセンター (Dallas)消化器内科博士研究員
  • 1997年04月 - 2004年01月  京都大学医学研究科臨床病態医科学(第2内科)文部技官/文部教官助手
  • 1996年05月 - 1997年04月  一般財団法人 生産開発科学研究所研究員

学歴

  •         - 1993年   京都大学   大学院医学研究科   内科系
  •         - 1985年   大阪医科大学   医学部   医学科

所属学協会

  • 米国消化器病学会   日本高齢消化器病学会   日本臨床免疫学会   日本超音波医学会   日本消化器内視鏡学会   日本分子生物学会   日本癌学会   日本消化器病学会   日本肝臓学会   日本内科学会   

研究活動情報

論文

  • Margherita Rimini; Bernardo Stefanini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Fabian Finkelmeier; Changhoon Yoo; José Presa; Elisabeth Amadeo; Virginia Genovesi; Maria Caterina De Grandis; Massimo Iavarone; Fabio Marra; Francesco Foschi; Emiliano Tamburini; Federico Rossari; Francesco Vitiello; Linda Bartalini; Caterina Soldà; Francesco Tovoli; Caterina Vivaldi; Sara Lonardi; Marianna Silletta; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Vera Himmelsbach; Margarida Montes; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Camera; Silvia Foti; Luca Aldrighetti; Stefano Cascinu; Andrea Casadei-Gardini; Fabio Piscaglia
    Liver international : official journal of the International Association for the Study of the Liver 2024年03月 [査読有り]
     
    INTRODUCTION: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short-mid term in advanced tumours is unclear. The present analysis investigates the role of BMI weight classes in a large sample of patients affected by HCC and receiving atezolizumab plus bevacizumab or lenvatinib as first-line treatment. METHODS AND MATERIAL: The cohort included consecutive patients affected by BCLC-c and BCLC-B HCC patients from a multicenter international study group who received atezolizumab plus bevacizumab or lenvatinib as first-line therapy. Population was stratified according to the BMI in under-, over- and normal-weight according to the conventional thresholds. The primary objective of the study was to evaluate the prognostic and predictive impact of BMI in patients affected by advanced or intermediate HCC. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analysed with log-rank tests. RESULTS: 1292 consecutive patients with HCC were analysed. 466 (36%) patients were treated with lenvatinib and 826 (64%) patients were treated with atezolizumab plus bevacizumab. In the atezolizumab plus bevacizumab arm, 510 (62%) patients were normal-weight, 52 (6%) underweight and 264 (32%) overweight. At the univariate analysis for OS, underweight patients had significantly shorter OS compared to normal-weight patients, whereas no differences were found between normal-weight versus overweight. Multivariate analysis confirmed that underweight patients had significantly shorter OS compared to normal-weight patients (HR: 1.7; 95% CI: 1.0-2.8; p = .0323). In the lenvatinib arm, 26 patients (5.6%) were categorized as underweight, 256 (54.9%) as normal-weight, and 184 (39.5%) as overweight. At the univariate analysis for OS, no significant differences were found between normal-weight versus underweight and between normal-weight versus overweight, which was confirmed at multivariate analysis. CONCLUSION: Our analysis highlighted a prognostic role of BMI in a cohort of patients with advanced HCC who received atezolizumab plus bevacizumab, while no prognostic role for low BMI was apparent in patients who received lenvatinib.
  • Satoru Hagiwara; Toru Takase; Itsuki Oda; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi Kudo
    Clinical Journal of Gastroenterology 2024年03月 
    Abstract A 53-year-old woman was diagnosed with liver dysfunction in August 20XX. Computed tomography (CT) revealed multiple hepatic AV shunts, and she was placed under observation. In March 20XX + 3, she developed back pain, and CT performed during an emergency hospital visit showed evidence of intrahepatic bile duct dilatation. She was referred to our gastroenterology department in May 20XX + 3. We conducted investigations on suspicion of hereditary hemorrhagic telangiectasia (HHT) with hepatic AV shunting based on contrast-enhanced CT performed at another hospital. HHT is generally discovered due to epistaxis, but there are also cases where it is diagnosed during examination of liver damage.
  • Lorenz Balcar; Bernhard Scheiner; Claudia Angela; Maria Fulgenzi; Antonio D'Alessio; Katharina Pomej; Marta Bofill Roig; Elias Laurin Meyer; Jaekyung Che; Naoshi Nishida; Pei-Chang Lee; Linda Wu; Celina Ang; Anja Krall; Anwaar Saeed; Bernardo Stefanini; Antonella Cammarota; Tiziana Pressiani; Yehia I Abugabal; Shadi Chamseddine; Brooke Wietharn; Alessandro Parisi; Yi-Hsiang Huang; Samuel Phen; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Johann von Felden; Kornelius Schulze; Marianna Silletta; Michael Trauner; Adel Samson; Henning Wege; Fabio Piscaglia; Peter R Galle; Rudolf Stauber; Masatoshi Kudo; Amit G Singal; Aleena Itani; Susanna V Ulahannan; Neehar D Parikh; Alessio Cortellini; Ahmed Kaseb; Lorenza Rimassa; Hong Jae Chon; David J Pinato; Matthias Pinter
    JHEP reports : innovation in hepatology 6 2 100982 - 100982 2024年02月 [査読有り]
     
    BACKGROUND & AIMS: Sex-related differences in the immune pathogenesis of hepatocellular carcinoma (HCC), particularly related to oestrogen-dependent secretion of pro-tumourigenic cytokines, are well-known. Whether sex influences the efficacy and safety of immunotherapy is not known. METHODS: We performed a restricted maximum likelihood random effects meta-analysis of five phase III trials that evaluated immune checkpoint inhibitors (ICIs) in advanced HCC and reported overall survival (OS) hazard ratios (HRs) stratified by sex to evaluate sex-related differences in OS. In a real-world cohort of 840 patients with HCC from 22 centres included between 2018 and 2023, we directly compared the efficacy and safety of atezolizumab + bevacizumab (A+B) between sexes. Radiological response was reported according to RECIST v1.1. Uni- and multivariable Cox regression analyses were performed for OS and progression-free survival (PFS). RESULTS: In the meta-analysis, immunotherapy was associated with a significant OS benefit only in male (pooled HR 0.79; 95% CI 0.73-0.86) but not in female (pooled HR 0.85; 95% CI 0.70-1.03) patients with HCC. When directly comparing model estimates, no differences in the treatment effect between sexes were observed. Among 840 patients, 677 (81%) were male (mean age 66 ± 11 years), and 163 (19%) were female (mean age 67 ± 12 years). Type and severity of adverse events were similar between the two groups. OS and PFS were comparable between males and females upon uni- and multivariable analyses (aHR for OS and PFS: 0.79, 95% CI 0.59-1.04; 1.02, 95% CI 0.80-1.30, respectively). Objective response rates (24%/22%) and disease control rates (59%/59%) were also similar between sexes. CONCLUSION: Female phase III trial participants experienced smaller OS benefit following ICI therapy for advanced HCC, while outcomes following A+B treatment were comparable between sexes in a large real-world database. Based on the ambiguous sex-related differences in survival observed here, further investigation of sex-specific clinical and biologic determinants of responsiveness and survival following ICIs are warranted. IMPACT AND IMPLICATIONS: While immune checkpoint inhibitors have emerged as standard of care for the treatment of hepatocellular carcinoma, there are conflicting reports on whether the efficacy of cancer immunotherapy differs between females and males. Our study suggests ambiguous sex-related differences in outcomes from immunotherapy in hepatocellular carcinoma. Further investigation of sex-specific clustering in clinicopathologic and immunologic determinants of responsiveness to immune checkpoint inhibitor therapy should be prioritised. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023429625.
  • Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi Nishida
    Liver cancer 13 1 56 - 69 2024年02月 [査読有り]
     
    INTRODUCTION: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (HCC). While immune checkpoint inhibitor has revolutionized the concept of cancer treatment, it has also led to unexpected tumor growth. Regulatory T cells express PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) receptors, which are proliferated and activated by antibody binding, and their ratio to CD8+ T cells is altered, which is one of the causes for hyper progressive disease (HPD). We examined the frequency of HPD in anti-PD-1/PD-L1 monotherapy and combination therapy with vascular endothelial growth factor (VEGF) antibody and anti-CTLA-4 antibodies. METHODS: This was a prospective and retrospective cohort study which enrolled 198 patients with unresectable HCC from January 2015 to December 2021 at the Kindai University Hospital. Fifty-eight patients received anti-PD-1/PD-L1 monotherapy, 119 patients combination with VEGF antibody, and 21 patients combination with anti-CTLA-4 antibody. We defined HPD as tumor growth rate (TGR) ratio ≥4, ΔTGR ≥40%, and tumor growth kinetics ratio ≥4. RESULTS: The HPD rate was 10.3% (6/58) in anti-PD-1/PD-L1 monotherapy, 1.7% (2/119) in combination with VEGF antibody, and 4.8% (1/21) in combination with anti-CTLA-4 antibody (p = 0.034). The odds ratio for HPD in the combined anti-CTLA-4 antibody group was 0.433 (95% confidence interval [CI]: 0.05-3.83) when compared to the anti-PD-1/PD-L1 monotherapy group and 2.93 (95% CI: 0.25-33.79) when compared to the combined VEGF antibody group. CONCLUSION: The frequency of HPD in unresectable HCC compared to anti-PD-1/PD-L1 monotherapy was decreased with the combination with anti-VEGF antibody and not increased with anti-CTLA-4 antibody. Anti-PD-1/PD-L1 combined with anti-CTLA-4 antibody is now available in real-world and needs to be further validated with accumulated clinical practice.
  • Silvia Camera; Margherita Rimini; Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Francesca Salani; Mariarosaria Marseglia; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Sara Lonardi; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Silvia Foti; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Targeted oncology 19 1 29 - 39 2024年01月 [査読有り]
     
    BACKGROUND: Data concerning the use of lenvatinib in very old patients (≥ 80 years) are limited, although the incidence of hepatocellular carcinoma (HCC) in this patient population is constantly increasing. OBJECTIVE: This analysis aimed to evaluate the efficacy and safety of lenvatinib in a large cohort of very old patients (≥ 80 years) with unresectable HCC. PATIENTS AND METHODS: The study was conducted on a cohort of 1325 patients from 46 centers in four Western and Eastern countries (Italy, Germany, Japan, and the Republic of Korea) who were undergoing first-line treatment with lenvatinib between July 2010 and February 2022. Patients were stratified according to age as very old (≥ 80 years) and not very old (< 80 years). RESULTS: The median overall survival (OS) was 15.7 months for patients < 80 years old and 18.4 months for patients ≥ 80 years old [hazard ratio (HR) = 1.02, 95% confidence interval (CI) 0.84-1.25, p = 0.8281]. Median progression free survival (PFS) was 6.3 months for patients < 80 years old and 6.5 months for patients ≥ 80 years old (HR = 1.07, 95% CI 0.91-1.25, p = 0.3954). No differences between the two study groups were found in terms of disease control rate (DCR; 80.8% versus 78.8%; p = 0.44) and response rate (RR; 38.2% versus 37.9%; p = 0.88). Patients < 80 years old experienced significantly more hand-foot skin reaction (HFSR) grade ≥ 2 and decreased appetite grade ≥ 2. Conversely, patients ≥ 80 years old experienced significantly more fatigue grade ≥ 2. In the very old group, parameters associated with prognosis were AFP, albumin-bilirubin (ALBI) grade, Barcelona Clinic Liver Cancer (BCLC), and Child-Pugh score. BCLC stage was the only independent predictor of overall survival (OS; HR = 1.59, 95% CI 1.11-2.29, p = 0.01115). CONCLUSIONS: Our study highlights the same efficacy and safety of lenvatinib between very old and not very old patients.
  • Satoru Hagiwara; Junko Tanizaki; Hidetoshi Hayashi; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi Kudo
    Cancer reports (Hoboken, N.J.) 7 2 e1960  2024年01月 [査読有り]
     
    BACKGROUND: Immune checkpoint inhibitors have been reported to have excellent therapeutic effects on various malignant tumors. However, immune-related adverse events can occur, targeting various organs. CASE PRESENTATION: A 49-year-old male with lung carcinoma was started on carboplatin + pemetrexed + nivolumab (every 3 weeks) + ipilimumab (every 6 weeks), and nivolumab/ipilimumab was administered in the 3rd course. Subsequently, fever and fatigue developed, and grade 3 liver damage was also noted, so he was admitted to Kindai University Hospital. A bone marrow aspirate examination was performed on the third day of illness, and a definitive diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made. It was determined that immediate therapeutic intervention was necessary, and pulse therapy with methylprednisolone was started on the third day of illness. After 3 days of pulse treatment, a rapid recovery of platelet values, a decrease in ferritin levels, and a decrease in lactate dehydrogenase were observed. Subjective symptoms such as fever and fatigue also quickly improved. CONCLUSION: Early diagnosis and treatment for HLH resulted in a positive response. The number of HLH cases may increase in the future due to the expansion of immune checkpoint inhibitor indications.
  • Satoru Hagiwara; Koichi Nakagawa; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Tomoki Yamamoto; Takuya Matsubara; Masatoshi Kudo
    Internal Medicine 2024年 
    In October 2021, a 51-year-old woman developed a skin rash. Abdominal computed tomography revealed a large splenic artery aneurysm and an intrahepatic portovenous shunt. As her splenic artery aneurysm was at risk of rupture, she was referred to the Kindai University Hospital and underwent coiling surgery. In October 2023, approximately two years after she had been initially referred, contrast-enhanced ultrasound revealed findings suggestive of focal nodular hyperplasia. No reports have confirmed the occurrence of liver masses in patients with hereditary hemorrhagic telangiectasia, which is considered to be an interesting finding when investigating the mechanism of tumor development.
  • Federico Rossari; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Changhoon Yoo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Francesca Bergamo; Elisabeth Amadeo; Francesco Vitiello; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Massimo Iavarone; Giuseppe Cabibbo; Margarida Montes; Francesco Giuseppe Foschi; Caterina Vivaldi; Caterina Soldà; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Hiraoka; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Mara Persano; Valentina Burgio; Fabio Piscaglia; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini; Margherita Rimini
    International journal of cancer 154 6 1043 - 1056 2023年11月 [査読有り]
     
    Atezolizumab plus bevacizumab (AB) and lenvatinib can be alternatively used as first-line systemic treatment of unresectable hepatocellular carcinoma (HCC). However, no direct comparison of the two regimens has been performed in randomized clinical trials, making the identification of baseline differential predictors of response of major relevance to tailor the best therapeutic option to each patient. Baseline clinical and laboratory characteristics of real-world AB-treated HCC patients were analyzed in uni- and multivariate analyses to find potential prognostic factors of overall survival (OS). Significant variables were incorporated in a composite score (α-FAtE) and it was tested for specificity and sensitivity in receiver operating characteristic (ROC) curve and in multivariate analysis for OS. The score was applied in uni- and multivariate analyses for OS of a comparable lenvatinib-treated HCC population. Finally, comparison between treatments was performed in patients with low and high α-FAtE scores and predictivity estimated by interaction analysis. Time-to-progression (TTP) was a secondary endpoint. OS of AB-treated HCC patients was statistically longer in those with α-fetoprotein <400 ng/mL (HR 0.62, p = .0407), alkaline phosphatase (ALP) <125 IU/L (HR 0.52, p = .0189) and eosinophil count ≥70/μL (HR 0.46, p = .0013). The α-FAtE score was generated by the sum of single points attributed to each variable among the above reported. In ROC curve analysis, superior sensitivity and specificity were achieved by the score compared to individual variables (AUC 0.794, p < .02). Patients with high score had longer OS (HR 0.44, p = .0009) and TTP (HR 0.34, p < .0001) compared to low score if treated with AB, but not with lenvatinib. Overall, AB was superior to lenvatinib in high score patients (HR 0.55, p = .0043) and inferior in low score ones (HR 1.75, p = .0227). At interaction test, low α-FAtE score resulted as negative predictive factor of response to AB (p = .0004). In conclusion, α-FAtE is a novel prognostic and predictive score of response to first-line AB for HCC patients that, if validated in prospective studies, could drive therapeutic choice between lenvatinib and AB.
  • Sirish Dharmapuri; Umut Özbek; Hiren Jethra; Tomi Jun; Thomas U Marron; Anwaar Saeed; Yi-Hsiang Huang; Mahvish Muzaffar; Matthias Pinter; Lorenz Balcar; Claudia Fulgenzi; Suneetha Amara; Arndt Weinmann; Nicola Personeni; Bernhard Scheiner; Tiziana Pressiani; Musharraf Navaid; Bertram Bengsch; Sonal Paul; Uqba Khan; Dominik Bettinger; Naoshi Nishida; Yehia Ibrahim Mohamed; Arndt Vogel; Anuhya Gampa; James Korolewicz; Antonella Cammarota; Ahmed Kaseb; Peter R Galle; Anjana Pillai; Ying-Hong Wang; Alessio Cortellini; Masatoshi Kudo; Antonio D'Alessio; Lorenza Rimassa; David James Pinato; Celina Ang
    World journal of gastrointestinal oncology 15 11 1900 - 1912 2023年11月 [査読有り]
     
    BACKGROUND: A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation of ICI. Deaths are reported in < 5% of patients treated with ICI. There are, however, no reliable markers to predict the onset and severity of IrAEs. We tested the association between neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at baseline with development of clinically significant IrAEs (grade ≥ 2) in hepatocellular carcinoma (HCC) patients treated with ICI. AIM: To test the association between NLR and PLR at baseline with development of clinically significant IrAEs (grade ≥ 2) in HCC patients treated with ICI. METHODS: Data was extracted from an international database from a consortium of 11 tertiary-care referral centers. NLR = absolute neutrophil count/absolute lymphocyte count (ALC) and PLR = platelet count/ALC. Cutoff of 5 was used for NLR and 300 for PLR based on literature. We also tested the association between antibiotic and steroid exposure to IrAEs. RESULTS: Data was collected from 361 patients treated between 2016-2020 across the United States (67%), Asia (14%) and Europe (19%). Most patients received Nivolumab (n = 255, 71%). One hundred sixty-seven (46%) patients developed at least one IrAE, highest grade 1 in 80 (48%), grade ≥ 2 in 87 (52%) patients. In a univariable regression model PLR > 300 was significantly associated with a lower incidence of grade ≥ 2 IrAEs (OR = 0.40; P = 0.044). Similarly, a trend was observed between NLR > 5 and lower incidence of grade ≥ 2 IrAEs (OR = 0.58; P = 0.097). Multivariate analyses confirmed PLR > 300 as an independent predictive marker of grade ≥ 2 IrAEs (OR = 0.26; P = 0.011), in addition to treatment with programmed cell death ligand 1 (PD-1)/cytotoxic T lymphocyte-associated protein-4 (OR = 2.57; P = 0.037) and PD-1/tyrosine kinase inhibitor (OR = 3.39; P = 0.01) combinations. Antibiotic use was not associated with IrAE incidence (OR = 1.02; P = 0.954). Patients treated with steroids had a > 2-fold higher incidence of grade ≥ 2 IrAEs (OR = 2.74; P < 0.001), although 74% were prescribed steroids for the treatment of IrAEs. CONCLUSION: Given that high baseline NLR and PLR are associated with a decreased incidence of IrAEs, lower baseline NLR and PLR may be predictive biomarkers for the appearance of IrAEs in HCC treated with ICI. This finding is in keeping with several studies in solid tumors that have shown that baseline NLR and PLR appear predictive of IrAEs.
  • Ciro Celsa; Giuseppe Cabibbo; Claudia Am Fulgenzi; Bernhard Scheiner; Antonio d'Alessio; Giulia F Manfredi; Naoshi Nishida; Celina Ang; Thomas U Marron; Anwaar Saeed; Brooke Wietharn; Matthias Pinter; Jaekyung Cheon; Yi-Hsiang Huang; Pei-Chang Lee; Samuel Phen; Anuhya Gampa; Anjana Pillai; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Natascha Roehlen; Robert Thimme; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Paul El Tomb; Susanna Ulahannan; Alessandro Parisi; Hong Jae Chon; Wei-Fan Hsu; Bernardo Stefanini; Elena Verzoni; Raffaele Giusti; Antonello Veccia; Annamaria Catino; Giuseppe Aprile; Pamela Francesca Guglielmini; Marilena Di Napoli; Paola Ermacora; Lorenzo Antonuzzo; Ernesto Rossi; Francesco Verderame; Fable Zustovich; Corrado Ficorella; Francesca Romana Di Pietro; Nicola Battelli; Giorgia Negrini; Francesco Grossi; Roberto Bordonaro; Stefania Pipitone; Maria Banzi; Serena Ricciardi; Letizia Laera; Antonio Russo; Ugo De Giorgi; Luigi Cavanna; Mariella Sorarù; Vincenzo Montesarchio; Paola Bordi; Leonardo Brunetti; Carmine Pinto; Melissa Bersanelli; Calogero Cammà; Alessio Cortellini; David J Pinato
    Journal of hepatology 2023年11月 [査読有り]
     
    BACKGROUND&AIMS: Immune-related liver injury(irLI) is commonly observed in patients with cancer treated with immune checkpoint inhibitors(ICIs). We aimed to compare incidence, clinical characteristics and outcomes of irLI between patients receiving ICIs for hepatocellular carcinoma(HCC) versus other solid tumours. METHODS: Two separate cohorts were included: 375 patients with advanced/unresectable HCC, Child-Pugh A class treated with first-line Atezolizumab+Bevacizumab from AB-real study and a non-HCC cohort, including 459 patients treated with first-line ICI therapy from INVIDIa-2 multicentre study. IrLI was defined as treatment-related increase of transaminases levels after exclusion of alternative aetiologies of liver injury. Incidence of irLI was adjusted for the duration of treatment exposure. RESULTS: In HCC patients, incidence of any-grade irLI was 11.4% over a median treatment exposure of 4.4 months(95%CI 3.7-5.2), compared to 2.6% in INVIDIa-2 cohort over a median treatment exposure of 12.4 months(95%CI 11.1-14.0). Exposure-adjusted-incidence of any-grade irLI was 22.1 per 100-Patient-years(PY) in HCC patients and 2.1 per 100-PY in non-HCC patients(p<0.001), with median time to irLI of 1.4 and 4.7 months, respectively. Among patients who developed irLI, systemic corticosteroids were administered in 16.3% of HCC and 75.0% of non-HCC patients(p<0.001) and irLI resolution was observed in 72.1% and 58.3%, respectively(p=0.362). In HCC patients, rates of hepatic decompensation and treatment discontinuation due to irLI were 7%. Grade 1-2 irLI was associated with improved overall survival in HCC patients only(HR 0.53, 95%CI 0.29-0.96). CONCLUSIONS: Despite higher incidence and earlier onset in patients with HCC, IrLI is characterised by high rates of remission, low requirement for corticosteroid therapy and low risk of decompensation compared to other solid tumours. Hepatotoxicity leads to discontinuation in 7% of patients with HCC and does not negatively affect oncological outcomes. IMPACT AND IMPLICATIONS: Immune-related liver injury (irLI) is common in patients with cancer receiving immune checkpoint inhibitors (ICI), but whether irLI is more frequent or it is associated with a worse clinical course in patients with hepatocellular carcinoma (HCC), compared to other tumours, is not known. Herein, we compared characteristics and outcomes of irLI in two prospective cohorts including patients treated with ICIs for HCC or for other oncological indications. irLI is significantly more common and it occurs earlier in patients with HCC, also after adjustment for duration of treatment exposure. However, outcomes of patients with HCC who developed irLI are not negatively affected in terms of requirement of corticosteroid therapy, hepatic decompensation, treatment discontinuation and overall survival.
  • 萩原 智; 上嶋 一臣; 西田 直生志; 依田 広; 三長 孝輔; 南 康範; 田北 雅弘; 青木 智子; 盛田 真弘; 千品 寛和; 松原 卓哉; 大丸 直哉; 稲村 昇; 工藤 正俊
    肝臓 64 11 567 - 574 (一社)日本肝臓学会 2023年11月 
    症例は30代男性.幼少期に完全大血管転位III型に対してFontan手術が施行され,近医に定期的に通院していた.20XX年7月腹部USで多発肝腫瘤を指摘され当院紹介受診となった.造影CTにて最大13cmの多発肝細胞癌と判明した(BCLC stage B).画像上は門脈圧亢進所見や明らかな肝形態異常を認めなかったが,肝生検でCongestive Hepatic Fibrosis Score 3であり,実際には線維化の進展を認めていた.肝内多発のため外科手術やRFAの適応外であった.また最大径の腫瘍は肝外に突出しており,腹腔内破裂の危険性もあることから,まずTACEを施行した.再発に応じて各種抗癌剤治療を行い,生存中である.画像上は肝線維化を示唆する所見はなかったが,Fontan術後の特殊な循環動態では,肝線維化が進展している可能性があり,本症例を通して肝癌サーベイランスの重要性を再考する.(著者抄録)
  • Ken Kamata; Mamoru Takenaka; Naoshi Nishida; Akane Hara; Yasuo Otsuka; Hidekazu Tanaka; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Yasutaka Chiba; Kazuko Sakai; Kazuto Nishio; Tomohiro Watanabe; Masatoshi Kudo
    International journal of clinical oncology 28 11 1511 - 1519 2023年11月 [査読有り]
     
    BACKGROUND: This prospective cohort study evaluated the feasibility of using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) samples for comprehensive mutational analysis of cancer-related genes using microtissues. METHODS: Fifty patients with suspected pancreatic cancer presenting consecutively at the Kindai University Hospital between January 2018 and January 2019 were enrolled. Cancerous tissues from EUS-FNB were obtained from each tumor and subjected to histological examination and mutational analysis. The primary endpoint was the collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing. Clinical history and genetic variations between the disease control and progressive disease groups of patients on chemotherapy were evaluated as secondary endpoints. RESULTS: The collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing was 93.6%. The cancer panel was sequenced for 25 patients with pancreatic cancer treated initially with systemic chemotherapy. Mutation in p53 and Smad4 were positively and negatively associated, respectively, with disease control at the initial evaluation. The median time to progression in 15 patients with p53 and without Smad4 mutations was 182.0 days; whereas, it was 92.5 days in other 10 patients; this difference was significant (p = 0.020). CONCLUSIONS: Tissue samples from EUS-FNB were suitable for mutational analysis. Pancreatic cancers with p53 and without Smad4 mutations responded better to chemotherapy and had a better prognosis than those others.
  • Yoriaki Komeda; George Tribonias; Masashi Kono; Kohei Handa; Shunsuke Omoto; Mamoru Takenaka; Satoru Hagiwara; Naoko Tsuji; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Inflammatory Intestinal Diseases 8 4 161 - 166 2023年10月 [査読有り]
     
    Introduction: Ustekinumab is an IgG1 kappa monoclonal antibody directed against the common p40 subunit of interleukin-12 and interleukin-23, which activate Th1- and Th17-mediated immune responses, respectively. It has proven efficacy for the treatment of moderate to severe ulcerative colitis (UC) in the UNIFI Phase III clinical trial; however, data on its efficacy in the real world is limited. In this study, we aimed to assess the real-world efficacy of ustekinumab.Methods: This observational study included 30 patients with UC who received ustekinumab from April 2020 to April 2022. We examined demographic information, disease type and activity (Mayo score, partial Mayo score [PMS]), use of biologics, concomitant use of predonisolone (PSL), 8-week ustekinumab clinical response rate, remission induction rate, 44- and 152-week remission maintenance rate, continuation rate, and 44-week steroid-free remission rate. The primary outcomes were the short- and long-term efficacy of ustekinumab.Results: Included patients (53% women; mean age: 41.2 years [16–80 years]) had an average disease duration of 86 weeks. Mayo’s score (median) was 7.4 and the PMS was 5.4. Two (7%), 24 (80%), and four (13%) patients had a Mayo endoscopic sub-score (MES) of MES1, MES2, and MES3, respectively. The median serum CRP was 1.0 mg/dL. Five patients had no history of biotherapy (naive), while 8 and 17 had a history of one and two or more biologic agents, respectively. Eight patients were PSL-resistant and 22 were PSL-dependent. The 8-week clinical response rate was 73%, and the clinical remission induction rate was 70%. The remission maintenance rates at 44 and 152 weeks were 67% and 63%, respectively. The ustekinumab retention rate was 67% (86-week mean follow-up period). Regarding biologic failure cases, the clinical response rate in the failure group with up to one biologic agent (including naive cases) was 84.6%, which was higher than the 58.0% rate in the failure group with two or more biologic agents (p=0.06). Steroid-free remission rates at 44 and 152 weeks were 63% each. In the logistic regression analysis parameters for discontinuation of ustekinumab, only PMS remained significant after multivariate analysis (p=0.018).Conclusion: Our study showed short-term and long-term ustekinumab effectiveness, especially with comparative low disease activity.
  • Naoshi Nishida; Masatoshi Kudo
    Liver Cancer 1 - 14 2023年10月 [査読有り]
     
    <b><i>Background:</i></b> Intrahepatic cholangiocarcinoma (iCCA) is often diagnosed at an advanced stage, leading to limited treatment options and a poor prognosis. So far, standard systemic therapy for advanced iCCA has been a combination of gemcitabine and cisplatin. However, recent advancements in the understanding of the molecular characteristics of iCCA have opened new possibilities for molecular-targeted therapies and immunotherapy. <b><i>Summary:</i></b> Reportedly, 9–36% of iCCA cases have an inflamed tumor immune microenvironment (TME) based on the immune gene expression signature, which is characterized by the presence of immune cells involved in anti-tumor immune responses. The majority of iCCA cases have a non-inflamed TME with a lack of effector T cells, rendering immune checkpoint inhibitors (ICIs) ineffective in these cases. Interestingly, alterations in the fibroblast growth factor receptor (<i>FGFR2</i>) gene and <i>IDH1/2</i> gene mutations are often observed in the non-inflamed TME in iCCA. Several mechanisms have been reported for the role of driver mutations on the establishment of TME unique for iCCA. For example, <i>IDH1/2</i> mutations, which cause an increase in DNA methylation, are associated with the downregulation and hypermethylation of antigen processing and presentation machinery, which may contribute to the establishment of a non-inflamed TME. Therefore, inhibitors targeting <i>IDH1/2</i> may restore the DNA methylation and expression status of molecules involved in antigen presentation, potentially improving the efficacy of ICIs. FGFR inhibitors may also have the potential to modulate immunosuppressive TME by inhibitingthe suppressor of cytokine signaling 1 and activating the interferon-γ signaling as a consequence of inhibition of the <i>FGFR</i> signal. From this perspective, understanding the molecular characteristics of iCCA, including the TME and driver mutations, is essential for the effective application of ICIs and molecular-targeted therapies. <b><i>Key Messages:</i></b> Combination approaches that target both the tumor and immune system hold promise for improving the outcomes of patients with iCCA. Further research and clinical trials are needed to validate these approaches and optimize the treatment strategies for iCCA.
  • 【薬物療法によって変貌する肝細胞癌治療:2023 Update】Early stage肝細胞癌 肝細胞癌での腫瘍免疫微小環境とアジュバント療法における免疫チェックポイント阻害剤の役割
    西田 直生志; 工藤 正俊
    肝胆膵 87 4 381 - 387 (株)アークメディア 2023年10月
  • Naoshi Nishida
    Hepatobiliary Surgery and Nutrition 12 5 790 - 794 2023年10月 [査読有り][招待有り]
  • Masatoshi Kudo; Tomoko Aoki; Kazuomi Ueshima; Kaoru Tsuchiya; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Naoshi Nishida; Chikara Ogawa; Tetsu Tomonari; Noriaki Nakamura; Hidekatsu Kuroda; Atsushi Takebe; Yoshifumi Takeyama; Masaaki Hidaka; Susumu Eguchi; Stephen L Chan; Masayuki Kurosaki; Namiki Izumi
    Liver cancer 12 4 321 - 338 2023年09月 [査読有り]
     
    Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achieving complete response (CR) is possible in many cases using curative conversion with resection, ablation, or super selective transarterial chemoembolization (TACE) with curative intent. This concept, i.e., curative conversion by combining systemic therapy and locoregional therapy, has not been reported before. This multicenter proof-of-concept study was conducted to show the value of curative conversion in immunotherapy-treated intermediate-stage HCC meeting TACE-unsuitable criteria.Methods: This study included 110 consecutive Child-Pugh A patients who received atezolizumab plus bevacizumab as first-line treatment for unresectable and TACE-unsuitable intermediate-stage HCC at seven centers in Japan. CR rate, drug-free rate, time to CR, change in liver function, efficacy in positron emission tomography (PET)-positive HCC, progression-free survival (PFS), and overall survival (OS) were assessed in patients who achieved CR using resection, ablation, super selective TACE with curative intent following atezolizumab plus bevacizumab or atezolizumab plus bevacizumab alone.Results: Clinical or pathological CR was achieved in 38 patients (35%) (median observation period: 21.2 months). The modalities of curative conversion in 35 patients were as follows: resection, 7; ablation, 13; and superselective TACE, 15. Three patients achieved clinical CR with atezolizumab plus bevacizumab therapy alone. Among the 38 CR patients, 25 achieved drug-free status. PFS was not reached, and three patients experienced recurrence after reaching CR. Regarding OS, there were no deaths in any of the CR patients. The albumin-bilirubin score did not deteriorate after locoregional therapy or resection. Of seven PET-positive patients who achieved CR with atezolizumab plus bevacizumab followed by curative conversion, five achieved drug-free status.Discussion/Conclusion: The achievement of CR rate by curative conversion in patients treated with atezolizumab plus bevacizumab as the preceding therapy for unresectable and TACE-unsuitable intermediate-stage HCC was 35%. Overall, 23% of patients achieved drug-free status and no recurrence was observed from this patient subgroup with CR and drug free status. Thus, achieving CR and/or drug-free status should be a therapeutic goal for patients with intermediate-stage HCC without vascular invasion or extrahepatic spread.
  • Masashi Kono; Yoriaki Komeda; George Tribonias; Saki Yoshida; Kenji Nomura; Kohei Handa; Tomoyuki Nagai; Satoru Hagiwara; Shunsuke Omoto; Mamoru Takenaka; Naoshi Nishida; Naoko Tsuji; Hiroshi Kashida; Masatoshi Kudo
    JGH Open 7 8 579 - 583 2023年08月 [査読有り]
     
    Abstract Background and Aim Serum leucine‐rich alpha‐2 glycoprotein level has been reported to be a useful biomarker in assessing mucosal healing in patients undergoing biotherapy, where mucosal lesions caused by ulcerative colitis are difficult to assess endoscopically. However, no such reports have been reported in biotherapy‐naïve cases. Methods Sixty‐eight patients with ulcerative colitis (UC) who were biotherapy‐naïve at Kindai University Hospital between October 2021 and October 2022 were enrolled. We prospectively examined the correlation between leucine‐rich alpha‐2 glycoprotein (LRG), C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), and Geboes scores with clinical endoscopic activity using the Mayo endoscopic subscore (MES). Results Mucosal healing was achieved in 39 (57%) patients. Univariate analysis revealed that the factors associated with mucosal healing were LRG (P = 0.0024), CRP (P = 0.1078), ESR (P = 0.0372), and Geboes scores (P = 0.0075). Logistic regression analysis identified LRG and Geboes scores as independent factors associated with mucosal healing assessed using MES (P = 0.0431 for LRG and P = 0.0166 for Geboes scores). Conclusion LRG was found to be the easiest marker to monitor disease activity and mucosal inflammation in UC patients with biotherapy‐naïve cases, with a performance equivalent to that of Geboes scores.
  • Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Takashi Niizeki; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Bernardo Stefanini; Atsushi Hiraoka; Takuya Sho; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Claudia Campani; Elisabeth Amadeo; Federico Rossari; Valentina Burgio; Stefano Cascinu; Mario Scartozzi; Andrea Casadei-Gardini
    European journal of cancer (Oxford, England : 1990) 189 112933 - 112933 2023年08月 [査読有り]
     
    INTRODUCTION: The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab. MATERIALS AND METHODS: A total of 1381 patients had PD at first-line therapy. 917 patients received lenvatinib as first-line treatment, and 464 patients atezolizumab plus bevacizumab as first-line. RESULTS: 49.6% of PD patients received a second-line therapy without any statistical difference in overall survival (OS) between lenvatinib (20.6months) and atezolizumab plus bevacizumab first-line (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After lenvatinib first-line, there wasn't any statistical difference between second-line therapy subgroups (p = 0.27; sorafenib HR: 1; immunotherapy HR: 0.69; other therapies HR: 0.85). Patients who underwent trans-arterial chemo-embolization (TACE) had a significative longer OS than patients who received sorafenib (24.7 versus 15.8months, p < 0.01; HR=0.64). After atezolizumab plus bevacizumab first-line, there was a statistical difference between second-line therapy subgroups (p < 0.01; sorafenib HR: 1; lenvatinib HR: 0.50; cabozantinib HR: 1.29; other therapies HR: 0.54). Patients who received lenvatinib (17.0months) and those who underwent TACE (15.9months) had a significative longer OS than patients treated with sorafenib (14.2months; respectively, p = 0.01; HR=0.45, and p < 0.05; HR=0.46). CONCLUSION: Approximately half of patients receiving first-line lenvatinib or atezolizumab plus bevacizumab access second-line treatment. Our data suggest that in patients progressed to atezolizumab plus bevacizumab, the systemic therapy able to achieve the longest survival is lenvatinib, while in patients progressed to lenvatinib, the systemic therapy able to achieve the longest survival is immunotherapy.
  • Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
    Liver cancer 12 2 103 - 115 2023年06月 [査読有り]
     
    Background. Hepatocellular carcinoma (HCC) is unique among malignancies, and its characteristics on contrast imaging modalities allow for a highly accurate diagnosis. The radiological differentiation of focal liver lesions is playing an increasingly important role, and the Liver Imaging Reporting and Data System (LI-RADS) adopts a combination of major features including arterial phase hyperenhancement (APHE) and washout pattern. Summary. Specific HCCs such as well or poorly differentiated type, subtypes including fibrolamellar or sarcomatoid and combined hepatocellular-cholangiocarcinoma does not often demonstrate APHE and washout appearance. Meanwhile, hypervascular liver metastases and hypervascular intrahepatic cholangiocarcinoma (ICC) can demonstrate APHE and washout. There are still other hypervascular malignant liver tumors (i.e., angiosarcoma, epithelioid hemangioendothelioma) and hypervascular benign liver lesions (i.e., adenoma, focal nodular hyperplasia, angiomyolipoma, flash filling hemangioma, reactive lymphoid hyperplasia, inflammatory lesion, arterioportal shunt), which need to be distinguished from HCC. When a patient has chronic liver disease, differential diagnosis of hypervascular liver lesions can be even more complicated. Meanwhile, artificial intelligence (AI) in medicine has been widely explored, and recent advancement in the field of deep learning has provided promising performance for the analysis of medical images. Especially, radiological imaging data contain diagnostic, prognostic, and predictive information which AI can extract. The AI researches have demonstrated high accuracy (over 90% accuracy) for classifying lesions with typical imaging features from some hepatic lesions. AI system has a potential to implement in clinical routine as decision support tools. However, for the differential diagnosis of many types of hypervascular liver lesions, further large-scale clinical validation still is required. Key Messages. Clinicians should be aware of the histopathological features, imaging characteristics and differential diagnoses of hypervascular liver lesions to a precise diagnosis and the more valuable treatment plan. We need to be familiar with such atypical cases to prevent a diagnostic delay, but AI based tools also need to lean a large number of typical and atypical cases.
  • Hiroki Kato; Satoru Hagiwara; Naoshi Nishida; Yoriaki Komeda; Akihiro Yoshida; Masatoshi Kudo
    Clinical journal of gastroenterology 16 3 397 - 401 2023年06月 [査読有り]
     
    This study aimed to demonstrate the effect of transcatheter arterial embolization (TAE) on hepatic segmental arterial mediolysis (SAM). The patient, a 68-year-old female, suddenly developed right upper abdominal pain in October 2021, which was initially relieved. However, she was rushed to a local hospital the next day when her abdominal pain recurred. An abdominal computed tomography scan suggested a ruptured hepatic aneurysm; therefore, she was transferred to our hospital and admitted on the same day. On the first day after admission, she underwent emergency catheterization and N-butyl-2-cyanoacrylate (NBCA)/lipiodol embolization for an aneurysm in the hepatic S6. A multi-detector computed tomography on hospital day 8 to probe for extrahepatic lesions revealed multiple beaded irregularities in the superior mesenteric and bilateral renal arteries. A head magnetic resonance angiography performed on the ninth day showed no aneurysms or irregularities. She did well after TAE, did not have rebleeding, and was discharged on hospital day 16. Rupture of an aneurysm associated with SAM occurs frequently in the colonic and gastroepiploic arteries, and rupture of a hepatic aneurysm is relatively rare. TAE hemostasis was able to save the patient by preventing intraperitoneal bleeding caused by hepatic segmental arterial mediolysis.
  • Naoshi Nishida; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo
    Cancers 15 8 2023年04月 [査読有り][招待有り]
     
    Cholangiocarcinoma (CCA) is a refractory cancer; a majority of CCAs represents a non-inflamed tumor phenotype that should be resistant to treatment, including immune checkpoint inhibitors (ICIs). In this study, we aimed to understand the molecular characteristics associated with non-inflamed CCAs. The genetic/epigenetic status of 36 CCAs was obtained from the Cancer Genome Atlas (PanCancerAtlas). CCAs were classified based on immune class using hierarchical clustering analysis of gene expressions related to tumor-infiltrating lymphocytes. The associations between immune class and genetic/epigenetic events were analyzed. We found that the tumors with alterations in FGFR2 and IDH1/2 had a "non-inflamed" tumor phenotype. A significant association was observed between the non-inflamed group and the downregulation of genes involved in antigen presentation (p = 0.0015). The expression of antigen-presenting machineries was inversely correlated with their DNA methylation levels, where 33.3% of tumors had an upregulation/low-methylation pattern, and 66.7% of tumors had a downregulation/high-methylation pattern. All tumors in the "inflamed" group exhibited an upregulation/low-methylation pattern. In contrast, 24 of 30 tumors in the non-inflamed group represent the downregulation/high-methylation pattern (p = 0.0005). Methylation with downregulation of antigen-presenting machineries is associated with the "non-inflamed" tumor phenotype of CCAs. This evidence provides important insights for developing new strategies for treating CCA.
  • Masahiro Morita; Naoshi Nishida; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Masatoshi Kudo
    Cancers 15 8 2023年04月 [査読有り][招待有り]
     
    Recently, the therapeutic combination of atezolizumab and bevacizumab was widely used to treat advanced hepatocellular carcinoma (HCC). According to recent clinical trials, immune checkpoint inhibitors (ICIs) and molecular target agents are expected to be key therapeutic strategies in the future. Nonetheless, the mechanisms underlying molecular immune responses and immune evasion remain unclear. The tumor immune microenvironment plays a vital role in HCC progression. The infiltration of CD8-positive cells into tumors and the expression of immune checkpoint molecules are key factors in this immune microenvironment. Specifically, Wnt/β catenin pathway activation causes "immune exclusion", associated with poor infiltration of CD8-positive cells. Some clinical studies suggested an association between ICI resistance and β-catenin activation in HCC. Additionally, several subclassifications of the tumor immune microenvironment were proposed. The HCC immune microenvironment can be broadly divided into inflamed class and non-inflamed class, with several subclasses. β-catenin mutations are important factors in immune subclasses; this may be useful when considering therapeutic strategies as β-catenin activation may serve as a biomarker for ICI. Various types of β-catenin modulators were developed. Several kinases may also be involved in the β-catenin pathway. Therefore, combinations of β-catenin modulators, kinase inhibitors, and ICIs may exert synergistic effects.
  • 【US Today 2023 超音波検査・診断最前線 腹部領域の最新動向を中心に】腹部領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望
    西田 直生志; 工藤 正俊
    INNERVISION 38 5 40 - 43 (株)インナービジョン 2023年04月 
    医療ではリアルタイムの対応が必要な場合が多く,厳しい時間的制約の下でのタスクはヒューマンエラーにつながりやすい。一方,人工知能(AI)の導入により,医療関係者は多様なデータから適切に処理された必要な情報をわかりやすい形で得ることができるようになり,医療の効率化とヒューマンエラーの防止が期待できる。加えて,疾患診断のみならず,予後予測や最適な治療アプローチの提案など,超音波診断の分野でも,さまざまなタスクを行うAIモデルが報告されている。本稿では,腹部超音波診断をサポートするAIにフォーカスして,その開発状況を概説する。(著者抄録)
  • Mathew Vithayathil; Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Valentina Zanuso; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato; Rohini Sharma
    Hepatology international 2023年04月 [査読有り]
     
    BACKGROUND: Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC. METHODS: 191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated. RESULTS: Patients in the overweight cohort (n = 94) had higher rates of non-alcoholic fatty liver disease (NAFLD) and lower rates of Hepatitis B compared to non-overweight cohort (n = 97). Baseline Child-Pugh class and Barcelona Clinic Liver Cancer stage were similar between cohorts, with lower rates of extrahepatic spread in the overweight group. Overweight patients had similar OS compared to non-overweight (median OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence median PFS (7.1 vs. 6.1 months; p = 0.42), ORR (27.2% vs. 22.0%; p = 0.44) and DCR (74.1% vs. 71.9%; p = 0.46). There were higher rates of atezolizumab-related fatigue (22.3% vs. 10.3%; p = 0.02) and bevacizumab-related thrombosis (8.5% vs. 2.1%; p = 0.045) in the overweight patients, but overall trAEs and treatment discontinuation were comparable between cohorts. CONCLUSION: Atezo/Bev has comparable efficacy in overweight HCC patients, with an increase in treatment-related fatigue and thrombosis. Combination therapy is safe and efficacious to use in overweight patients, including those with underlying NAFLD.
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    Cancers 15 7 2023年03月 [査読有り]
     
    Immune checkpoint inhibitors (ICIs) aim to induce immune responses against tumors and are less likely to develop drug resistance than molecularly targeted drugs. In addition, they are characterized by a long-lasting antitumor effect. However, since its effectiveness depends on the tumor's immune environment, it is essential to understand the immune environment of hepatocellular carcinoma to select ICI therapeutic indications and develop biomarkers. A network of diverse cellular and humoral factors establishes cancer immunity. By analyzing individual cases and classifying them from the viewpoint of tumor immunity, attempts have been made to select the optimal therapeutic drug for immunotherapy, including ICIs. ICI treatment is discussed from the viewpoints of immune subclass of HCC, Wnt/β-catenin mutation, immunotherapy in NASH-related HCC, the mechanism of HPD onset, and HBV reactivation.
  • Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Francesca Salani; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Marta Schirripa; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Journal of cancer research and clinical oncology 149 10 7565 - 7577 2023年03月 [査読有り]
     
    INTRODUCTION: The best first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B remains unknown. The aim of the present study was to perform a real-world analysis on a large sample of patients with unresectable HCC with CP B treated with atezolizumab plus bevacizumab Vs Lenvatinib. METHODS: The study population included patients affected by advanced (BCLC-C) or intermediate (BCLC-B) HCC patients not suitable for locoregional therapies from both the Western and Eastern world (Italy, Germany, Republic of Korea and Japan), who received atezolizumab plus bevacizumab or Lenvatinib as first-line treatment. All the study population presented a CP class of B. The primary endpoint of the study was the overall survival (OS) of CP B patients treated with Lenvatinib compared to atezolizumab plus bevacizumab. Survival curves were estimated using the product-limit method of Kaplan-Meier. The role of stratification factors was analyzed with log-rank tests. Finally, an interaction test was performed for the main baseline clinical characteristics. RESULTS: 217 CP B HCC patients were enrolled in the study: 65 (30%) received atezolizumab plus bevacizumab, and 152 (70%) received lenvatinib. The mOS for patients receiving Lenvatinib was 13.8 months (95% CI: 11.6-16.0), compared to 8.2 months (95% CI 6.3-10.2) for patients receiving atezolizumab plus bevacizumab as first-line treatment (atezolizumab plus bevacizumab Vs Lenvatinib: HR 1.9, 95% CI 1.2-3.0, p = 0.0050). No statistically significant differences were highlighted in terms of mPFS. The multivariate analysis confirmed that patients receiving Lenvatinib as first-line treatment have a significantly longer OS compared to patients receiving atezolizumab plus bevacizumab (HR 2.01; 95% CI 1.29-3.25, p = 0.0023). By evaluating the cohort of patients who received atezolizumab plus bevacizumab, we found that Child B patients with ECOG PS 0, or BCLC B stage or ALBI grade 1 were those who had benefited from the treatment thus showing survival outcomes no significantly different compared to those receiving Lenvatinib. CONCLUSION: The present study suggests for the first time a major benefit from Lenvatinib compared to atezolizumab plus bevacizumab in a large cohort of patients with CP B class HCC.
  • Margherita Rimini; Mara Persano; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Fabio Piscaglia; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Lorenza Rimassa; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Targeted oncology 18 2 221 - 233 2023年03月 [査読有り]
     
    BACKGROUND: Atezolizumab plus bevacizumab has recently been approved as a new first-line standard of care for patients with unresectable hepatocellular carcinoma (HCC). OBJECTIVE: We performed a real-world study to evaluate the impact of the IMbrave150 trial inclusion criteria on the safety and efficacy of treatment outside of clinical trials. METHODS: We analyzed patients treated with atezolizumab plus bevacizumab for unresectable HCC from four different countries. No specific inclusion and exclusion criteria were applied, except for the absence of previous systemic therapies for HCC. The entire population was split into two groups according to concordance with the inclusion criteria as reported in the IMbrave150 trial in 'IMbrave150-in' and 'IMbrave150-out' patients, and safety and efficacy in the two groups of patients were evaluated. RESULTS: Overall, 766 patients were included in the analysis: 561/766 (73%) in the 'IMbrave150-in' group and 205/766 (27%) in the 'IMbrave150-out' group. Median overall survival (OS) and median progression-free survival (PFS) were 16.3 versus 14.3 months (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.35-0.65; p < 0.0001] and 8.3 versus 6.0 months (HR 0.79, 95% CI 0.63-0.99; p = 0.0431) in 'IMbrave150-in' and 'IMbrave150-out' patients, respectively. Multivariate analysis confirmed that patients included in the 'IMbrave150-in' group had significantly longer OS compared with patients included in the 'IMbrave150-out' group (HR 0.76, 95% CI 0.47-0.97; p = 0.0195). In 'IMbrave150-in' patients, the albumin-bilirubin (ALBI) grade was not associated with OS, whereas in 'IMbrave150-out' patients, those with ALBI grade 1 reported a significant benefit in terms of OS compared with those with ALBI grade 2 (16.7 vs. 5.9 months; HR 4.40, 95% CI 2.40-8.08; p > 0.0001). No statistically significant differences were reported in the 'IMbrave150-in' and 'IMbrave150-out' groups in terms of safety profile. CONCLUSION: Adherence to the IMbrave150 trial inclusion criteria favorably impacts the prognosis of patients receiving atezolizumab plus bevacizumab. Among patients who did not meet the IMbrave150 inclusion criteria, those with ALBI grade 1 could benefit from the treatment.
  • Thomas Talbot; Antonio D'Alessio; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas U Marron; Tomi Jun; Sirish Dharmapuri; Celina Ang; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Claudia A M Fulgenzi; Suneetha Amara; Abdul Rafeh Naqash; Anuhya Gampa; Anjana Pillai; Yinghong Wang; Uqba Khan; Pei-Chang Lee; Yi-Hsiang Huang; Bertram Bengsch; Dominik Bettinger; Yehia I Mohamed; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Masatoshi Kudo; Arndt Weinmann; Peter R Galle; Ambreen Muhammed; Alessio Cortellini; Arndt Vogel; David J Pinato
    Liver international : official journal of the International Association for the Study of the Liver 43 3 695 - 707 2023年03月 [査読有り]
     
    BACKGROUND & AIMS: Different approaches are available after progression of disease (PD) to immune checkpoint inhibitors (ICI) for hepatocellular carcinoma (HCC), including continuation of ICI, treatment switching to tyrosine kinase inhibitors (TKIs) and cessation of anticancer therapy. We sought to characterise the relationship between radiologic patterns of progression and survival post-ICI, also appraising treatment strategies. METHODS: We screened 604 HCC patients treated with ICIs, including only those who experienced PD by data cut-off. We evaluated post-progression survival (PPS) according to treatment strategy at PD and verified its relationship with radiologic patterns of progression: intrahepatic growth (IHG), new intrahepatic lesion (NIH), extrahepatic growth (EHG), new extrahepatic lesion (NEH) and new vascular invasion (nVI). RESULTS: Of 604 patients, 364 (60.3%) experienced PD during observation. Median PPS was 5.3 months (95%CI: 4.4-6.9; 271 events). At data cut-off, 165 patients (45%) received no post-progression anticancer therapy; 64 patients (17.6%) continued ICI beyond PD. IHG (HR 1.64 [95%CI:1.21-2.22]; p=0.0013) and nVI (HR 2.15 [95%CI:1.38-3.35]; p=0.0007) were associated with shorter PPS. Multivariate models adjusted for progression patterns, treatment line, and ALBI grade and ECOG-PS at PD confirmed receipt of ICI beyond PD with (HR 0.17, 95%CI 0.09-0.32; p<0.0001), or without subsequent TKI (HR 0.39, 95%CI 0.26-0.58; p<0.0001) as predictors of prolonged PPS versus no anticancer therapy. CONCLUSIONS: ICI-TKI sequencing is a consolidated option in advanced HCC. nVI and IHG predict poorer prognosis. Despite lack of recommendation, continuation of ICI beyond progression in HCC is adopted clinically: future efforts should appraise which patients benefit from this approach.
  • Yasuo Otsuka; Yoriaki Komeda; Masayuki Takeda; Takayuki Takahama; Masashi Kono; Mamoru Takenaka; Satoru Hagiwara; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Case reports in medicine 2023 2092157 - 2092157 2023年02月 [査読有り]
     
    A 76-year-old woman presented with lower abdominal pain and nausea and was referred to the gastroenterology department in our institution. Previous contrast-enhanced computed tomography (CE-CT) for follow-up after breast cancer surgery had indicated a soft tissue mass below the right diaphragm, which was considered a benign change. CE-CT performed at the first visit to our department revealed further thickening of the soft tissue mass with extension to the liver surface. In addition, ascites and nodules were observed in the abdominal cavity. Histopathological examination of a biopsy specimen revealed peritoneal invasion of atypical epithelioid cells with trabecular and glandular patterns. The tumor cells were positive for AE1/AE2, calretinin, WT-1, D2-40, HEG1, EMA, BAP1, and MTAP and negative for carcinoembryonic antigen, MOC-31, Ber-Ep4, ER, PgR, TTF-1, claudin 4, and desmin. A diagnosis of epithelioid mesothelioma was made. The patient received chemotherapy with cisplatin (75 mg/m2) and pemetrexed (500 mg/m2). After six courses of combined chemotherapy, pemetrexed was administered as a single agent. At the time of writing this report, she was undergoing over the 30th course of chemotherapy without any significant side effects. Diffuse malignant peritoneal mesothelioma is a rare, fatal, and progressive disease. Our patient achieved long-term survival of more than 5 years with maintenance therapy using single-agent pemetrexed.
  • Andrea Casadei-Gardini; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Mara Persano; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Stefano Cascinu; Alessandro Cucchetti
    European journal of cancer (Oxford, England : 1990) 180 9 - 20 2023年02月 [査読有り]
     
    BACKGROUND AND AIMS: Atezolizumab plus bevacizumab and lenvatinib have not been compared in a randomised controlled trial. We conducted a retrospective multi-centre study to compare the clinical efficacy and safety of lenvatinib and atezolizumab with bevacizumab as a first-line treatment for patients with unresectable HCC in the real-world scenario. METHODS: Clinical features of lenvatinib and atezolizumab plus bevacizumab patients were balanced through inverse probability of treatment weighting (IPTW) methodology, which weights patients' characteristics and measured outcomes of each patient in both treatment arms. Overall survival (OS) was the primary end-point. RESULTS: The analysis included 1341 patients who received lenvatinib, and 864 patients who received atezolizumab plus bevacizumab. After IPTW adjustment, atezolizumab plus bevacizumab did not show a survival advantage over lenvatinib HR 0.97 (p = 0.739). OS was prolonged by atezolizumab plus bevacizumab over lenvatinib in viral patients (HR: 0.76; p = 0.024). Conversely, OS was prolonged by lenvatinib in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease (HR: 1.88; p = 0.014). In the IPTW-adjusted population, atezolizumab plus bevacizumab provided better safety profile for most of the recorded adverse events. CONCLUSION: Our study did not identify any meaningful difference in OS between atezolizumab plus bevacizumab and lenvatinib. Although some hints are provided suggesting that patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease might benefit more from lenvatinib therapy and patients with viral aetiology more from atezolizumab plus bevacizumab.
  • Y Linda Wu; Grace van Hyfte; Umut Özbek; Marlene Reincke; Anuhya Gampa; Yehia I Mohamed; Naoshi Nishida; Brooke Wietharn; Suneetha Amara; Pei-Chang Lee; Bernhard Scheiner; Lorenz Balcar; Matthias Pinter; Arndt Vogel; Arndt Weinmann; Anwaar Saeed; Anjana Pillai; Lorenza Rimassa; Abdul Rafeh Naqash; Mahvish Muzaffar; Yi-Hsiang Huang; Ahmed O Kaseb; Masatoshi Kudo; David J Pinato; Celina Ang
    Frontiers in oncology 13 1128569 - 1128569 2023年02月 [査読有り]
     
    BACKGROUND: In patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular carcinoma (HCC). We aimed to investigate whether beta blockers (BBs), which can mediate portal hypertension, conferred survival benefits in patients treated with immune checkpoint inhibitors (ICIs). METHODS: We conducted a retrospective, observational study of 578 patients with unresectable HCC treated with ICI from 2017 to 2019 at 13 institutions across three continents. BB use was defined as exposure to BBs at any time during ICI therapy. The primary objective was to assess the association of BB exposure with overall survival (OS). Secondary objectives were to evaluate the association of BB use with progression-free survival (PFS) and objective response rate (ORR) according to RECIST 1.1 criteria. RESULTS: In our study cohort, 203 (35%) patients used BBs at any point during ICI therapy. Of these, 51% were taking a nonselective BB. BB use was not significantly correlated with OS (hazard ratio [HR] 1.12, 95% CI 0.9-1.39, P = 0.298), PFS (HR 1.02, 95% CI 0.83-1.26, P = 0.844) or ORR (odds ratio [OR] 0.84, 95% CI 0.54-1.31, P = 0.451) in univariate or multivariate analyses. BB use was also not associated with incidence of adverse events (OR 1.38, 95% CI 0.96-1.97, P = 0.079). Specifically, nonselective BB use was not correlated with OS (HR 0.94, 95% CI 0.66-1.33, P = 0.721), PFS (HR 0.92, 0.66-1.29, P = 0.629), ORR (OR 1.20, 95% CI 0.58-2.49, P = 0.623), or rate of adverse events (OR 0.82, 95% CI 0.46-1.47, P = 0.510). CONCLUSION: In this real-world population of patients with unresectable HCC treated with immunotherapy, BB use was not associated with OS, PFS or ORR.
  • Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Bernardo Stefanini; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Valentina Burgio; Angelo Della Corte; Francesca Ratti; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Oncology 101 5 283 - 291 2023年01月 [査読有り]
     
    INTRODUCTION: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its prognostic role has been demonstrated in patients treated with sorafenib and lenvatinib. The aim of this real-world study is to investigate the association between clinical outcomes and PNI in patients being treated with atezolizumab plus bevacizumab. METHODS: The overall cohort of this multicentric study included 871 consecutive HCC patients from 4 countries treated with atezolizumab plus bevacizumab in first-line therapy. The PNI was calculated as follows: 10 × serum albumin concentration (g/dL) + 0.005 × peripheral lymphocyte count (number/mm3). RESULTS: For only 773 patients, data regarding lymphocyte counts and albumin levels were available, so only these patients were included in the final analysis. The cut-off point of the PNI was determined to be 41 by receiver operating characteristic (ROC) analysis. 268 patients (34.7%) were categorized as the PNI-low group, while the remaining 505 (65.3%) patients as the PNI-high group. At the univariate analysis, high PNI was associated with longer overall survival (OS) (22.5 vs. 10.1 months, HR 0.34, p < 0.01) and progression-free survival (PFS) (8.7 vs. 5.8 months, HR 0.63, p < 0.01) compared to patients with low PNI. At the multivariate analysis, high versus low PNI resulted as an independent prognostic factor for OS (HR 0.49 , p < 0.01) and PFS (HR 0.82, p = 0.01). There was no difference in objective response rate (ORR) between the two groups (high 26.1% vs. low 19.8%, p = 0.09), while disease control rate (DCR) was significantly higher in the PNI-high group (76.8% vs. 66.4%, p = 0.01). CONCLUSION: PNI is an independent prognostic factor for OS and PFS in HCC patients on first-line treatment with atezolizumab plus bevacizumab.
  • Yoriaki Komeda; Masashi Kono; Hiroshi Kashida; George Tribonias; Sho Masaki; Ryutaro Takada; Tomoyuki Nagai; Satoru Hagiwara; Naoshi Nishida; Mamoru Takenaka; Hajime Honjo; Shigenaga Matsui; Naoko Tsuji; Masatoshi Kudo
    Annals of gastroenterology 36 1 97 - 102 2023年 [査読有り]
     
    BACKGROUND: The standard therapy for acute severe ulcerative colitis (ASUC) is intravenous corticosteroids; however, 30% of ulcerative colitis (UC) patients do not recover with corticosteroids alone. Few studies have reported the efficacy and safety of tofacitinib for ASUC with steroid resistance. We report a case series of successful first-line treatment consisting of tofacitinib (20 mg/day) administered to ASUC patients with steroid resistance. METHODS: Patients diagnosed with ASUC at our institution between October 2018 and February 2020 were retrospectively evaluated. They were administered a high dose of tofacitinib (20 mg) after showing no response to steroid therapy in a dose of 1-1.5 mg/kg/day. RESULTS: Eight patients with ASUC, 4 (50%) men, median age 47.1 (range 19-65) years, were included. Four patients were newly diagnosed, and the median UC duration was 4 (range 0-20) years. Six of the 8 patients were able to avoid colectomy. One patient (patient 2) had no response; however, remission was achieved after switching from tofacitinib to infliximab. One patient (patient 6) with no response to tofacitinib underwent total colectomy. Only one patient (patient 4) experienced an adverse event, local herpes zoster, treated with acyclovir without tofacitinib discontinuation. CONCLUSIONS: Clinical remission without serious adverse events can be achieved with high probability and colectomy can be avoided by first administering high-dose tofacitinib to steroid-resistant ASUC patients. Tofacitinib may be one of the first-line treatment options for steroid-resistant ASUC.
  • Naoshi Nishida; Masatoshi Kudo
    Ultrasonography (Seoul, Korea) 42 1 10 - 19 2023年01月 [査読有り][招待有り]
     
    With the development of more advanced methods for the diagnosis and treatment of diseases, the data required for medical care are becoming complex, and misinterpretation of information due to human error may result in serious consequences. Human error can be avoided with the support of artificial intelligence (AI). AI models trained with various medical data for diagnosis and management of liver diseases have been applied to hepatitis, fatty liver disease, liver cirrhosis, and liver cancer. Some of these models have been reported to outperform human experts in terms of performance, indicating their potential for supporting clinical practice given their high-speed output. This paper summarizes the recent advances in AI for liver disease and introduces the AI-aided diagnosis of liver tumors using B-mode ultrasonography.
  • Mara Persano; Margherita Rimini; Toshifumi Tada; Goki Suda; Shigeo Shimose; Masatoshi Kudo; Jaekyung Cheon; Fabian Finkelmeier; Ho Yeong Lim; Lorenza Rimassa; José Presa; Gianluca Masi; Changhoon Yoo; Sara Lonardi; Francesco Tovoli; Takashi Kumada; Naoya Sakamoto; Hideki Iwamoto; Tomoko Aoki; Hong Jae Chon; Vera Himmelsbach; Tiziana Pressiani; Takumi Kawaguchi; Margarida Montes; Caterina Vivaldi; Caterina Soldà; Fabio Piscaglia; Atsushi Hiraoka; Takuya Sho; Takashi Niizeki; Naoshi Nishida; Christoph Steup; Massimo Iavarone; Giovanni Di Costanzo; Fabio Marra; Mario Scartozzi; Emiliano Tamburini; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Marianna Silletta; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Fujimasa Tada; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Hisashi Kosaka; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Antonella Cammarota; Valentina Burgio; Stefano Cascinu; Andrea Casadei-Gardini
    Journal of cancer research and clinical oncology 149 9 5591 - 5602 2022年12月 [査読有り]
     
    PURPOSE: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. METHODS: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea). RESULTS: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p < 0.01; odds ratio 0.60). For patients who achieved complete response (CR), overall survival (OS) was not reached in both arms, but the result from univariate Cox regression model showed 62% reduction of death risk for patients treated with atezolizumab plus bevacizumab (p = 0.05). In all multivariate analyses, treatment arm was not found to be an independent factor conditioning OS. Comparing ORR achieved in the two arms, there was a statistically significant difference in favor of lenvatinib compared to atezolizumab plus bevacizumab in all subgroups except for Eastern patients, Child-Pugh B patients, presence of portal vein thrombosis, α-feto-protein ≥ 400 ng/mL, presence of extrahepatic disease, albumin-bilirubin (ALBI) grade 2, and no previous locoregional procedures. CONCLUSION: Lenvatinib achieves higher ORR in all patient subgroups. Patients who achieve CR with atezolizumab plus bevacizumab can achieve OS so far never recorded in HCC patients. This study did not highlight any factors that could identify patient subgroups capable of obtaining CR.
  • Yue Linda Wu; Claudia Angela Maria Fulgenzi; Antonio D'Alessio; Jaekyung Cheon; Naoshi Nishida; Anwaar Saeed; Brooke Wietharn; Antonella Cammarota; Tiziana Pressiani; Nicola Personeni; Matthias Pinter; Bernhard Scheiner; Lorenz Balcar; Yi-Hsiang Huang; Samuel Phen; Abdul Rafeh Naqash; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Rohini Sharma; Alessio Cortellini; Vincent E Gaillard; Hong Jae Chon; David J Pinato; Celina Ang
    Cancers 14 23 2022年11月 [査読有り]
     
    Systemic inflammation is a key risk factor for hepatocellular carcinoma (HCC) progression and poor outcomes. Inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) may have prognostic value in HCC treated with standard of care atezolizumab plus bevacizumab (Atezo-Bev). We conducted a multicenter, international retrospective cohort study of patients with unresectable HCC treated with Atezo-Bev to assess the association of NLR and PLR with overall survival (OS), progression-free survival (PFS), and objective response rates. Patients with NLR ≥ 5 had a significantly shorter OS (9.38 vs. 16.79 months, p < 0.001) and PFS (4.90 vs. 7.58 months, p = 0.03) compared to patients with NLR < 5. NLR ≥ 5 was an independent prognosticator of worse OS (HR 2.01, 95% CI 1.22-3.56, p = 0.007) but not PFS. PLR ≥ 300 was also significantly associated with decreased OS (9.38 vs. 15.72 months, p = 0.007) and PFS (3.45 vs. 7.11 months, p = 0.04) compared to PLR < 300, but it was not an independent prognosticator of OS or PFS. NLR and PLR were not associated with objective response or disease control rates. NLR ≥ 5 independently prognosticated worse survival outcomes and is worthy of further study and validation.
  • Satoru Hagiwara; Yoriaki Komeda; Naoshi Nishida; Akihiro Yoshida; Masatoshi Kudo
    Cancer reports (Hoboken, N.J.) 5 11 e1721  2022年11月 [査読有り]
     
    BACKGROUND: Although reports of gastrointestinal perforation after immune-related adverse events (irAE) enteritis are rare, the anti- vascular endothelial growth factor (VEGF) effect of bevacizumab may be involved in gastrointestinal perforation. We report a rare case of gastrointestinal perforation in a patient with hepatocellular carcinoma treated with atezolizumab/bevacizumab combination therapy and infliximab before steroid use. CASE: A 72-year-old man, who received seven courses of atezolizumab/bevacizumab for hepatocellular carcinoma due to hepatitis B, was admitted to our department with idiopathic abdominal pain and diarrhea (grade 2 [G2]). Computed tomography (CT) and colonoscopy confirmed edema in the gastrointestinal tract. Perforation of the jejunum was observed in a CT performed on the third day and an emergency operation was performed. Intraoperative findings showed severe edema of the jejunum and leakage of feces into the abdominal cavity. The patient was diagnosed with irAE enteritis comprehensively with severe wall thickening on CT and colonoscopy, negative stool culture, and pathological findings of CD8-positive cells. Infliximab was administered before initiating steroids, to prevent reperforation. The enteritis improved by the 22nd day; however, CT performed on the 35th day of illness showed relapse of gastrointestinal wall thickening and G2 diarrhea symptoms; therefore, prednisolone (PSL) 60 mg/day was started on the 36th day of illness. After introducing PSL, enteritis did not reoccur, and the patient was discharged on the 63rd day of illness after admission. CONCLUSION: There are no reports of gastrointestinal perforation by atezolizumab/bevacizumab for hepatocellular carcinoma, and prior administration of infliximab. We therefore report the clinical course and management.
  • Claudia Angela Maria Fulgenzi; Jaekyung Cheon; Antonio D'Alessio; Naoshi Nishida; Celina Ang; Thomas U Marron; Linda Wu; Anwaar Saeed; Brooke Wietharn; Antonella Cammarota; Tiziana Pressiani; Nicola Personeni; Matthias Pinter; Bernhard Scheiner; Lorenz Balcar; Andrea Napolitano; Yi-Hsiang Huang; Samuel Phen; Abdul Rafeh Naqash; Caterina Vivaldi; Francesca Salani; Gianluca Masi; Dominik Bettinger; Arndt Vogel; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Peter R Galle; Masatoshi Kudo; Lorenza Rimassa; Amit G Singal; Rohini Sharma; Alessio Cortellini; Vincent E Gaillard; Hong Jae Chon; David James Pinato
    European journal of cancer (Oxford, England : 1990) 175 204 - 213 2022年11月 [査読有り]
     
    BACKGROUND: IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). METHODS: We generated a prospectively maintained database including patients treated with atezolizumab plus bevacizumab for unresectable HCC across Europe, Asia and USA. Clinico-pathologic characteristics were assessed for their prognostic influence on overall survival (OS) and progression-free survival (PFS) in univariable and multivariate analyses. Overall response rate by RECIST v1.1 and treatment-related adverse events (TRAEs) per CTCAE v.5.0 were reported. RESULTS: Out of 433 patients, 296 Child-Pugh A and ECOG performance status01 patients received atezolizumab plus bevacizumab in first line and were included. Patients were mostly male (82.7%), cirrhotic (75%) with history of viral hepatitis (65.9%). Overall, 68.9% had Barcelona Clinic Liver Cancer C-stage HCC with portal vein tumour thrombosis (PVTT, 35%) and extrahepatic spread (EHS, 51.7%). After a median follow-up of 10.0 months (95% confidence interval (CI): 9.4-10.4), median OS and PFS were 15.7 (95% CI: 14.5-NE) and 6.9 months (95% CI: 6.1-8.3), respectively. In the response-evaluable patients (n = 273), overall response rate was 30.8%. Overall, 221 patients (74.6%) developed TRAEs, with 70 (23.6%) reporting grade 3 or higher TRAEs; 25 (8.4%) patients had bleeding events. OS was independently associated with baseline Albumin-bilirubin (ALBI) grade and PVTT. Shorter PFS was associated with AFP≥ 400 ng/ml, worse ALBI and presence of EHS. CONCLUSION: This global observational study confirms the reproducible safety and efficacy of atezolizumab plus bevacizumab in routine clinical practice. Within Child-Pugh-A criteria, the presence of PVTT and higher ALBI grade identify patients with poorer survival.
  • Mathew Vithayathil; Antonio D'Alessio; Claudia A M Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato; Rohini Sharma
    Liver international : official journal of the International Association for the Study of the Liver 42 11 2538 - 2547 2022年11月 [査読有り]
     
    BACKGROUND AND AIMS: Combination atezolizumab/bevacizumab is the gold standard for first line-treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC. METHODS: 191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age≥65 years) and younger (age<65 years) age patients. Treatment-related adverse events (trAEs) were evaluated. RESULTS: The elderly (n=116) had higher rates of non-alcoholic fatty liver disease (19.8% vs. 2.7%; p<0.001), presenting with smaller tumours (6.2cm vs 7.9cm, p=0.02) with less portal vein thrombosis (31.9 vs. 54.7%, p=0.002), with fewer patients presenting with BCLC-C stage disease (50.9 vs. 74.3%, p=0.002). There was no significant difference in OS (median 14.9 vs. 15.1 months; HR 1.15, 95% CI 0.65-2.02 p=0.63) and PFS (median 7.1 vs. 5.5 months; HR 1.11, 95% CI 0.54-1.92; p=0.72) between older age and younger age. Older patients had similar ORR (27.6% vs. 20.0%; p=0.27) and DCR (77.5% vs. 66.1%; p=0.11) compared to younger patients. Atezolizumab-related (40.5% vs. 48.0%; p=0.31) and bevacizumab-related (44.8% vs. 41.3%; p=0.63) trAEs were comparable between groups. Rates of grade ≥3 trAEs and toxicity-related treatment discontinuation were similar between older and younger age patients. Patients 75 years and older had similar survival and safety outcomes compared to younger patients. CONCLUSIONS: Atezolizumab and bevacizumab therapy is associated with comparable efficacy and tolerability in older age patients with unresectable HCC.
  • Yasunori Minami; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    Cancers 14 19 2022年10月 [査読有り]
     
    BACKGROUND: The treatment of the hepatitis C virus (HCV) has reduced the risk of hepatocellular carcinoma (HCC)-related mortality. Many patients with advanced HCC have achieved longer survival through systemic chemotherapy. However, survivors of HCC may develop liver cancer during and after treatment. Therefore, the present study investigated prognostic factors for survival in patients with HCV-related HCC in the new era of molecular targeted therapy. METHODS: A total of 359 patients with HCV-related HCC treated with first-line chemotherapy were reviewed. A Cox proportional hazards model and Kaplan-Meier curve were used to identify prognostic factors associated with survival outcomes. RESULTS: The median follow-up duration was 16.0 months (range, 1.0-115.7) and the median duration of first-line systemic therapy was 3.73 months (range, 0.7-86.9). The achievement of a sustained virological response (SVR) (p  <  0.001), albumin-bilirubin (ALBI) grade II/III (p  <  0.001), Barcelona Clinic Liver Cancer (BCLC) stage C (p  =  0.005), extrahepatic spread (p < 0.001), baseline AFP (alpha-fetoprotein) level ≥ 90 (p = 0.038), baseline DCP (des-γ-carboxy prothrombin) level ≥ 500 (p < 0.001), and a fibrosis-4 (FIB-4) index ≥ 4 (p  =  0.003) were identified as prognostic factors for overall survival. CONCLUSIONS: The achievement of SVR was most strongly associated with overall survival. Other factors, such as the BCLC stage, extrahepatic spread, baseline tumor marker (AFP/DCP) levels, ALBI grade, and FIB-4 index need to be considered in the management of patients with HCV-related HCC.
  • Satoru Hagiwara; Takeshi Yoshida; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Cishina; Yoriaki Komeda; Akihiro Yoshida; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 52 10 888 - 892 2022年10月 [査読有り]
     
    AIM: We report a rare case of immune-related cholangitis in which the natural course could be demonstrated. CASE PRESENTATION: Eight courses of pembrolizumab maintenance therapy were given as first-line treatment for squamous cell lung cancer; however, the patient was subsequently hospitalized due to a rapid increase in hepatobiliary enzymes. On endoscopic ultrasound, the common bile duct was dilated to 11 mm, and the wall, throughout its length from the papilla, was thickened. Endoscopic retrograde cholangiopancreatography showed no obvious stenosis in the lower bile duct; however, a parapapillary diverticulum was found, and papillary incision and bile duct plastic stent insertion were carried out. However, the liver disorder did not improve and overt jaundice appeared subsequently; therefore, an immune-related cholangitis was suspected, and prednisolone (PSL) 35 mg/day was introduced from day 59 of admission. Following PSL initiation, a decrease in serum bilirubin level was observed; however, significant decrease was not observed in alkaline phosphatase. Given the history of recurrent infectious cholangitis, magnetic resonance cholangiopancreatography was carried out on day 70 of admission. The intrahepatic bile duct showed stenosis and dilated findings, which was considered to be a factor for repeated infectious cholangitis. CONCLUSION: No previous case reports have described the changes and progression in bile duct images in immune-related adverse events. Therefore, this case is noteworthy for considering the progression of immune-related cholangitis.
  • Antonio D'Alessio; Claudia Angela Maria Fulgenzi; Naoshi Nishida; Martin Schönlein; Johann von Felden; Kornelius Schulze; Henning Wege; Vincent E Gaillard; Anwaar Saeed; Brooke Wietharn; Hannah Hildebrand; Linda Wu; Celina Ang; Thomas U Marron; Arndt Weinmann; Peter R Galle; Dominik Bettinger; Bertram Bengsch; Arndt Vogel; Lorenz Balcar; Bernhard Scheiner; Pei-Chang Lee; Yi-Hsiang Huang; Suneetha Amara; Mahvish Muzaffar; Abdul Rafeh Naqash; Antonella Cammarota; Nicola Personeni; Tiziana Pressiani; Rohini Sharma; Matthias Pinter; Alessio Cortellini; Masatoshi Kudo; Lorenza Rimassa; David J Pinato
    Hepatology (Baltimore, Md.) 76 4 1000 - 1012 2022年10月 [査読有り]
     
    BACKGROUND & AIMS: Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first-line treatment of unresectable hepatocellular carcinoma (HCC). No evidence exists as to its use in routine clinical practice in patients with impaired liver function. APPROACH & RESULTS: In 216 HCC patients consecutively treated with AtezoBev across 11 tertiary centres we retrospectively evaluated treatment-related adverse events (trAEs) graded (G) according to CTCAE v5.0, including in the analysis all patients treated according to label (n=202, 94%). We also assessed overall survival (OS), progression-free survival (PFS), overall response (ORR) and disease control rates (DCR) defined by RECIST v1.1. Disease was mostly secondary to viral hepatitis, namely Hepatitis C (n=72; 36%) and Hepatitis B infection (n=35, 17%). Liver function was graded as Child-Pugh (CP)-A in 154 patients (76%) and CP-B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared to CP-A, CP-B patients showed comparable rates of trAEs. Presence and grade of varices at pre-treatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow-up of 9.0 months (95%CI, 7.8-10.1), median OS was 14.9 months (95%CI, 13.6-16.3), while median PFS was 6.8 months (95%CI, 5.2-8.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes. CONCLUSIONS: This study confirms reproducible safety and efficacy of AtezoBev in routine practice. CP-B patients reported similar tolerability compared to CP-A, warranting prospective evaluation of AtezoBev in this treatment-deprived population.
  • 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 肝細胞癌の新たな免疫クラス分類
    盛田 真弘; 西田 直生志; 工藤 正俊
    肝胆膵 85 3 345 - 353 (株)アークメディア 2022年09月
  • 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 Wnt/β-catenin変異を有するHCCの二面性(Inflamed and non-inflamed)
    青木 智子; 西田 直生志; 工藤 正俊
    肝胆膵 85 3 369 - 374 (株)アークメディア 2022年09月
  • Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Yoriaki Komeda; Akihiro Yoshida; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 52 9 754 - 761 2022年09月 [査読有り]
     
    AIM: The risk of hepatitis B virus (HBV) reactivation with immune checkpoint inhibitors (ICIs) is an important issue that has not yet been fully investigated. ICI is also expected to have an antiviral effect on HBV due to its immune tolerance inhibitory effect. We herein investigated the risk of HBV reactivation and the antiviral effect of ICI administration. METHODS: This study included 892 patients on ICIs between September 2014 and May 2021 at our hospital. The frequency of HBV reactivation and antiviral effects were investigated. RESULTS: Among the 892 patients who underwent ICI, 27 were hepatitis B surface antigen (HBsAg) positive. HBV reactivation was evaluated in 24 cases, among which 4.1% (1/24) had HBV reactivation. Nucleic acid analog prophylaxis was not administered to patients with reactivation. In a study of 15 cases, the amount of HBsAg decreased from baseline; 2.18 ± 0.77 log to 48 weeks later; 1.61 ± 1.38 log (p = 0.17). Forty-eight weeks after the start of ICI, disappearance of HBsAg was observed in two out of 15 cases (13.3%), and one case each with and without nucleic acid analog. CONCLUSION: In rare cases, HBsAg-positive patients may be reactivated by ICI administration. On the other hand, when ICI is administered, it is expected to have an antiviral effect on HBV due to its immune tolerance inhibitory effect, and future drug development is expected. This article is protected by copyright. All rights reserved.
  • Margherita Rimini; Wonseok Kang; Valentina Burgio; Mara Persano; Tamoko Aoki; Shigeo Shimose; Toshifumi Tada; Takashi Kumada; Takuya Sho; Eleonora Lai; Ciro Celsa; Claudia Campani; Matteo Tonnini; Emiliano Tamburini; Atsushi Hiraoka; Koichi Takaguchi; Naoshi Nishida; Hideki Iwamoto; Ei Itobayashi; Kunihiko Tsuji; Naoya Sakamoto; Toru Ishikawa; Hidenori Toyoda; Masatoshi Kudo; Takumi Kawaguchi; Takeshi Hatanaka; Kazugiro Nouso; Goki Suda; Giuseppe Cabibbo; Fabio Marra; Angelo Della Corte; Francesca Ratti; Federica Pedica; Francesco De Cobelli; Luca Aldrighetti; Mario Scartozzi; Stefano Cascinu; Andrea Casadei-Gardini
    Hepatology research : the official journal of the Japan Society of Hepatology 52 12 1050 - 1059 2022年08月 [査読有り]
     
    BACKGROUND: The identification of new prognostic factors able to stratify HCC patients candidate to first line therapy is an urgent. In the present work we validated the prognostic value of the LEP index. MATHERIALS AND METHODS: Data of Eastern and Western patients treated with lenvatinib as first-line for BCLC stage B or C HCC were recollected. LEP index was composed by three class of risk according with our previously study. The 'low risk'group includes patients with PNI >43.3 and with previous TACE. The 'medium risk' group includes patients with PNI >43.3 but without previous TACE and patients with PNI <43.3, ALBI grade 1 and BCLC-B. The 'high risk'group includes patients with PNI <43.3, ALBI grade 2 and patients with PNI <43.3, ALBI grade 1 and BCLC-C. RESULTS: 717 patients were included. Median OS was 20.7 months (95% CI 16.1-51.6) in patients with low risk (n = 223), 16.7 months (95% CI 13.3-47.0) in medium risk (n = 264) and 10.7 months (95% CI 9.3-12.2) in high risk (n = 230) [HR 1, 1.29 and 1.92 respectively; p < 0.0001]. Median PFS was 7.3 months (95% CI 6.3-46.5) in patients with low risk, 6.4 months (95% CI 5.3-8.0) in medium and 4.9 months (95% CI 4.3-5.5) in high risk [HR 1, 1.07, 1.47 respectively; p = 0.0009]. CONCLUSION: The LEP index confirms its prognostic value on an external cohort of HCC patients treated with Lenvatinib. This article is protected by copyright. All rights reserved.
  • Ayana Okamoto; Ken Kamata; Takeshi Miyata; Tomoe Yoshikawa; Rei Ishikawa; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Yasutaka Chiba; Toshiharu Sakurai; Naoshi Nishida; Masayuki Kitano; Masatoshi Kudo
    Clinical endoscopy 55 4 558 - 563 2022年07月 [査読有り]
     
    Background/Aims: Bispectral index (BIS) monitors process and display electroencephalographic data and are used to assess the depth of anesthesia. This study retrospectively evaluated the usefulness of BIS monitoring during endoscopic ultrasonography (EUS). Methods: This study included 725 consecutive patients who underwent EUS under sedation with propofol. BIS monitoring was used in 364 patients and was not used in 361. The following parameters were evaluated: (1) median dose of propofol; (2) respiratory and circulatory depression; (3) occurrence of body movements; (4) awakening score >8 at the time; and (5) awakening score 2 hours after leaving the endoscopy room. Results: The BIS group received a significantly lower median dose of propofol than the non-BIS group (159.2 mg vs. 167.5 mg; p=0.015) in all age groups. For patients aged ≥75 years, the reduction in heart rate was significantly lower in the BIS group than in the non-BIS group (1.2% vs. 9.1%; p=0.023). Moreover, the occurrence of body movements was markedly lower in the BIS group than in the non-BIS group (8.5% vs. 39.4%; p<0.001). Conclusions: During EUS examination, BIS monitoring is useful for maintaining a constant depth of anesthesia, especially in patients 75 years of age or older.
  • Thomas Talbot; Antonio D'Alessio; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas Marron; Tomi Jun; Sirish Dharmapuri; Celina Ang; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Claudia Angela Maria Fulgenzi; Suneetha Amara; Abdul Rafeh Naqash; Anuhya Gampa; Anjana Pillai; Yinghong Wang; Uqba Khan; Pei-Chang Lee; Yi-Hsiang Huang; Bertram Bengsch; Dominik Bettinger; Yehia Abugabal; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Masatoshi Kudo; Arndt Weinmann; Peter Galle; Ambreen Muhammed; Alessio Cortellini; Arndt Vogel; David J. Pinato
    JOURNAL OF HEPATOLOGY 77 S383 - S383 2022年07月 [査読有り]
  • Rohini Sharma; Anjana Pillai; Thomas Urban Marron; Petros Fessas; Anwaar Saeed; Tomi Jun; Sirish Dharmapuri; David Szafron; Abdul Rafeh Naqash; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Chieh-Ju Lee; Pei-Chang Lee; Anushi Bulumulle; Sonal Paul; Dominic Bettinger; Hannah Hildebrand; Mohammed Yehia; Tiziana Pressiani; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Masatoshi Kudo; Naoshi Nishida; Nicola Personeni; Lorenza Rimassa; David James Pinato
    Hepatology communications 6 7 1776 - 1785 2022年07月 [査読有り]
     
    The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HCC) has changed the treatment paradigm. There are emerging questions regarding the efficacy of subsequent anticancer therapies. The primary aim of this retrospective, multicenter study was to examine the types of anticancer treatment received after ICIs and to assess the impact on post-ICI survival. We established an international consortium of 11 tertiary-care referral centers located in the USA (n = 249), Europe (n = 74), and Asia (n = 97), and described patterns of care following ICI therapy. The impact of subsequent therapy on overall survival (OS) was estimated using the Kaplan-Meier method and presented with a 95% confidence interval (CI). A total of 420 patients were treated with ICIs for advanced HCC after one line of systemic therapy (n = 371, 88.8%): 31 (8.8%) had died, 152 (36.2%) received best supportive care (BSC) following ICIs, and 163 patients (38.8%) received subsequent anticancer therapy. Tyrosine kinase inhibitors (TKIs, n = 132, 80.9%), in particular sorafenib (n = 49, 30.0%), were the most common post-ICI therapy followed by external beam radiotherapy (n = 28, 17.2%), further immunotherapy (n = 21, 12.9%), locoregional therapy (n = 23, 14.1%), chemotherapy (n = 9, 5.5%), and surgery (n = 6, 3.6%). Receipt of post-ICI therapy was associated with longer median OS compared with those who had received BSC (12.1 vs. 3.3 months; hazard ratio [HR]: 0.4 (95% CI: 2.7-5.0). No difference in OS was noted in those patients who received TKI before ICIs compared with those who received ICIs followed by TKI. Conclusion: Post-ICI therapy is associated with OS in excess of 12 months, suggesting a role for therapeutic sequencing. OS from TKI therapy was similar to that reported in registration studies, suggesting preserved efficacy following ICIs.
  • Sirish Dharmapuri; Umut Ozbek; Anwaar Saeed; Mahvish Muzaffar; Suneetha Amara; Nicola Personeni; Tiziana Pressiani; Naoshi Nishida; Sonal Paul; Dominik Bettinger; Uqba Khan; Petros Fessas; Yi-Hsiang Huang; Ahmed Omar Kaseb; Anjana Pillai; Lorenza Rimassa; David J. James Pinato; Celina Ang
    JOURNAL OF CLINICAL ONCOLOGY 40 16 E16204 - E16204 2022年06月 [査読有り]
  • Brett Marinelli; Edward Kim; Antonio D'Alessio; Mario Cedillo; Ishan Sinha; Neha Debnath; Masatoshi Kudo; Naoshi Nishida; Anwaar Saeed; Hannah Hildebrand; Ahmed O Kaseb; Yehia I Abugabal; Anjana Pillai; Yi-Hsiang Huang; Uqba Khan; Mahvish Muzaffar; Abdul Rafeh Naqash; Rahul Patel; Aaron Fischman; Vivian Bishay; Dominik Bettinger; Max Sung; Celina Ang; Myron Schwartz; David J Pinato; Thomas Marron
    Journal for immunotherapy of cancer 10 6 2022年06月 [査読有り]
     
    BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a locoregional inducer of immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes. METHODS: From a retrospective multicenter dataset of 323 patients treated with ICI, we identified 31 patients who underwent >1 TACE 60 days before or concurrently, with nivolumab at a single center. We derived a propensity score-matched cohort of 104 patients based on Child-Pugh Score, portal vein thrombosis, extrahepatic metastasis and alpha fetoprotein (AFP) who received nivolumab monotherapy. We described overall survival (OS), progression-free survival (PFS), objective responses according to modified RECIST criteria and safety in the multimodal arm in comparison to monotherapy. RESULTS: Over a median follow-up of 9.3 (IQR 4.0-16.4) months, patients undergoing multimodal immunotherapy with TACE achieved a significantly longer median (95% CI) PFS of 8.8 (6.2-23.2) vs 3.7 (2.7-5.4) months (log-rank 0.15, p<0.01) in the monotherapy group. Multimodal immunotherapy with TACE demonstrated a numerically longer OS compared with ICI monotherapy with a median 35.1 (16.1-Not Evaluable) vs 16.6 (15.7-32.6) months (log-rank 0.41, p=0.12). In the multimodal treatment group, there were three (10%) grade 3 or higher adverse events (AEs) attributed to immunotherapy compared with seven (6.7%) in the matched ICI monotherapy arm. There were no AEs grade 3 or higher attributed to TACE in the multimodal treatment arm. At 3 months following each TACE in the multimodal arm, there was an overall objective response rate of 84%. There were no significant changes in liver functional reserve 1 month following each TACE. Four patients undergoing multimodal treatment were successfully bridged to transplant. CONCLUSIONS: TACE can be safely integrated with programmed cell death 1 blockade and may lead to a significant delay in tumor progression and disease downstaging in selected patients.
  • Hidekazu Tanaka; Ken Kamata; Rika Ishihara; Hisashi Handa; Yasuo Otsuka; Akihiro Yoshida; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Journal of gastroenterology and hepatology 37 5 841 - 846 2022年05月 
    BACKGROUND AND AIM: Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is useful for the diagnosis of lesions inside and outside the digestive tract. This study evaluated the value of artificial intelligence (AI) in the diagnosis of gastric submucosal tumors by CH-EUS. METHODS: This retrospective study included 53 patients with gastrointestinal stromal tumors (GISTs) and leiomyomas, all of whom underwent CH-EUS between June 2015 and February 2020. A novel technology, SiamMask, was used to track and trim the lesions in CH-EUS videos. CH-EUS was evaluated by AI using deep learning involving a residual neural network and leave-one-out cross-validation. The diagnostic accuracy of AI in discriminating between GISTs and leiomyomas was assessed and compared with that of blind reading by two expert endosonographers. RESULTS: Of the 53 patients, 42 had GISTs and 11 had leiomyomas. Mean tumor size was 26.4 mm. The consistency rate of the segment range of the tumor image extracted by SiamMask and marked by the endosonographer was 96% with a Dice coefficient. The sensitivity, specificity, and accuracy of AI in diagnosing GIST were 90.5%, 90.9%, and 90.6%, respectively, whereas those of blind reading were 90.5%, 81.8%, and 88.7%, respectively (P = 0.683). The κ coefficient between the two reviewers was 0.713. CONCLUSIONS: The diagnostic ability of CH-EUS results evaluated by AI to distinguish between GISTs and leiomyomas was comparable with that of blind reading by expert endosonographers.
  • Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Yoriaki Komeda; Akihiro Yoshida; Ah-Mee Park; Masako Sato; Akira Kawada; Hajime Nakano; Hiroshi Nakagawa; Masatoshi Kudo
    Scientific reports 12 1 6100 - 6100 2022年04月 [査読有り]
     
    Abstract Liver damage affects the prognosis of patients with erythropoietic protoporphyria (EPP). However, there is no radical cure for EPP patients with severe liver damage. This study aims to investigate the effectiveness of phlebotomy in patients with severe liver damage. We examined seven patients diagnosed with EPP and liver damage between 2010 and 2020. Of the 7 cases, phlebotomy was performed in 3 cases with severe hepatic disorder, and the improvement effect of hepatic disorder was observed in all cases. In addition, as an additional study, we also investigated the mechanism by which liver damage becomes more severe. Liver biopsy samples were stained with hematoxylin and eosin and immunohistochemistry was used to examine the expression of adenosine triphosphate-binding transporter G2 (ABCG2). Liver biopsies were performed in 3 of 7 patients with EPP. Of these three patients, ABCG2 expression was low in two patients, especially in the protoporphyrin (PP) deposition area. Two patients with reduced ABCG2 expression subsequently developed severe liver damage. However, the causal relationship between the decreased expression of ABCG2 and the exacerbation of liver damage has not been directly proved, and further investigation is required in the future. This study demonstrated the effectiveness of phlebotomy in EPP patients with severe liver damage.
  • Naoshi Nishida; Makoto Yamakawa; Tsuyoshi Shiina; Yoshito Mekada; Mutsumi Nishida; Naoya Sakamoto; Takashi Nishimura; Hiroko Iijima; Toshiko Hirai; Ken Takahashi; Masaya Sato; Ryosuke Tateishi; Masahiro Ogawa; Hideaki Mori; Masayuki Kitano; Hidenori Toyoda; Chikara Ogawa; Masatoshi Kudo
    J Gastroenterol 57 4 309 - 321 2022年04月 [査読有り]
     
    BACKGROUND: Ultrasonography (US) is widely used for the diagnosis of liver tumors. However, the accuracy of the diagnosis largely depends on the visual perception of humans. Hence, we aimed to construct artificial intelligence (AI) models for the diagnosis of liver tumors in US. METHODS: We constructed three AI models based on still B-mode images: model-1 using 24,675 images, model-2 using 57,145 images, and model-3 using 70,950 images. A convolutional neural network was used to train the US images. The four-class liver tumor discrimination by AI, namely, cysts, hemangiomas, hepatocellular carcinoma, and metastatic tumors, was examined. The accuracy of the AI diagnosis was evaluated using tenfold cross-validation. The diagnostic performances of the AI models and human experts were also compared using an independent test cohort of video images. RESULTS: The diagnostic accuracies of model-1, model-2, and model-3 in the four tumor types are 86.8%, 91.0%, and 91.1%, whereas those for malignant tumor are 91.3%, 94.3%, and 94.3%, respectively. In the independent comparison of the AIs and physicians, the percentages of correct diagnoses (accuracies) by the AIs are 80.0%, 81.8%, and 89.1% in model-1, model-2, and model-3, respectively. Meanwhile, the median percentages of correct diagnoses are 67.3% (range 63.6%-69.1%) and 47.3% (45.5%-47.3%) by human experts and non-experts, respectively. CONCLUSION:  The performance of the AI models surpassed that of human experts in the four-class discrimination and benign and malignant discrimination of liver tumors. Thus, the AI models can help prevent human errors in US diagnosis.
  • Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio
    JOURNAL OF CLINICAL ONCOLOGY 40 4 2022年02月 [査読有り]
  • Linda Wu; Umut Ozbek; Grace van Hyfte; Marlene Reincke; Anuhya Gampa; Yehia I. Abugabal; Naoshi Nishida; Brooke Wietharn; Suneetha Amara; Lorenz Balcar; Matthias Pinter; Arndt Vogel; Arndt Weinmann; Anwaar Saeed; Lorenza Rimassa; Abdul Rafeh Naqash; Mahvish Muzaffar; Yi-Hsiang Huang; David James Pinato; Celina Ang
    JOURNAL OF CLINICAL ONCOLOGY 40 4 2022年02月 [査読有り]
  • Yamagishi S; Doman K; Mekada Y; Nishida N; Kudo M
    Journal of Image and Graphics 10 1 50 - 55 2022年02月 [査読有り]
  • Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
    Cancers 14 2 2022年01月 [査読有り]
     
    Combination therapy with immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor inhibitors has been approved as a first-line treatment for unresectable hepatocellular carcinoma (HCC), indicating a critical role of ICIs in the treatment of HCC. However, 20% of patients do not respond effectively to ICIs; mutations in the activation of the Wnt/β-catenin pathway are known to contribute to primary resistance to ICIs. From this point of view, non-invasive detection of Wnt/β-catenin activation should be informative for the management of advanced HCC. Wnt/β-catenin mutations in HCC have a dual aspect, which results in two distinct tumor phenotypes. HCC with minimal vascular invasion, metastasis, and good prognosis is named the "Jekyll phenotype", while the poorly differentiated HCC subset with frequent vascular invasion and metastasis, cancer stem cell features, and high serum Alpha fetoprotein levels, is named the "Hyde phenotype". To differentiate these two HCC phenotypes, a combination of the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging and fluoro-2-deoxy-D-glucose-PET/CT may be useful. The former is applicable for the detection of the Jekyll phenotype, as nodules present higher enhancement on the hepatobiliary phase, while the latter is likely to be informative for the detection of the Hyde phenotype by showing an increased glucose uptake.
  • Naoshi Nishida
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 119 7 626 - 641 2022年07月 [査読有り][招待有り]
  • Tomoko Aoki; Naoshi Nishida; Masatoshi Kudo
    The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 70 1 53 - 81 2022年01月 [査読有り]
     
    Immune checkpoint inhibitors have become the mainstay of treatment for hepatocellular carcinoma (HCC). However, they are ineffective in some cases. Previous studies have reported that genetic alterations in oncogenic pathways such as Wnt/β-catenin are the important triggers in HCC for primary refractoriness. T-cell exhaustion has been reported in various tumors and is likely to play a prominent role in the emergence of HCC due to chronic inflammation and cirrhosis-associated immune dysfunction. Immunosuppressive cells including regulatory T-cells and tumor-associated macrophages infiltrating the tumor are associated with hyperprogressive disease in the early stages of immune checkpoint inhibitor treatment. In addition, stellate cells and tumor-associated fibroblasts create an abundant desmoplastic environment by producing extracellular matrix. This strongly contributes to epithelial to mesenchymal transition via signaling activities including transforming growth factor beta, Wnt/β-catenin, and Hippo pathway. The abundant desmoplastic environment has been demonstrated in pancreatic ductal adenocarcinoma and cholangiocarcinoma to suppress cytotoxic T-cell infiltration, PD-L1 expression, and neoantigen expression, resulting in a highly immunosuppressive niche. It is possible that a similar immunosuppressive environment is created in HCC with advanced fibrosis in the background liver. Although sufficient understanding is required for the establishment of immune therapies of HCC, further investigations are still required in this field.
  • Ambreen Muhammed; Claudia Angela Maria Fulgenzi; Sirish Dharmapuri; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas U Marron; Tomi Jun; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Musharraf Navaid; Abdul Rafeh Naqash; Anuhya Gampa; Umut Ozbek; Junk-Yi Lin; Ylenia Perone; Bruno Vincenzi; Marianna Silletta; Anjana Pillai; Yinghong Wang; Uqba Khan; Yi-Hsiang Huang; Dominik Bettinger; Yehia I Abugabal; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Luca Di Tommaso; Masatoshi Kudo; Arndt Vogel; Francesco A Mauri; Alessio Cortellini; Rohini Sharma; Antonio D'Alessio; Celina Ang; David J Pinato
    Cancers 14 1 2021年12月 [査読有り]
     
    Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutrophiles to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), and prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), and radiologic responses. In our 362 patients treated with immunotherapy, median OS and PFS were 9 and 3.5 months, respectively. Amongst tested inflammatory biomarkers, patients with NLR ≥ 5 had shorter OS (7.7 vs. 17.6 months, p < 0.0001), PFS (2.1 vs. 3.8 months, p = 0.025), and lower objective response rate (ORR) (12% vs. 22%, p = 0.034); similarly, patients with PLR ≥ 300 reported shorter OS (6.4 vs. 16.5 months, p < 0.0001) and PFS (1.8 vs. 3.7 months, p = 0.0006). NLR emerged as independent prognostic factors for OS in univariate and multivariate analysis (HR 1.95, 95%CI 1.45-2.64, p < 0.001; HR 1.73, 95%CI 1.23-2.42, p = 0.002) and PLR remained an independent prognostic factor for both OS and PFS in multivariate analysis (HR 1.60, 95%CI 1.6-2.40, p = 0.020; HR 1.99, 95%CI 1.11-3.49, p = 0.021). Systemic inflammation measured by NLR and PLR is an independent negative prognostic factor in HCC patients undergoing ICI therapy. Further studies are required to understand the biological mechanisms underlying this association and to investigate the predictive significance of circulating inflammatory biomarkers in HCC patients treated with ICIs.
  • Masatoshi Kudo; Robert Montal; Richard S Finn; Florian Castet; Kazuomi Ueshima; Naoshi Nishida; Philipp K Haber; Youyou Hu; Yasutaka Chiba; Myron Schwartz; Tim Meyer; Riccardo Lencioni; Josep M Llovet
    Clinical cancer research : an official journal of the American Association for Cancer Research 28 16 3443 - 3451 2021年12月 [査読有り]
     
    PURPOSE: Due to the increased number of sequential treatments used for advanced HCC, there is a need for surrogate endpoints of overall survival (OS). We analyze if objective response (OR) is an independent predictor and surrogate endpoint of OS. EXPERIMENTAL DESIGN: A systematic review of randomized clinical trials (RCTs) in advanced HCC published between 2010 and 2020 was conducted to explore OS surrogacy of OR by RECIST and mRECIST. In parallel, RCTs exploring the impact of OR on OS in a time-dependent multivariate analysis were integrated in a meta-analysis. RESULTS: Out of 65 RCTs identified in advanced HCC, we analyzed 34 studies including 14,056 patients that reported OS and OR by either RECIST (n=23), mRECIST (n=5) or both (n=6). When exploring surrogacy, the trial-level correlation between OR odds ratio and OS hazard ratio was R=0.677 by mRECIST and R=0.532 by RECIST. Meta-analysis of five RCT assessing predictors of survival in multivariate analysis found that patients with OR by mRECIST presented a pooled HR for OS of 0.44 (95% CI, 0.27-0.70, p<0.001) compared with non-responders. Responses to atezolizumab-bevacizumab had a greater impact on OS than tyrosine-kinase inhibitor responses. CONCLUSIONS: OR-mRECIST is an independent predictor of OS in patients with advanced HCC. Although correlation of OR-mRECIST and OS is better than with OR-RECIST, the level of surrogacy is modest. Thus, it can be used as endpoint in proof-of-concept phase II trials, but the data does not support its use as a primary endpoint of phase III investigations assessing systemic therapies.
  • Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Yasunori Minami; Yoriaki Komeda; Tomoko Aoki; Masahiro Takita; Masahiro Morita; Hirokazu Chishina; Akihiro Yoshida; Hiroshi Ida; Masatoshi Kudo
    Cells 10 11 2021年11月 [査読有り]
     
    The incidence of hepatocellular carcinoma (HCC) related to non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. We analyzed 16 surgically resected HCC cases in which the background liver was pathologically diagnosed as NAFLD. Specimens with Brunt classification grade 3 or higher were assigned as the fibrotic progression group (n = 8), and those with grade 1 or lower were classified as the non-fibrosis progression group (n = 8). Comprehensive mutational and methylome analysis was performed in cancerous and noncancerous tissues. The target gene mutation analysis with deep sequencing revealed that CTNNB1 and TP53 mutation was observed in 37.5% and TERT promoter mutation was detected in 50% of cancerous samples. Furthermore, somatic mutations in non-cancerous samples were less frequent, but were observed regardless of the progression of fibrosis. Similarly, on cluster analysis of methylome data, status for methylation events involving non-cancerous liver was similar regardless of the progression of fibrosis. It was found that, even in cases of non-progressive fibrosis, accumulation of gene mutations and abnormal methylation within non-cancerous areas were observed. Patients with NAFLD require a rigorous liver cancer surveillance due to the high risk of HCC emergence based on the accumulation of genetic and epigenetic abnormalities, even when fibrosis is not advanced.
  • Petros Fessas; Muntaha Naeem; Matthias Pinter; Thomas U Marron; David Szafron; Lorenz Balcar; Anwaar Saeed; Tomi Jun; Sirish Dharmapuri; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Musharraf Navaid; Pei-Chang Lee; Anushi Bulumulle; Bo Yu; Sonal Paul; Neil Nimkar; Dominik Bettinger; Hannah Hildebrand; Yehia I Abugabal; Tiziana Pressiani; Nicola Personeni; Naoshi Nishida; Masatoshi Kudo; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Anjana Pillai; Lorenza Rimassa; Abdul Rafeh Naqash; Elad Sharon; Alessio Cortellini; David J Pinato
    Liver cancer 10 6 583 - 592 2021年11月 [査読有り]
     
    Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indications; however, the effect of ATB is undefined in HCC. Methods: In a large international cohort of 450 ICI recipients from Europe, North America, and Asia, we categorized patients according to timing of ATB focusing on exposure within -30 to +30 days from ICI (early immunotherapy period [EIOP]). EIOP was evaluated in association with overall survival (OS), progression-free survival (PFS), and best radiologic response using RECIST 1.1 criteria. Results: Our study comprised mostly cirrhotic (329, 73.3%) males (355, 79.1%) with a Child-Turcotte Pugh class of A (332, 73.9%), receiving ICI after 1 therapy line (251, 55.9%) for HCC of Barcelona clinic liver cancer stage C (325, 72.4%). EIOP (n = 170, 37.9%) was independent of baseline clinicopathologic features of HCC and correlated with longer PFS (6.1 vs. 3.7 months, log-rank p = 0.0135). EIOP+ patients had similar OS, overall response, and disease control rates (DCRs) compared to EIOP. The effect of EIOP persisted in landmark time analyses and in multivariable models, confirming the independent predictive role of EIOP in influencing PFS following adjustment for covariates reflective of tumor burden, liver function, and ICI regimen administered. In patients receiving programmed cell death-1 receptor/ligand inhibitors monotherapy, EIOP was also associated with higher DCRs (61.4% vs. 50.9%, p = 0.0494). Conclusions: Unlike other oncological indications, ATB in the 30 days before or after ICI initiation is associated with improved benefit from immunotherapy, independent of disease and treatment-related features. Evaluation of the immune microbiologic determinants of response to ICI in HCC warrants further investigation.
  • Tomoko Aoki; Naoshi Nishida; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Akira Yamada; Keitaro Sofue; Masakatsu Tsurusaki; Masatoshi Kudo
    Liver cancer 10 6 615 - 628 2021年11月 [査読有り]
     
    Introduction: Immune checkpoint inhibitors (ICIs) are promising agents for the treatment of hepatocellular carcinoma (HCC). However, the establishment of noninvasive measure that could predict the response to ICIs is challenging. This study aimed to evaluate tumor responses to ICIs using the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI), which was shown to reflect Wnt/β-catenin activating mutation. Methods: A total of 68 intrahepatic HCC nodules from 18 patients with unresectable HCC and Child-Pugh class A liver function who received anti-programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) monotherapy were enrolled in this study. All patients had viable intrahepatic lesions evaluable using the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI within the 6 months prior to the treatment. The relative enhancement ratio was calculated, and the time to nodular progression (TTnP) defined as 20% or more increase in each nodule was compared between higher or hypo-enhancement HCC nodules. Then, the progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) were compared between patients with and without HCC nodules with higher enhancement on hepatobiliary phase images. Results: The median PFS was 2.7 (95% confidence interval [CI]: 1.4-4.0) months in patients with HCC nodules with higher enhancement (n = 8) and 5.8 (95% CI: 0.0-18.9) months in patients with hypointense HCC nodules (n = 10) (p = 0.007). The median TTnP of HCC nodules with higher enhancement (n = 23) was 1.97 (95% CI: 1.86-2.07) months and that of hypointense HCC nodules (n = 45) was not reached (p = 0.003). The ORR was 12.5% (1/8) versus 30.0% (3/10); the disease control rate was 37.5% (3/8) versus 70.0% (7/10), respectively, in patients with or without higher enhancement intrahepatic HCC nodules. Conclusion: The TTnP on HCC nodules with higher enhancement and the median PFS in patients who carried higher enhancement intrahepatic HCC nodules were significantly shorter than those in hypointense HCC nodules with anti-PD-1/PD-L1 monotherapy. The intensity of the nodule on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI is a promising imaging biomarker for predicting unfavorable response with anti-PD-1/PD-L1 monotherapy in patients with HCC.
  • 工藤 正俊; 青木 智子; 上嶋 一臣; 西田 直生志
    肝胆膵 83 3 475 - 483 (株)アークメディア 2021年09月
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    Liver cancer 10 5 535 - 538 2021年09月 [査読有り]
  • Naoshi Nishida
    Cancers 13 15 2021年07月 [査読有り]
     
    The tumor immune microenvironment, including hepatocellular carcinoma (HCC), is complex, consisting of crosstalk among tumor components such as the cancer cells, stromal cells and immune cells. It is conceivable that phenotypic changes in cancer cells by genetic and epigenetic alterations affect the cancer-stroma interaction and anti-cancer immunity through the expression of immune checkpoint molecules, growth factors, cytokines, chemokines and metabolites that may act on the immune system in tumors. Therefore, predicting the outcome of ICI therapy requires a thorough understanding of the oncogenic signaling pathways in cancer and how they affect tumor immune evasion. In this review, we have detailed how oncogenic signaling pathways can play a role in altering the condition of the cellular components of the tumor immune microenvironment such as tumor-associated macrophages, regulatory T cells and myeloid-derived suppressor cells. The RAS/MAPK, PI3K/Akt, Wnt/β-catenin and JAK/STAT pathways have all been implicated in anti-tumor immunity. We also found that factors that reflect the immune microenvironment of the tumor, including the status of oncogenic pathways such as the volume of tumor-infiltrating T cells, expression of the immune checkpoint protein PD-1 and its ligand PD-L1, and activation of the Wnt/β-catenin signaling pathway, predict a response to ICI therapy in HCC cases.
  • Yasunori Minami; Masahiro Morita; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    Ultrasound in medicine & biology 47 10 2930 - 2935 2021年07月 [査読有り]
     
    Developments in image fusion technology made it possible to visualize the ablative margin on ultrasound (US). The purpose of the present study was to assess the ablative area of radiofrequency ablation for hepatocellular carcinoma and compare it with the ablative hyperechoic zone with a non-enhanced area on contrast-enhanced US/contrast-enhanced computed tomography (CEUS/CECT) in the same cross-section. This retrospective study included 25 patients with 27 hepatocellular carcinomas. The long and short dimensions of the ablative hyperechoic zone were measured using B-mode US, and those of the non-enhanced area were assessed with CEUS/CECT on the same cross-section measured with B-mode US, using image fusion techniques. The technical effectiveness of ablation with an adequate ablative margin in a single session was determined in all patients. The long and short dimensions of the ablative hyperechoic zone ranged between 15.0 and 40.7 mm (mean: 27.3 ± 6.9 mm) and between 14.0 and 33.0 mm (mean: 23.3 ± 5.8 mm), respectively. R values for the long and short dimensions were 0.99 and 0.98, respectively, between B-mode US and CEUS, and 0.96 and 0.92, respectively, between B-mode US and CECT. The ablative hyperechoic zone may be regarded as a necrotic lesion after radiofrequency ablation.
  • Kota Takashima; Yoriaki Komeda; Toshiharu Sakurai; Sho Masaki; Tomoyuki Nagai; Shigenaga Matsui; Satoru Hagiwara; Mamoru Takenaka; Naoshi Nishida; Hiroshi Kashida; Konosuke Nakaji; Tomohiro Watanabe; Masatoshi Kudo
    World journal of gastrointestinal pharmacology and therapeutics 12 4 79 - 89 2021年07月 [査読有り]
     
    BACKGROUND: Preparation for colon capsule endoscopy (CCE) requires a large liquid laxative volume for capsule excretion, which compromises the procedure's tolerability. AIM: To assess the safety and utility of castor oil-boosted bowel preparation. METHODS: This prospective cohort study including 20 patients (age range, 16-80 years; six men and 14 women) suspected of having colorectal disease was conducted at Kindai University Hospital from September 2017 to August 2019. All patients underwent CCE because of the following inclusion criteria: previous incomplete colonoscopy in other facility (n = 20), history of abdominal surgery (n = 7), or organ abnormalities such as multiple diverticulum (n = 4) and adhesion after surgery (n = 6). The exclusion criteria were as follows: Dysphagia, history of allergic reactions to the drugs used in this study (magnesium citrate, polyethylene glycol, metoclopramide, and castor oil), possibility of pregnancy, possibility of bowel obstruction or stenosis based on symptoms, or scheduled magnetic resonance imaging within 2 wk after CCE. The primary outcome was the capsule excretion rate within the battery life, as evaluated by the total large bowel observation rate, large bowel transit time, and bowel creasing level using a five-grade scale in different colorectal segments. The secondary outcomes were complications, colorectal lesion detection rates, and patients' tolerability. RESULTS: The castor oil-based regimen was implemented in 17 patients. Three patients cancelled CCE because they could tolerate castor oil, but not liquid laxatives. The capsule excretion rate within the battery life was 88% (15/17). The mean large bowel transit time was 236 min. Approximately 70% of patients had satisfactory colon cleansing levels. CCE detected colon polyps (14/17, 82%) and colonic diverticulum (4/12, 33%). The sensitivity, specificity, and diagnostic accuracy rates for detecting colorectal polyps (size ≥ 6 mm) were 76.9%, 75.0%, and 76.4%, respectively. The sensitivity, specificity, and diagnostic accuracy rates for detection of diverticulum were 100% each. Twelve patients (71%) rated CCE as more than "good", confirming the new regimen's tolerability. No serious adverse events occurred during this study. CONCLUSION: The castor oil-based regimen could reduce bowel preparation dose and improve CCE tolerability.
  • Petros Fessas; Muntaha Naeem; Thomas U. Marron; David Szafron; Elad Sharon; Anwar Saeed; Tomi Jun; Sirish Dharmapuri; Abdul R. Naqash; Thoetchai Peeraphatdit; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Musharraf Navaid; ChiehJu Lee; Pei-Chang Lee; Anushi Bulumulle; Bo Yu; Sonal Paul; Neil Nimkar; Dominik Bettinger; Hannah Hildebrand; Yehia I. Abugabal; Tiziana Pressiani; Nicola Personeni; Naoshi Nishida; Masatoshi Kudo; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Anjana Pillai; Lorenza Rimassa; David J. Pinato
    CANCER RESEARCH 81 13 2021年07月 [査読有り]
  • Masahiro Morita; Naoshi Nishida; Kazuko Sakai; Tomoko Aoki; Hirokazu Chishina; Masahiro Takita; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Kazuto Nishio; Yukari Kobayashi; Kazuhiro Kakimi; Masatoshi Kudo
    Liver cancer 10 4 380 - 393 2021年07月 [査読有り]
     
    Introduction: Although immune checkpoint inhibitors (ICIs) have been considered as promising agents for the treatment of advanced hepatocellular carcinoma (HCC), previous clinical trials revealed that the response to anti-programmed cell death protein 1 (anti-PD-1) monotherapy was as low as 20%. Identifying subgroups that respond well to ICIs is clinically important. Here, we studied the prognostic factors for anti-PD-1 antibody treatment based on the molecular and immunological features of HCC. Methods: Patients who were administered anti-PD1 antibody for advanced HCC at Kindai University Hospital were included. Clinicopathological backgrounds and antitumor responses were examined in 34 cases where tumor tissues before treatment were available. Transcriptome analysis was performed using 40 HCC samples obtained from surgical resection, and immune status was compared between 20 HCCs with activating mutations in β-catenin and those without the mutations using transcriptome-based immunogram. Results: Univariate analysis showed that the disease control rate was significantly better in patients with α-fetoprotein < 400 ng/mL, negative for β-catenin/glutamate synthetase (GS) staining, high combined positive score (CPS) of programmed death-ligand 1 (PD-L1), and increased infiltration of CD8+ cells in tumor tissues. Among them, negative staining of β-catenin/GS, CPS of PD-L1 ≥ 1, and high degree of CD8+ tumor-infiltrating lymphocytes (TILs) were significantly associated with longer survival in both progression-free survival (PFS) and overall survival (OS). The combination of these factors well stratified the survival of the patients on anti-PD-1 antibody in both PFS and OS (p < 0.0001 and p = 0.0048 for PFS and OS, respectively). In addition, the immunogram revealed that tumor-carrying mutations in β-catenin showed downregulation of immune-related genes, especially in those related to priming and activation by dendritic cells, interferon-γ response, inhibitory molecules, and regulatory T cells. Discussion/Conclusion: The combined score including Wnt/β-catenin activation, CPS of PD-L1, and degree of CD8+ TILs in HCC is informative for predicting the response to ICI in HCC cases. Constitutive activation of β-catenin can induce an immune cold phenotype with downregulation of immune-related genes, and immunohistochemistry-based evaluation is beneficial for identifying the subgroup that shows a good response to ICI.
  • Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Akihiro Yoshida; Yasunori Minami; Masatoshi Kudo
    Hepatology research : the official journal of the Japan Society of Hepatology 51 7 767 - 774 2021年07月 [査読有り]
     
    AIM: Both entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are widely used to treat chronic hepatitis B (CHB) in Japan. However, it remains unclear whether the efficacy of TAF in decreasing the hepatitis B surface antigen (HBsAg) level, and its safety, are superior to those of ETV. This study aimed to report the long-term effects and safety of 96-week ETV and TAF treatment in patients with CHB. METHODS: A prospective comparative observational study was undertaken on the following two groups: patients with CHB who received continuous ETV (n = 32) and patients with CHB who were switched from ETV to TAF upon request (n = 48). The HBsAg, urinary β2-microglobulin (β2MG)/creatinine (Cr), urinary N-acetyl-β-D-glucosaminidase (NAG)/Cr, and serum alanine aminotransferase (ALT) levels, estimated glomerular filtration rate (eGFR), and bone mineral density (lumbar spine and femur) at 96 weeks were compared. RESULTS: The two groups did not significantly differ with respect to mean age, male / female patient ratio, or rate of hepatitis B e antigen-positive status. The mean changes in serum HBsAg level and eGFR at 96 weeks were not significantly different between the two groups. The β2MG/Cr and NAG/Cr levels at 96 weeks were similar between the two groups. Additionally, the bone mineral density of the lumbar spine and femur as well as the serum ALT did not significantly differ. CONCLUSIONS: When compared with patients who received continuous ETV, those who were introduced to TAF after ETV showed similar effects in terms of the decrease in HBsAg level and safety.
  • Akihiro Yoshida; Mamoru Takenaka; Kota Takashima; Hidekazu Tanaka; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Yoriaki Komeda; Naoshi Nishida; Masatoshi Kudo
    Journal of clinical medicine 10 13 2021年06月 [査読有り]
     
    Unsuccessful stent replacement in transpapillary biliary drainage with plastic stents (PSs) has a significant impact on patient prognosis; thus, a safe and reliable replacement method is required. We aimed to compare the snare-over-the-guidewire (SOG) method, wherein the PS lumen is used as an access route to the biliary tract and the PS is removed with a snare inserted via the inserted guidewire, with the conventional side-of-stent (SOS) method, wherein the biliary approach is performed from the side of the PS. This retrospective single-center study included 244 consecutive patients who underwent biliary PS replacement between January 2018 and July 2020. The procedural success rates were compared between the two methods. A predictive analysis of unsuccessful PS replacement was also performed. The procedural success rate in the SOG group was significantly higher than that in the SOS group (p = 0.026). In the proximal biliary stenosis lesion, the same trend was observed (p = 0.025). Multivariate analysis also showed that the SOS method (p = 0.0038), the presence of proximal biliary stenosis (p < 0.0001), and parapapillary diverticulum (p = 0.0007) were predictors of unsuccessful PS replacement. The SOG method may be useful for biliary PS replacement, especially in cases of proximal hilar bile duct stenosis.
  • Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio
    JOURNAL OF CLINICAL ONCOLOGY 39 15 2021年05月 [査読有り]
  • Satoru Hagiwara; Tomohiro Watanabe; Masatoshi Kudo; Kosuke Minaga; Yoriaki Komeda; Ken Kamata; Masatomo Kimura; Hidetoshi Hayashi; Kazuhiko Nakagawa; Kazuomi Ueshima; Yasunori Minami; Tomoko Aoki; Masahiro Takita; Masahiro Morita; Hirokazu Cishina; Hiroshi Ida; Ah-Mee Park; Naoshi Nishida
    Scientific reports 11 1 9242 - 9242 2021年04月 [査読有り]
     
    Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) are widely used to treat advanced metastatic cancers. Neutralisation of PD-1 or CTLA-4 by ICIs results in immune-related adverse events (irAEs). The clinicopathological features of twelve patients with hepatic irAEs were evaluated and compared to those of ten patients with autoimmune hepatitis (AIH) or graft-versus-host disease (GVHD). No significant difference was seen in serum levels of transaminases, whereas serum levels of IgG and anti-nuclear antibody were higher in patients with AIH than in those with GVHD or hepatic irAEs. Inflammation was limited to the liver lobes in patients with GVHD or hepatic irAEs, whereas patients with AIH exhibited both portal and lobular inflammation. Immunohistochemical analyses revealed a predominant infiltration of CD8+ T cells and defective accumulation of regulatory T cells (Tregs) expressing forkhead box p3 (FOXP3) in the lobular areas of patients with hepatic irAEs and GVHD. In contrast, periportal lesions of patients with AIH were characterised by an infiltration of CD4+ T cells, CD8+ T cells, CD20+ B cells, and FOXP3+ Tregs. Overall, the activation of CD8+ T cells in the absence of activation of Tregs potentially underlies the immunopathogenesis of hepatic irAEs.
  • Tomohiro Yamazaki; Mamoru Takenaka; Shunsuke Omoto; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Atsushi Nakai; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Yoriaki Komeda; Tomohiro Watanabe; Naoshi Nishida; Keiko Kamei; Ippei Matsumoto; Yoshifumi Takeyama; Takaaki Chikugo; Yasutaka Chiba; Masatoshi Kudo
    Journal of clinical medicine 10 9 2021年04月 [査読有り]
     
    This study aimed to investigate whether the incorporation of contrast-enhanced harmonic endoscopic ultrasound (CH-EUS) into the international consensus guidelines (ICG) for the management of intraductal papillary mucinous neoplasm (IPMN) could improve its malignancy diagnostic value. In this single-center retrospective study, 109 patients diagnosed with IPMN who underwent preoperative CH-EUS between March 2010 and December 2018 were enrolled. We analyzed each malignancy diagnostic value (sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV)) by replacing fundamental B-mode EUS with CH-EUS as the recommended test for patients with worrisome features (WF) (the CH-EUS incorporation ICG) and comparing the results to those obtained using the 2017 ICG. The malignancy diagnostic values as per the 2017 ICG were 78.9%, 42.3%, 60.0%, and 64.7% for Se, Sp, PPV, and NPV, respectively. The CH-EUS incorporation ICG plan improved the malignancy diagnostic values (Se 78.9%/Sp, 53.8%/PPV, 65.2%/NPV 70.0%). CH-EUS may be useful in determining the appropriate treatment strategies for IPMN.
  • Makoto Yamakawa; Tsuyoshi Shiina; Koichiro Tsugawa; Naoshi Nishida; Masatoshi Kudo
    INTERNATIONAL ULTRASONICS SYMPOSIUM (IEEE IUS 2021) 2021年 [査読有り]
     
    The quality and quantity of training data is vital for computer-aided diagnosis (CADx) based on deep learning. However, the biomedical industry lacks large database of ultrasound images. Therefore, The Japan Society of Ultrasonics in Medicine (JSUM) is currently constructing an ultrasound image database for liver tumors, breast tumors, and heart diseases. As of August 2021, the project has collected more than 140,000 ultrasound images and videos. This database contains ultrasound images, their corresponding labels, and annotation information. That is, the ultrasound image data contains information related to the size and location of the tumor. In this study, we developed a CADx to classify liver tumors and breast tumors by utilizing approximately 71,000 liver tumor and 14,000 breast tumor ultrasound images from the abovementioned database. We classified liver tumors into four classes: cysts, hemangiomas, hepatocellular carcinomas, and metastatic liver cancers. Similarly, we classified breast tumors into four classes: breast cancer, fibroadenoma, cysts, and others. We used a convolutional neural network based on VGG19 for these classifications, and evaluated the accuracy of each case unit by k-fold cross-validation, thereby achieving an accuracy of 91.1% and 85.2% for four-class classification of liver tumor and breast tumor, respectively. In addition, the accuracy, sensitivity, and specificity of the benign/malignant classification based on this result was, respectively, 94.3%, 82.8%, and 96.7% for liver tumors and 89.9% 92.6% and 86.6% for breast tumors. Furthermore, when compared with the results obtained in a previous study that utilized a small database, using a large database provided a higher accuracy for both liver and breast tumors.
  • Yoriaki Komeda; Hisashi Handa; Ryoma Matsui; Shohei Hatori; Riku Yamamoto; Toshiharu Sakurai; Mamoru Takenaka; Satoru Hagiwara; Naoshi Nishida; Hiroshi Kashida; Tomohiro Watanabe; Masatoshi Kudo
    PloS one 16 6 e0253585  2021年 [査読有り]
     
    Convolutional neural networks (CNNs) are widely used for artificial intelligence (AI)-based image classification. Residual network (ResNet) is a new technology that facilitates the accuracy of image classification by CNN-based AI. In this study, we developed a novel AI model combined with ResNet to diagnose colorectal polyps. In total, 127,610 images consisting of 62,510 images with adenomatous polyps, 30,443 with non-adenomatous hyperplastic polyps, and 34,657 with healthy colorectal normal mucosa were subjected to deep learning after annotation. Each validation process was performed using 12,761 stored images of colorectal polyps by a 10-fold cross validation. The efficacy of the ResNet system was evaluated by sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy. The sensitivity, specificity, PPV, NPV, and diagnostic accuracy for adenomatous polyps at WLIs were 98.8%, 94.3%, 90.5%, 87.4%, and 92.8%, respectively. Similar results were obtained for adenomatous polyps at narrow-band imagings (NBIs) and chromoendoscopy images (CEIs) (NBIs vs. CEIs: sensitivity, 94.9% vs. 98.2%; specificity, 93.9% vs. 85.8%; PPV, 92.5% vs. 81.7%; NPV, 93.5% vs. 99.9%; and overall accuracy, 91.5% vs. 90.1%). The ResNet model is a powerful tool that can be used for AI-based accurate diagnosis of colorectal polyps.
  • Tomi Jun; Umut Ozbek; Sirish Dharmapuri; Camille Hardy-Abeloos; Huili Zhu; Jung-Yi Lin; Nicola Personeni; Tiziana Pressiani; Naoshi Nishida; Pei-Chang Lee; Chieh-Ju Lee; Hannah Hildebrand; Neil Nimkar; Sonal Paul; Petros Fessas; Muntaha Naeem; Dominik Bettinger; Uqba Khan; Anwaar Saeed; Yi-Hsiang Huang; Masatoshi Kudo; Lorenza Rimassa; Thomas U Marron; David J Pinato; Celina Ang
    Therapeutic advances in medical oncology 13 17588359211010937 - 17588359211010937 2021年 [査読有り]
     
    Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs), are also known to disrupt the microbiome, but data on their association with ICI outcomes are conflicting. Methods: We conducted a retrospective, multicenter, international cohort study including 314 hepatocellular carcinoma (HCC) patients treated with ICIs from 2017 to 2019 to assess the association between PPI or H2RA exposure (up to 30 days before ICI) and overall survival. Secondary outcomes included overall response rate (ORR) and development of any treatment-related adverse events (AEs). Results: Baseline PPI/H2RA exposure was not associated with overall survival in univariable (HR 1.01, 95% CI 0.75-1.35) or multivariable analysis (HR 0.98, 95% CI 0.71-1.36). Baseline PPI/H2RA exposure was not associated with either ORR (OR 1.32, 95% CI 0.66-2.65) or AEs (OR 1.07, 95% CI 0.54-2.12) in multivariable analysis. Conclusions: Our results suggest that exposure to PPI/H2RA prior to ICIs does not adversely affect outcomes in HCC patients.
  • Naoshi Nishida
    Clinical and molecular hepatology 27 1 87 - 90 2021年01月 [査読有り][招待有り]
  • David M Hughes; Sarah Berhane; C A Emily de Groot; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Shinji Satomura; Naoshi Nishida; Masatoshi Kudo; Toru Kimura; Yukio Osaki; Ruwanthi Kolamunage-Dona; Ruben Amoros; Tom Bird; Marta Garcίa-Fiñana; Philip Johnson
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 19 1 162 - 170 2021年01月 [査読有り]
     
    BACKGROUND & AIMS: Ultrasound (US)-based screening has been recommended for patients with an increased risk of hepatocellular carcinoma (HCC). US analysis, however, is limited in patients who are obese or have small tumors. The addition of serum level of α-fetoprotein (AFP) measurements to US analysis can increase detection of HCC. We analyzed data from patients with chronic liver disease, collected over 15 years in an HCC surveillance program, to develop a model to assess risk of HCC. METHODS: We collected data from 3450 patients with chronic liver disease undergoing US surveillance in Japan from March 1998 through April 2014, and followed them up for a median of 8.83 years. We performed longitudinal discriminant analysis of serial AFP measurements (median number of observations/patient, 56; approximately every 3 months) to develop a model to determine the risk of HCC. We validated the model using data from 2 cohorts of patients with chronic liver disease in Japan (404 and 2754 patients) and 1 cohort in Scotland (1596 patients). RESULTS: HCC was detected in 413 patients (median tumor diameter, 1.8 cm), during a median follow-up time of 6.60 years. In the development data set, the model identified patients who developed HCC with an area under the curve of 0.78; it correctly identified 74.3% of patients who did develop HCC, and 72.9% of patients who did not. Overall, 73.1% of patients were classified correctly. The model could be used to assign patients to a high-risk group (27.5 HCCs/1000 patient-years) vs a low-risk group (4.9 HCCs/1000 patient-years). A similar performance was observed when the model was used to assess patients with cirrhosis. Analysis of the validation cohorts produced similar results. CONCLUSIONS: We developed and validated a model to identify patients with chronic liver disease who are at risk for HCC based on change in serum AFP level over time. The model could be used to assign patients to high-risk vs low-risk groups, and might be used to select patients for surveillance.
  • 西田 直生志; 工藤 正俊
    肝臓 61 12 623 - 636 (一社)日本肝臓学会 2020年12月 
    近年、社会機能の種々の場面で人工知能(artificial intelligence:AI)を導入する試みがなされている。医療においても、医療従事者の負担軽減や見逃し防止を目的としてAI診断の導入が始まっており、内視鏡検査のAI診断補助、胸部レントゲンの病変スクリーニング、病理検査のAI遠隔診断など、既に実用化、あるいは実用化が近いものが出てきている。加えて、病変検出や診断のみならず、治療法選択などの疾患マネージメントを視野に入れた報告もなされている。画像診断支援はAIに親和性の高い分野であり、本邦でも重点的にAI開発がなされるべき分野として、日本医療研究開発機構の臨床研究等ICT基盤構築・人工知能実装研究事業の枠組みでの大規模なデータベース構築とAI開発が進んでいる。一方、超音波分野のAI開発に関しては、画像データの取得に際して術者依存性が高いこと、機器ベンダーや機種が多く、さらに画質パラメータが複数あるなど、画像の多様性が高く、データベース構築やAI開発に際してのハードルとなっている。本稿では、医療分野での画像診断領域AIの現状を概説し、特に超音波AIにフォーカスして、その特有の問題点を取り上げ、近未来の超音波AI支援システム展開において取り組むべき課題を述べる。(著者抄録)
  • Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    Hepatobiliary surgery and nutrition 9 6 777 - 779 2020年12月 [査読有り][招待有り]
  • 青木 智子; 南 康範; 鶴崎 正勝; 盛田 真弘; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 松井 繁長; 西田 直生志; 樫田 博史; 工藤 正俊
    日本門脈圧亢進症学会雑誌 26 4 244 - 248 (一社)日本門脈圧亢進症学会 2020年11月 
    デンバーシャント術は難治性腹水症に対して行われる腹腔-静脈シャント術である。2014〜2018年にデンバーシャント術を施行した7例を対象とし、非代償性肝硬変に伴うトルバプタン不応腹水への有効性と安全性を検討した。奏効の内訳は、(1)腹満感など自覚症状の改善:57%、(2)体重・画像など他覚的所見の改善:71%、(3)治療内容の改善:腹水穿刺の中止29%、利尿薬減量71%であった。総合評価からデンバーシャント術の奏効率は86%であった。術後合併症は、播種性血管内凝固症候群(n=3)、創部し開(n=1)、特発性細菌性腹膜炎(n=1)、肝性脳症(n=1)、右心不全(n=1)を認め、保存的治療で軽快した。腹水コントロール不良で基礎疾患の病勢進行により術後30日目に永眠した症例が1例いた。デンバーシャント術は非代償性肝硬変症に伴うトルバプタン不応の難治性腹水に対して施行可能で有効な治療法と考える。(著者抄録)
  • Tomoko Aoki; Masatoshi Kudo; Kazuomi Ueshima; Masahiro Morita; Hirokazu Chishina; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Masakatsu Tsurusaki; Naoshi Nishida
    Cancers 12 10 2020年10月 
    Although programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) blockade is effective in a subset of patients with hepatocellular carcinoma (HCC), its therapeutic response is still unsatisfactory. Alternatively, the potential impact of the lenvatinib in patients who showed tumor progression on PD-1/PD-L1 blockade is unknown. In this work, we evaluated the safety and efficacy of lenvatinib administration after PD-1/PD-L1 checkpoint blockade. The outcome and safety of lenvatinib administered after PD-1/PD-L1 blockade failure was analyzed retrospectively in 36 patients. Tumor growth was assessed every 4-8 weeks using modified Response Evaluation Criteria in Solid Tumors. The mean relative dose intensity of lenvatinib was 87.6% and 77.8% in patients receiving a starting dose of 8 (interquartile range (IQR), 77.5-100.0) mg and 12 (IQR, 64.4-100.0) mg, respectively. Since lenvatinib therapy initiation, the median progression-free survival was 10 months (95% confidence interval (CI): 8.3-11.8) and the median overall survival was 15.8 months (95% CI: 8.5-23.2). The objective response rate was 55.6%, and the disease control rate was 86.1%. No particular safety concerns were observed. Lenvatinib demonstrated considerable antitumor effects with acceptable safety in patients with progressive and unresectable HCC when administered right after PD-1/PD-L1 blockade failure.
  • Naoshi Nishida
    Clinical and molecular hepatology 26 4 480 - 483 2020年10月 [査読有り][招待有り]
  • Naoshi Nishida
    Hepatobiliary surgery and nutrition 9 5 640 - 643 2020年10月 [査読有り][招待有り]
  • Philip Johnson; Sarah Berhane; Emily de Groot; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Shinji Satomura; Yukio Osaki; Masatoshi Kudo; Naoshi Nishida; Toru Kimura; Ruwanthi Kolamunnage-Dona; Thomas Bird; Ruben Amoros; Marta Garcia-Finana; David M. Hughes
    JOURNAL OF HEPATOLOGY 73 S387 - S388 2020年08月
  • Naoshi Nishida; Kazuko Sakai; Masahiro Morita; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yoriaki Komeda; Mamoru Takenaka; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Kazuto Nishio; Masatoshi Kudo
    Liver cancer 9 4 426 - 439 2020年08月 [査読有り]
     
    Background and Aim: Immune checkpoint inhibitors are promising agents for the treatment of hepatocellular carcinomas (HCC) refractory to conventional therapies. To enhance the efficacy of this treatment, immunological and molecular characteristics of HCC with programmed cell death ligand 1 (PD-L1) should be explored. Methods: Clinical backgrounds, PD-L1 expression, and the amount of CD8+ tumor-infiltrating mononuclear cells (TIMCs) were analyzed in 154 HCCs. The expression of 3 stem cell markers and co-inhibitory receptors on tumor cells and TIMCs, respectively, were examined by immunohistochemical analysis. Somatic mutations in the 409 cancer-associated genes and TERT promoter were determined; HCCs were classified based on the presence of gene alterations affecting the 8 oncogenic pathways. The results were validated using the dataset from the Cancer Genome Atlas. Results: The expression of PD-L1 in the HCCs was positively correlated with progressive tumor features, the presence of cytokeratin 19 (CK19), Sal-like protein 4 (SALL4), and the mutations of genes involving the phosphatidyl inositol 3-kinase (PI3K)-Akt pathway. Although CD8+ cells were densely infiltrated in PD-L1-positive tumors, these TIMCs frequently expressed multiple co-inhibitory receptors. However, a subset of PD-L1-positive tumors characterized by activating mutations of the PI3K-Akt pathway showed a low degree of TIMCs. Conversely, PD-L1-negative HCCs were associated with mutations in the β-catenin pathway and a small number of TIMCs, although the expression of co-inhibitory receptors was rare. Conclusions: PD-L1-positive HCCs frequently showed an inflamed phenotype with stem cell features; a subset of PD-L1-positive HCCs with mutations in the PI3K-Akt pathway showed a non-inflamed phenotype. In HCCs with dense infiltration of TIMCs, CD8+ cells expressed multiple co-inhibitory receptors, suggesting T cell exhaustion. On the other hand, PD-L1-negative HCCs showed mutations leading to β-catenin activation and exhibited a non-inflamed background. These characteristics should be taken into consideration for developing novel combination therapies using immune checkpoint inhibitors.
  • Naoko Tsuji; Yasuko Umehara; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Gastroenterology report 8 4 293 - 298 2020年08月 [査読有り]
     
    Background: There have been few studies in the English literature regarding verrucous gastritis (VG). The present study investigated the clinical and endoscopic features of verrucous antral gastritis, especially focusing on Helicobacter pylori infection, nutrition, and gastric atrophy. Methods: We performed a retrospective study of patients who underwent routine endoscopy with indigo carmine chromoendoscopy and a comparative study was conducted between VG-positive and VG-negative groups. VG was subdivided into classical and numerous types based on the number and distribution of verrucous lesions. Demographic, clinical, and endoscopic data including body mass index (BMI), serum albumin and cholesterol, gastric atrophy, reflux oesophagitis, Barrett's oesophagus, and H. pylori status were collected. Univariate and multivariable analyses were performed to identify factors associated with VG. Results: We analysed the data of 621 patients undergoing routine endoscopy and found that VG (n = 352) was significantly associated with increased BMI (1.12 [1.05-1.18], P < 0.01), reflux esophagitis (1.96 [1.10-3.28], P < 0.01), and H. pylori negativity with or without a history of eradication (9.94 [6.00-16.47] and 6.12 [3.51-10.68], P < 0.001, respectively). Numerous-type (n = 163) VG was associated with both closed- and open-type gastric atrophy (9.9 [4.04-21.37] and 8.10 [3.41-19.24], P < 0.001, respectively). There were no statistical differences between groups regarding age, sex, total cholesterol, albumin, and bile-colored gastric juice. Conclusions: Verrucous antral gastritis was related to increased BMI, reflux esophagitis, and H. pylori negativity. Numerous-type verrucous lesions were associated with gastric atrophy. These indicate that VG may be a physiological phenomenon due to high gastric acidity, mechanical overload, and vulnerability of background mucosa.
  • Naoshi Nishida; Masatoshi Kudo
    Cancers 12 5 2020年05月 [査読有り]
     
    Immunotherapies are promising approaches for treating hepatocellular carcinomas (HCCs) refractory to conventional therapies. However, a recent clinical trial of immune checkpoint inhibitors (ICIs) revealed that anti-tumor responses to ICIs are not satisfactory in HCC cases. Therefore, it is critical to identify molecular markers to predict outcome and develop novel combination therapies that enhance the efficacy of ICIs. Recently, several attempts have been made to classify HCC based on genome, epigenome, and transcriptome analyses. These molecular classifications are characterized by unique clinical and histological features of HCC, as well immune phenotype. For example, HCCs exhibiting gene expression patterns with proliferation signals and stem cell markers are associated with the enrichment of immune infiltrates in tumors, suggesting immune-proficient characteristics for this type of HCC. However, the presence of activating mutations in β-catenin represents a lack of immune infiltrates and refractoriness to ICIs. Although the precise mechanism that links the immunological phenotype with molecular features remains controversial, it is conceivable that alterations of oncogenic cellular signaling in cancer may lead to the expression of immune-regulatory molecules and result in the acquisition of specific immunological microenvironments for each case of HCC. Therefore, these molecular and immune characteristics should be considered for the management of HCC using immunotherapy.
  • Makoto Yamakawa, Tsuyoshi Shiina, Naoshi Nishida, Masatoshi Kudo
    Japanese Journal of Applied Phys 59 SKKE09  2020年04月 [査読有り]
     
    In recent years there have been many studies on computer-aided diagnosis (CAD) using convolutional neural networks (CNNs). For CAD of a tumor, data are generally obtained by cropping a region of interest (ROI), including a tumor, in an image. However, ultrasonic diagnosis also uses information from around a tumor. Therefore, in CAD using ultrasound images, diagnostic accuracy could be improved by using a ROI that includes the periphery of the tumor. In this study, we examined how much of the surrounding area should be included in a ROI for a CNN using ultrasound images of liver tumors. We used the ratio between the maximum diameter of the tumor and the ROI size as the index for ROI cropping. Our results show that the diagnostic accuracy was maximized when this index is 0.6. Therefore, optimal ROI cropping is important in CNNs for ultrasonic diagnosis. (C) 2020 The Japan Society of Applied Physics
  • Mamoru Takenaka; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Yoriaki Komeda; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yasutaka Chiba; Chang-Il Kwon; Seok Jeong; Tae Hoon Lee; Masatoshi Kudo
    Surgical endoscopy 34 3 1432 - 1441 2020年03月 [査読有り]
     
    BACKGROUND: Balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography (BE-ERCP) has been reported to be effective for patients with surgically altered gastrointestinal anatomy. However, selective biliary cannulation remains difficult in BE-ERCP. We examined the usefulness of a modified double-guidewire technique using an uneven double lumen cannula (the uneven method) for BE-ERCP in patients with surgically altered gastrointestinal anatomy. METHODS: To clarify the usefulness of the uneven method for selective biliary cannulation in BE-ERCP in comparison to the pancreatic guidewire (PGW) method, 40 patients with surgically altered gastrointestinal anatomy who underwent BE-ERCP with successful placement of a guidewire in the pancreatic duct were evaluated. The uneven method was used in 18 cases (uneven group) and the PGW method was used in the remaining 22 cases (PGW group). RESULTS: The technical success rate of biliary cannulation was higher in the uneven group than in the PGW group (83.3 vs. 59.0%; P = 0.165). In addition, the time to biliary cannulation were significantly shorter in the uneven group than in the PGW group (6 vs. 18 min; P = 0.004; respectively). In the PGW group, post-ERCP pancreatitis (PEP) occurred in 3 of 22 cases (13.6%). No adverse events, including PEP, occurred in the uneven group. CONCLUSIONS: The uneven method may be a useful option of selective biliary cannulation in BE-ERCP for the patients with surgically altered gastrointestinal anatomy.
  • Takahiro Nakashima; Issei Tsutsumi; Hiroki Takami; Keisuke Doman; Yoshito Mekada; Naoshi Nishida; Masatoshi Kudo
    INTERNATIONAL WORKSHOP ON ADVANCED IMAGING TECHNOLOGY (IWAIT) 2020 11515 2020年 
    The ultrasound examination is a difficult operation because a doctor not only operates an ultrasound scanner but also interprets images in rea time, which may increase the risk of overlooking tumors. To prevent that, we study a liver tumor detection method using convolutional neural networks toward realizing computer-assisted diagnosis systems. In this paper, we propose a liver tumor detection method within a false positive reduction framework. The proposed method uses YOLOv3 [1] in order to find tumor candidate regions in real-time, and also uses VGG16 [2] to reduce false positives. The proposed method using YOLOv3 [1] and VGG16 [2] achieved an F-measure of 0.837, which showed the effectiveness of the proposed method for liver tumor detection. Future work includes the collection of training data from more hospitals and their effective use for improving the detection accuracy.
  • Naoshi Nishida; Masatoshi Kudo
    Frontiers in oncology 10 594580 - 594580 2020年 [査読有り][招待有り]
     
    Recent advancement in artificial intelligence (AI) facilitate the development of AI-powered medical imaging including ultrasonography (US). However, overlooking or misdiagnosis of malignant lesions may result in serious consequences; the introduction of AI to the imaging modalities may be an ideal solution to prevent human error. For the development of AI for medical imaging, it is necessary to understand the characteristics of modalities on the context of task setting, required data sets, suitable AI algorism, and expected performance with clinical impact. Regarding the AI-aided US diagnosis, several attempts have been made to construct an image database and develop an AI-aided diagnosis system in the field of oncology. Regarding the diagnosis of liver tumors using US images, 4- or 5-class classifications, including the discrimination of hepatocellular carcinoma (HCC), metastatic tumors, hemangiomas, liver cysts, and focal nodular hyperplasia, have been reported using AI. Combination of radiomic approach with AI is also becoming a powerful tool for predicting the outcome in patients with HCC after treatment, indicating the potential of AI for applying personalized medical care. However, US images show high heterogeneity because of differences in conditions during the examination, and a variety of imaging parameters may affect the quality of images; such conditions may hamper the development of US-based AI. In this review, we summarized the development of AI in medical images with challenges to task setting, data curation, and focus on the application of AI for the managements of liver tumor, especially for US diagnosis.
  • Masahiro Morita; Chikara Ogawa; Akina Omura; Teruyo Noda; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Hiroshi Seno; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    Internal medicine (Tokyo, Japan) 59 4 471 - 477 2020年 [査読有り]
     
    Objective The usefulness of contrast-enhanced ultrasonography (CEUS) for making decisions in the treatment of liver abscess is unknown. Methods We evaluated the internal blood flow in the arterial-predominant phase by CEUS using Sonazoid® in 21 patients. The stain area rate was evaluated in maximum parting plane of abscess in CEUS. Patients were divided into two groups: the vascular phase enhancement (VE) group, in which ≥50% of the abscess cavity was enhanced (12 patients), and the vascular phase non-enhancement (VNE) group, in which <50% of the abscess cavity was enhanced (9 patients). The rate of patients who were cured by conservative treatment alone was examined in both groups. The defect rate of all liver abscesses in the post-vascular phase was also evaluated. Results In the VE group, improvement by conservative treatment alone was obtained in 11 out of 12 patients (91.7%), while in the VNE group, improvement by conservative treatment alone was obtained in only 1 out of 9 patients (11.1%), a significant difference (p<0.001). In the VE group, one patient did not improve with conservative treatment alone because the abscess ruptured near the liver surface. In the VE group, the abscess size was smaller than in the VNE group. By examining the defect rate in the post-vascular phase, it was found that 16 out of 21 patients (76.2%) showed 71% or more defects. Conclusion The enhancement rate in the arterial-predominant phase of CEUS was considered useful for determining the treatment approach for liver abscess.
  • Minami Y; Minami T; Takita M; Hagiwara S; Ida H; Ueshima K; Nishida N; Kudo M
    Hepatology research : the official journal of the Japan Society of Hepatology 50 1 67 - 74 2020年01月 [査読有り]
     
    AIM: To retrospectively investigate the potential benefit of ultrasound-ultrasound (US-US) overlay fusion guidance for local controllability of radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC). METHODS: Patients (n = 101) with 121 HCCs (mean ± SD, 1.8 ± 0.7 cm) who underwent RFA guided by US-US overlay fusion were included in the retrospective study. By overlaying pre/postoperative US, the tumor image could be projected onto the ablative hyperechoic zone. The ablative margin could thereby be evaluated three-dimensionally during the RFA procedure. As a control group, all 325 patients with 453 HCCs who underwent conventional RFA during the same study period were selected. RESULTS: The total number of RF needle insertions per tumor for ablation was significantly more in the US overlay fusion group (mean 1.9 vs. 1.2; P < 0.01). The technical success rates of ablation after a single session were 100% (101/101) and 96.6% (314/325) for the US overlay fusion group and the control group, respectively. For early assessment of RFA response, 5-mm safety margins were achieved in 89.3% (108/121) and 47.0% (213/453) of nodules in the US overlay fusion group and the control group, respectively (P < 0.01). During the follow-up period (median 19 months), the 2-year local tumor progression rates were 0.8% (1/121) and 6.0% (27/453) in the US overlay fusion group and the control group, respectively (P = 0.022, log-rank test). CONCLUSIONS: US-US overlay fusion guidance can be highly effective for safety margin achievement in RFA for HCC, providing a lower risk of local tumor progression.
  • Kudo Masatoshi; Ueshima Kazuomi; Chan Stephen L; Minami Tomohiro; Chishina Hirokazu; Aoki Tomoko; Takita Masahiro; Hagiwara Satoru; Minami Yasunori; Ida Hiroshi; Takenaka Mamoru; Sakurai Toshiharu; Watanabe Tomohiro; Morita Masahiro; Ogawa Chikara; Wada Yoshiyuki; Ikeda Masafumi; Ishii Hiroshi; Izumi Namiki; Nishida Naoshi
    HEPATOLOGY 70 133A - 134A 2019年10月 [査読有り]
  • Hagiwara S; Nishida N; Ida H; Ueshima K; Minami Y; Takita M; Komeda Y; Kudo M
    Journal of medical virology 91 10 1804 - 1810 2019年10月 [査読有り]
     
    Tenofovir alafenamide (TAF) is a newly developed prodrug of tenofovir (TFV). We divided 48 chronic hepatitis B patients who had taken entecavir (ETV) for ≥2 years into two groups: the ETV continuation (n = 24) and the TAF switching (n = 24) groups, and compared the antiviral effects and safety until 48 weeks after the start of the study. There were no significant differences in the alterations in the serum levels of HBs antigen (HBsAg) level between the ETV continuation and the TAF switching groups at 24 or 48 weeks. We also examined the effect of baseline HBsAg level on the decrease of HBsAg during the treatment; in the TAF switching group, the decrease of HBsAg level at 48 weeks was more significant in patients with low baseline HBsAg (<800 IU/mL) than those with high baseline HBsAg ( >800 IU/mL) (change of HBsAg; - 0.029 vs - 0.132 for high and low baseline HBsAg, respectively, P = .007). Also, the effect on renal function was found to be comparable between the TAF switch group and the ETV continuation group. In this study, switching from ETV to TAF may represent higher efficacy for a decrease of HBsAg than a continuation of ETV among the patients with low baseline HBsAg level.
  • Tanaka H; Kamata K; Takenaka M; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Minaga K; Yamao K; Sakurai T; Watanabe T; Nishida N; Chiba Y; Kitano M; Kudo M
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 51 8 1130 - 1134 2019年08月 [査読有り]
     
    BACKGROUND AND AIMS: Contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) is used for the diagnosis of pancreatic cancer (PC). Here, we examined the usefulness of CH-EUS for evaluating therapeutic responses in PC. METHODS: The study included 23 patients with PC who received chemotherapy. Patients underwent contrast-enhanced computed tomography (CE-CT) and CH-EUS before chemotherapy and at the time of evaluation of the therapeutic response. Patients with a ≧50% reduction in serum carbohydrate antigen 19-9 levels after chemotherapy were defined as "super responders". The incidence of an avascular area in the tumor on CH-EUS after chemotherapy was compared between "super responders" and non-super responders. RESULTS: Nine patients were included in the "super responders" group.Tumor reduction rates did not differ significantly between CE-CT and CH-EUS in the "super responders". The appearance of an avascular area was detected in 7 of 9 super responders (77.8%) and in 4 of 14 non-super responders (28.6%), and the difference was significant (P = 0.036). The mean survival time of patients with an avascular area after chemotherapy was longer than that of without an avascular area. CONCLUSIONS: Detection of avascular areas by CH-EUS after chemotherapy may predict long-term survival of patients with PC.
  • Kudo M; Ueshima K; Chan S; Minami T; Chishina H; Aoki T; Takita M; Hagiwara S; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Wada Y; Ikeda M; Ishii H; Izumi N; Nishida N
    Cancers 11 8 2019年07月 [査読有り]
     
    Although transcatheter arterial chemoembolization (TACE) is the standard of care for intermediate-stage hepatocellular carcinoma (HCC), this is a largely heterogeneous disease that includes a subgroup of patients who do not benefit from TACE. The treatment strategy for this subgroup of patients currently remains an unmet need in clinical practice. Here, we performed a proof-of-concept study that lenvatinib may be a more favorable treatment option over TACE as an initial treatment in intermediate-stage HCC patients with large or multinodular tumours exceeding the up-to-seven criteria. This proof-of-concept study included 642 consecutive patients with HCC initially treated with lenvatinib or conventional TACE (cTACE) between January 2006 and December 2018. Of these patients, 176 who received lenvatinib or cTACE as an initial treatment and met the eligibility criteria (unresectable, beyond the up-to-seven criteria, no prior TACE/systemic therapy, no vascular invasion, no extrahepatic spread and Child-Pugh A liver function) were selected for the study. Propensity score matching was used to adjust for patient demographics. After propensity-score matching, the outcome of 30 patients prospectively treated with lenvatinib (14 in clinical trials, one in an early access program and 15 in real world settings) and 60 patients treated with cTACE as the initial treatment was compared. The change of albumin-bilirubin (ALBI) score from baseline to the end of treatment were -2.61 to -2.61 for 30 patients in the lenvatinib group (p = 0.254) and -2.66 to -2.09 in the cTACE group (p < 0.01), respectively. The lenvatinib group showed a significantly higher objective response rate (73.3% vs. 33.3%; p < 0.001) and significantly longer median progression-free survival than the cTACE group (16.0 vs. 3.0 months; p < 0.001). Overall survival was significantly longer in the lenvatinib group than in the cTACE group (37.9 vs. 21.3 months; hazard ratio: 0.48, p < 0.01). In patients with large or multinodular intermediate-stage HCC exceeding the up-to-seven criteria with Child-Pugh A liver function, who usually do not benefit from TACE, lenvatinib provides a more favorable outcome than TACE.
  • Yamao K; Takenaka M; Yoshikawa T; Ishikawa R; Okamoto A; Yamazaki T; Nakai A; Omoto S; Kamata K; Minaga K; Hagiwara S; Sakurai T; Nishida N; Chiba Y; Watanabe T; Kudo M
    Internal medicine (Tokyo, Japan) 58 14 1993 - 2002 2019年07月 [査読有り]
     
    Objective Although modified FOLFIRINOX (mFOLFIRINOX, mFFX) is widely used for patients with advanced pancreatic ductal adenocarcinoma (PDAC), maintenance of the standard dose intensity is often difficult due to the high incidence of neutropenic events. Pegylated granulocyte colony-stimulating factor (G-CSF) (Peg G) is a long-lasting G-CSF agent that is applicable for prophylaxis against neutropenic complications. The aim of this study was to assess the clinical safety and efficacy of mFFX combined with secondary prophylaxis using Peg G in advanced PDAC patients. Methods Advanced PDAC patients who had received more than two cycles of mFFX were analyzed. The clinical safety and efficacy were compared between patients in the Peg G group and those in the non-Peg G group in a retrospective manner. Results Among 45 patients treated with mFFX, 28 exhibited grade 3-4 neutropenia or febrile neutropenia. Among these 28 patients, 4 who received only 1 or 2 mFFX cycles were excluded from this study. Finally, 11 patients in the Peg G group and 13 in the non-Peg G group were enrolled. The combination therapy with Peg G and mFFX markedly prolonged the progression-free survival compared with the non-Peg G group, and its effects were associated with a reduced incidence of neutropenic events as well as lower rates of dosage reduction, delayed chemotherapy due to neutropenic events and altered blood cell counts after chemotherapy. Conclusion The scheduled administration of secondary prophylactic Peg G prolonged the progression-free survival in patients treated with mFFX. The combination therapy of Peg G and mFFX may be recommended in patients who exhibit grade 3-4 neutropenic events after prior mFFX cycles.
  • Kono M; Sakurai T; Okamoto K; Nagai T; Komeda Y; Kashida H; Minaga K; Kamata K; Takenaka M; Hagiwara S; Watanabe T; Nishida N; Enoki E; Inoue H; Matsumura I; Kudo M
    Internal medicine (Tokyo, Japan) 58 14 2029 - 2033 2019年07月 [査読有り]
     
    Autoimmune diseases including inflammatory bowel disease (IBD) occur in association with myelodysplastic syndrome (MDS). MDS-associated IBD frequently demonstrates a complicated course. We herein report the first case with MDS-associated IBD that was successfully treated with ustekinumab (UST), an anti-interleukin (IL) 12/23p40 monoclonal antibody. A 63-year-old man with a 7-year history of MDS was referred for examination of diarrhea, abdominal pain and fever. A blood examination revealed a marked elevation of C-reactive protein. Colonoscopy showed multiple ulcers in the terminal ileum. He was resistant to anti-tumor necrosis factor (TNF)-α antibody and azacitidine. Subsequently, UST treatment reduced colonic IL-17 and IL-6 expression and the patient currently maintains a state of remission.
  • Ueshima K; Nishida N; Hagiwara S; Aoki T; Minami T; Chishina H; Takita M; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Hiraoka A; Johnson P; Kudo M
    Cancers 11 7 2019年07月 [査読有り]
     
    BACKGROUND: This study investigated the impact of baseline liver function according to the Child-Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of patients with unresectable hepatocellular carcinoma treated with lenvatinib. METHODS: A total of 82 lenvatinib treated patients were included. The correlations of baseline liver function according to the Child-Pugh score and ALBI grade with treatment outcomes, including objective response rate per mRECIST (modified Response Evaluation Criteria in the Solid Tumor), time to treatment failure, treatment duration, and likelihood of treatment discontinuation due to adverse events, were assessed in patients with hepatocellular carcinoma treated with lenvatinib. Patients were divided into four groups: (1) Child-Pugh score 5 and ALBI grade 1 (group 1), (2) Child-Pugh score 5 and ALBI grade 2 (group 2), (3) Child-Pugh score 6 (group 3), and (4) Child-Pugh score ≥7 (group 4). Univariate and multivariate analyses were performed to identify the factors contributing to the objective response rate and likelihood of discontinuation due to adverse events. Results: Among the 82 patients analyzed, group 1 had the highest objective response rate (57.1%) and the lowest likelihood of treatment discontinuation because of adverse events (11.1%) among the four groups (p < 0.05 and p < 0.05). Multivariate analysis identified ALBI grade 1 and baseline AFP level <200 ng/mL as the significant predictors of a high objective response rate (p < 0.05 and p < 0.01), and confirmed that patients with ALBI grade 1 had the lowest probability of treatment discontinuation due to adverse events (p < 0.01). Conclusions: Patients with Child-Pugh score of 5 and ALBI grade 1 predicted a higher response rate and lower treatment discontinuation due to adverse events by lenvatinib treatment.
  • Yokomichi N; Nishida N; Umeda Y; Taniguchi F; Yasui K; Toshima T; Mori Y; Nyuya A; Tanaka T; Yamada T; Yagi T; Fujiwara T; Yamaguchi Y; Goel A; Kudo M; Nagasaka T
    Liver cancer 8 4 239 - 254 2019年07月 [査読有り]
     
    Objective: Keratin 19 (K19) expression is a potential predictor of poor prognosis in patients with hepatocellular carcinoma (HCC). To clarify the feature of K19-proficient HCC, we traced epigenetic footprints in cultured cells and clinical materials. Patients and Methods: In vitro, KRT19 promoter methylation was analyzed and 5-aza-2'-deoxycytidine with trichostatin A (TSA) treatment was performed. Among 564 surgically resected HCCs, the clinicopathological relevance of K19-proficent HCCs was performed in comparison with hepatocytic (HepPar-1 and arginase-1), epithelial-mesenchymal transition (E-cadherin and vimentin), biliary differentiation-associated (K7 and NOTCH-1) markers, and epigenetic markers (KRT19 promoter/long interspersed nucleotide element-1 [LINE-1] methylation status). Results: KRT19 promoter methylation was clearly associated with K19 deficiency and 5-aza-2'-deoxycytidine with TSA treatment-stimulated K19 re-expression, implicating DNA methylation as a potential epigenetic process for K19 expression. After excluding HCCs with recurrence, TNM stage as IIIB or greater, preoperative therapy, transplantation, and combined hepatocellular cholangiocarcinoma, we assessed 125 of 564 HCC cases. In this cohort, K19 expression was found in 29 HCCs (23.2%) and corresponded with poor survival following surgery (p = 0.025) and extrahepatic recurrence-free survival (p = 0.017). Compared with K19-deficient HCCs, lower KRT19 promoter methylation level was observed in K19-proficient HCCs (p < 0.0001). Conversely, HCC with genome-wide LINE-1 hypermethylation was frequently observed in K19-proficient HCCs (p = 0.0079). Additionally, K19 proficiency was associated with K7 proficiency (p = 0.043), and reduced E-cadherin and HepPar-1 expression (p = 0.043 and p < 0.0001, respectively). Conclusions: K19-proficient HCC exhibited poor prognosis owing to extrahepatic recurrence, with molecular signatures differing from those in conventional cancer stem cells, providing novel insights of the heterogeneity underlying tumor development.
  • Masashi Kono; Toshiharu Sakurai; Kazuki Okamoto; Shou Masaki; Tomoyuki Nagai; Yoriaki Komeda; Ken Kamata; Kosuke Minaga; Kentarou Yamao; Mamoru Takenaka; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Internal Medicine 58 9 1263 - 1266 2019年05月 [査読有り]
  • Minami Y; Nishida N; Kudo M
    European radiology 29 9 5045 - 5051 2019年04月 [査読有り]
     
    Percutaneous radiofrequency ablation (RFA), a generally accepted alternative therapy for patients with liver metastases, is a minimally invasive approach with a favorable safety profile and a lower rate of major complications. The use of RFA or combined RFA plus resection can produce total tumor clearance in patients with unresectable liver metastases. However, the relatively high rate of local tumor progression has prevented the widespread use of RFA. Furthermore, its efficacy is controversial because there have been no comparisons for its effect on overall survival compared with standard options such as systemic chemotherapy. Meanwhile, immunotherapy has become a major research focus for oncology based on the recent successes reported for immune checkpoint inhibitors for melanoma, non-small cell lung cancer, gastric cancer, and other cancers. Immune checkpoints negatively regulate T cell function, and inhibition prevents the blockade of the immune system by cancer cells to prevent their destruction. Unfortunately, only some patients (< 25%) respond to immuno-oncology drugs, whereas other patients acquire resistance. However, RFA can induce massive necrotic cell death which might activate immunity and the presentation of cryptic antigens to induce tumor-specific T cell response. Because RFA can induce the rapid release of large amounts of tumor antigens, it can potentially stimulate transient immune responses to much tumor antigens. Combination therapies have induced synergistic enhancement of anticancer immune response in preclinical studies, indicating great promise for the future of oncologic treatment. Key Points center dot Only some patients respond to immuno-oncology drugs. center dot RFA causes the release of large amounts of cellular debris, a source of tumor antigens that elicit immune responses against tumors. center dot Combination RFA for liver metastases and immune checkpoint inhibitor therapies might synergistically enhance antitumor immunity.
  • Yoriaki Komeda; Tomohiro Watanabe; Toshiharu Sakurai; Masashi Kono; Kazuki Okamoto; Tomoyuki Nagai; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Naoko Tsuji; Hiroshi Kashida; Masatoshi Kudo
    World Journal of Gastroenterology 25 12 1502 - 1512 2019年03月 [査読有り]
  • Nishida N; Yamakawa M; Shiina T; Kudo M
    Hepatol Int Feb 21. doi: 10.1007/s12072-01 4 416 - 421 2019年02月 [査読有り]
     
    An ultrasound (US) examination is a common noninvasive technique widely applied for diagnosis of a variety of diseases. Based on the rapid development of US equipment, many US images have been accumulated and are now available and ready for the preparation of a database for the development of computer-aided US diagnosis with deep learning technology. On the contrary, because of the unique characteristics of the US image, there could be some issues that need to be resolved for the establishment of computer-aided diagnosis (CAD) system in this field. For example, compared to the other modalities, the quality of a US image is, currently, highly operator dependent; the conditions of examination should also directly affect the quality of US images. So far, these factors have hampered the application of deep learning-based technology in the field of US diagnosis. However, the development of CAD and US technologies will contribute to an increase in diagnostic quality, facilitate the development of remote medicine, and reduce the costs in the national health care through the early diagnosis of diseases. From this point of view, it may have a large enough potential to induce a paradigm shift in the field of US imaging and diagnosis of liver diseases.
  • Makoto Yamakawa; Tsuyoshi Shiina; Naoshi Nishida; Masatoshi Kudo
    2019 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS) 2330 - 2333 2019年 
    The Japan Society of Ultrasonics in Medicine (JSUM) is currently constructing an ultrasound image database. This database collects B-mode images of liver tumors and breast tumors, and B-mode videos of heart disease. In the past year, 31,000 liver tumor images have been collected from 11 institutions and 14,000 breast tumor images have been collected from 5 institutions. We are developing computer-aided detection (CADe) and computer-aided diagnosis ( CADx) systems for liver and breast tumors based on deep learning using this database. In this paper, we report on CADx to estimate liver tumor types as a first trial. The data used in this study are 159 cyst cases (338 images), 68 hemangioma cases (279 images), 73 hepatocellular carcinoma (HCC) cases (241 images), and 24 metastatic liver cancer cases (122 images), collected at one facility. We developed the CADx system that estimates four types of liver tumor using a convolutional neural network based on VGGNet. The accuracy of the developed 4-class classification CADx was 88.0%. The accuracy by tumor type was 98.1% for cysts, 86.8% for hemangiomas, 86.3% for HCC, and 29.2% for metastatic liver cancer, with increasing accuracy observed for larger data sets. We also developed CADx to estimate whether a liver tumor is benign or malignant. The accuracy of this 2-class classification CADx was 94.8%, the sensitivity was 93.8%, and the specificity was 95.2%. Both 4-class classification and 2-class classification CADx had relatively high accuracy. However, in this study, we used only a small amount data collected from a single facility. In the future, we plan to verify our results using a larger amount of data collected from multiple facilities. In addition, we prototyped CAD software and are currently developing it with feedback from doctors.
  • Nishida N; Kudo M
    Hepatol Int [Epub ahead of print] 3 doi: 10.1007/s12072-018-9921-7 - 252 2019年01月 [査読有り]
     
    Recently, immune checkpoint inhibitors are becoming one of the key agents of systemic treatment of cancer. The anti-cancer mechanism of this type of agent is totally different from that of conventional therapies; blockade of regulatory receptors and ligand of immune checkpoint molecules arose anti-tumor immunity with durable response. However, owing to its unique action to host immune system, immune checkpoint inhibitors sometimes induce immune-related adverse events (irAEs) which has not been observed for conventional chemotherapies. It has been reported that irAEs are manageable by discontinuation of immune checkpoint inhibitors and corticosteroid. However, severe irAEs might lead to the unsuccessful management of cancer treatment. It is conceivable that irAEs during the treatment of immune checkpoint blockade might mimic the autoimmune disease of the specific organ, such as autoimmune hepatitis (AIH). However, detail of the pathogenesis of irAEs has not been well estimated. In this review, we specially focused on this important issue and discussed the liver toxicity of this type of agent in the context of comparison of clinical and pathological findings of liver damage related to irAEs and AIH.
  • Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Ken Kamata; Kosuke Minaga; Kentarou Yamao; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Kazuhiko Nakagawa; Masatoshi Kudo
    Digestion [Epub ahead of print] 3 1 - 9 2018年12月 [査読有り]
     
    Background: Although Gankyrin is overexpressed in many malignancies, the role of Gankyrin for tumorigenesis and chemoresistance remains to be elucidated in sporadic colorectal cancer (CRC). Aims: We investigate whether Gankyrin affects Adenomatous polyposis coli (Apc) inactivation-induced tumorigenesis and therapeutic response to anti-angiogenic agents. Methods: Epithelial cell-specific APC and/or Gankyrin-deficient mice were used. The patients with metastatic CRC (n = 53) who were enrolled in this study underwent resection of primary cancer followed by systemic chemotherapy containing bevacizumab. We determined whether gene expression in CRC tissues before chemotherapy is associated with radiological responses. Results: Deletion of Gankyrin in epithelial cell reduced the expression of c-Myc, a critical mediator of the APC signaling pathway, and interleukin-6. Gankyrin deficiency decreased the expression of Bmi1, a downstream molecule of c-Myc, and the activity of V-Akt murine thymoma viral oncogene homolog and extracellular signal-regulated protein kinase, leading to reduced Apc inactivation-induced tumorigenesis. Of 53 patients, 38 (72%) had increased Gankyrin expression in tumor cells. The enhanced Gankyrin expression in tumor cells was associated with unfavorable progression-free survival (log-rank test p = 0.026). Conclusion: Gankyrin in epithelial cell contributes to the development of sporadic CRC and the expression could serve as a biomarker to predict therapeutic response in patients with metastatic CRC.
  • Naoshi Nishida; Masatoshi Kudo
    HEPATOLOGY 68 1271A - 1272A 2018年10月
  • Naoshi Nishida; Takafumi Nishimura; Toshimi Kaido; Kosuke Minaga; Kentaro Yamao; Ken Kamata; Mamoru Takenaka; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Tomohiro Watanabe; Masatoshi Kudo
    Cancers 10 10 367 - 367 2018年09月 [査読有り]
     
    Hepatocellular carcinoma (HCC) causes one of the most frequent cancer-related deaths; an HCC subset shows rapid progression that affects survival. We clarify molecular features of aggressive HCC, and establish a molecular scoring system that predicts metastasis after curative treatment. In total, 125 HCCs were examined for TP53, CTNNB1, and TERT promoter mutation, methylation of 8 tumor suppressor genes, and 3 repetitive DNA sequences to estimate promoter hypermethylation and global hypomethylation. A fractional allelic loss (FAL) was calculated to represent chromosomal instability through microsatellite analysis. Molecular subclasses were determined using corresponding and hierarchical clustering analyses. Next, twenty-five HCC patients who underwent liver transplantation were analyzed for associations between molecular characteristics and metastatic recurrence; survival analyses were validated using a publicly available dataset of 376 HCC cases from the Cancer Genome Atlas (TCGA). An HCC subtype characterized by TP53 mutation, high FAL, and global hypomethylation was associated with aggressive tumor characteristics, like vascular invasion; CTNNB1 mutation was a feature of the less-progressive phenotype. A number of molecular risk factors, including TP53 mutation, high FAL, significant global hypomethylation, and absence of CTNNB1 mutation, were noted to predict shorter recurrence-free survival in patients who underwent liver transplantation (p = 0.0090 by log-rank test). These findings were validated in a cohort of resected HCC cases from TCGA (p = 0.0076). We concluded that molecular risks determined by common genetic and epigenetic alterations could predict metastatic recurrence after curative treatments, and could be a marker for considering systemic therapy for HCC patients.
  • Yoshida Akihiro; Hagiwara Satoru; Watanabe Tomohiro; Nishida Naosihi; Ida Hiroshi; Sakurai Toshiharu; Komeda Yoriaki; Yamao Kentaro; Takenaka Mamoru; Enoki Eisuke; Kimura Masatomo; Miyake Masako; Kawada Akira; Kudo Masatoshi
    Internal Medicine 57 17 2505 - 2509 2018年09月 [査読有り]
     
    症例は27歳男性で、小児期から光線性皮膚症に罹患しており、約1年前に全身性エリテマトーデスと診断されていた。この時点で肝胆道酵素値などが著明に上昇しており、最終的に骨髄性プロトポルフィリン症(EPP)関連肝障害と診断された。今回、全身疲労と血清中のAST、ALT、GGT、総ビリルビン値が再び上昇した。肝生検により、EPP関連肝障害の増悪であると診断した。血漿交換を計5回施行したが血中のAST、ALT、プロトポルフィリン値が低下しなかったため、200〜400mLの瀉血を毎週行ったところ、血清中の肝酵素値、AST、ALT、プロトポルフィリン値は著明に減少し、症状も軽減した。
  • Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Atsushi Nakai; Hidekazu Tanaka; Yasutaka Chiba; Tomohiro Watanabe; Toshiharu Sakurai; Naoshi Nishida; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Masayuki Kitano; Masatoshi Kudo
    Digestive Endoscopy 30 5 659 - 666 2018年09月 [査読有り]
  • Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency
    Naosuke Yokomichi; Naoshi Nishida; Yuzo Umeda; Fumitaka Taniguchi; Kazuya Yasui; Toshiaki Toshima; Yoshiko Mori; Akihiro Nyuya; Takehiro Tanaka; Takeshi Yamada; Takahito Yagi; Toshiyoshi Fujiwara; Yoshiyuki Yamaguchi; Ajay Goel; Masatoshi Kudo; Takeshi Nagasaka
    Liver Cancer 2018年08月 [査読有り]
  • Nishida N; Kudo M
    Hepatol Res 48 8 622 - 634 2018年07月 [査読有り]
     
    Hepatocellular carcinoma (HCC) is one of the most common cancers with a high recurrence rate. Currently, tyrosine kinase inhibitors (TKIs) are the first-line treatment for cases refractory to conventional therapies. However, the acquisition of somatic mutations can result in TKI resistance. Clinical evidence suggests that acquired immunity contributes to the suppression of tumor recurrence, indicating the potential of induced antitumor immune reaction for the treatment of HCC. Recently, immune checkpoint inhibitors have become available for the treatment of malignancies. They are effective regardless of the response to prior therapies and a durable effect can be expected, which should be attributed to an adaptive immunity to HCC components. The results of phase I/II trials of nivolumab, an anti-programmed cell death-1 antibody, showed that 20% of patients showed objective response and that nivolumab was effective regardless of prior sorafenib treatment and viral status. Nivolumab received expedited Food and Drug Administration approval in 2017 for the treatment of advanced HCC after failure or intolerance to sorafenib. However, the majority of the patients remain refractory, likely due to the solid immune suppressive status, which involves many stromal cells, humoral mediators, and suppressive checkpoint molecules. Therefore, current clinical trials are focusing on how immunosuppressive conditions in HCC might be overcome using immune checkpoint inhibitors in combination with different types of immune checkpoint blockades, TKIs, and other conventional treatments. The development of immune checkpoint inhibitors is rapidly progressing and these inhibitors are likely to be key agents for HCC treatment in the near feature.
  • Kazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Ayana Okamoto; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Toshiharu Sakurai; Tomonori Tanaka; Hiroki Sakamoto; Kiyoshige Fujimoto; Naoshi Nishida; Masatoshi Kudo
    Frontiers in Immunology 9 918  2018年05月 [査読有り]
     
    Cap polyposis is a rare gastrointestinal disease characterized by multiple inflammatory polyps located between the distal colon and the rectum. Despite the lack of clarity regarding its pathogenesis, mucosal prolapse, chronic inflammatory responses, and Helicobacter pylori infection are considered key contributors to the development of this disease entity. Although it is now generally accepted that dysbiosis of gut microbiota is associated with intestinal and extra-intestinal diseases, alterations of intestinal microbiota have been poorly defined in cap polyposis. Here, we report a patient with H. pylori-negative cap polyposis who was successfully treated with antibiotics and exhibited dramatic alterations in intestinal microbiota composition after antibiotic treatment. The patient was treated with oral administration of ampicillin and metronidazole and showed regression of cap polyposis 6 months after antibiotic treatment. Fecal microbiota analysis using the next-generation sequencing technology revealed a significant alteration in the intestinal microbiota composition following antibiotic treatment-a marked reduction of Blautia, Dorea, and Sutterella was observed concomitant with a marked increase in Fusobacterium. These data suggest that cap polyposis may originate from dysbiosis and that microbiome-targeted therapy may be useful in this disorder.
  • Yasunori Minami; Tomohiro Minami; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi Kudo
    European Radiology 28 5 1986 - 1993 2018年05月 [査読有り]
     
    Objectives: To assess the clinical feasibility of US-US image overlay fusion with evaluation of the ablative margin in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Methods: Fifty-three patients with 68 HCCs measuring 0.9–4.0 cm who underwent RFA guided by US-US overlay image fusion were included in this retrospective study. By an overlay of pre-/postoperative US, the tumor image could be projected onto the ablative hyperechoic zone. Therefore, the ablative margin three-dimensionally could be shown during the RFA procedure. US-US image overlay was compared to dynamic CT a few days after RFA for assessment of early treatment response. Accuracy of graded response was calculated, and the performance of US-US image overlay fusion was compared with that of CT using a Kappa agreement test. Results: Technically effective ablation was achieved in a single session, and 59 HCCs (86.8 %) succeeded in obtaining a 5-mm margin on CT. The response with US-US image overlay correctly predicted early CT evaluation with an accuracy of 92.6 % (63/68) (k = 0.67 95 % CI: 0.39–0.95). Conclusion: US-US image overlay fusion can be proposed as a feasible guidance in RFA with a safety margin and predicts early response of treatment assessment with high accuracy. Key points: • US-US image overlay fusion visualizes the ablative margin during RFA procedure. • Visualizing the margin during the procedure can prompt immediate complementary treatment. • US image fusion correlates with the results of early evaluation CT.
  • 鎌田 研; 西田 直生志; 樫田 博史; 筑後 孝章; 千葉 康敬; 中居 卓也; 竹山 宜典; Andrea Lisotti; Pietro Fusaroli; 工藤 正俊; 竹中 完; 北野 雅之; 大本 俊介; 宮田 剛; 三長 孝輔; 山雄 健太郎; 今井 元; 櫻井 俊治
    日本消化器内視鏡学会雑誌 60 9 1611 - 1620 一般社団法人 日本消化器内視鏡学会 2018年 

    【背景と目的】孤立性胆嚢病変の鑑別診断は課題が残されている.本研究の目的は,胆嚢孤立性病変に対する造影ハーモニックEUS(CH-EUS)の有用性を評価すること.

    【方法】2007年3月から2014年2月までの間に,孤立性胆嚢病変を有する125人の患者に対してCH-EUSを施行し,レトロスペクティブにCH-EUSの有用性を検討した.はじめに,胆嚢病変と胆泥の鑑別診断能に関して,通常のBモードEUS(FB-EUS)とCH-EUSを比較検討した.その後,良悪性鑑別に対する診断能を両検査間で比較検討した.CH-EUSのVascular imageおよびPerfusion imageにおける血流パターンを5人の医師によるブラインドリーディングにて評価した.

    【結果】胆嚢病変と胆泥の鑑別診断能に関して,FB-EUSの感度は82%,特異度は100%,正診率は95%であった.一方,CH-EUSの感度は100%,特異度は99%,正診率は99%であった.良悪性鑑別に関して,腫瘍の大きさあるいは形状に基づいて診断した場合のFB-EUSの診断感度は61-87%,特異度は71-88%,正診率は74-86%であった.CH-EUSにてVascular imageにおけるirregular vessel patternあるいはPerfusion imageにおけるheterogeneous enhancementを悪性所見とした場合の診断感度は90%,特異度は98%,正診率は96%であり,FB-EUSの診断能と比較し有意に良好であった.

    【結語】CH-EUSは,孤立性胆嚢病変の鑑別診断において有用である.

  • Mamoru Takenaka; Ken Kamata; Kosuke Minaga; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Endoscopic Ultrasound 7 5 349 - 349 2018年 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Hiroshi Ida; Toshiharu Sakurai; Kazuomi Ueshima; Masahiro Takita; Yoriaki Komeda; Norihiro Nishijima; Yukio Osaki; Masatoshi Kudo
    Antiviral Therapy 23 6 513 - 521 2018年 [査読有り]
  • Ken Kamata; Mamoru Takenaka; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi Kudo
    GASTROINTESTINAL ENDOSCOPY 87 1 158 - 163 2018年01月 [査読有り]
     
    Background and Aims: EUS-guided FNA (EUS-FNA) is used for the diagnosis of pancreatic adenocarcinoma, but sometimes the method results in a false negative. Occasionally, an avascular area may be observed within the pancreatic adenocarcinoma tumor during contrast-enhanced harmonic EUS (CH-EUS). The aim of this study was to evaluate whether the diagnostic sensitivity of EUS-FNA for pancreatic adenocarcinoma was affected by the presence of avascularity on CH-EUS. Methods: Two hundred ninety-two patients with pancreatic adenocarcinoma who presented at Kindai University Hospital for EUS-FNA and CH-EUS between June 2009 and August 2013 were retrospectively evaluated. This was a single-center retrospective analysis of prospectively collected data held in a registry. The overall sensitivity of EUS-FNA for the diagnosis of pancreatic adenocarcinoma was calculated. The sensitivities of cytology, histology, and the combination of cytology and histology were also evaluated. These variables were individually evaluated according to the presence or absence of an avascular area on CH-EUS to assess whether the diagnostic sensitivity of EUS-FNA for pancreatic adenocarcinoma was related to the presence of an avascular area within the tumors. Results: The overall sensitivity of EUS-FNA was 90.8% (265/292). The sensitivities of EUS-FNA for lesions with and without an avascular area were 72.9% (35/48) and 94.3% (230/244), respectively, with the difference being statistically significant (P <.001). Conclusions: EUS-FNA has lower sensitivity for pancreatic adenocarcinoma with avascular areas on CH-EUS.
  • Ken Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Tosiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Yasutaka Chiba; Takuya Nakai; Yoshifumi Takeyama; Andrea Lisotti; Pietro Fusaroli; Masatoshi Kudo
    Digestive Endoscopy 30 1 98 - 106 2018年01月 [査読有り]
     
    Background and Aim: Differential diagnosis of localized gallbladder lesions is challenging. The aim of the present study was to evaluate the utility of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for diagnosis of localized gallbladder lesions. Methods: One hundred and twenty-five patients with localized gallbladder lesions were evaluated by CH-EUS between March 2007 and February 2014. This was a single-center retrospective study. Utilities of fundamental B-mode EUS (FB-EUS) and CH-EUS in the differentiation of gallbladder lesions and sludge plug were initially compared. Thereafter, these two examinations were compared with respect to their accuracy in the diagnosis of malignant lesions. Five reviewers blinded to the clinicopathological results evaluated microcirculation patterns in the vascular and perfusion images. Results: In the differentiation between gallbladder lesions and sludge plug, FB-EUS had a sensitivity, specificity, and accuracy of 82%, 100%, and 95%, respectively, whereas CH-EUS had a sensitivity, specificity, and accuracy of 100%, 99%, and 99%, respectively. FB-EUS-based diagnosis of carcinomas based on tumor size and/or shape had a sensitivity, specificity, and accuracy of 61–87%, 71–88%, and 74–86%, respectively. Additional information regarding irregular vessel patterns in the vascular image and/or heterogeneous enhancement in the perfusion image on CH-EUS increased the sensitivity, specificity, and accuracy for the diagnosis of carcinomas to 90%, 98%, and 96%, respectively. There was a significant difference between FB-EUS and CH-EUS in terms of carcinoma diagnosis. Conclusion: CH-EUS was useful for the evaluation of localized gallbladder lesions.
  • Naoshi Nishida; Masatoshi Kudo
    Oncology (Switzerland) 93 1 160 - 164 2017年12月 [査読有り]
     
    During tumor development, several immunosuppressive molecules are released from cancer cells and contribute to the establishment of immunosuppressive tumor environment. In tumor tissues, cytokines, chemokines, growth factors, and metabolites are present and could counter the effects of immune checkpoint inhibitors. From this point of view, monotherapy of anti-PD-1/PD-L1 antibody might not be enough to exert a sufficient antitumor effect additional blockade of immunosuppressive molecules in tumor microenvironment could enhance the antitumor effect of anti-PD-1/PD-L1 antibody. Importantly, the production of immunosuppressive molecules in cancer cells is attributed to the activation of cellular signaling through genetic and epigenetic alterations and environmental stimulation, such as inflammation and hypoxia. In this review, we focus on the establishment of immunosuppressive microenvironment of hepatocellular carcinoma in the context of activation of oncogenic signals, and discuss how the immunosuppressive condition could be overcome using tyrosine kinase inhibitors.
  • Kosuke Minaga; Mamoru Takenaka; Masayuki Kitano; Yasutaka Chiba; Hajime Imai; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES 31 11 4764 - 4772 2017年11月 [査読有り]
     
    Treatment of unresectable malignant hilar biliary stricture (UMHBS) is challenging, especially after failure of repeated transpapillary endoscopic stenting. Endoscopic ultrasonography-guided intrahepatic biliary drainage (EUS-IBD) is a recent technique for intrahepatic biliary decompression, but indications for its use for complex hilar strictures have not been well studied. The aim of this study was to assess the feasibility and safety of EUS-IBD for UMHBS after failed transpapillary re-intervention. Retrospective analysis of all consecutive patients with UMHBS of Bismuth II grade or higher who, between December 2008 and May 2016, underwent EUS-IBD after failed repeated transpapillary interventions. The technical success, clinical success, and complication rates were evaluated. Factors associated with clinical ineffectiveness of EUS-IBD were explored. A total of 30 patients (19 women, median age 66 years [range 52-87]) underwent EUS-IBD for UMHBS during the study period. Hilar biliary stricture morphology was classified as Bismuth II, III, or IV in 5, 13, and 12 patients, respectively. The median number of preceding endoscopic interventions was 4 (range 2-14). EUS-IBD was required because the following procedures failed: duodenal scope insertion (n = 4), accessing the papilla after duodenal stent insertion (n = 5), or achieving desired intrahepatic biliary drainage (n = 21). Technical success with EUS-IBD was achieved in 29 of 30 patients (96.7%) and clinical success was attained in 22 of these 29 (75.9%). Mild peritonitis occurred in three of 30 (10%) and was managed conservatively. Stent dysfunction occurred in 23.3% (7/30). There was no procedure-related mortality. On multivariable analysis, Bismuth IV stricture predicted clinical ineffectiveness (odds ratio = 12.7, 95% CI 1.18-135.4, P = 0.035). EUS-IBD may be a feasible and effective rescue alternative with few major complications after failed transpapillary endoscopic re-intervention in patients with UMHBS, particularly for Bismuth II or III strictures.
  • Toshiharu Sakurai; Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    CANCER SCIENCE 108 10 1996 - 2003 2017年10月 [査読有り]
     
    Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation. We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon. Although the invitro function of gankyrin is well known, its role invivo remains to be elucidated. We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre;gankyrin(f/f)) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre;gankyrin(f/f)). Gankyrin upregulates vascular endothelial growth factor expression in tumor cells. Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential. Chronic inflammation enhances gankyrin expression in the human liver. Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC. Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
  • Ken Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Haruhiko Imamoto; Takushi Yasuda; Andrea Lisotti; Pietro Fusaroli; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 32 10 1686 - 1692 2017年10月 [査読有り]
     
    Background and Aim: The study aims to evaluate contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for the differential diagnosis of submucosal tumors (SMT) of the upper gastrointestinal tract. Methods: Between June 2008 and May 2015, 157 consecutive patients with submucosal lesions of the upper gastrointestinal tract were evaluated by CH-EUS. This was a single-center retrospective analysis of prospectively collected data in a registry. The data from 73 patients who later underwent surgical resection were analyzed in this study. Surgical specimens served as the final diagnoses. The two CH-EUS variables of blood flow (hyper-enhancement vs hypo-enhancement) and homogeneity of enhancement pattern were evaluated. Results: The final diagnoses were 58 gastrointestinal stromal tumors (GISTs) and 15 benign SMTs (two lipomas, five leiomyomas, five schwannomas, two glomus tumors, and one ectopic pancreas). On CH-EUS, 49 of 58 (84.5%) GISTs presented with hyper-enhancement, whereas 4 of 15 (26.7%) benign SMTs showed hyper-enhancement; 21 of 58 (36.2%) GISTs showed inhomogeneous contrast enhancement, while only 2 of 15 (13.3%) benign SMTs demonstrated inhomogeneous contrast enhancement. If hyper-enhancement was considered to indicate GISTs, the sensitivity, specificity, and accuracy were 84.5%, 73.3%, and 82.2%, respectively. If inhomogeneous enhancement was considered to indicate GISTs, the sensitivity, specificity, and accuracy were 36.2%, 86.7%, and 46.6%, respectively. In lesions of less than 2cm, hyper-enhancement was a more sensitive indicator of GISTs than inhomogeneous enhancement. Conclusions: Hyper-enhancement and inhomogeneous enhancement were found to be a characteristic of GISTs. CH-EUS was useful for discrimination of benign SMTs from GISTs.
  • Toshiharu Sakurai; Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Cancer Science 108 10 1996 - 2003 2017年10月 [査読有り]
     
    Most hepatocellular carcinomas (HCC) develop as a result of chronic liver inflammation. We have shown that the oncoprotein gankyrin is critical for inflammation-induced tumorigenesis in the colon. Although the in vitro function of gankyrin is well known, its role in vivo remains to be elucidated. We investigated the effect of gankyrin in the tumor microenvironment of mice with liver parenchymal cell-specific gankyrin ablation (Alb-Cre gankyrinf/f) and gankyrin deletion both in liver parenchymal and non-parenchymal cells (Mx1-Cre gankyrinf/f). Gankyrin upregulates vascular endothelial growth factor expression in tumor cells. Gankyrin binds to Src homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1), mainly expressed in liver non-parenchymal cells, resulting in phosphorylation and activation of signal transducer and activator of transcription 3 (STAT3). Gankyrin deficiency in non-parenchymal cells, but not in parenchymal cells, reduced STAT3 activity, interleukin (IL)-6 production, and cancer stem cell marker (Bmi1 and epithelial cell adhesion molecule [EpCAM]) expression, leading to attenuated tumorigenic potential. Chronic inflammation enhances gankyrin expression in the human liver. Gankyrin expression in the tumor microenvironment is negatively correlated with progression-free survival in patients undergoing sorafenib treatment for HCC. Thus, gankyrin appears to play a critical oncogenic function in tumor microenvironment and may be a potential target for developing therapeutic and preventive strategies against HCC.
  • Satoru Hagiwara; Naoshi Nishida; Ah-Mee Park; Yoriaki Komeda; Toshiharu Sakurai; Tomohiro Watanabe; Masatoshi Kudo
    SCIENTIFIC REPORTS 7 1 10440  2017年09月 [査読有り]
     
    Although Hepatitis B virus (HBV) X gene mutations are frequently detected in HBV-related human hepatocellular carcinoma (HCC) patients, causative HBx mutations in the development of HCC have not yet been determined. We herein identified C1485T and C1653T mutations in the HBx gene as independent risk of HCC for HBV through the analysis using serum from chronic hepatitis B patients. We generated transgenic mice expressing wild-type (WT-HBxTg) and mutant (C1485T-HBxTg) HBx to assess the carcinogenic potential of mutated HBx. C1485T-HBxTg mice were more susceptible to diethylnitrosamine-induced hepatocarcinogenesis than WT-HBxTg mice and control non-Tg mice. The promotion of hepatocarcinogenesis in C1485T-HBxTg mice was accompanied by the activation of beta-catenin and Jun N-terminal kinase (JNK) signaling pathways as well as the production of reactive oxygen species, whereas the activation of nuclear factor-kappa B in the livers of C1485T-HBxTg mice was attenuated. These results demonstrate that the HBx C1485T mutation contributes to human and murine hepatocarcinogenesis.
  • Watanabe T; Yamashita K; Arai Y; Minaga K; Kamata K; Nagai T; Komeda Y; Takenaka M; Hagiwara S; Ida H; Sakurai T; Nishida N; Strober W; Kudo M
    Journal of immunology (Baltimore, Md. : 1950) 198 10 3886 - 3896 2017年05月 [査読有り]
     
    In previous studies, we found that human IgG4-related autoimmune pancreatitis (AIP) and murine AIP are driven by activation of plasmacytoid dendritic cells (pDCs) producing IFN-alpha. In the present studies we examined additional roles of pDC-related mechanisms in AIP pathogenesis, particularly those responsible for induction of fibrosis. We found that in murine AIP (MRL/Mp mice treated with polyinosinic-polycytidylic acid) not only the pancreatic infiltration of immune cells but also the development of fibrosis were markedly reduced by the depletion of pDCs or blockade of type I IFN signaling; moreover, such treatment was accompanied by a marked reduction of pancreatic expression of IL-33. Conversely, polyinosinic-polycytidylic acid-induced inflamed pancreatic tissue in murine AIP exhibited increased expression of type I IFNs and IL-33 (and downstream IL-33 cytokines such as IL-13 and TGF-beta 1). pDCs stimulated by type I IFN were the source of the IL-33 because purified populations of these cells isolated from the inflamed pancreas produced a large amount of IL-33 upon activation by TLR9 ligands, and such production was abrogated by the neutralization of type I IFN. The role of IL-33 in murine AIP pathogenesis was surprisingly important because blockade of IL-33 signaling by anti-ST2 Ab attenuated both pancreatic inflammation and accompanying fibrosis. Finally, whereas patients with both conventional pancreatitis and IgG4-related AIP exhibited increased numbers of acinar cells expressing IL-33, only the latter also exhibited pDCs producing this cytokine. These data thus suggest that pDCs producing IFN-alpha and IL-33 play a pivotal role in the chronic fibro-inflammatory responses underlying murine AIP and human IgG4-related AIP.
  • Toshiharu Sakurai; Hiroaki Higashitsuji; Hiroshi Kashida; Tomohiro Watanabe; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Masayuki Kitano; Naoshi Nishida; Takaya Abe; Hiroshi Kiyonari; Katsuhiko Itoh; Jun Fujita; Masatoshi Kudo
    ONCOTARGET 8 15 24762 - 24776 2017年04月 [査読有り]
     
    Although long-standing colonic inflammation due to refractory inflammatory bowel disease (IBD) promotes the development of colitis-associated cancer (CAC), the molecular mechanisms accounting for the development of CAC remains largely unknown. In this study, we investigated the role of gankyrin in the development of CAC since gankyrin is overexpressed in sporadic colorectal cancers. We analyzed gene expression of colon tissues obtained from 344 patients with IBD and CAC and found that expression of gankyrin was much higher in colonic mucosa of patients with refractory IBD than in those with IBD in remission. Expression of gankyrin was upregulated in inflammatory cells as well as tumor cells in colonic mucosa of patients with CAC. Over-expressing studies utilizing tagged ganlyrin-cDNA identified physical interaction between ganlyrin and Src homology 2-containing protein tyrosine phosphatase-1 (SHP-1). Importantly, the interaction between ganlyrin and SHP1 leads to inhibition of STAT3 activation and to enhancement of TNF-alpha and IL-17 in inflammatory cells. To further address the role of gankyrin in the development of CAC, we created mice with intestinal epithelial cell-specific gankyrin ablation (Vil-Cre; Gankyrin(f/f)) and deletion of gankyrin in myeloid and epithelial cells (Mx1Cre; Gankyrin(f/f)). Gankyrin deficiency in myeloid cells, but not in epithelial cells, reduced the activity of mitogen activated protein kinase and the expression of stem cell markers, leading to attenuated tumorigenic potential. These findings provide important insights into the pathogenesis of CAC and suggest that gankyrin is a promising target for developing therapeutic and preventive strategies against CAC.
  • Serum microRNA profile that predict initial effect of sorafenib in patients with advanced hepatocellular carcinoma
    Nishida N; Arizumi T; Hagiwara S; Ida H; Sakurai T; Kudo M
    Liver Cancer 6 113 - 125 2017年 [査読有り]
  • Identification of a HBx mutation that enhances human hepatocarcinogenesis through the activation of the JNK and Wnt pathways.
    Hagiwara S; Nishida N; Sakurai T; Park AM; Komeda Y; Kitano M; Kudo M
    BMC Cancer in press 2017年 [査読有り]
  • Treatment response and tolerability in elderly patients with chronic hepatitis C: subgroup analysis in ReGIT-J study.
    Nishikawa H; Enomoto H; Saito M; Aizawa N; Tsuda Y; Higuchi K; Okazaki K; Seki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M; Osaki Y; Nishiguchi S
    Acta Gastro-Ent Belg in press 2017年 [査読有り]
  • Kwok WY; Hagiwara S; Nishida N; Watanabe T; Sakurai T; Ida H; Minami Y; Takita M; Minami T; Iwanishi M; Chishina H; Kono M; Ueshima K; Komeda Y; Arizumi T; Enoki E; Nakai T; Kumabe T; Nakashima O; Kondo F; Kudo M
    Oncology 92 Suppl 1 16 - 28 2017年
  • Shunsuke Omoto; Mamoru Takenaka; Masayuki Kitano; Takeshi Miyata; Ken Kamata; Kosuke Minaga; Tadaaki Arizumi; Kentaro Yamao; Hajime Imai; Hiroki Sakamoto; Yogesh Harwani; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi Kudo
    Oncology 93 1 55 - 60 2017年 [査読有り]
     
    Objectives: This study evaluated whether quantitative perfusion analysis with contrast-enhanced harmonic (CH) endoscopic ultrasonography (EUS) characterizes pancreatic tumors, and compared the hemodynamic parameters used to diagnose pancreatic carcinoma. Methods: CH-EUS data from pancreatic tumors of 76 patients were retrospectively analyzed. Time-intensity curves (TIC) were generated to depict changes in signal intensity over time, and 6 parameters were assessed: baseline intensity, peak intensity, time to peak, intensity gain, intensity at 60 s (I-60), and reduction rate. These parameters were compared between pancreatic carcinomas (n = 41), inflammatory pseudotumors (n = 14), pancreatic neuroendocrine tumors (n = 14), and other tumors (n = 7). All 6 TIC parameters and subjective analysis for diagnosing pancreatic carcinoma were compared. Results: Values of peak intensity and I-60 were significantly lower and time to peak was significantly longer in the groups with pancreatic carcinomas than in the other 3 tumor groups (p < 0.05). Reduction rate was significantly higher in pancreatic carcinomas than in pancreatic neuroendocrine tumors (p < 0.05). Areas under the receiver-operating characteristic curves for the diagnosis of pancreatic carcinoma using subjective analysis, baseline intensity, peak intensity, intensity gain, I-60, time to peak, and reduction rate, were 0.817, 0.664, 0.810, 0.751, 0.845, 0.777, and 0.725, respectively. I-60 was the most accurate parameter for differentiating pancreatic carcinomas from the other groups, giving values of sensitivity/specificity of 92.7/68.6% when optimal cutoffs were chosen. Conclusions: In pancreatic carcinomas, TIC patterns were markedly different from the other tumor types, with I-60 being the most accurate diagnostic parameter. Quantitative perfusion analysis is useful for differentiating pancreatic carcinomas from other pancreatic tumors. (C) 2017 S. Karger AG, Basel
  • Hajime Imai; Mamoru Takenaka; Shunsuke Omoto; Ken Kamata; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Toshiharu Sakurai; Naoshi Nishida; Tomohiro Watanabe; Masayuki Kitano; Masatoshi Kudo
    Oncology 93 1 69 - 75 2017年 [査読有り]
  • Kazuki Okamoto; Tomohiro Watanabe; Yoriaki Komeda; Tatsuya Kono; Kouta Takashima; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Tomoyuki Nagai; Yutaka Asakuma; Mamoru Takenaka; Toshiharu Sakurai; Shigenaga Matsui; Naoshi Nishida; Takaaki Chikugo; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 35 - 42 2017年 [査読有り]
     
    Background: Colonoscopic removal of adenomatous polyps or early cancer prevents death from colorectal cancer. Endoscopic submucosal dissection (ESD), which enables endoscopists to perform en bloc resection of flat or depressed colorectal tumors > 20 mm, has recently been introduced and become a standard procedure in Japan. Although postoperative bleeding (POB) is a major complication associated with ESD, risk factors for POB have not been fully identified. Methods: A total of 451 patients (509 lesions) who underwent colorectal ESD were retrospectively analyzed to identify clinical parameters associated with POB. Results: POB occurred in 14 patients, and 7 of them had received antithrombotic therapy before ESD. Uni- and multivariate analyses revealed that antithrombotic therapy and rectal tumor location were strongly associated with POB following colorectal ESD. The incidence of POB was higher in patients on heparin bridge therapy (HBT) for the replacement of antithrombotic therapy than in patients with no HBT. Four of 7 patients (57.1%) on antithrombotic therapy experienced POB from the rectal lesions. Conclusion: Antithrombotic therapy and rectal lesions result in a higher POB incidence after colorectal ESD. (C) 2017 S. Karger AG, Basel
  • Kentaro Yamao; Mamoru Takenaka; Hajime Imai; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 76 - 80 2017年 [査読有り]
     
    Introduction: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disorder characterized by multiple fibrotic strictures of the bile duct. More than 40% of deaths in PSC patients are related to malignant tumors, including cholangiocarcinoma. Primary hepatic adenosquamous carcinoma (ASC) is a rare subtype of cholangiocarcinoma containing adenocarcinoma (AC) and squamous cell carcinoma (SCC) components, with a poorer prognosis than other cholangiocarcinomas. We report the first case of a hepatic ASC in a patient with PSC. Case Report: A 28-year-old man was referred for diagnosis and treatment of a liver abscess suspected by contrast-enhanced computed tomography (CECT). He had a history of ulcerative colitis and PSC. Abdominal CE-CT revealed a 60-mm-diameter ring-shaped mass with central necrosis in the left lobe. Magnetic resonance imaging demonstrated a poorly circumscribed low-signal-intensity mass in T1-weighted imaging and a high-signal-intensity mass with a scattered low-signal-intensity area in T2-weighted imaging. Abdominal ultrasonography showed a hypoechoic component with a diffuse hyperechoic area in the tumor. Ultrasound-guided biopsy and histological examination showed tumor cells with both squamous and glandular differentiation. Left lobectomy was performed. Microscopic examination revealed 2 components, including moderately differentiated AC and well-differentiated SCC. The final diagnosis was hepatic ASC. Conclusion: This is the first reported case of hepatic ASC in a patient with PSC. Patients with PSC should be recognized as being at a risk of not only general cholangiocarcinoma, hepatocellular carcinoma, and metastatic liver tumor, but also ASC. (c) 2017 S. Karger AG, Basel
  • Kentaro Yamao; Mamoru Takenaka; Atsushi Nakai; Shunske Omoto; Ken Kamata; Kosuke Minaga; Takeshi Miyata; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Ippei Matsumoto; Yosihumi Takeyama; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 81 - 86 2017年 [査読有り]
     
    Pancreatic intraepithelial neoplasia (PanIN) is a microscopic papillary noninvasive lesion arising from the pancreatic ductal epithelium. However, the natural history and time to progression of high-grade PanIN remain unclear. Herein, we report 2 cases of high-grade PanIN without morphological changes of the main pancreatic duct (MPD) over relatively long periods. In the first case, a 63-year-old man was identified with MPD dilation. Magnetic resonance cholangiopan-creatography showed localized stenosis in the pancreatic body with distal MPD dilation. Endoscopic retrograde pancreatography (ERP) was attempted because of possible highgrade PanIN but was unsuccessful. At 15-month follow-up, there was no change in the form of the MPD in various images. However, ERP was re-performed because of possible high-grade PanIN, and cytology showed adenocarcinoma. Postoperative pathology indicated diffuse lesions corresponding to high-grade PanINs in the MPD stenosis and surrounding branches. Final diagnosis was high-grade PanIN. In the second case, a 77-year-old man was identified with MPD dilation. Magnetic resonance cholangiography showed localized stenosis in the MPD of the pancreatic head with distal MPD dilation. He was diagnosed with MPD stenosis caused by chronic pancreatitis, and further examination was not recommended. At 25 months, the patient was referred to our hospital because of a mild change in MPD dilation. ERP showed localized irregular stenosis in the MPD, and cytology showed suspected adenocarcinoma. Postoperative pathology indicated a localized lesion with high-grade PanIN in the branch duct around the MPD stenosis. Final diagnosis was high-grade PanIN. In conclusion, we report 2 cases of high-grade PanIN without morphological changes of the MPD over relatively long periods. Even if a definite diagnosis is not obtained at initial examination, a strict follow-up observational study should be performed. Re-examination, including ERP, should also be considered in cases with risk factors of pancreatic cancer, even if there is no change in MPD form. (c) 2017 S. Karger AG, Basel
  • Yoriaki Komeda; Hisashi Handa; Tomohiro Watanabe; Takanobu Nomura; Misaki Kitahashi; Toshiharu Sakurai; Ayana Okamoto; Tomohiro Minami; Masashi Kono; Tadaaki Arizumi; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 30 - 34 2017年 [査読有り]
  • Chikara Ogawa; Masahiro Morita; Akina Omura; Teruyo Noda; Atsushi Kubo; Toshihiro Matsunaka; Hiroyuki Tamaki; Mitsushige Shibatoge; Akemi Tsutsui; Tomonori Senoh; Takuya Nagano; Kouichi Takaguchi; Joji Tani; Asahiro Morishita; Hirohito Yoneyama; Tsutomu Masaki; Akio Moriya; Masaharu Ando; Akihiro Deguchi; Yasutaka Kokudo; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    Oncology 93 Suppl 1 113 - 119 2017年 [査読有り]
     
    OBJECTIVE: To determine the relationship between treatment outcomes and hand-foot syndrome (HFS), and the relationship between survival rate and post-progression treatment after sorafenib therapy. METHODS: The study assessed 314 patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib at 5 general hospitals in Kagawa Prefecture, Japan. RESULTS: At the start of sorafenib therapy, 23.6% of the patients had HCC of a Child-Pugh class other than A. The initial sorafenib dose was 800 mg in 9.2% of the patients and 400 mg in 64.3%. Time to progression was 129 days (95% CI: 87.3-170.7) and the median overall survival (OS) was 392 days (95% CI: 316.0-468.0). The OS of the patients with Child-Pugh class A HCC was significantly better than that of the patients with Child-Pugh class B HCC (p < 0.0001). The survival curves for Child-Pugh class A-5 points and class A-6 points were significantly different, with that for class A-5 points being better (p < 0.0001). A significant difference was observed between the patients who exhibited HFS and those who did not, with the former exhibiting a better survival rate (p < 0.001). In addition, the survival rate of the patients who received post-progression treatment after sorafenib therapy was significantly better than that of the patients who did not (p < 0.001). CONCLUSION: In sorafenib therapy, patients with HFS and those who received post-progression treatment exhibited good OS.
  • Yoriaki Komeda; Hiroshi Kashida; Toshiharu Sakurai; Yutaka Asakuma; George Tribonias; Tomoyuki Nagai; Masashi Kono; Kosuke Minaga; Mamoru Takenaka; Tadaaki Arizumi; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Yasutaka Chiba; Masatoshi Kudo
    Oncology 93 1 49 - 54 2017年 [査読有り]
  • Kazuki Okamoto; Shigenaga Matsui; Tomohiro Watanabe; Yutaka Asakuma; Yoriaki Komeda; Ayana Okamoto; Ishikawa Rei; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Takaaki Chikugo; Masatoshi Kudo
    Oncology 93 1 9 - 14 2017年 [査読有り]
     
    Introduction: Endoscopic submucosal dissection (ESD) has been widely used in the resection of superficial esophageal cancers. Since its use has been extended to cases involving large esophageal tumors occupying nearly the whole or the whole circumference of the lumen, the occurrence of esophageal stricture has increased. Although endoscopic injection of triamcinolone (TA) is widely used for the prevention of postoperative stricture, a significant number of patients still develop stricture after TA injection therapy. Methods: We performed a retrospective study to identify the clinical parameters that predispose post-ESD patients to esophageal stricture after TA injection therapy. Results: A total of 207 patients who were diagnosed with superficial esophageal cancer and subsequently underwent ESD were enrolled in this study. Among these patients, 53 patients and 57 lesions bearing mucosal defects covering greater than two-thirds of the esophageal circumference after ESD were treated with TA injection therapy. The rate of esophageal stricture was found to be highest in cases involving mucosal defects that covered more than seven-eighths of the circumference. Conclusion: Endoscopic TA injection is not sufficient for preventing esophageal stricture in patients bearing mucosal defects covering more than seven-eighths of the esophageal circumference after ESD. (C) 2017 S. Karger AG, Basel
  • Ken Kamata; Mamoru Takenaka; Kosuke Minaga; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    Oncology 93 1 87 - 88 2017年 [査読有り]
  • Toshiharu Sakurai; Teppei Adachi; Masashi Kono; Tadaaki Arizumi; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Yoriaki Komeda; Mamoru Takenaka; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 27 - 29 2017年 [査読有り]
     
    The prophylactic closure of mucosal defects after endoscopic resection is known to prevent postoperative bleeding in colorectal lesions. However, closure of large mucosal defects is difficult with conventional clips only, and several closure techniques have been previously described; use of an Endoloop, 8-ring loop, or loop clip and a small incision around the mucosal defect. Given that the prophylactic closure requires much cost and time, the application should be limited to high-risk cases. Medication of antithrombotics or antiplatelet agents would be one of the reasonable indications for prophylactic closure of mucosal defects after endoscopic resection of colorectal tumors. (C) 2017 S. Karger AG, Basel
  • Teppei Adachi; Shigenaga Matsui; Tomohiro Watanabe; Kazuki Okamoto; Ayana Okamoto; Masashi Kono; Mitsunari Yamada; Tomoyuki Nagai; Yoriaki Komeda; Kosuke Minaga; Ken Kamata; Kentaro Yamao; Mamoru Takenaka; Yutaka Asakuma; Toshiharu Sakurai; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 15 - 19 2017年 [査読有り]
  • Mitsunari Yamada; Toshiharu Sakurai; Yoriaki Komeda; Tomoyuki Nagai; Ken Kamata; Kosuke Minaga; Kentaro Yamao; Mamoru Takenaka; Satoru Hagiwara; Shigenaga Matsui; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    Oncology 93 1 20 - 26 2017年 [査読有り]
     
    Background: Although the stem cell marker Bmi1 is over-expressed in many malignancies, its role in inflammation-associated cancer is unclear. Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Methods: To assess the involvement of Bmi1 in the development of CAC, we analyzed the gene expression of colon tissues collected from 111 patients with IBD and CAC. Results: In the colonic mucosa of patients with ulcerative colitis, the expression of Bmi1 correlated significantly with the expression of inflammatory cytokines such as IL-6, IL-17, IL-23, and tumor necrosis factor alpha (TNF-alpha). In the colonic mucosa of patients with Crohn's disease, the expression of Bmi1 correlated significantly with the expression of TNF-alpha and IL-23. The expression of Bmi1 was enhanced in the colonic mucosae of refractory IBD, suggesting that Bmi1 expression might be related to increased cancer risk. In addition, patients with high Bmi1 expression showed significantly lower response rates upon subsequent anti-TNF-alpha therapy as compared to patients with low Bmi1 expression. In human CAC specimens, the expression of Bmi1 was upregulated in nontumor tissues as well as tumors. Conclusions: Bmi1 expression is related to a refractory clinical course of IBD and upregulated in refractory IBD and CAC. Measurement of Bmi1 expression is a promising approach for the advanced treatment and personalized management of IBD patients. (C) 2017 S. Karger AG, Basel
  • Ken Kamata; Mamoru Takenaka; Atsushi Nakai; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Tomohiro Matsuda; Kentaro Yamao; Hajime Imai; Yasutaka Chiba; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Takaaki Chikugo; Ippei Matsumoto; Yoshifumi Takeyama; Masatoshi Kudo
    Oncology 93 1 102 - 106 2017年 [査読有り]
  • Yasuko Umehara; Satoru Hagiwara; Naoshi Nishida; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Tomohiro Watanabe; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 548 - 555 2017年 [査読有り]
     
    Objective: It is a generally accepted fact that eradication of hepatitis virus C inhibits the subsequent development of hepatocellular carcinoma (HCC). On the contrary, a significant population of patients developed HCC despite sustained virological responses (SVRs) to interferon (IFN) therapy. Methods: A total of 415 patients with chronic hepatitis C, who were treated at our hospital between 2004 and 2014, were enrolled for this study. We examined the risk factors for HCC development after IFN therapy. Results: After analyzing various clinical parameters, it was concluded that a serum albumin (ALB) level <4.0 g/dL and the presence or absence of SVR achievement were risk factors for the development of HCC. When analyzing pre-and posttreatment factors, only a serum ALB level <4.0 g/dL was considered a significant risk factor. The presence or absence of liver fibrosis progression was not identified as a risk factor. Conclusions: In patients with a serum ALB level <4.0 g/dL before IFN therapy, hepatic carcinogenesis after SVR achievement need to be considered. Furthermore, the serum ALB level may be more useful than the degree of fibrosis for the prediction of HCC after SVR in chronic hepatitis C. (C) 2017 S. Karger AG, Basel
  • Masashi Kono; Naoshi Nishida; Satoru Hagiwara; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Yoriaki Komeda; Toshiharu Sakurai; Mamoru Takenaka; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Yasunori Minami; Kazuomi Ueshima; Tomohiro Watanabe; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 556 - 564 2017年 [査読有り]
     
    Background and Aims: Direct-acting antivirals (DAAs) dramatically improve the sustained virological response (SVR) of chronic hepatitis C (CHC) patients. However, continuous liver damage after SVR may be a risk of hepatocellular carcinoma (HCC). We clarified pretreatment characteristics related to sustained liver damage after SVR. Methods: A total of 286 CHC patients were treated with an interferon-free DAA regimen. Among them, 250 patients achieved SVR for 12 weeks after the end of treatment (SVR12); these individuals were classified based on a-fetoprotein (AFP) and alanine transaminase (ALT) levels posttreatment. Baseline characteristics significantly associated with AFP > 5 ng/mL and ALT level >= 20 IU/L after SVR were clarified using multivariate analyses. Results: Among the pretreatment factors examined, serum AFP values and the presence of fatty liver (FL) were significantly associated with abnormal AFP (p < 0.0001) and ALT levels 12 weeks after SVR12 (SVR24; p = 0.0109). For 126 patients who showed an increase in baseline AFP level, FL, fibrosis-4 (FIB-4) index, and albumin levels before treatment were related to abnormal AFP at SVR24 (p = 0.0005, 0.0232, and 0.0400 for FL, FIB-4 index, and albumin, respectively). Similarly, for 150 patients with abnormal baseline ALT levels, FL was associated with an ALT level = 30 IU/L after SVR (p = 0.0430). Conclusions: High FIB-4 index, low albumin level, and FL before DAA treatment were associated with a risk of sustained liver damage with AFP and ALT elevation after SVR; patients with these factors should be carefully monitored for emergence of HCC. (C) 2017 S. Karger AG, Basel
  • Hiroshi Ida; Satoru Hagiwara; Masashi Kono; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Yasunori Minami; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 565 - 573 2017年 [査読有り]
     
    Background: Interferon-based antiviral therapies against hepatitis C virus (HCV) infection have been shown to reduce the incidence of hepatocellular carcinoma (HCC) in patients with sustained viral response (SVR). Recently, direct-acting antivirals (DAAs) have been proven to be much more effective in achieving SVR than interferon-based therapies. However, whether DAAs can efficiently prevent the occurrence of HCC after SVR remains controversial. To clarify this issue, we analyzed the clinical features of patients in whom HCC developed after achievement of SVR with DAAs for chronic HCV infection. Summary: Among patients who achieved SVR with daclatasvir and asunaprevir (n = 100), HCC developed in 17 patients (HCC group; n = 17) and did not develop in 83 patients (non-HCC group; n = 83) during a mean observation period of 15 months. A multivariate Cox proportional hazards analysis identified past history of HCC and male sex as significant risk factors for the emergence of HCC after DAAs. Sixteen cases with HCC after DAAs were in the very early or early stage (16/ 17, 94.1%), and one case was in the advanced stage (1/17, 5.9%) with portal venous tumor thrombus. Radiofrequency ablation and/or transarterial chemoembolization were performed in most cases as curative therapy (16/17, 94.1%). Key Messages: SVR by DAAs did not completely prevent the occurrence of HCC. However, even if HCC did develop after SVR, curative anticancer therapy was applicable in most cases. (C) 2017 S. Karger AG, Basel
  • Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 583 - 588 2017年 [査読有り]
     
    Background: Tumors classified based on the Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) are heterogeneous in nature. Previously, the Kinki criterion was proposed for a more precise subclassification of tumors in BCLC-stage B. However, tumors in sub-stage B2 include various size and number of HCCs even with the Kinki criteria, which could lead to heterogeneity for overall survival (OS). In this study, we assessed how the size and number of tumors affect the OS and time to progression (TTP) in patients with Kinki criteria stage B2 tumors and treated with transarterial chemoembolization (TACE). Methods: Of 906 HCC patients treated with TACE at Kindai University Hospital, 236 patients with HCC considered as Kinki criteria stage B2 were examined. They were classified into the following 4 groups according to the maximum tumor diameter and number of tumors: B2a group, tumor size <= 6 cm and total number of tumors <= 6; B2b group, size <= 6 cm and number >6; B2c group, size >6 cm and number <= 6; and B2d group, size >6 cm and number >6. The OS and TTP of patients in each group were compared. Results: There were 131 patients (55.5%) in the B2a group, 58 (24.6%) in the B2b group, 41 (17.4%) in the B2c group, and 6 (0.03%) in the B2d group. Comparison of the survivals revealed that the median OS was 2.8 years (95% CI 2.0-3.5) in the B2a group, 2.8 years (95% CI 2.0-3.3) in the B2b group, 1.9 years (95% CI 0.8-4.0) in the B2c group, and 2.3 years (95% CI 1.2-ND [no data]) in the B2d group, respectively (p = 0.896). The median TTP in B2a, B2b, B2c, and B2d sub-substage HCC were13.2, 12.1, 13.8, and 11.5 months, respectively (p = 0.047). The median TTP in B2a + B2c sub-substage patients was longer than that in B2b + B2d sub-substage HCC patients (14.0 months and 10.4 months; p = 0.002). Conclusion: No significant differences were observed in the OS among HCC patients subclassified based on the maximum tumor diameter and tumor number in Kinki criteria stage B2. Consequently, Kinki criteria stage B2 HCC is a homogeneous subgroup in terms of OS prediction. However, shorter TTP in B2b + B2c sub-substage HCC patients than that in B2a + B2c sub-substage HCC patients suggests that different treatment strategy, such as systemic therapy with targeted agents instead of TACE, may be suitable to preserve the liver function. (C) 2017 S. Karger AG, Basel
  • Tadaaki Arizumi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Ken Kamata; Kosuke Minaga; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 589 - 597 2017年 [査読有り]
     
    Background: Transarterial chemoembolization (TACE) is recommended for patients with hepatocellular carcinoma (HCC) in Barcelona Clinic Liver Cancer (BCLC) stage B. However, because of the heterogeneity of HCC in BCLC stage B; various subclassification systems have been proposed to predict the prognosis of patients. Previously, we proposed the Kinki criteria for precise classification of HCC cases in BCLC stage B. In this study, we compared the time to TACE refractoriness in HCC patients with Kinki criteria substages B1 and B2-HCC. Summary: Between January 2006 and December 2013, 592 HCC patients (substage B1, n = 118; substage B2, n = 170) underwent TACE. Time to progression under TACE treatment was defined as the time to untreatable progression (TTUP). TTUP and changes in liver function were analyzed in patients with substages B1 and B2-HCC. The median TTUP was 25.7 months (95% CI 19.3-37.3) and 16.4 months (95% CI 13.1-20.2) in patients with substage B1-HCC and substage B2-HCC, respectively (p = 0.0050). In patients with substage B2-HCC, median Child-Pugh scores after the first TACE session was significantly different from those after third and fifth TACE sessions (first-third, p = 0.0020; first-fifth, p = 0.0008). Key Message: TACE refractoriness occurred earlier in patients with substage B2-HCC than those with substage B1-HCC; deterioration of liver function with repeated TACE was more obvious in HCC cases with stage-B1 tumor. Shorter TTUP and impaired liver function due to repeated TACE could be responsible for the shorter survival in patients with substage B2-HCC. (C) 2017 S. Karger AG, Basel
  • Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 611 - 617 2017年 [査読有り]
     
    Objectives: Previously, no therapeutic agent has been known to improve the overall survival compared with placebo in patients with hepatocellular carcinoma (HCC), who have progressed after sorafenib. In this patient population, regorafenib was first demonstrated to confer a survival benefit in the RESORCE trial, and subsequently it was approved as a second-line treatment for patients with advanced HCC. An open-label expanded access program (EAP) of regorafenib was implemented for compassionate use. We investigated the efficacy and safety of regorafenib based on our experience of the RESORCE trial and the EAP. Methods: Data from 5 patients from the RESORCE trial and 6 from the EAP were analyzed retrospectively. All patients had tolerated prior sorafenib and were progressing during sorafenib treatment. Results: The median progression-free survival was 9.2 months (95% CI 2.3-16.1). One patient achieved a partial response and 7 achieved stable disease. The objective response rate was 9.1%, and the disease control rate was 72.7%. No treatment-associated mortalities were observed. Grade 3 hypophosphatemia was observed in 2 patients, grade 2 anorexia was observed in 5 patients, and grade 3 neutropenia was observed in 2 patients. Grade 2 and grade 3 thrombocytopenia were observed in 2 and 3 patients, respectively. All treatment-related adverse events were improved by reduction or interruption of regorafenib. Five patients showed decreased serum albumin levels. Conclusion: Sorafenib and regorafenib sequential therapy presents a safe and effective treatment option for patients with advanced HCC. (C) 2017 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 35 6 618 - 622 2017年 [査読有り]
     
    With the development of molecular targeting therapy, several treatment options for advanced hepatocellular carcinoma (HCC) have become available in cases where curative and other palliative treatments, such as radiofrequency ablation, surgical resection, and transarterial chemoembolization, are not applicable. However, with the detection of a variety of mutations in cancer-related genes in a single tumor, molecular heterogeneity is commonly observed in HCC. Therefore, mutations in the major cellular signaling pathways underlie the development of resistance to molecular targeting agents. On the contrary, immune checkpoint inhibitors have proven effective in patients who are refractory to conventional treatments and molecular targeting therapy. Several clinical trials are currently investigating the efficacy of immune checkpoint inhibitors both individually and in combination with other types of anticancer agents. In this review, we focus on the potential of immune checkpoint blockade in the treatment of human HCC. (C) 2017 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 92 40 - 49 2017年 [査読有り]
     
    Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the prognosis of patients with advanced stage of disease remains unfavorable. Several immune therapies have been applied to HCC, and their responses have not been satisfactory. The immune response to cancer is determined by the balance between the antigenicity of the tumor and the microenvironment of cancer tissues. Generally, accumulated genetic mutations are observed in HCC, which may lead to increased neoantigens on cancer cells with high antigenicity. However, cancer cells may evade the immune system because of alterations in molecules and cellular pathways involved in antigen processing and presentation. In addition, hypoxia in tissue induces several cytokines, chemokines, and immunosuppressive molecules from HCC cells and stromal cells. These cells also produce cytokines that attract regulatory T cells infiltrating tumor tissues and contribute to establishing an immunosuppressive microenvironment. Some cancers show a good response to immune checkpoint therapy. However, prolonged stabilization of disease for this treatment is reportedly 12-41% in patients with advanced cancer. Therefore, immunosuppressive forces in the microenvironment of HCC may cause resistance to immune therapy, and modification of the tumor microenvironment may restore normal anticancer immunity. In this review, we focus on the immunological microenvironment of HCC tissues and discuss how the immunosuppressive environment of HCC should be modulated to achieve a favorable response to immune therapy, such as immune checkpoint therapy, in HCC. (C) 2016 S. Karger AG, Basel
  • Toshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
    INFLAMMATORY BOWEL DISEASES 23 1 57 - 65 2017年01月 [査読有り]
     
    Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and HSPA4 are involved in the refractory clinical course and development of CAC. RNA-binding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, HSPA4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.
  • Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Iwanishi; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Masatoshi Kudo
    ONCOLOGY 92 3 - 9 2017年 [査読有り]
     
    Introduction: Recently, the treatment of chronic hepatitis C has markedly advanced. A phase III clinical study of combination therapy with sofosbuvir (SOF) and ledipasvir (LDV) was conducted in Japan, and the additive therapeutic effects were reported. In this study, we report the results of treatment in our hospital. Methods: Of 147 patients with chronic type C liver disease who had consulted our hospital since September 2015 and received SOF/LDV therapy, in 91 subjects a sustained virological response of 12 weeks (SVR12) could be evaluated. Results: In all 91 patients, end treatment response was achieved. Subsequently, recrudescence was noted in 1 before the completion of treatment (week 12); an SVR12 was achieved in 90 patients (99%). The following adverse reactions were observed in 3 patients (3.3%): bradycardia, paroxysmal atrial fibrillation, and heart failure with QT prolongation, which were associated with heart disease. Conclusion: A favorable SVR was achieved by SOF/LDV therapy even in elderly patients, those with liver cirrhosis, or those having undergone radical treatment of liver cancer. Furthermore, a high tolerance was demonstrated, but adverse reactions associated with the heart may appear in patients with heart disease as an underlying disease; strict management during treatment is necessary. (C) 2016 S. KargerAG, Basel
  • Masashi Kono; Yasunori Minami; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Yoriaki Komeda; Toshiharu Sakurai; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 92 29 - 34 2017年 [査読有り]
     
    Objective: To compare contrast tissue harmonic imaging (THI) with low mechanical index (MI) and conventional contrast harmonic imaging (CHI) with respect to lesion visibility of hepatocellular carcinoma (HCC). Methods: One hundred and twenty-five patients (84 men and 41 women, age range 39-94 years, mean age 74 years) with 100 naive HCCs and 30 lesions after radiofrequency ablation (RFA) for HCC were evaluated. One hundred and four patients had liver cirrhosis of Child-Pugh class A, and the remaining 21 had Child-Pugh class B cirrhosis. The lesion conspicuity and intratumoral echogenicity during the postvascular phase were compared using conventional CHI and contrast THI with low MI. Results:The MI values ranged from 0.20 to 0.30 on conventional CHI and from 0.30 to 0.35 on contrast THI. Regarding HCC lesion conspicuity, contrast THI with low MI was clearer in 79 lesions (60.8%), equal in 34 lesions (26.2%), and less clear in 17 lesions (13.1%) when compared with conventional CHI. The lesion conspicuity with contrast THI was significantly better than that with conventional CHI (p < 0.01). All of the postablative lesions were well delineated in patients who received RFA. Conclusion: Low-MI contrast THI was superior to conventional CHI with respect to lesion visibility of HCCs and might offer good imaging for the guiding of RFA. (C) 2016 S. Karger AG, Basel
  • Wing Yee Kwok; Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Lda; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Lwanishi; Hirokazu Chishina; Masashi Kono; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Eisuke Enoki; Takuya Nakai; Tsutomu Kumabe; Osamu Nakashima; Fukuo Kondo; Masatoshi Kudo
    ONCOLOGY 92 16 - 28 2017年 [査読有り]
     
    The patient was a 20-year-old male in whom a hepatic hyper vascular mass accompanied by intratumoral hemorrhage was detected on examination for epigastric pain. Based on the enlargement of the mass and diagnostic imaging, hepatocellular adenoma (HCA) was suspected and hepatectomy was performed. The lesion was diagnosed as malignant transformation of P-catenin-activated HCA. There are only few reports of cases with malignant transformation of HCA in Japan; it is necessary to accumulate cases to investigate it. (C) 2016 S. Karger AG, Basel
  • Toshiharu Sakurai; Hiroshi Kashida; Yoriaki Komeda; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masayuki Kitano; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
    INFLAMMATORY BOWEL DISEASES 23 1 66 - 74 2017年01月 [査読有り]
     
    Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel disease (IBD). Stress response proteins Cirp and heat shock protein A4 are involved in the refractory clinical course and development of CAC. RNAbinding motif protein 3 (RBM3) is induced in response to various stresses and is upregulated in several cancers. However, the role of RBM3 in CAC is unclear. Methods: We assessed RBM3 expression and function in 263 human intestinal mucosa samples from patients with IBD and in Rbm3-deficient (Rbm3(-/-)) mice. Results: Expression of RBM3 was correlated with the expression of stress response proteins Cirp, heat shock protein A4, and HSP27 in the colonic mucosa of patients with IBD. Significant correlation was observed between the expression of RBM3 and that of Bcl-xL or stem cell markers. RBM3 expression increased and significantly correlated with R-spondin expression in the colonic mucosa of patients with refractory IBD, a condition associated with increased cancer risk, and RBM3 was overexpressed in human CACs. In the murine CAC model, Rbm3 deficiency decreased R-spondin and Bcl-xL expression and increased apoptotic cell number in the colonic mucosa, leading to reduced tumor multiplicity. Transplantation of wild-type and Rbm3(-/-) bone marrow did not alter tumor burden, indicating the importance of RBM3 in epithelial cells. Conclusions: Our findings indicated that RBM3 was required for efficient inflammatory carcinogenesis in the murine CAC model and suggested that RBM3 could be a predictive biomarker of CAC risk and a new therapeutic target for cancer prevention in patients with IBD.
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 92 10 - 15 2017年 [査読有り]
     
    Objective: In order to evaluate the influence of liver inflammation on liver stiffness measurement (LSM) by the simultaneous use of shear wave and strain imaging (combinational elastography), shear wave and strain imaging were compared before and after initial therapy for autoimmune hepatitis (AIH). Methods: Nine AIH patients initially treated with steroid were enrolled. Transient elastography and real-time tissue elastography were performed just before and 1 month after the start of initial steroid treatment. Blood samples, LSM, and the liver fibrosis index (LFI) were compared. Results: Aspartate aminotransferase (p = 0.002) and alanine aminotransferase (ALT) (p = 0.015) were significantly decreased after initial treatment. The LSM was 15.5 +/- 9.6 kPa at baseline, decreasing to 7.2 +/- 2.3 kPa after initial treatment p = 0.034). The LFI was 1.67 +/- 0.67 at baseline and 1.61 +/- 0.66 after initial treatment; no significant change in LFI was recognized (p = 0.842). Between Delta ALT and Delta LSM, a significant regression equation could be calculated as follows: Delta ALT = -0.55 + 0.654 x Delta LSM. Conclusions: Combinational elastography was useful in evaluating not only the degree of liver fibrosis, but also the degree of liver inflammation in AIH. (C) 2017 S. Karger AG, Basel
  • Ken Kamata; Mamoru Takenaka; Masayuki Kitano; Shunsuke Omoto; Takeshi Miyata; Kosuke Minaga; Kentaro Yamao; Hajime Imai; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 23 4 661 - 667 2017年01月 [査読有り]
     
    AIM To assess the long-term outcomes of this procedure after removal of self-expandable metal stent (SEMS). The efficacy and safety of endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) with SEMS were also assessed. METHODS Between January 2010 and April 2015, 12 patients with acute calculous cholecystitis, who were deemed unsuitable for cholecystectomy, underwent EUS-GBD with a SEMS. EUS-GBD was performed under the guidance of EUS and fluoroscopy, by puncturing the gallbladder with a needle, inserting a guidewire, dilating the puncture hole, and placing a SEMS. The SEMS was removed and/or replaced with a 7-Fr plastic pigtail stent after cholecystitis improved. The technical and clinical success rates, adverse event rate, and recurrence rate were all measured. RESULTS The rates of technical success, clinical success, and adverse events were 100%, 100%, and 0%, respectively. After cholecystitis improved, the SEMS was removed without replacement in eight patients, whereas it was replaced with a 7-Fr pigtail stent in four patients. Recurrence was seen in one patient (8.3%) who did not receive a replacement pigtail stent. The median follow-up period after EUS-GBD was 304 d (78-1492). CONCLUSION EUS-GBD with a SEMS is a possible alternative treatment for acute cholecystitis. Long-term outcomes after removal of the SEMS were excellent. Removal of the SEMS at 4-wk after SEMS placement and improvement of symptoms might avoid migration of the stent and recurrence of cholecystitis due to food impaction.
  • Naoshi Nishida; Tadaaki Arizumi; Satoru Hagiwara; Hiroshi Ida; Toshiharu Sakurai; Masatoshi Kudo
    LIVER CANCER 6 2 113 - 125 2017年 [査読有り]
     
    Background: Several studies suggest the role of circulating microRNAs (miRNAs) as biomarkers of hepatocellular carcinoma (HCC). However, the serum miRNA profile associated with the response to sorafenib remains to be elucidated. The aim of this study was to clarify the specific miRNAs in serum that could predict the early response of HCC to sorafenib treatment. Summary: Analyzing the sera from 16 HCC patients, we selected five miRNAs that showed differences in serum levels between patients with and without tumor responses among 179 known secretory miRNAs by using locked nucleic acid probe -based quantitative PCR. Through further analysis using a validation cohort that included 53 HCC patients who underwent sorafenib treatment and 8 healthy control subjects, we found that miR-181a-5p and miR-3395p showed significant differences in serum levels among patients with partial response (PR), stable disease (SD), and progressive disease (PD), where PR patients showed the highest and PD the lowest levels. We also analyzed the factors associated with disease control (DC; PR or SD) 3 months after the initiation of sorafenib treatment; patients with DC showed a significantly higher level of serum miR-181a-5p than non -DC patients or healthy control subjects (p = 0.0349 and 0.0180 for DC vs. non -DC and control vs. non -DC by Tukey-Kramer test, respectively). We further conducted multivariate analysis among HCC patients with Barcelona Clinic Liver Cancer stage C using extrahepatic metastasis, serum decarboxyprothrombin, and miR-181a-5p levels as covariables; serum miR-181a-5p was the only independent factor for achieving DC (p = 0.0092, odds ratio 0.139, and 95% confidence interval 0.011-0.658). In addition, miR-181a-5p level was also the only independent factor affecting overall survival (p = 0.0194, hazard ratio 0.267, and 95% confidence interval 0.070-0.818). Key Messages: A high serum level of miR-181a-5p before treatment is associated with DC after the initiation of sorafenib. (C) 2016 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Yoriaki Komeda; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
    LIVER CANCER 6 3 227 - 235 2017年 [査読有り]
     
    Aim/Background: The ultimate aim of any treatment for hepatocellular carcinoma (HCC) is to improve overall survival (OS); however, the clinical significance of time to progression (TTP) after transarterial chemoembolization (TACE) is unclear. This retrospective study examined the association between OS and the newly defined time to TACE progression (TTTP) to assess whether TTTP can be an alternative to OS in HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B. Methods: Between January 2006 and December 2013, 592 patients with HCC (BCLC B1, n = 118; BCLC B2, n = 170) underwent TACE. TTTP was then redefined as time to progression from the first image taken after TACE. The relationship between TTTP and OS was then examined based on survival time. Results: Survival analysis revealed significant differences in the OS of patients with BCLC B1 and those with BCLC B2 (median OS: 42.3 months, 95% confidence interval [CI] 34.4-50.7; and 29.3 months, 95% CI 26.1-37.6, respectively, p = 0.0348). The median TTTP values were 9.5 months (95% CI 7.0-10.9) and 5.3 months (95% CI 4.6-6.7), respectively (p = 0.0078). There was a moderate positive correlation between OS and TTTP for both B1 (R-2 = 0.6563, p = 0.0045) and B2 (R-2 = 0.6433, p = 0.0052) substages. There was also a positive correlation between OS and TTTP for the combined B1 and B2 substages (R-2 = 0.6590, p = 0.0024). Conclusions: There was a moderate correlation between the TTTP and OS of patients with HCC after TACE therapy, where the patients with short TTTP represented short OS, indicating that TTTP is an alternative parameter for survival analysis of HCC patients with BCLC stage B tumors who undergo TACE. (C) 2017 S. Karger AG, Basel
  • Naoshi Nishida; Norihisa Yada; Satoru Hagiwara; Toshiharu Sakurai; Masayuki Kitano; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 31 9 1646 - 1653 2016年09月 [査読有り]
     
    Background and AimNon-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC). Previously, we reported that DNA oxidation induced epigenetic alteration of tumor suppressor genes (TSGs) and contributed to HCC emergence. Here, we examine the associations between clinicopathological characteristics of NAFLD and advanced oxidative DNA damage that is associated with TSG methylation in the NAFLD liver. MethodsLiver biopsies from 65 NAFLD patients were analyzed for clinicopathological features and oxidative DNA damage using immunohistochemistry of 8-hydroxydeoxyguanosine (8-OHdG). Abnormal DNA methylation in the promoters of 6 TSGs, HIC1, GSTP1, SOCS1, RASSF1, CDKN2A, and APC, was examined using MethyLight. Associations between clinicopathological characteristics, methylation of TSGs, and accumulation of 8-OHdG were analyzed. ResultsWe found that aspartate aminotransferase/alanine aminotransferase ratio, the fibrosis-4 index, and serum -fetoprotein (AFP) level were associated with degree of 8-OHdG, and AFP was an independent factor among them (P=0.0271). Regarding pathological findings, hepatocellular ballooning and stage of fibrosis were also associated with oxidative DNA damage (P=0.0021 and 0.0054); ballooning was an independent risk for detecting high degree of 8-OHdG in hepatocytes (odds ratio 7.38, 95% confidence interval 1.41-49.13, P=0.0171). Accumulation of methylated TSGs was significantly associated with deposition of 8-OHdG (P=0.0362). ConclusionsPatients with high serum AFP and high degree of ballooning showed accumulation of oxidative DNA damage that could be a seed of DNA methylation responsible for hepatocarcinogenesis. These characteristics could be risk of HCC; such patients require urgent intervention such as lifestyle modification.
  • Kosuke Minaga; Masayuki Kitano; Hajime Imai; Yogesh Harwani; Kentaro Yamao; Ken Kamata; Takeshi Miyata; Shunsuke Omoto; Kumpei Kadosaka; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 22 30 6917 - 6924 2016年08月 [査読有り]
     
    AIM: To assess anti-migration potential of six biliary covered self-expandable metal stents (C-SEMSs) by using a newly designed phantom model. METHODS: In the phantom model, the stent was placed in differently sized holes in a silicone wall and retracted with a retraction robot. Resistance force to migration (RFM) was measured by a force gauge on the stent end. Radial force (RF) was measured with a RF measurement machine. Measured flare structure variables were the outer diameter, height, and taper angle of the flare (ODF, HF, and TAF, respectively). Correlations between RFM and RF or flare variables were analyzed using a linear correlated model. RESULTS: Out of the six stents, five stents were braided, the other was laser-cut. The RF and RFM of each stent were expressed as the average of five replicate measurements. For all six stents, RFM and RF decreased as the hole diameter increased. For all six stents, RFM and RF correlated strongly when the stent had not fully expanded. This correlation was not observed in the five braided stents excluding the laser cut stent. For all six stents, there was a strong correlation between RFM and TAF when the stent fully expanded. For the five braided stents, RFM after full stent expansion correlated strongly with all three stent flare structure variables (ODF, HF, and TAF). The laser-cut C-SEMS had higher RFMs than the braided C-SEMSs regardless of expansion state. CONCLUSION: RF was an important anti-migration property when the C-SEMS did not fully expand. Once fully expanded, stent flare structure variables plays an important role in anti-migration.
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    HEPATOLOGY 64 1 306 - 306 2016年07月 [査読有り]
  • Kosuke Minaga; Masayuki Kitano; Hiroki Sakamoto; Takeshi Miyata; Hajime Imai; Kentaro Yamao; Ken Kamata; Shunsuke Omoto; Kumpei Kadosaka; Toshiharu Sakurai; Naoshi Nishida; Yasutaka Chiba; Masatoshi Kudo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 9 4 483 - 494 2016年07月 [査読有り]
     
    Background: Interventional endoscopic ultrasound (EUS)-guided procedures such as EUS-guided celiac ganglia neurolysis (EUS-CGN) and EUS-guided broad plexus neurolysis (EUS-BPN) were developed to treat abdominal cancer-associated pain; however, these procedures are not always effective. The aim of this study was to explore predictors of pain response in EUS-guided neurolysis for pancreatic cancer-associated pain. Methods: This was a retrospective analysis of prospectively collected data of 112 consecutive patients who underwent EUS-BPN in our institution. EUS-CGN was added in cases of visible celiac ganglia. The neurolytic-spread area was divided into six sections and evaluated by post-procedural computed tomography scanning. Pain intensity was assessed using a visual analog scale (VAS), and a decrease in VAS scores by 3 points after neurolysis was considered a good pain response. Univariable and multivariable logistic regression analyses were performed to explore predictors of pain response at 1 and 4 weeks, and complications. Results: A good pain response was obtained in 77.7% and 67.9% of patients at 1 and 4 weeks, respectively. In the multivariable analysis of these patients, the combination method (EUS-BPN plus CGN) was a significant positive predictive factor at 1 week (odds ratio = 3.69, p = 0.017) and 4 weeks (odds ratio = 6.37, p = 0.043). The numbers of neurolytic/contrast spread areas (mean SD) were 4.98 +/- 1.08 and 4.15 +/- 1.12 in patients treated with the combination method and single method, respectively (p < 0.001). There was no significant predictor of complications. Conclusions: EUS-BPN in combination with EUS-CGN was a predictor of a good pain response in EUS-guided neurolysis for pancreatic cancer-related pain. The larger number of neurolytic/contrast spread areas may lead to better outcomes in patients receiving combination treatment.
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    HEPATOLOGY 63 5 1744 - 1745 2016年05月 [査読有り]
  • Naoshi Nishida; Masatoshi Kudo
    Journal of Japanese Society of Gastroenterology 113 5 775 - 784 2016年05月 [査読有り]
  • Takeshi Miyata; Masayuki Kitano; Shunsuke Omoto; Kumpei Kadosaka; Ken Kamata; Hajime Imai; Hiroki Sakamoto; Naoshi Nisida; Yogesh Harwani; Takamichi Murakami; Yoshifumi Takeyama; Yasutaka Chiba; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 22 12 3381 - 3391 2016年03月 [査読有り]
     
    AIM: To assess the usefulness of contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS) for lymph node metastasis in pancreatobiliary carcinoma. METHODS: All patients suspected of pancreatobiliary carcinoma with visible lymph nodes after standard EUS between June, 2009 and January, 2012 were enrolled. In the primary analysis, patients with successful EUS-fine needle aspiration (FNA) were included. The lymph nodes were assessed by several standard EUS variables (short and long axis lengths, shape, edge characteristic and echogenicity), color Doppler EUS variable [central intranodal blood vessel (CIV) presence] and CH-EUS variable (heterogeneous/homogeneous enhancement patterns). The diagnostic accuracy relative to EUS-FNA was calculated. In the second analysis, N-stage diagnostic accuracy of CH-EUS was compared with EUS-FNA in patients who underwent surgical resection. RESULTS: One hundred and nine patients (143 lymph nodes) fulfilled the criteria. The short axis cutoff >= 13 mm predicted malignancy with a sensitivity and specificity of 72% and 85%, respectively. These values were 72% and 63% for the long axis cut-off >= 20 mm, 62% and 75% for the round shape variable, 81% and 30% for the sharp edge variable, 66% and 61% for the hypoechogenicity variable, 70% and 72% for the CIV-absent variable, and 83% and 91% for the heterogeneous CH-EUS-enhancement variable, respectively. CH-EUS was more accurate than standard and color Doppler EUS, except the short axis cut-off. Notably, three patients excluded because of EUS-FNA failure were correctly N-staged by CH-EUS. CONCLUSION: CH-EUS complements standard and color Doppler EUS and EUS-FNA for assessment of lymph node metastases.
  • Reply: Hepatocyte damage due to protoporphyrin deposition
    Hagiwara S; Nishida N; Kudo M
    Hepatology 64 306  2016年 [査読有り]
  • Satoshi Kitai; Masatoshi Kudo; Naoshi Nishida; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
    LIVER CANCER 5 3 175 - 189 2016年 [査読有り]
     
    Background & Aims: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC. Methods: Of the 58,886 patients with HCC registered in the nationwide survey of the Liver Cancer Study Group of Japan (January 2000-December 2005), we included 1,344 patients with primary HCC and Child-Pugh (C-P) grade C for analysis in this retrospective study. Among the patients analyzed, 108 underwent LT, 273 were treated by local ablation therapy (LAT), 370 were treated by transarterial chemoembolization (TACE), and 593 received best supportive care (BSC). The effect of LT, LAT, and TACE on overall survival (OS) was analyzed using multivariate and propensity score analyses. Results: Patient characteristics did not differ significantly between each treatment group and the BSC group, after propensity score matching. LAT (hazard ratio [HR]) = 0.568; 95% confidence interval [CI], 0.40-0.80) and TACE (HR = 0.691; 95% CI, 0.50-0.96) were identified as significant contributors to OS if the C-P score was less than 11 and tumor conditions met the Milan criteria. Conclusions: For patients with HCC within the Milan criteria and with a C-P score of 10 or 11, locoregional treatment can be used as a salvage treatment if LT is not feasible. Copyright (C) 2016 S. Karger AG, Basel
  • Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Tomohiro Minami; Mina Iwanishi; Hirokazu Chishina; Kazuomi Ueshima; Yoriaki Komeda; Tadaaki Arizumi; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 620 - 626 2016年 [査読有り]
     
    Objective: Treatment for chronic hepatitis C has recently developed in a very rapid manner. In Japan, in September 2014, IFN-free asunaprevir (ASV) and daclatasvir (DCV) became available for combination therapy. We report the treatment outcomes achieved at our hospital using this combination therapy. Methods: Sustained virological response (SVR) 24 could be evaluated in 120 of 125 patients with chronic liver disease type C who visited our hospital and were treated with ASV/DCV after September 2014, and these patients were analyzed. Results: SVR24 was achieved in 106 patients (88%). End-of-treatment response was not achieved in 10 patients (8.3%). Five of them carried multiple-resistant NS3/4A or NS5A region, and administration was discontinued early in 4 patients due to adverse effects. After ASV/DCV treatment, hepatocellular carcinoma (HCC) developed in 2 patients (1.7%) and recurred in 5 (4.2%). Conclusions: ASV/DCV treatment achieved favorable SVR in elderly and hepatic cirrhosis patients and patients in whom HCC was cured. However, an increase in the incidence of HCC development in patients who markedly respond to direct-acting antivirals treatment is expected and surveillance of HCC becomes more important. (C) 2016 S. Karger AG, Basel
  • Naoshi Nishida; Masashi Kono; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Tashiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 632 - 639 2016年 [査読有り]
     
    Background: An interferon-free regimen including sofosbuvir and ribavirin (RBV) for patients with hepatitis C virus (HCV) genotype 2 (G2) infection leads to a drastic improvement of sustained virological response (SVR). However, the safety, tolerability, and efficacy in patients aged 75 or older have not been completely understood. Summary: Fifty-six patients with HCV G2 infection who were treated with sofosbuvir and weight-based dose of RBV were enrolled. Thirty-seven patients aged and 19 patients aged were classified as the aged and non-aged groups, respectively. The aged group was characterized by significantly more number of women, history of hepatocellular carcinoma, low serum albumin (ALB) level, low hemoglobin (Hb) concentration, low estimated glomerular filtration rate (eGFR), and high fibrosis-4 index (p = 0.0029). Forty-one patients were evaluated for SVR at 12 weeks after the end of therapy (SVR12); of them, all but one completed the treatment scheduled for 12 weeks. The aged group showed lower SVR12 rate than the non aged group (81.3%for aged and 96.0%for non-aged groups). Although the Hb concentration and eGFR are significantly lower in the aged group throughout the clinical course, all patients in the aged group completed the 12-week treatment with a gradual increase of serum ALB level. Key Messages: The combination of sofosbuvir plus RBV is tolerable and beneficial in patients aged >75. However, intensive management of anemia by dose reduction of RBV is necessary, which could lead to a low SVR12 rate compared to that observed in patients younger than 75 years. (C) 2016 S. Karger AG, Basel
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 650 - 653 2016年 [査読有り]
     
    Objective: We have reported about real-time tissue elastography (RTE), which displays relative strain by measuring the relative distortion of the tissue, and found this information to be useful for diagnosing liver fibrosis. However, its use in predicting hepatocellular carcinoma has not been reported as yet. Here, we investigated RTE to predict liver carcinogenesis in patients with chronic hepatitis C virus (HCV) infection. Methods: We enrolled 160 patients with chronic HCV, who were followed up for 39.9 +/- 22.9 weeks (median). They underwent RTE and then ultrasounds every 3-6 months. Results: Respective cumulative liver cancer incidences for years 1, 2, 3, 4, and 5 were, for the entire cohort: 2.0, 5.6, 8.8, 13.1, and 23.9%; for those whose liver fibrosis index (LFI) was <= 2.0: 0.0, 0.0, 0.0, 0.0, and 0.0%; for those whose LFI was 2-2.8:0.0, 7.4, 7.4, 13.2 and 19.9%; and for those whose LFI was >2.8: 12.9, 12.9, 21.7, 31.4, and 31.4% (p = 0.011; log-rank test). Conclusions: Measurements of LFI by strain imaging can effectively predict liver cancer risk in patients with chronic HCV infection. (C) 2016 S. Karger AG, Basel
  • Masahiro Takita; Mina Iwanishi; Tomohiro Minami; Masashi Kono; Hirokazo Chishina; Tadaaki Arizumi; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Nishida Naoshi; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 654 - 658 2016年 [査読有り]
     
    Objective: The objective of treatment for polycystic liver disease is to reduce the liver volume and reduce or resolve compression symptoms such as abdominal fullness and abdominal pain due to hepatomegaly. Liver cysts are treated internally by puncture and aspiration of the cyst contents or hepatic artery embolization and surgically by cyst fenestration or hepatectomy, but no clear consensus has been reached concerning their selection. We introduced monoethanolamine oleate (EO) sclerotherapy therapy for liver cysts in 1999 and reported its effectiveness. In this study, cases were added, and the results including those of long-term follow-up were evaluated. Subjects: Twenty-two patients (5 males and 17 females, mean age 65.2) who underwent EO infusion therapy for liver cysts between January 1999 and June 2011 were evaluated. Methods: Liver cysts were punctured under ultrasound guidance, and a 7Fr pigtail catheter was inserted. After aspirating the cyst contents, EO was infused, and a clamp was applied for 24 h. Then, the catheter was declamped, cyst contents were aspirated again, and the catheter was removed. After the treatment, the cyst size was measured, and the patients were followed up. Results: Eight simple cysts in 8 patients (simple cyst group) and 21 cysts in 14 patients with multiple cysts (polycystic liver disease group) were treated and followed up over a median of 78 months (0-203 months). The mean volume reduction rate was 99% in the simple cyst group and 91% in the polycystic liver disease group (p = 0.04). One procedural accident resulting in liver abscess formation was observed in 1 patient 1 week after discharge, and it required drain placement and antibiotic administration. While mild abdominal pain was observed in a few patients, it was resolved spontaneously under observation. Conclusion: EO infusion therapy achieves fairly high treatment response in the volume reduction (99%) and sustained shrinkage over long-term follow-up. Therefore, this is a breakthrough technique in the treatment of polycystic liver disease as well as simple cyst and should be a standard of care in the treatment of this disease. (C) 2016 S. Karger AG, Basel
  • Hirokazu Chishina; Satoru Hagiwara; Naoshi Nishida; Kazuomi Ueshima; Toshiharu Sakurai; Hiroshi Ida; Yasunori Minami; Masahiro Takita; Masashi Kono; Tomohiro Minami; Mina Iwanishi; Yasuko Umehara; Tomohiro Watanabe; Yoriaki Komeda; Tadaaki Arizumi; Masotoshi Kudo
    DIGESTIVE DISEASES 34 6 659 - 664 2016年 [査読有り]
     
    Objective: Refractory ascites reduces the quality of life of liver cirrhosis patients. Albumin preparation and diuretics, such as furosemide, have been used to treat refractory ascites, but the effect was poor in many patients. In this study, we analyzed patients treated with tolvaptan (TLV) at our hospital and investigated predictors of the effect. Methods: The subjects were 70 patients for whom TLV was introduced to treat refractory ascites who could be analyzed between November 2013 and March 2015 at our hospital. Patient background before initiation of oral TLV treatment, the dose of diuretics, and each item of biochemical tests of blood and urine were investigated, and factors correlated with the treatment effect were analyzed. An increase of >= 1,000 ml in the daily urine volume from the day before oral treatment or a decrease of kg in the body weight within 7 days as an early effect was observed in 33 patients and not observed in 37 patients. TLV treatment was continued for 60 days or longer in 12 of the 37 patients in whom no early effect was observed, and the presence or absence of a delayed effect and predictors of the effect were investigated. A decrease in as cites on abdominal CT with improvement of subjective symptoms at 60 days was defined as a delayed effect. Results: When early predictors of the effect were investigated by univariate analysis, serum blood urea nitrogen (BUN) and serum creatinine (Cr) were significantly higher in the non responder group (BUN: p = 0.03, Cr: p = 0.04), but no factor independently associated with the treatment effect was extracted on multivariate analysis. The delayed effect was noted in 4 (33.3%) of the 12 patients, but no predictor of the effect before treatment was identified. However, reactions, such as an increase in serum Na and reduction of urinary osmotic pressure, were observed early after TLV administration in some patients in whom the delayed effect was observed. Conclusions: The diuretic effect of TLV may decrease in renal hypofunction patients. Since the delayed effect was noted in a specific ratio of patients, continuation of TLV administration is an option even though the early treatment effect is poor unless ascites aggravates or adverse effects develop. (C) 2016 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 671 - 678 2016年 [査読有り]
     
    Background: The standard treatment option that is available for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE). However, the condition of the patients with BCLC stage B disease is heterogeneous showing different tumor statuses and Child Pugh scores; treatment strategies other than TACE are frequently employed for the patients in this stage. Based on the subclassification system proposed by Bolondi et al. [Semin Liver Dis 2012;32:348-359], we developed the Kinki criteria focusing on a substaging for BCLC stage B disease, which is simpler and should be more suitable in actual clinical setting in Japan. In this study, we evaluated the performance of Kinki criteria. Summary: This study included 1,633 HCC patients who received first line treatment at the Kindai University Hospital. Patients were classified into subgroups based on the Kinki criteria and the survival time was estimated for each group. There were 156 (33.3%) patients in subclass B1, 278 (59.3%) in B2, and 35 (7.4%) in B3. The median overall survival times and 95% CI for BCLC B subclasses B1, B2, and B3 were 4.3 years (3.7-4.9), 2.9 years (2.2-3.4), and 1.1 years (0.5-1.8), respectively (p < 0.001). Key Messages: Classification of HCC patients in BCLC stage B based on the Kinki criteria showed statistically significant differences in survival, indicating the performance of Kinki criteria, which takes Child Pugh score and tumor status into account for determining treatment options for HCC in BCLC stage B. (C) 2016 S. Karger AG, Basel
  • Yasunori Minami; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Tadaaki Arizumi; Masahiro Takita; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 687 - 691 2016年 [査読有り]
     
    Objective: Radiofrequency ablation (RFA) induces gas bubbles in ablation zones, and the ablative margin cannot be evaluated accurately on ultrasound (US) during and immediately after RFA. This study assessed the usefulness of US-US fusion imaging to visualize the ablative margin of RFA for liver metastasis. Methods: RFA guided by US-US fusion imaging was performed on 12 targeted tumors in 10 patients. Secondary hepatic malignancies included patients with colorectal cancer (n = 4), breast cancer (n = 2), lung cancer (n = 1), gastrointestinal stromal tumor (n = 1), pancreatic neuroendocrine tumor (n = 1), and adrenocortical carcinoma (n = 1). The maximal diameter of the tumors ranged from 0.8 to 4.0 cm (mean SD 1.6 +/- 0.9 cm). Results: The mean number of electrode insertions was 1.6 per session (range 1-3). Technically, effective ablation was achieved in a single session in all patients, and safety ablative margins were confirmed on contrast-enhanced CT for early assessment of tumor response. There were no serious adverse events or procedure-related complications. During the follow-up period (median 220 days, range 31-417 days), none of the patients showed local tumor progression. Conclusion: US-US fusion imaging could show the tumor images before ablation and the ablative area on US in real time. The image overlay of US-US fusion imaging made it possible to evaluate the ablative margin three dimensionally according to the US probe action. Therefore, US-US fusion imaging can contribute to RFA therapy with a safety margin, that is, the so-called precise RFA. (C) 2016 S. Karger AG, Basel
  • Tomoyuki Nagai; Tokuzo Arao; Kazuto Nishio; Kazuko Matsumoto; Satoru Hagiwara; Toshiharu Sakurai; Yasunori Minami; Hiroshi Ida; Kazuomi Ueshima; Naoshi Nishida; Kazuko Sakai; Nagahiro Saijo; Kanae Kudo; Hiroyasu Kaneda; Daisuke Tamura; Keiichi Aomatsu; Hideharu Kimura; Yoshihiko Fujita; Seiji Haji; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 702 - 707 2016年 [査読有り]
     
    Background: Epithelial-mesenchymal transition (EMT) is considered to play a critical role in cancer progression and metastasis. However, the impact of EMT on the prognosis of hepatocellular carcinoma (HCC) is still elusive. In this study, we examined the relationship between the expression of EMT markers and recurrence-free survival (RFS) and overall survival (OS) in HCC patients after hepatic resection. Summary:The mRNA expression of 15 genes related to EMT was assessed by quantitative real-time polymerase chain reaction in cancerous tissues from 72 patients who underwent hepatic resection of HCC between January 2005 and December 2010 at our hospital. The upregulation of TWIST and the downregulation of tight junction protein ZO-1 (TJP1) were significantly associated with shorter RFS as well as OS. Increased levels of TWIST and decreased levels of TJP1 should be predictive markers for poor prognosis in patients with HCC after hepatectomy; those could serve as potential biomarkers for the treatment of HCC. Key Messages: A low level of TJP1 and high level of TWIST expression were prognostic factors predicting HCC after hepatic resection. (C) 2016 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 34 6 708 - 713 2016年 [査読有り]
     
    Accumulation of genetic and epigenetic alterations is a hallmark of cancer genomes, including those in hepatocellular carcinoma (HCC). Particularly, in human HCC, epigenetic changes are more frequently observed than genetic changes in a variety of cancer-related genes, suggesting a potential role for epigenetic alterations during hepatocarcinogenesis. Several environmental factors, such as inflammation, obesity, and steatosis, are reported to affect the epigenetic status in hepatocytes, which could play a role in HCC development. In addition, genetic mutations in histone modulators and chromatin regulators would be critical for the acceleration of epigenetic alteration. It is also possible that major genetic mutations of HCC, such as TP53 and CNTTB1 mutations, are associated with the disturbance of epigenetic integrity. For example, specific TP53 mutations frequently induced by aflatoxin B1 exposure might affect histone modifiers and nucleosome remodelers. Generally, epigenetic alteration is reversible, because of which dysregulation of transcription takes place, without affecting protein structure. Therefore, differentiation therapy is one of the potential approaches for HCC with advanced epigenetic alterations. On the other hand, a tumor carrying an accumulation of genetic mutations would result in many abnormal proteins that could be recognized as non-self and could be targets for immune reactions; thus, immune-checkpoint blockers should be effective for HCCs with genetic hypermutation. Although the emergence of genetic and epigenetic alterations could be linked to each other and there could be some crossover or convergence between these cancer pathways, characterization of the mutation spectrum of genetic and epigenetic alterations could influence future HCC treatment. (C) 2016 S. Karger AG, Basel
  • Satoru Hagiwara; Naoshi Nishida; Hirokazu Chishina; Hiroshi Ida; Toshiharu Sakurai; Yoriaki Komeda; Masayuki Kitano; Masatoshi Kudo
    INTERNAL MEDICINE 55 22 3273 - 3277 2016年 [査読有り]
     
    The patient was a 67-year-old female with liver cirrhosis due to hepatitis C. She was administered furosemide at 20 mg/day and spironolactone at 25 mg/day, but the ascites did not improve. Despite the additional administration of tolvaptan at 3.75 mg/day, the response to ascites was still poor. While the dose of tolvaptan was thereafter increased to 7.5 mg/day on the 7th hospital day, the ascites still persisted. However, she continued to receive tolvaptan (7.5 mg/day) because the worsening of her subjective symptoms was mild and she wished to do so. The ascites was later found to have almost completely disappeared on computed tomography (CT) at 6 months.
  • Satoru Hagiwara; Naoshi Nishida; Ah-Mee Park; Toshiharu Sakurai; Akira Kawada; Masatoshi Kudo
    HEPATOLOGY 62 5 1638 - 1639 2015年11月 [査読有り]
  • Naoshi Nishida; Toshimi Kaido; Masatoshi Kudo
    HEPATOLOGY 62 1151A - 1152A 2015年10月 [査読有り]
  • Atsushi Yamada; Takahiro Horimatsu; Yoshinaga Okugawa; Naoshi Nishida; Hajime Honjo; Hiroshi Ida; Tadayuki Kou; Toshihiro Kusaka; Yu Sasaki; Makato Yagi; Takuma Higurashi; Norio Yukawa; Yusuke Amanuma; Osamu Kikuchi; Manabu Muto; Yoshiyuki Ueno; Atsushi Nakajima; Tsutomu Chiba; C. Richard Boland; Ajay Goel
    CLINICAL CANCER RESEARCH 21 18 4234 - 4242 2015年09月 [査読有り]
     
    Purpose:<bold> </bold>Circulating microRNAs (miRNA) are emerging as promising diagnostic biomarkers for colorectal cancer, but their usefulness for detecting early colorectal neoplasms remains unclear. This study aimed to identify serum miRNA biomarkers for the identification of patients with early colorectal neoplasms. Experimental Design: A cohort of 237 serum samples from 160 patients with early colorectal neoplasms (148 precancerous lesions and 12 cancers) and 77 healthy subjects was analyzed in a three-step approach that included a comprehensive literature review for published biomarkers, a screening phase, and a validation phase. RNA was extracted from sera, and levels of miRNAs were examined by real-time RT-PCR. Results:<bold> </bold>Nine miRNAs (miR-18a, miR-19a, miR-19b, miR-20a, miR-21, miR-24, miR-29a, miR-92, and miR-125b) were selected as candidate biomarkers for initial analysis. In the screening phase, serum levels of miR-21, miR-29a, and miR-125b were significantly higher in patients with early colorectal neoplasm than in healthy controls. Elevated levels of miR-21, miR-29a, and miR-125b were confirmed in the validation phase using an independent set of subjects. Area under the curve (AUC) values for serum miR-21, miR-29a, miR-125b, and their combined score in discriminating patients with early colorectal neoplasm from healthy controls were 0.706, 0.741, 0.806, and 0.827, respectively. Serum levels of miR-29a and miR-125b were significantly higher in patients who had only small colorectal neoplasms (<= 5 mm) than in healthy subjects. Conclusions:<bold> </bold>Because serum levels of miR-21, miR-29a, and miR-125b discriminated patients with early colorectal neoplasm from healthy controls, our data highlight the potential clinical use of these molecular signatures for noninvasive screening of patients with colorectal neoplasia. (C) 2015 AACR.
  • Keisuke Toda; Takeshi Nagasaka; Yuzo Umeda; Takehiro Tanaka; Takashi Kawai; Tomokazu Fuji; Fumitaka Taniguchi; Kazuya Yasui; Nobuhito Kubota; Yuko Takehara; Hiroshi Tazawa; Shunsuke Kagawa; Dong-Sheng Sun; Naoshi Nishida; Ajay Goel; Toshiyoshi Fujiwara
    CLINICAL EPIGENETICS 7 1 73  2015年07月 [査読有り]
     
    Background: The gene expressions of netrin-1 dependence receptors, DCC and UNC5C, are frequently downregulated in many cancers. We hypothesized that downregulation of DCC and UNC5C has an important growth regulatory function in gastric tumorigenesis. Results: In the present study, a series of genetic and epigenetic analyses for DCC and UNC5C were performed in a Japanese cohort of 98 sporadic gastric cancers and corresponding normal gastric mucosa specimens. Loss of heterozygosity (LOH) analyses and microsatellite instability (MSI) analysis was applied to determine chromosomal instability (CIN) and MSI phenotypes, respectively. More than 5 % methylation in the DCC and UNC5C promoters were found in 45 % (44/98) and 32 % (31/98) gastric cancers, respectively, and in 9 % (9/105) and 5 % (5/105) normal gastric mucosa, respectively. Overall, 70 % (58 of 83 informative cases) and 51 % (40 of 79 informative cases) of gastric cancers harbored either LOH or aberrant methylation in the DCC and UNC5C genes, respectively. In total, 77 % (51 of 66 informative cases) of gastric cancers showed cumulative defects in these two dependence receptors and were significantly associated with chromosomal instability. Both DCC and UNC5C were inactivated in 97 % of CIN-positive gastric cancers and in 55 % of CIN-negative gastric cancers. Conclusions: Defect in netrin receptors is a common feature in gastric cancers. DCC alterations are apparent in the early stages, and UNC5C alterations escalate with the progression of the disease, suggesting that the cumulative alterations of netrin-1 receptors was a late event in gastric cancer progression and emphasizing the importance of this growth regulatory pathway in gastric carcinogenesis.
  • Toshiharu Sakurai; Yoshihisa Okazaki; Yoriaki Komeda; Teppei Adachi; Satoru Hagiwara; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 148 4 S141 - S141 2015年04月 [査読有り]
  • Toshiharu Sakurai; Norihisa Yada; Tomohiro Watanabe; Tadaaki Arizumi; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Jun Fujita; Masatoshi Kudo
    CANCER SCIENCE 106 4 352 - 358 2015年04月 [査読有り]
     
    Most hepatocellular carcinomas (HCCs) develop in the context of chronic liver inflammation. Oxidative stress is thought to play a major role in the pathogenesis of HCC development. In this study, we examined whether cold-inducible RNA-binding protein (Cirp) controls reactive oxygen species (ROS) accumulation and development of HCC by using murine models of hepatocarcinogenesis and human liver samples. Cirp expression, ROS accumulation, and CD133 expression were increased in the liver of tumor-harboring mice. Cirp deficiency reduced production of interleukin-1 and interleukin-6 in Kupffer cells, ROS accumulation, and CD133 expression, leading to attenuated hepatocarcinogenesis. Thioacetamide treatment enhanced hepatic expression of CD133 and phosphorylated signal transducer and activator of transcription 3 (STAT3), which was prevented by treatment with the antioxidant butylated hydroxyanisole. Intriguingly, the risk of human HCC recurrence is positively correlated with Cirp expression in liver. Cirp appears to play a critical carcinogenic function and its expression might be a useful biomarker for HCC risk prediction.
  • Toshiharu Sakurai; Hiroshi Kashida; Satoru Hagiwara; Naoshi Nishida; Tomohiro Watanabe; Jun Fujita; Masatoshi Kudo
    DIGESTIVE DISEASES AND SCIENCES 60 4 850 - 857 2015年04月 [査読有り]
     
    Aims and Methods Heat shock protein A4 (HSPA4, also called Apg-2), a member of the HSP110 family, regulates the immune response in the gut. Here, we assessed the involvement of HSPA4 in gastric ulcer healing by using fibroblasts from wild-type and HSPA4-deficient mice, a murine gastric ulcer model, and samples from 65 patients with gastric cancer. Results HSPA4 expression was inversely correlated with gastric ulcer healing following endoscopic resection of gastric cancer. In the human gastric mucosa, the expression of HSPA4 was inversely correlated with the expression of stromal cell-derived factor 1 (SDF-1), its cognate receptor CXC chemokine receptor 4(CXCR4), the stromal cell marker vimentin, and the epithelial-mesenchymal transition regulator Twist. HSPA4 was overexpressed in stromal cells as well as in human gastric cancer cells. HSPA4 deficiency increased the expression of SDF-1 and CXCR4, as well as the number of fibroblast-specific protein 1-positive cells, leading to accelerated ulcer healing in the murine gastric ulcer model. Deletion of HSPA4 promoted cell migration in mouse fibroblasts through increased expression of SDF-1 and Twist. Conclusion HSPA4 regulates the expression of SDF-1 and Twist in fibroblasts, thereby controlling gastric ulcer healing.
  • Teppei Adachi; Toshiharu Sakurai; Hiroshi Kashida; Hiromasa Mine; Satoru Hagiwara; Shigenaga Matsui; Koji Yoshida; Naoshi Nishida; Tomohiro Watanabe; Katsuhiko Itoh; Jun Fujita; Masatoshi Kudo
    INFLAMMATORY BOWEL DISEASES 21 1 31 - 39 2015年01月 [査読有り]
     
    Background: Expression of heat shock protein A4 (HSPA4, also called Apg-2), a member of the HSP110 family, is induced by several forms of stress. The physiological and pathological functions of HSPA4 in the intestine remain to be elucidated. Methods: We assessed HSPA4 expression and function by generating HSPA4-deficient mice and using 214 human intestinal mucosa samples from patients with inflammatory bowel disease (IBD). Results: In the colonic mucosa of patients with IBD, a significant correlation was observed between the expression of HSPA4 and antiapoptotic protein Bcl-2, a T-cell-derived cytokine IL-17 or stem cell markers, such as Sox2. In refractory ulcerative colitis, a condition associated with increased cancer risk, expression of HSPA4 and Bcl-2 was increased in inflammatory cells of colonic mucosae. HSPA4 was overexpressed both in cancer cells and immune cells of human colorectal cancers. Patients with high expression of HSPA4 or Bmi1 showed significantly lower response rates upon subsequent steroid therapy as compared with patients with low expression of each gene. HSPA4-deficient mice exhibit more apoptosis and less expression of IL-17/IL-23 in inflammatory cells and less number of Sox(2+) cells after administration of dextran sodium sulfate than control mice. Transduction of HspaA4(+/-) bone marrow into wild-type mice reduced the immune response. Conclusions: Upregulation of Bcl-2 and IL-17 by HSPA4 would control apoptosis of inflammatory cells and immune response in the gut, which might develop treatment resistance in IBD. HSPA4 and Bmi1 would be a useful biomarker for refractory clinical course and a promising approach for a therapeutic strategy in patients with IBD.
  • Naoshi Nishida; Masatoshi Kudo
    Annals of Translational Medicine 3 1 1  2015年01月 [査読有り]
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    World Journal of Hepatology 7 23 2427 - 2431 2015年 [査読有り]
     
    The ideal goal of chronic hepatitis B (CHB) treatment should be suppression of emergence of hepatocellular carcinoma through the disappearance of hepatitis B s antigen (HBsAg) rather than the control of serum hepatitis B virus-DNA level. For this purpose, various types of combination therapies using nucleoside analogs (NAs) and interferon (IFN) have been conducted. The therapeutic effects of combination of two different kinds of agents are better than those of the monotherapy using NAs or IFN alone, probably because different pharmaceutical properties might act in a coordinated manner. Recently, combination therapies with NAs and IFN and sequential therapies with NAs administration followed by IFN therapy have been routinely employed. We previously reported that combination therapy using entecavir (ETV) and pegylated (PEG)-IFN showed antiviral effects in 71% of CHB patients the effect of this combination was better than that using lamivudine (LAM) and PEG-IFN. This is partially explained by the better antiviral effects of ETV than those of LAM. In our analysis, the cohort of CHB consisted of the patients who showed a flare-up of hepatitis before antiviral therapy, and their baseline HBsAg levels were relatively low. Therefore, in addition to the combination of the agents, the appropriate selection of patients is critical to achieve a good viral response.
  • Masatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida
    DIGESTIVE DISEASES 33 6 765 - 770 2015年 [査読有り]
     
    This review outlines the significance of establishing general rules, a nationwide follow-up survey, and clinical practice guidelines for liver cancer in Japan. The general rules are an essential part of hepatocellular carcinoma (HCC) treatment, enabling a 'common language' to be used in daily clinical practice and for the nationwide follow-up survey. The Japanese General Rules for the Clinical and Pathological Study of Primary Liver Cancer, which provide detailed descriptions of HCC, are excellent and are unique to Japan. Items in the General Rules for the Clinical and Pathological Study of Primary Liver Cancer are used substantially in another important project, the Nationwide Follow-Up Survey of Primary Liver Cancer, which has been rigorously undertaken with great effort by the Liver Cancer Study Group of Japan biannually since 1969. Both evidence-based and consensus-based treatment algorithms for HCC are used to complement each other in clinical practice in Japan. (C) 2015 S. Karger AG, Basel
  • Naoshi Nishida; Masayuki Kitano; Toshiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 771 - 779 2015年 [査読有り]
     
    Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide, and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage. Many molecular targeted agents are being developed for the treatment of advanced HCC; however, the only promising drug to have been developed is sorafenib, which acts as a multi-kinase inhibitor. Unfortunately, a subgroup of HCC is resistant to sorafenib, and the majority of these HCC patients show disease progression even after an initial satisfactory response. To date, a number of studies have examined the underlying mechanisms involved in the response to sorafenib, and trials have been performed to overcome the acquisition of drug resistance. The anti-tumor activity of sorafenib is largely attributed to the blockade of the signals from growth factors, such as vascular endothelial growth factor receptor and platelet-derived growth factor receptor, and the downstream RAF/mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK cascade. The activation of an escape pathway from RAF/MEK/ERK possibly results in chemoresistance. In addition, there are several features of HCCs indicating sorafenib resistance, such as epithelial-mesenchymal transition and positive stem cell markers. Here, we review the recent reports and focus on the mechanism and prediction of chemoresistance to sorafenib in HCC. (C) 2015 S. Karger AG, Basel
  • Masatoshi Kudo; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida
    DIGESTIVE DISEASES 33 6 780 - 790 2015年 [査読有り]
     
    Challenges of clinical practice and research on hepatocellular carcinoma (HCC) were reviewed. There are several differences in clinical practice between Japan and the Western countries such as tumor markers, understanding of pathological early HCC, imaging diagnosis, treatment strategy, staging system and subclassification of HCC. Further studies are warranted for the clinical practices of Japan to be adopted in the rest of the world. (C) 2015 5. Karger AG, Basel
  • Naoshi Nishida; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 708 - 714 2015年 [査読有り]
     
    Objectives: Triple therapy using peg-interferon, ribavirin and simeprevir (PEG-IFN/RBV/SMV) has reportedly resulted in high-sustained virological response (SVR) rates in patients with chronic hepatitis C (CHC), especially in naive cases and relapsers to prior PEG-IFN/RBV therapy. Here, we retrospectively analyzed the antiviral response associated with a triple regimen, in the context of early reduction of viral load during treatment. Methods: Forty-six CHC patients with HCV genotype 1b were treated with PEG-IFN/RBV/SMV triple therapy: 20 were naive cases, 12 were relapsers and 14 were non-responders to prior PEG-IFN/RBV therapy. We evaluated rapid virological response (RVR), complete early virological response (EVR), viral clearance at the end of the treatment (EOT) and at 12 weeks after the EOT (SVR12). In addition, we quantified the serum HCV-RNA on the 1st day and the 7th day after initiating treatment. Results: Multivariate analysis revealed that response to prior treatment was identified as an independent factor for achieving SVR12 after triple therapy (p = 0.0005). The achievement of serum HCV-RNA <2 log(10) IU/ml on day 7, RVR, EVR and EOT were associated with SVR12 (p = 0.0050, p = 0.0002, p = 0.0009 and p = 0.0002, respectively). Conclusions: Rapid decline of HCV is a predictive factor for the achievement of SVR12, even in antiviral triple therapy with PEG-IFN/RBV/SMV. An extended treatment period should be applied for patients who show detectable serum HCV-RNA at week 4. (C) 2015 S. Karger AG, Basel
  • Masatoshi Kudo; Tadaaki Arizumi; Kazuomi Ueshima; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida
    DIGESTIVE DISEASES 33 6 751 - 758 2015年 [査読有り]
     
    Intermediate stage hepatocellular carcinoma (HCC) is a very heterogeneous tumor in terms of tumor size (>3 cm similar to over 10 cm), tumor number (4 similar to over 20) and liver function (Child-Pugh score 5-9). However, transarterial chemoembolization is the only recommended treatment option according to the Barcelona Clinic Liver Cancer (BCLC) staging. Bolondi's subclassification of BCLC B stage is feasible; however, there are several weak points. Therefore, by modifying Bolondi's subclassification, we have proposed a more simplified subclassification, Kinki criteria. The Kinki criteria consist of 2 factors: liver function (Child-Pugh score 5-7 or 8, 9) and tumor status (Beyond Milan and within up-to-7 criteria; IN and OUT). The Kinki criteria classifies BCLC B stage from B1 (Child-Pugh score 5-7 and within up-to-7), B2 (Child-Pugh score 5-7 and beyond up-to-7) and B3 (Child-Pugh score 8, 9 and any tumor status). These criteria are simple and easy to apply to clinical practice. Therefore, these criteria will stratify the heterogeneous population of BCLC B group patient well and give the treatment indication according to each substage. These criteria should be further validated both retrospectively and prospectively. (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masayuki Kitano; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 728 - 734 2015年 [査読有り]
     
    Objectives: Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of significant increase in progression-free survival as well as overall survival (OS) in the 2-phase III trials. We examined efficacy and adverse events (AEs) in patients treated with sorafenib over a 6-year period since approval in Japan. Methods: Two hundred and forty-one patients treated with sorafenib at the Kinki University Hospital were retrospectively analyzed clinically for the factors related to survival periods, tumor response evaluated by the Response Evaluation Criteria In Cancer of the Liver (RECICL) and AEs. Results: OS was 14.3 months. According to the RECICL, the objective response and disease control rates were 18.6% (43 of 241) and 61.1% (137 of 241), respectively. AEs were seen in 77.3% (187 of 241), with Grade 3 or higher in 23.6% (57 of 241). The most frequent AE was hand-foot skin reaction in 109 patients (45.0%), and 28 patients (11.8%) showed Grade 3 or higher. Significant factors contributing to the OS were treatment duration (p = 0.0204), up-to-7 criteria (p = 0.0400), increase of Child-Pugh score (p = 0.0008) and tumor response determined by the RECICL (p = 0.0007). Conclusion: Based on the analysis, using many cases at a single center, we concluded that continuation of treatment with sorafenib for >= 90 days without decrease of liver function was critical if tumor response was determined as stable disease or higher. (C) 2015 S. Karger AG, Basel
  • Naoshi Nishida; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshirna; Toshiharu Sakurai; Masayuki Kitano; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 745 - 750 2015年 [査読有り]
     
    Objectives: Several studies revealed that the proportion of hepatocellular carcinoma (HCC) without hepatitis virus infection (NBNC-HCC) is increasing. On the other hand, epigenetic alterations are reportedly responsible for HCC development. Here, we identified HCC risk factors that are associated with DNA methylation in the background liver tissue of NBNC-HCC patients. Methods: We performed methylation analysis in 37 pairs of virus-positive and 22 pairs of NBNC-HCC and non-cancerous livers using a HumanMethylation450 BeadChip array. After the selection of differentially methylated CpGs (DM-CpGs) in cancerous and non-cancerous livers, we analyzed DNA methylation of DM-CpGs within the adjacent non-cancerous liver tissue that is affected by specific HCC risk factors. Results: A total of 38,331 CpGs were selected as DM-CpGs using the following criteria: difference of beta-value between HCC and non-cancerous liver and false discovery rate (FDR) q < 1.0E-12. We subsequently selected the DM-CpGs that had methylation differences with the background liver tissue (that has FDR q < 0.35). Among the virus-positive patients, the type of hepatitis virus was mostly associated with differences in methylation within the background liver tissues. However, we found that background methylation patterns were most significantly associated with aging in NBNC patients. Interestingly, age-related methylation differences in DM-CpGs were also observed in NBNC-HCC tissues. Conclusions: Hepatitis viruses affect the methylation profiles within background liver tissues. However, difference in background methylation was mostly associated with age in NCBC-HCC patients; some age-related methylation events could contribute to emergence of NBNC-HCC in elderly individuals. (C) 2015 S. Karger AG, Basel
  • Yasunori Minami; Takamichi Murakami; Masayuki Kitano; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 33 6 759 - 764 2015年 [査読有り]
     
    Cone-beam CT (CBCT) is generated during a rotational sweep of the C-arm around the patient, and can be a valuable imaging technique, providing in situ cross-sectional imaging. It is easy to evaluate the morphologic characteristics of hepatic arteries from multiple views with the use of various reconstruction techniques, such as maximum intensity projection (MIP) and volume rendering. CBCTangiography is capable of providing more information than the standard 2-dimensional angiography in visualizing hepatocellular carcinomas (HCCs) and targeting tumors though precise microcatheter placement in close proximity to HCCs. It can also be useful in evaluating treatment success at the time of the procedure. It is anticipated that CBCT could reduce radiation exposure, the overall procedure time and contrast material use because it allows immediate feedback for an efficient angiographic procedure. Therefore, CBCT angiography is an exciting technology with the potential to significantly impact the practice of interventional radiology. The purpose of this article is to provide a review of the principles, clinical applications and technique of CBCT angiography for HCC treatment. (C) 2015 S. Karger AG, Basel
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Satoru Hagiwara; Kazuomi Ueshima; Hiroshi Ida; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 89 Suppl 2 53 - 59 2015年 [査読有り]
     
    Objective: The aim of this study was to prospectively assess the usefulness of the reliability index, namely the percentage of the net amount of effective shear wave velocity (VsN). Methods: One hundred and sixty-eight patients with chronic liver disease, who underwent ultrasound elastography, were consecutively enrolled. Shear wave measurement (SWM), FibroScan, virtual touch quantification, and shear wave elastography were performed for all patients, and the variations in the measurement results were compared with VsN. The absolute average value of the difference between SWM_Vs and Vs measured using other elastography devices is termed vertical bar Delta Vs vertical bar. VsN was classified into three groups: 50, <50, and 0 (failure measurement). In these groups, there was a significant difference in abdominal circumference, body mass index, the distance between the ultrasound probe surface and the liver, and vertical bar Delta Vs vertical bar. When the distance between the ultrasound probe surface and the liver was >2cm, VsN tended to be significantly lower (p < 0.001). Results: When VsN was <50, bVsI became high, and there was variation in the results between each device. Conclusions:The results of this study show that VsN is a useful value to decide whether Vs is appropriate or not. (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakural; Naoshi Nishida; Masayuki Kitano; Masatoshi Kudo
    ONCOLOGY 89 Suppl 2 4 - 10 2015年 [査読有り]
     
    Objective: Transarterial chemoembolization (TACE) is recommended as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for curative therapy and without portal invasion. The Assessment for Retreatment with TACE (ART) scoring system was recently proposed for identifying patients who would not show sufficient survival benefit from repeated TACE. We reevaluated the performance of ART in HCC patients treated in Japan, where selective TACE is commonly used. Methods: Between 2000 and 2013, 988 patients with HCC underwent TACE at Kinki University Hospital, and 627 received >= 2 sessions of TACE. Seventy-six patients who underwent >= 2 TACE sessions within 90 days were investigated for their performance of the ART score in the context of overall survival (OS). Results: Only 12% (76/627) of patients underwent >= 2 TACE sessions within 90 days. Of those, 52 patients showed a low ART score (0-1.5), and 24 had a high ARTscore (>= 2.5); the median OS was 20.2 and 37.6 months, respectively (p = 0.8207). Conclusion:The ART scoring system did not demonstrate a sufficiently predictive impact on OS among the patients who underwent 2 TACE sessions within 90 days. Application of the ART score should be carefully considered because differences in TACE procedures and post-TACE treatment can affect the results while evaluating OS. (C) 2015 S. Karger AG, Basel
  • Yasunori Minami; Tomohiro Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Masakatsu Tsurusaki; Yukinobu Yagyu; Kazuomi Ueshima; Naoshi Nishida; Takamichi Murakami; Masatoshi Kudo
    ONCOLOGY 89 Suppl 2 27 - 32 2015年 [査読有り]
     
    Objective: To investigate whether balloon-occluded transcatheter arterial chemoembolization (b-TACE) can produce a more dense accumulation of iodized oil in various stages of hepatocellular carcinoma (HCC), from single to uncountable, to overcome inferior local control. Materials and Methods: We studied 27 patients with HCC, including single to uncountable multiple lesions, who underwent b-TACE between August 2013 and April 2015. Dynamic CT was performed at baseline and 1-3 months after b-TACE. The treatment effect (TE) after b-TACE was evaluated using the Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan. Results: In the countable HCC group, contrast-enhanced CT demonstrated RECICL TE4 in 43.8% (14/32), TE3 in 12.5% (4/32), TE2 in 37.5% (12/32), and TEl in 6.3% (2/32) of patients. For the TACE-naive cohort, the objective response rate was 52.9%. The objective response rate was 60% for the previously lACE-treated cohort. In the uncountable multiple HCC group, the objective response rate was 0% (0/10), with progressive disease in 90% (9/10) of patients. Conclusion: Our observations suggested that b-TACE did not reduce the efficacy of retreatment for HCC with an insufficient outcome from conventional TACE, but it could not improve the efficacy of treatment for uncountable multiple HCCs. (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Mina Iwanishi; Tomohiro Minami; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Hiroshi Ida; Yasunori Minami; Toshiharu Sakurai; Masayuki Kitano; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 89 Suppl 2 47 - 52 2015年 [査読有り]
     
    Introduction: Barcelona Clinic Liver Cancer (BCLC) stage B, an intermediate stage, includes various conditions of hepatocellular carcinoma (HCC). This heterogeneity of the patients with intermediate-stage HCC makes it difficult to predict their survival rates. In the present study, we examined the validity of the modified Bolondi classification (Kinki criteria) as a subclassification of patients with BCLC stage B HCC. Methods: Of 906 patients who underwent conventional transarterial chemoembolization at Kinki University Hospital, 753, who met the inclusion criteria, were examined. Of these 753 patients, 425 (56.4%) with BCLC stage B were subclassified using the Kinki criteria to examine the survival rate. Results: According to the Kinki criteria, 158 (37.2%) were subclassified into subclass B1,236 (55.53) into B2, and 31(7.3%) into B3. The comparison of the survival rates showed that the median overall survival was 3.9 years (95% CI, 3.2-4.6) in the BCLC subclass B1 group, 2.5 years (95% Cl, 2.2-3.1) in the B2 group, and 1.1 years (95% Cl, 0.6-1.5) in the B3 group (p < 0.001). Conclusion: When the BCLC stage B patients were subclassified according to the Kinki criteria, survival curves were stratified with significant differences, suggesting that the Kinki criteria were suitable for the subclassification of the intermediate-stage HCC patients. (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Tomohiro Minami; Masashi Kono; Hirokazu Chishina; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    LIVER CANCER 4 4 253 - 262 2015年 [査読有り]
     
    Background and Aims: Patients with intermediate-stage hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE) are considered to be candidates for sorafenib. The aim of this study was to evaluate the superiority of conversion of treatment to sorafenib on overall survival (OS) for cases refractory to TACE. Methods: This was a retrospective cohort study carried out on 497 patients with HCC who were treated with TACE therapy at our hospital between January 2008 and December 2013. Fifty-six patients were diagnosed as refractory to TACE during their clinical course and they were divided into two cohorts, (1) those who switched from TACE to sorafenib and (2) those who continued TACE. The overall survival (OS) after the time of being refractory to TACE was evaluated between the two groups. Results: After refractoriness to TACE therapy was confirmed, 24 patients continued with TACE (TACE-group) and 32 patients underwent treatment conversion to sorafenib (sorafenib-group). The median OS was 24.7 months in the sorafenib-group and 13.6 months in the TACE-group ( p=0.002). Conclusions: Conversion to sorafenib significantly improves the OS in patients refractory to TACE therapy with intermediate-stage HCC. Administration of sorafenib is therefore recommended in such circumstances of TACE treatment failure. Copyright (C) 2015 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Haruhiko Takeda; Yukio Osaki; Masahiro Takita; Tatsuo Inoue; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY 49 12 1578 - 1587 2014年12月 [査読有り]
     
    To test the hypothesis that use of the response evaluation criteria in cancer of the liver (RECICL), an improved evaluation system designed to address the limitations of the response evaluation criteria in solid tumors 1.1 (RECIST1.1) and modified RECIST (mRECIST), provides for more accurate evaluation of response of patients with hepatocellular carcinoma (HCC) to treatment with sorafenib, a molecularly targeted agent, as assessed by overall survival (OS). The therapeutic response of 156 patients with advanced HCC who had been treated with sorafenib therapy for more than 1 month was evaluated using the RECIST1.1, mRECIST, and RECICL. After categorization as showing progressive disease (PD), stable disease (SD), or objective response, the association between OS and categorization was examined using the Kaplan-Meier method to develop survival curves. The 141 cases categorized as PD or SD by the RECIST1.1, but objective response by the mRECIST and RECICL, were further analyzed for determination of the association between OS and categorization. Only categorization using the RECICL was found to be significantly correlated with OS (p = 0.0033). Among the patients categorized as SD or PD by the RECIST1.1, reclassification by the RECICL but not the mRECIST was found to be significantly associated with OS and allowed for precise prediction of prognosis (p = 0.0066). Only the use of the RECICL allowed for identification of a subgroup of HCC patients treated with sorafenib with improved prognosis. The RECICL should, therefore, be considered a superior system for assessment of therapeutic response.
  • Toshiharu Sakurai; Hiroshi Kashida; Tomohiro Watanabe; Satoru Hagiwara; Tsunekazu Mizushima; Hideki Iijima; Naoshi Nishida; Hiroaki Higashitsuji; Jun Fujita; Masatoshi Kudo
    CANCER RESEARCH 74 21 6119 - 6128 2014年11月 [査読有り]
     
    Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and is reported to be associated with refractory inflammatory bowel disease (IBD). Defective apoptosis of inflammatory cell populations seems to be a relevant pathogenetic mechanism in refractory IBD. We assessed the involvement of stress response protein cold-inducible RNA-binding protein (Cirp) in the development of intestinal inflammation and CAC. In the colonic mucosa of patients with ulcerative colitis, expression of Cirp correlated significantly with the expression of TNF alpha, IL23/IL17, antiapoptotic proteins Bcl-2 and Bcl-xL, and stem cell markers such as Sox2, Bmi1, and Lgr5. The expression of Cirp and Sox2 was enhanced in the colonic mucosae of refractory ulcerative colitis, suggesting that Cirp expression might be related to increased cancer risk. In human CAC specimens, inflammatory cells expressed Cirp protein. Cirp(-/-) mice given dextran sodium sulfate exhibited decreased susceptibility to colonic inflammation through decreased expression of TNF alpha, IL23, Bcl-2, and Bcl-xL in colonic lamina propria cells compared with similarly treated wild-type (WT) mice. In the murine CAC model, Cirp deficiency decreased the expression of TNF alpha, IL23/IL17, Bcl-2, Bcl-xL, and Sox2 and the number of Dclk1(+) cells, leading to attenuated tumorigenic potential. Transplantation of Cirp(-/-) bone marrow into WT mice reduced tumorigenesis, indicating the importance of Cirp in hematopoietic cells. Cirp promotes the development of intestinal inflammation and colorectal tumors through regulating apoptosis and production of TNF alpha and IL23 in inflammatory cells. (C) 2014 AACR.
  • Atsushi Yamada; Takahiro Horimatsu; Yoshinaga Okugawa; Naoshi Nishida; Tadayuki Kou; Toshihiro Kusaka; Hajime Honjo; Yusuke Amanuma; Osamu Kikuchi; Manabu Muto; Ajay Goel; C. Richard Boland
    CANCER RESEARCH 74 19 2014年10月 [査読有り]
  • Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
    WORLD JOURNAL OF GASTROENTEROLOGY 20 15 4160 - 4166 2014年04月 [査読有り]
     
    Radiofrequency ablation (RFA) is commonly applied for the treatment of hepatocellular carcinoma (HCC) because of the facile procedure, and the safety and effectiveness for the treatment of this type of tumor. On the other hand, it is believed that HCC cells should spread predominantly through the blood flow of the portal vein, which could lead to the formation of intrahepatic micrometastases. Therefore, monitoring tumor response after the treatment is quite important and accurate assessment of treatment response is critical to obtain the most favorable outcome after the RFA. Indeed, several reports suggested that even small HCCs of <= 3 cm in diameter might carry intrahepatic micrometastases and/or microvascular invasion. From this point of view, for preventing local recurrences, RFA should be performed ablating a main tumor as well as its surrounding non-tumorous liver tissue where micrometastases and microvascular invasion might exist. Recent advancement of imaging modalities such as contrast-enhanced ultrasonic, computed tomography, and magnetic resonance imaging are playing an important role on assessing the therapeutic effects of RFA. The local recurrence rate tends to be low in HCC patients who were proven to have adequate ablation margin after RFA; namely, not only disappearance of vascular enhancement of main tumor, but also an adequate ablation margin. Therefore, contrast enhancement gives important findings for the diagnosis of recurrent HCCs on each imaging. However, hyperemia of non-tumorous liver surrounding the ablated lesion, which could be attributed to an inflammation after RFA, may well obscure the findings of local recurrence of HCCs after RFA. Therefore, we need to carefully address to these imaging findings given the fact that diagnostic difficulties of local recurrence of HCC. Here, we give an overview of the current status of the imaging assessment of HCC response to RFA. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
  • Nishiguchi S; Enomoto H; Aizawa N; Nishikawa H; Osaki Y; Tsuda Y; Higuchi K; Okazaki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M
    Journal of gastroenterology 49 3 492 - 501 2014年03月 [査読有り]
     
    We conducted a multicenter randomized clinical trial to determine the optimal treatment strategy against chronic hepatitis C virus (HCV) with genotype 1b and a high viral load (G1b/high). The study subjects included 153 patients with G1b/high. Patients were initially treated with PEG-IFN alpha-2a alone and then randomly assigned to receive different treatment regimens. Ribavirin (RBV) was administered to all patients with HCV RNA at week 4. Patients negative for HCV RNA at week 4 were randomly assigned to receive PEG-IFN alpha-2a (group A) or PEG-IFN alpha-2a/RBV (group B). Patients who showed HCV RNA at week 4 but were negative at week 12 were randomly assigned to receive weekly PEG-IFN alpha-2a (group C) or biweekly therapy (group D). Patients who showed HCV RNA at week 12 but were negative at week 24 were randomly assigned to receive PEG-IFN alpha-2a/RBV (group E) or PEG-IFN alpha-2a/RBV/fluvastatin (group F). Overall, the rate of sustained virological response (SVR) was 46 % (70/153). The total SVR rate in the group (A, D, and F) of response-guided therapy was significantly higher than that in the group (B, C, and E) of conventional therapy [70 % (38/54) versus 52 % (32/61), p = 0.049]. Although IL28-B polymorphism and Core 70 mutation were significantly associated with efficacy, patients with rapid virological response (RVR) and complete early virological response (cEVR) achieved high SVR rates regardless of their status of IL-28B polymorphism and Core 70 mutation. In addition to knowing the IL-28B polymorphism and Core 70 mutation status, understanding the likelihood of virological response during treatment is critical in determining the appropriate treatment strategy.
  • Naoshi Nishida; Norihisa Yada; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo
    HEPATOLOGY 60 758A - 758A 2014年 [査読有り]
  • Naoshi Nishida; Takafumi Nishimura; Takuya Nakai; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 658 - 663 2014年 [査読有り]
     
    Objective: To clarify the progression pattern of abnormal DNA methylation during the development of hepatocellular carcinoma (HCC) using a comprehensive methylation assay. Methods: We used an Infinium HumanMethylation450 BeadChip array that can analyze >485,000 CpG sites distributed throughout the genome for a comprehensive methylation study of 117 liver tissues consisting of 59 HCC and 58 noncancerous livers. Altered DNA nnethylation patterns during tumor progression were also analyzed. Results: We identified 38,330 CpG sites with significant differences in methylation levels between HCCs and noncancerous livers (DM-CpGs) using strict criteria. Of the DM-CpGs, 92% were hypomethylated and only 3,051 CpGs (8%) were hypermethylated in HCC. The DM-CpGs were more prevalent within intergenic regions with isolated CpGs. In contrast, DM-CpGs that were hypermethylated in HCC were predominantly located within promoter regions and CpG islands (p < 0.0001). The association between methylation profiles of DM-CpGs and tumor size was statistically significant, especially in hepatitis C virus (HCV)-positive cases (p = 0.0001). Conclusions: We clarified the unique characteristics of DM-CpGs in human HCCs. The stepwise progression of alterations in DNA methylation was a common feature of HCV-related hepatocarcinogenesis. (C) 2014 S. Karger AG, Basel
  • Masashi Kono; Tatsuo Inoue; Masatoshi Kudo; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Kazuorni Ueshima; Naoshi Nishida; Takamichi Murakami
    DIGESTIVE DISEASES 32 6 670 - 677 2014年 [査読有り]
     
    Objective:The purpose of this study was to evaluate the risk factors for local recurrence with radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) measuring <= 2 cm. Methods: This study involved 234 patients with 274 HCCs measuring cm who had undergone RFA as the initial treatment. The mean tumor diameter was 1.478 cm. The median follow-up period was 829 days. We evaluated the post-RFA cumulative local recurrence rate and analyzed the risk factors contributing to clinical outcomes. Results: Cumulative local recurrence rates were 9, 19 and 19% at 1,2 and 3 years, respectively. Among the 145 cases with a complete safety margin (SM) after RFA, only 4 developed local tumor recurrence and the cumulative rates of local tumor recurrence at 1, 2 and 3 years were 2, 3 and 3%, respectively. Among the 129 cases with incomplete SM, local tumor recurrence developed in 34 and the cumulative rates of local tumor progression at 1, 2 and 3 years were 14, 36 and 36%, respectively. In multivariate analysis, significant risk factors were tumor location (liver surface), irregular gross type and SM <5 mm. Conclusion: Even with HCC measuring cm, location and gross type of tumor should be carefully evaluated before RFA is performed. (C) 2014 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshirna; Hirokazu Chishina; Masashi Kono; Mashiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 705 - 710 2014年 [査読有り]
     
    Background: Sorafenib is a molecular-targeting agent showing improved overall survival (OS) for advanced hepatocellular carcinoma (HCC). Although tumor dormancy, characterized by stable tumor status or stable disease (SD) without tumor regression, is a unique feature of sorafenib treatment, the contribution of SD to OS remains debatable. This study aimed to clarify the correlation between SD periods and OS in patients with HCC treated with sorafenib. Methods: From May 2009 to January 2013, 269 patients with advanced-stage HCC were treated with sorafenib at the Kinki University Hospital. The antitumor response of sorafenib was evaluated in 158 patients using the modified Response Evaluation Criteria in Solid Tumors, and patients with SD were divided into two subgroups according to the median duration of SD: short SD (<3 months) and long SD (>= 3 months). The relationship between the duration of SD and OS was analyzed among patients with complete (CR) and partial response (PR), and long and short SD using the Kaplan-Meier method. Results:The median OS was 5.7 months in the short SD, 20.8 months in the long SD and 17.9 months in the CR + PR group. Although the duration of OS was significantly longer in the long SD group than the short SD group, no difference in OS was detected between the patients with CR + PR and patients with long SD. The impact of long SD on OS could be as strong as that of CR + PR. Conclusion: Achievement of long SD is one of the important goals for improving survival in patients with HCC treated with sorafenib. (C) 2014 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 733 - 739 2014年 [査読有り]
     
    Background: Sorafenib is a multikinase inhibitor targeting Raf and protein tyrosine kinases, which are involved in cell growth and tumor angiogenesis. Sorafenib administration induces temporary inhibition of tumor growth and a decrease in arterial blood flow in a considerable number of hepatocellular carcinoma (HCC) patients. We retrospectively evaluated the association between decreased blood flow and the overall survival (OS) of HCC patients after the initiation of sorafenib therapy. Patients and Methods: Therapeutic responses of 158 advanced HCC patients with hypervascular tumors who had received sorafenib for more than 1 month were analyzed. To assess their therapeutic response, patients underwent radiological evaluation before and every 4-6 weeks after the initiation of sorafenib treatment. After the classification of patients into three groups based on the change in arterial enhancement during treatment (no change, decrease and disappearance), the OS of each group was compared using the Kaplan-Meier method. Results:Statistically significant differences in OS were observed among the three groups (p < 0.001). A decrease or disappearance of arterial enhancement was significantly associated with improved OS compared to patients with no change in arterial enhancement; the median OS was 19.9 months (95% confidence interval, CI, 16.4-24.5 months) and 6.0 months (95% CI, 4.0-8.8 months), respectively (p < 0.001). However, there was no difference in OS between the decrease and disappearance groups (p = 0.88). Conclusion: We conclude that decreased arterial enhancement during sorafenib treatment was associated with the longest OS and could therefore reflect an effective response. (C) 2014 S. Karger AG, Basel
  • Naoshi Nishida; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 740 - 746 2014年 [査読有り]
     
    Objectives: DNA methylation-dependent transcriptional inactivation of tumor suppressor genes (TSGs) is critical for the pathogenesis of hepatocellular carcinoma (HCC). This study identifies potential TSGs in HCCs using methylation profiling and pharmacological unmasking of methylated TSGs. Methods: Methylation profiling was performed on 22 pairs of HCCs and their corresponding noncancerous liver tissues using the Infinium HumanMethylation27 BeadChip. We also determined the gene reexpression after treatment with 5-aza-2'-deoxycytidine (5-Aza-dC) and trichostatin A (TSA) in 5 HCC cell lines. Results: We selected CpGs that exhibited a significant increase in methylation in HCC tissues compared with that of the noncancerous control group. Two hundred and thirteen CpGs on different gene promoters with a mean difference in the beta value >= 0.15 and a value of p < 0.05 were selected. Of the 213 genes, 45 genes were upregulated in 3 or more HCC cell lines with multiplier value of differences after 5-Aza-dC and TSA treatment. Conclusions: We identified several potential TSGs that participate in transcription inactivation through epigenetic interactions in HCC. The results of this study are important for the understanding of functionally important epigenetic alterations in HCC. (C) 2014 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 32 6 786 - 790 2014年 [査読有り]
     
    Hepatitis virus infections can be accompanied by extrahepatic manifestations that may be caused by the host's immune reaction to the viral infection. Vascular involvement is one of these manifestations and is occasionally associated with life-threatening conditions due to systemic organ failure. The unique profile of hepatitis-related vascular involvement is associated with infection by different types of hepatitis viruses. For example, polyarteritis nodosa is more frequently reported in patients with chronic hepatitis B than those with chronic hepatitis C. Similarly, membranous nephropathy is a notable manifestation among hepatitis B virus-positive patients. In contrast, patients infected with hepatitis C virus are at risk for cryoglobulinemia and membranoproliferative glomerulonephritis. Antiviral therapy is necessary to control these kinds of vasculitis related to hepatitis virus infections; however, imnnunosuppressive agents may be required to treat severe cases. New antiviral drugs for viral hepatitis could improve the prognosis of vascular and renal involvement. (C) 2014 S. Karger AG, Basel
  • Tadaaki Arizumi; Kazuomi Ueshima; Hirokazu Chishina; Masashi Kono; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 87 Suppl 1 32 - 36 2014年 [査読有り]
     
    Background: Transcatheter arterial chemoembolization (TACE) failure or refractoriness is an indication for sorafenib therapy in patients with advanced hepatocellular carcinoma. The study evaluated the validity of the definition of TACE failure or refractoriness as proposed by the Liver Cancer Study Group of Japan (LCSGJ) through a retrospective analysis of sorafenib treatment. Methods: Out of 265 patients with advanced hepatocellular carcinoma who were treated with sorafenib at our hospital, 45 experienced TACE failure or refractoriness and were included in this study and retrospectively analyzed. Results: Multivariate analysis only identified the number of ineffective TACE procedures performed before starting sorafenib treatment as significant factors. Overall survival (OS) after starting sorafenib was statistically longer in patients treated with <= 2 consecutive ineffective TACE procedures before sorafenib administration than in patients treated with >= 3 consecutive ineffective TACE procedures (p < 0.005). This result matched the LCSGJ criteria. Conclusion: In patients treated with sorafenib, OS was extended with <= 2 consecutive ineffective TACE procedures compared to that with >= 3 consecutive ineffective TACE procedures. Thus, if tumors are uncontrolled, TACE should not be repeated. The result of this study supports the definition of TACE failure or refractoriness proposed by the LCSGJ. (C) 2014 S. Karger AG, Basel
  • Tomohiro Minami; Yasunori Minami; Hirokazu Chishina; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 87 Suppl 1 55 - 62 2014年 [査読有り]
     
    Purpose: The purpose of this study was to evaluate the usefulness of the combination guidance of contrast-enhanced US (CEUS) and fusion imaging in radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) with poor conspicuity on B-mode US and CEUS/fusion imaging. Materials and Methods: We conducted a retrospective cohort study, which included 356 patients with 556 HCCs that were inconspicuous on B-mode US. A total of 192 patients with 344 HCCs, 123 patients with 155 HCCs, and 37 patients with 57 HCCs underwent RFA under CEUS guidance, fusion imaging guidance, and the combination of CEUS and fusion imaging guidance. Results: The average number of treatment sessions was 1.1 (range: 1-2) in the CEUS guidance group, 1.1 (range: 1-2) in the fusion imaging guidance group, and 1.1 (range: 1-3) in the combination of CEUS and fusion imaging guidance group. Treatment analysis did not reveal significantly more RFA treatment sessions in the combination guidance group than in the other groups (p = 0.97, Student's t test). During the follow-up period (1.1-85.3 months, mean +/- SD, 43.2 +/- 59.5), the 3-year local tumor progression rates were 4.9, 7.2, and 5.9% in the CEUS guidance group, the fusion imaging guidance group, and the combination guidance group, respectively (p = 0.84, log-rank test). Conclusion: In spite of selection bias, session frequency and local tumor progression were not different under the combination guidance with CEUS and fusion imaging in RFA. The combination of fusion imaging and CEUS guidance in RFA therapy is an effective treatment for HCC with poor conspicuity on B-mode US and CEUS/fusion imaging. (C) 2014 S. Karger AG, Basel
  • Norihisa Yada; Toshiharu Sakurai; Tomohiro Minami; Tadaaki Arizumi; Masahiro Takita; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 87 Suppl 1 118 - 123 2014年 [査読有り]
     
    Objective: To investigate the relationship between tissue elasticity before and after antiviral therapy and shear wave as well as strain elastography. Methods: FibroScan and real-time tissue elastography were performed before and after antiviral therapy for chronic hepatitis C, and treatment efficacy and elastographic findings were comparatively analyzed. Elasticity was evaluated by measuring liver stiffness (LS) in kilopascals using FibroScan, and the liver fibrosis index (LFI) was assessed by real-time tissue elastography. Results: LS and LFI correlated well before and after therapy (r = 0.567, p = 0.003 and r = 0.576, p = 0.002, respectively). In the group without a sustained virological response (SVR), LS increased in 4 of 5 patients. Patients with an increase in both LS and LFI were all in the non-SVR group (3/3, 100%). In addition, LS increased in all patients except 1 in the non-SVR group (4/5, 80%). In the SVR group, both LS and LFI decreased in all patients except 1 (18/19, 94.7%). In the patient with an increase in LS despite achieving SVR, LS decreased quickly after alcohol cessation. Conclusions: With a few exceptions, SVR improved LS. All patients with an increase in LFI were in the non-SVR group, even though LFI decreased in 2 patients. Our findings suggest that an LFI increase indicates lack of treatment efficacy with antiviral therapy. LFI may be useful for the assessment of treatment efficacy in patients with worsening of LS despite achieving SVR with antiviral therapy. (C) 2014 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    LIVER CANCER 3 3-4 417 - 427 2014年 [査読有り]
     
    Hepatocellular carcinoma (HCC) is a common cancer worldwide and develops against a background of chronic liver damage. A variety of HCC-related genes are known to be altered by genetic and epigenetic mechanisms. Therefore, information regarding alteration of the genetic and epigenetic profiles in HCC is essential for understanding the biology of this type of tumor. Methylation at CpG sites in gene promoters is known to affect the transcription of the corresponding genes. Abnormal regional hypermethylation is observed in the 5' region of several tumor suppressor genes (TSGs) in HCC, and this hypermethylation may promote carcinogenesis through the transcriptional inactivation of downstream TSGs. The DNA damage induced by oxidation is a trigger of abnormal DNA methylation and inactivation of TSGs through recruitment of the polycomb repressive complex to the promoter sequence. Thus, oxidative stress may be responsible for the emergence of HCC from chronic hepatitis and liver cirrhosis through the epigenetic alteration of TSGs. There have been several attempts to apply epigenetic information to the diagnosis and treatment of HCC. The predictive value of selected methylation events on survival in HCC patients has been reported, and the methylation profile of background liver could be associated with recurrence-free survival of HCC patients who have undergone hepatectomy. Another study detected methylated DNA from HCC cells in serum, and the circulating tumor DNA was regarded as a potential tumor marker. In addition, several trials of HCC therapy have targeted the epigenetic machinery and were based upon comprehensive analyses of DNA methylation of this type of tumor. Here, we present an overview of research regarding DNA methylation status in human HCC and describe the clinical application of epigenetic information to HCC. Copyright (C) 2014 S. Karger AG, Basel
  • Hiroshi Sadamori; Takahito Yagi; Kunitoshi Shigeyasu; Yuzo Umeda; Masahiro Sugihara; Naosuke Yokomichi; Toshiaki Ohara; Naoshi Nishida; Takeshi Nagasaka; Ajay Goel; Toshiyoshi Fujiwara
    Hepatology research : the official journal of the Japan Society of Hepatology 43 12 1368 - 73 2013年12月 [査読有り]
     
    We present a case in which combination chemotherapy was used to successfully treat hepatocellular carcinoma (HCC) with rapid progression of lymph node (LN) metastases after liver resection. In addition, epithelial to mesenchymal transition (EMT) markers were examined immunohistochemically. A 43-year-old man who had been diagnosed with HCC showed an enlarged LN near the hepatic artery proper. After extended left lobectomy with lymphadenectomy in the hepatoduodenal ligament, he experienced rapid progression of metastases to the para-aortic and mediastinal LN. Partial remission was achieved after induction and maintenance of combination chemotherapy using etoposide, carboplatin, epirubicin and 5-fluorouracil. As a consequence of this treatment, the patient survived 10 months. Immunohistochemical studies demonstrated that HCC cells in the metastatic LN showed low expression of E-cadherin and high expression of N-cadherin and vimentin, indicating EMT. Combination chemotherapy may prove effective for patients with HCC accompanied by LN metastases that show features of EMT.
  • Naoshi Nishida; Masatoshi Kudo
    Digestive Diseases 31 5-6 447 - 453 2013年11月 [査読有り]
     
    Hepatocellular carcinoma (HCC) is a major cause of cancer death, and its development is influenced by the status of inflammation and oxidative stress in the liver. Although oxidative stress might induce genetic changes and play a role in HCC development, many epigenetic alterations have also been reported in this type of tumor, suggesting the importance of epigenetic instability in hepatocarcinogenesis. Epigenetic instability results in 2 types of DNA alterations: hypermethylation of the promoter of tumor suppressor genes (TSGs), and hypomethylation of nonpromoter CpG, such as repetitive elements and satellite DNA. The former causes transcriptional inactivation of TSGs, while the latter reportedly induces chromosomal instability and an abnormal activation of oncogenes as well as mobile genetic elements. Oxidative stress could induce epigenetic instability and inactivate TSGs through the recruitment of the polycomb repressive complex to the promoter sequence carrying DNA damage induced by oxidation. Inflammatory cytokines from immune cells also reportedly induce expression of several histone and DNA modulators. On the other hand, DNA oxidation could lead to activation of DNA repair pathways and affect the binding of methyl cytosine-binding protein to DNA, which could cause DNA hypomethylation. The decrease of the level of methyl group donors also contributes to the alteration in the methylation status. These mechanisms should act in concert and induce epigenetic instability, leading to HCC. © 2013 S. Karger AG, Basel.
  • Naoshi Nishida; Masatoshi Kudo; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Takeshi Nagasaka; Ajay Goel
    HEPATOLOGY 58 1065A - 1066A 2013年10月 [査読有り]
  • Nishida N; Kudo M; Nishimura T; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Inoue T; Minami Y; Ueshima K; Sakurai T; Yokomichi N; Nagasaka T; Goel A
    PloS one 8 9 e72312  2013年09月 [査読有り]
     
    Global DNA hypomethylation is a characteristic feature of cancer cells that closely associates with chromosomal instability (CIN). However, the association between these characteristics during hepatocarcinogenesis remains unclear. Herein, we determined the relationship between hypomethylation and CIN in human hepatocellular carcinoma (HCC) by analyzing 179 HCCs, 178 matched non-tumor livers and 23 normal liver tissues. Hypomethylation at three different repetitive DNA (rDNA) sequences and hypermethylation of 12 CpG loci, including 11 tumor suppressor gene (TSG) promoters, were quantified using MethyLight or combined bisulfite restriction analysis. Fractional allelic loss (FAL) was used as a marker for CIN, calculated by analyzing 400 microsatellite markers. Gains and losses at each chromosome were also determined using semi-quantitative microsatellite analysis. The associations between rDNA hypomethylation and FAL, as well as between TSG hypermethylation and FAL were investigated. Significantly more hypomethylation was observed in HCC tissues than in normal liver samples. Progression of hypomethylation during carcinogenesis was more prominent in hepatitis C virus (HCV)-negative cases, which was in contrast to our previous reports of significantly increased TSG methylation levels in HCV-positive tumors. Absence of liver cirrhosis and higher FAL scores were identified as independent contributors to significant hypomethylation of rDNA in HCC. Among the chromosomal alterations frequently observed in HCC, loss of 8p, which was unique in the earliest stages of hepatocarcinogenesis, was significantly associated with hypomethylation of rDNA by multivariable analysis (p=0.0153). rDNA hypomethylation was also associated with a high FAL score regardless of tumor differentiation (p=0.0011, well-differentiated; p=0.0089, moderately/poorly-differentiated HCCs). We conclude that DNA hypomethylation is an important cause of CIN in the earliest step of HCC, especially in a background of non-cirrhotic liver.
  • Yoshitaka Inaba; Fumihiko Kanai; Takeshi Aramaki; Takanobu Yamamoto; Toshihiro Tanaka; Koichiro Yamakado; Shuichi Kaneko; Masatoshi Kudo; Kazuho Imanaka; Shinichi Kora; Norifumi Nishida; Nobuyuki Kawai; Hiroshi Seki; Osamu Matsui; Hitoshi Arioka; Yasuaki Arai
    EUROPEAN JOURNAL OF CANCER 49 13 2832 - 2840 2013年09月 [査読有り]
     
    Background: TSU-68 is an antitumour drug that acts by inhibiting angiogenesis. We evaluated the efficacy and safety of TSU-68 in combination with transarterial chemoembolisation (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC). Patients and Methods: In this multicenter, open-label phase II study, we randomised patients with HCC who had been treated with a single session of TACE to receive either 200 mg TSU-68 twice daily or no medication. The primary end-point was progression-free survival (PFS). Results: A total of 103 patients were enrolled. Median PFS was 157.0 days (95% confidence interval [CI], 124.0-230.0 days) in the TSU-68 group and 122.0 days (95% CI, 73.0-170.0 days) in the control group. The hazard ratio was 0.699 (95% CI, 0.450-1.088). Fatigue, elevated aspartate aminotransferase (AST), elevated alkaline phosphatase, oedema and anorexia were more frequent in the TSU-68 group than in the control group. The most frequent grade 3/4 adverse events were AST elevation (46% of patients in the TSU-68 group and 12% of controls) and alanine aminotransferase elevation (26% of patients in the TSU-68 group and 8% of controls). Two deaths, grade 5 hepatic failure and melena were noted in the TSU-68 group. Conclusion: This exploratory study shows a trend towards prolonged PFS with TSU-68 treatment after a single session of TACE, but this observation was not statistically significant. The two deaths were related to the study treatment. These results suggest that further examination of the study design is necessary to determine whether TSU-68 has any clinical benefits when combined with TACE. (C) 2013 Elsevier Ltd. All rights reserved.
  • Hiromasa Mine; Toshiharu Sakurai; Hiroshi Kashida; Shigenaga Matsui; Naoshi Nishida; Tomoyuki Nagai; Satoru Hagiwara; Tomohiro Watanabe; Masatoshi Kudo
    Digestive Diseases and Sciences 58 8 2337 - 2344 2013年08月 [査読有り]
  • Satoru Hagiwara; Masatoshi Kudo; Yukio Osaki; Hiroo Matsuo; Tadashi Inuzuka; Akihiro Matsumoto; Eiji Tanaka; Toshiharu Sakurai; Kazuomi Ueshima; Tatsuo Inoue; Norihisa Yada; Naoshi Nishida
    Journal of Medical Virology 85 6 987 - 995 2013年06月 [査読有り]
     
    The ideal approach to treat chronic hepatitis B remains controversial. This pilot study aimed to evaluate the effectiveness of peginterferon (PEG-IFN) α-2b and entecavir hydrate (ETV) as a combination therapy for patients with chronic hepatitis B, particularly in the context of virological response and the reduction of intrahepatic covalently closed circular DNA (cccDNA). A total of 17 patients with hepatitis B virus (HBV) genotype C were enrolled in this study. All subjects were treated with this combination therapy for 48 weeks and observed for an additional 24 weeks. All patients underwent liver biopsy before and after the therapy period. Changes in cccDNA levels and liver histology were monitored between biopsies. Among the 11 patients who exhibited pre-therapy hepatitis B e antigen (HBeAg), 8 (73%) showed evidence of HBeAg seroconversion by the end of the follow-up period. Serum HBV DNA levels decreased by 5.2 and 3.3log copies/ml (mean) by the end of the therapy and follow-up periods, respectively. In addition, intrahepatic cccDNA decreased significantly to 1.4logcopies/μg (mean) by the end of the therapy period. Among the 11 patients who did not experience viral relapse, only 2 (18%) exhibited high levels of cccDNA (> 4.5logcopies/μg) by the end of the treatment period. In contrast, all relapsed subjects exhibited significantly higher levels of cccDNA than subjects who did not relapse (P=0.027). The combination regimen is a promising approach to treat chronic hepatitis B and may achieve significant reduction in serum HBV DNA and intrahepatic cccDNA. © 2013 Wiley Periodicals, Inc.
  • ソラフェニブ治療におけるJNK活性の重要性-CD133との関連も含めて
    萩原 智; 櫻井 俊治; 上嶋 一臣; 永井 知行; 西田 直生志; 工藤 正俊
    The Liver Cancer Journal The Liver Cancer Journal 5 58 - 59 2013年06月
  • Kazuhiro Yoshida; Takeshi Nagasaka; Yuzo Umeda; Naosuke Yokomichi; Yoshiko Mori; Nobuhito Kubota; Tatsuya Morikawa; Yuko Takehara; Kiyoto Takehara; Kunitoshi Shigeyasu; Akihiro Nyuya; Rikiya Shiwaku; Manabu Suno; Naoshi Nishida; Toshiyoshi Fujiwara; Ajay Goel
    GASTROENTEROLOGY 144 5 S98 - S98 2013年05月 [査読有り]
     
    0
  • Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    GASTROENTEROLOGY 144 5 S1041 - S1041 2013年05月 [査読有り]
     
    0
  • Naosuke Yokomichi; Takeshi Nagasaka; Naoshi Nishida; Yuzo Umeda; Yoshiko Mori; Tatsuya Morikawa; Nobuhito Kubota; Kazuhiro Yoshida; Yuko Takehara; Kiyoto Takehara; Kunitoshi Shigeyasu; Akihiro Nyuya; Rikiya Shiwaku; Manabu Suno; Toshiyoshi Fujiwara; Ajay Goel
    GASTROENTEROLOGY 144 5 S719 - S720 2013年05月 [査読有り]
     
    0
  • Yoshiaki Nagata; Toshiharu Sakurai; Masaki Takayama; Tomoyuki Nagai; Masanori Kawasaki; Yutaka Asakuma; Satoru Hagiwara; Naoshi Nishida; Shigenaga Matsui; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 144 5 S883 - S883 2013年05月 [査読有り]
     
    0
  • Nobuhito Kubota; Takeshi Nagasaka; Keisuke Toda; Yoshiko Mori; Tatsuya Morikawa; Yuzo Umeda; Naosuke Yokomichi; Kazuhiro Yoshida; Yuko Takehara; Kiyoto Takehara; Akihiro Nyuya; Rikiya Shiwaku; Kunitoshi Shigeyasu; Manabu Suno; Naoshi Nishida; Toshiyoshi Fujiwara; Ajay Goel
    GASTROENTEROLOGY 144 5 S527 - S527 2013年05月 [査読有り]
  • Yoshiko Mori; Takeshi Nagasaka; Hiroshi Tazawa; Yuzo Umeda; Tatsuya Morikawa; Nobuhito Kubota; Kazuhiro Yoshida; Yuko Takehara; Naosuke Yokomichi; Kiyoto Takehara; Kunitoshi Shigeyasu; Akihiro Nyuya; Rikiya Shiwaku; Manabu Suno; Naoshi Nishida; Toshiyoshi Fujiwara; Ajay Goel
    GASTROENTEROLOGY 144 5 S85 - S85 2013年05月 [査読有り]
     
    0
  • Takafumi Nishimura; Yukiko Mori; Shinji Uemoto; Naoshi Nishida
    JOURNAL OF CLINICAL ONCOLOGY 31 15 2013年05月 [査読有り]
  • Tatsuya Morikawa; Takeshi Nagasaka; Kazuhiro Yoshida; Yoshiko Mori; Nobuhito Kubota; Yuko Takehara; Naosuke Yokomichi; Naoshi Nishida; Kiyoto Takehara; Kunitoshi Shigeyasu; Akihiro Nyuya; Rikiya Shiwaku; Manabu Suno; Toshiyoshi Fujiwara; Ajay Goel
    GASTROENTEROLOGY 144 5 S601 - S602 2013年05月 [査読有り]
  • Yoshiaki Nagata; Masatoshi Kudo; Tomoyuki Nagai; Tomohiro Watanabe; Masanori Kawasaki; Yutaka Asakuma; Satoru Hagiwara; Naoshi Nishida; Shigenaga Matsui; Hiroshi Kashida; Toshiharu Sakurai
    DIGESTIVE DISEASES AND SCIENCES 58 2 381 - 388 2013年02月 [査読有り]
     
    Intestinal-type gastric carcinomas progress through several sequential steps, including atrophic gastritis, intestinal metaplasia, dysplasia, and cancer. We investigated heat shock protein 27 (HSP27) expression in gastric neoplasia and background gastric mucosa to assess its involvement in gastric carcinogenesis. We used real-time quantitative polymerase chain reaction to examine HSP27 expression in gastric neoplasias and background gastric mucosae of 30 patients with intraepithelial neoplasias and in gastric mucosae of 30 patients without gastric neoplasia. Immunohistochemical staining was performed on 30 advanced gastric cancer tissues. HSP27 expression was negatively associated with atrophic gastritis. HSP27 expression in the background gastric mucosa of neoplasia-bearing patients was significantly lower than in the mucosa of those without gastric neoplasia. In tumor necrosis factor alpha-treated gastric cancer cells, HSP27 knockdown increased cell death and accumulation of the reactive oxygen species that link inflammation to cancer. Poorly differentiated tumors most frequently had high HSP27 levels. Dedifferentiation of cancer cells is associated with an epithelial-mesenchymal transition (EMT) signaling pathway. In gastric cancer MKN-1 cells, HSP27 knockdown upregulated E-cadherin and downregulated vimentin and smooth muscle actin, but this did not occur in MKN-74 cells. HSP27 expression in gastric mucosae is inversely correlated with intraepithelial neoplasia, a probable precursor to gastric cancer, and HSP27 expression in cancer is positively correlated with poor differentiation.
  • Mutsuko Minata; Masatoshi Kudo; Kouji H. Harada; Iwao Ikai; Naoshi Nishida
    Oncology (Switzerland) 84 1 88 - 92 2013年02月 [査読有り]
     
    Objectives: Hepatocellular carcinoma (HCC) frequently recurs even after curative resection. The purpose of this study was to examine how background liver affects postoperative recurrence of HCC that underwent curative resection using expression of cancer-related molecules in the adjacent noncancerous liver of HCC patients. Methods: We examined expression of E-cadherin and vascular endothelial growth factor in noncancerous liver tissues of 133 HCC patients who underwent curative resection of tumors using immunohistochemical analysis. Associations between expressions of these molecules and disease-free survival of HCC were analyzed using the Kaplan-Meier method. Results: The average period of follow-up of the patients was 6.7 years. Multivariate analyses revealed that low platelet count and negative expression of E-cadherin in adjacent noncancerous liver were significantly associated with metastatic recurrence [p = 0.017, hazard ratio (HR) = 1.31 for low platelet count, and p = 0.009, HR = 1.43 for negative expression of E-cadherin, respectively]. Conclusions: Expression levels of E-cadherin in adjacent noncancerous liver after surgical resection was associated with metastatic HCC recurrence later on. Analysis of E-cadherin expression should provide important information for predicting recurrence after curative resection of HCC. Copyright © 2013 S. Karger AG, Basel.
  • Tatsuo Inoue; Masatoshi Kudo; Kinuyo Hatanaka; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Naoshi Nishida
    ONCOLOGY 84 Supplement 1 51 - 57 2013年 [査読有り]
     
    Objective: Contrast-enhanced ultrasonography (CEUS) with Sonazoid and dynamic computed tomography (CT) were used to evaluate radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC). Local recurrence rate was used as the gold standard of evaluation. Methods: From January 2007 to December 2011,86 HCCs from 70 patients were treated with RFA. CEUS with Sonazoid and dynamic CT were then used to evaluate the effect of RFA. For CEUS and dynamic CT, effects were classified as follows: (1) complete ablated response with safety margin >5 mm (CRSM+); (2) complete ablated response but with safety margin <5 mm (CRSM-); (3) incomplete, residual tumor detected after treatment. Results: CEUS judged 33 cases as CRSM+, while dynamic CT identified 49 cases. None of these 33 cases from the CEUS group had local recurrences, while dynamic CT had 1 case. CEUS judged 49 cases as CRSM-, compared to 34 cases with dynamic CT. Of these, 9 cases of CEUS and 8 cases of dynamic CT showed local recurrences. Two cases diagnosed as 'incomplete' by CEUS and dynamic CT had recurrences within 1 year. Conclusion: CEUS can be used to assess the efficacy of RFA for HCC, with the potential to reduce the number of CT scans required for confirmation. Copyright (C) 2013 S. Karger AG, Basel
  • Naoshi Nishida; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Masatoshi Kudo
    Digestive Diseases 31 5-6 459 - 466 2013年 [査読有り]
     
    Chronic hepatitis C (CHC) triggers oxidative stress and contributes to the emergence of hepatocellular carcinoma (HCC). We previously reported that tumor suppressor gene (TSG) methylation is a critical factor during the early stages of hepatocarcinogenesis. In this study, we clarify the association between oxidative stress and epigenetic alterations during hepatocarcinogenesis. We examined DNA oxidation and methylation profiles in 128 liver biopsy samples from CHC patients. The DNA oxidation and methylated TSG numbers were quantified using immunohistochemical analysis of 8-hydroxydeoxyguanosine (8-OHdG) and quantitative PCR for 11 TSGs, respectively. The quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) assay in HepG2 and fetal liver Hc cells treated with H< inf> 2< /inf> O< inf> 2< /inf> was used to quantify trimethyl-H3K4, acetylated-H4K16 (an active chromatin marker), trimethyl-H3K27 (a repressive chromatin marker) and 8-OHdG. We analyzed 30 promoters of 25 different TSGs by qPCR. The high levels of 8-OHdG was the only variable that was significantly associated with the increased number of methylated TSGs in CHC (p < 0.0001). The ChIP-qPCR revealed that after H< inf> 2< /inf> O< inf> 2< /inf> treatment of the cell lines, the 8-OHdG-bound promoters showed a modification from an active chromatin (trimethyl-H3K4 and acetylated-H4K16 dominant) to a repressive chromatin (trimethyl-H3K27 dominant) status. We conclude that oxidative stress alters the chromatin status, which leads to abnormal methylation of TSGs, and contributes to hepatocarcinogenesis in CHC patients.
  • Toshiharu Sakurai; Masatoshi Kudo; Tomohiro Watanabe; Katsuhiko Itoh; Hiroaki Higashitsuji; Tadaaki Arizumi; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Manabu Fukumoto; Jun Fujita
    DIGESTIVE DISEASES 31 5-6 440 - 446 2013年 [査読有り]
     
    Objective: Mild hypothermia (32-33 degrees C) shows protective effects in patients with brain damage and cardiac arrest. Although cold-inducible RNA-binding protein (CIRP) contributes to the protective effects of hypothermia through extracellular signal-regulated kinase activation in fibroblasts, the effects of hypothermia in the liver remain unclear. Methods: We analysed the effects of cold temperature on fulminant hepatitis, a potentially fatal disease, using the D-galactosamine (GalN)/lipopolysaccharide (LPS) and concanavalin (con) A-induced hepatitis models in mice. After GalN/LPS administration and anaesthesia, mice in the hypothermia group were kept at 25 degrees C and those in control group were kept at 35 degrees C. After concanavalin A (con A) administration, the mice in the hypothermia group were placed in a chamber with an ambient temperature of 6 degrees C for 1.5 h. Results: Hypothermia attenuated liver injury and prolonged survival. Activation of c-Jun N-terminal kinase and Akt, which are involved in reactive oxygen species (ROS) accumulation, was suppressed by low temperature. Hypothermia significantly decreased oxidized protein levels, and treatment with N-acetyl-L-cysteine, an antioxidant, attenuated GalN/LPS-induced liver injury. In con A-induced hepatitis, CIRP expression was upregulated and Bid expression was downregulated, resulting in decreased apoptosis of hepatocytes in the hypothermia group. Conclusions: These data suggest that hypothermia directly protects hepatocytes from cell death via reduction of ROS production in fulminant hepatitis. (C) 2013 S. Karger AG, Basel
  • Naoshi Nishida; Shinichi Iwamura; Hiroshi Ida; Satoshi Hagiwara; Yoshinori Kagioka; Yasunori Minami; Yoji Maetani; Kyo Itoh; Masatoshi Kudo
    DIGESTIVE DISEASES 31 5-6 408 - 414 2013年 [査読有り]
     
    Budd-Chiari syndrome (BCS) is a rare condition characterized by hepatic venous outflow obstruction. In this report, we present 4 cases of BCS with complete and incomplete obstruction of the inferior vena cava (IVC) and hepatic vein (HV). Each case showed different and unique features of liver damage, which were attributed to the site and degree of obstruction. Interestingly, improved liver functions such as increased serum albumin levels, decreased hyaluronic acid levels and a normal indocyanine green clearance test were evident within 1 month of the balloon angioplasty. Pericellular fibrosis and hypervascular regenerative nodules were also reversible after obstruction removal. Therefore, it is very important to manage this rare disease before it progresses to liver cirrhosis. (C) 2013 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo
    ONCOLOGY 84 Supplement 1 93 - 97 2013年 [査読有り]
     
    Hepatocellular carcinoma (HCC) typically develops in the liver with chronic hepatitis and cirrhosis, and activation of oncogenes and inactivation of tumor suppressor genes occurs during carcinogenesis via genetic and epigenetic mechanisms. Recent advancements in the development of analyses for examining the cancer genome have revealed information regarding genetic alterations in HCC tissues. According to previous studies, the incidence of recurrent genetic alterations in individual genes was thought to be relatively rare and limited to a subset of a few cancer-specific genes such as tumor suppressor p53, RB genes and oncogenes such as CTNNB1. However, recent whole-genome analyses and exome sequencing of tumor DNA have revealed numerous novel alterations of cancer-related genes and pathways critical for HCC development. In addition, various risk factors for HCC, such as the presence or absence of hepatitis B and C virus, may affect the mutation profile of the corresponding cancer genome. On the other hand, genome-wide association studies have also identified important single-nucleotide polymorphisms involved in HCC development, which may allow detection of a group at high risk of HCC emergence. Such analyses will clarify how this malignancy can be treated, diagnosed and prevented more effectively. Copyright (C) 2013 S. Karger AG, Basel
  • Naoshi Nishida; Tadaaki Arizumi; Masahiro Takita; Tonnoyuki Nagai; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuonni Ueshima; Toshiharu Sakurai; Hiroshi Ida; Masatoshi Kudo
    ONCOLOGY 84 Supplement 1 82 - 87 2013年 [査読有り]
     
    Objectives: Hepatocellular carcinoma (HCC) is one of the common cancers worldwide. Accurate diagnosis of tumor progression is critical for the appropriate management of HCC. Here, we established a sensitive assay to detect and quantify tumor-derived DNA in the serum of HCC patients. Methods: Aberrant methylation of the APC gene was quantified in 23 HCC patients and 8 healthy volunteers using 100 mu l of serum. For sensitive detection and accurate quantification of tumor DNA, we combined seminested polymerase chain reaction (PCR) with TaqMan PCR, which could amplify the APC gene regardless of the methylation status and detect the methylated and unmethylated sequences separately. The ratio of methylated to unmethylated sequences was quantified. Results: The methylated APC gene was detected in all HCC patients examined, but no healthy volunteers showed amplification of methylated sequences in serum. HCC patients with portal vein thrombosis showed a significantly higher methylated to unmethylated APC gene ratio in serum than those without portal vein thrombosis (p = 0.0029). Conclusions: Considering the strong association between the ratio of the methylated to unmethylated APC sequences in serum and the presence of portal vein thrombosis, methylation status of APC sequences could be a promising marker for improving HCC management. Copyright (C) 2013 S. Karger AG, Basel
  • Mutsuko Minata; Kouji H. Harada; Masatoshi Kudo; Iwao Ikai; Naoshi Nishida
    ONCOLOGY 84 Supplement 1 75 - 81 2013年 [査読有り]
     
    Objectives: Hepatocellular carcinoma (HCC) frequently recurs even after curative resection. The purpose of this study was to identify factors predictive for postoperative recurrence of HCC in patients who underwent curative resection using immunohistochemistry. Methods: Expression of vascular endothelial growth factor (VEGF), E-cadherin and cyclin D1 in HCC tissue were analyzed for 133 HCC patients who underwent curative resection of tumors using immunohistochemical analysis. Relationships of expressions and disease-free survival of HCC were evaluated using univariate and multivariate analyses. Results: The average period of follow-up of the patients was 6.7 years. Multivariate analyses revealed that only strong expression of VEGF in HCC tissue was significantly associated with metastatic recurrence (p < 0.001, hazard ratio, HR, 3.32). Conclusions: Evaluating VEGF in HCC tissue after surgical resection has predictive value for metastatic HCC recurrence. The ability to risk stratify should improve the treatment strategies after hepatectomy. Copyright (C) 2013 S. Karger AG, Basel
  • Tomoyuki Nagai; Ueshima Kazuomi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 27 225 - 225 2012年12月 [査読有り]
  • Hagiwara S; Sakurai T; Takita M; Ueshima K; Minami Y; Inoue T; Yada N; Kitai S; Nagai T; Hayaishi S; Arizumi T; Nishida N; Kudo M
    Dig Dis 30 6 561 - 567 2012年11月 [査読有り]
     
    OBJECTIVE: Increasing evidence suggests the efficacy of maintenance therapy with interferon (IFN) for chronic hepatitis C (CHC) in reducing the risk of hepatocellular carcinoma (HCC). The aim of this study was to determine clinical characteristics on the risk of occurrence of HCC in CHC patients receiving maintenance IFN therapy. METHODS: A total of 55 patients were treated in a single center with PEG-IFNα-2a monotherapy for CHC and evaluated for variables predictive of the occurrence of HCC. RESULTS: The cumulative incidences of HCC were 0.092, 0.117 and 0.161 at 3, 5 and 7 years, respectively. Serum ALT level (>40 IU/l) in the 6th month after commencement of IFN therapy and BMI >25 were associated with shorter time-to-HCC emergence using multivariate analysis (relative risk 16.034, p = 0.01 for ALT >40 IU/l; relative risk 6.020, p = 0.026 for BMI >25, respectively). The IL28B SNP was extracted as a significant factor for the occurrence of HCC. CONCLUSIONS: Maintenance therapy with the use of long-term low-dose PEG-IFNα-2a is effective for preventing HCC occurrence irrespective of the IL28B SNP, at least for a subset of CHC patients. The initial response of serum ALT levels and BMI provides a prognostic value for determining the risk of developing HCC later in life.
  • 当院における肝細胞癌分子標的治療の現状
    上嶋 一臣; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第6回日本肝がん分子標的治療研究会 記録 SORAFENIB PRACTICE BOOK: Sorafenib治療の実践!!多数症例の使用経験を踏まえた治療の実践と問題点の解決を示す 25 - 30 アークメディア 2012年10月
  • Naoshi Nishida; Masatoshi Kudo; Takeshi Nagasaka; Iwao Ikai; Ajay Goel
    HEPATOLOGY 56 3 994 - 1003 2012年09月 [査読有り]
     
    We aimed to identify the specific subset of tumor suppressor genes (TSGs) that are methylation-silenced during the earliest steps of hepatocarcinogenesis, and to further evaluate whether these genes can serve as predictive biomarkers of hepatocellular carcinoma (HCC) emergence. A total of 482 liver tissues including 177 pairs of HCCs and matched nontumor livers and 128 liver biopsies from chronic hepatitis C (CHC) patients were analyzed for quantitative methylation analysis in 24 TSG promoters and three MINT loci. The tumors were classified as early, less-progressed, and highly progressed HCCs using histology and radiological approaches. A subset of TSGs that harbored distinctly high levels of methylation in early HCCs were selected. Based on the methylation profiles of these genes, Kaplan-Meier analyses were performed to determine time-to-HCC occurrence in CHC patients. Subsequently, multivariate analysis was performed using age, gender, fibrosis stage, and number of methylated TSGs as covariates. Among TSGs analyzed, a subset of eight TSGs (HIC1, GSTP1, SOCS1, RASSF1, CDKN2A, APC, RUNX3, and PRDM2) demonstrated a distinct cluster by hierarchical clustering and receiver operating characteristic analyses. This subset of TSGs showed significantly higher methylation levels in the early HCCs (P < 0.0001). In the CHC patients, methylation frequencies in these TSGs were associated with shorter time-to-HCC occurrence (P < 0.0001), and number of methylated genes was an independent risk factor for HCC (hazard ratio = 5.21, 95% confidence interval = 2.25-11.76, P = 0.0002). Conclusion: Epigenetic inactivation of a subset of TSGs plays a critical role in the earliest steps of hepatocarcinogenesis. Furthermore, epigenetic inactivation of these genes in CHC provides a prognostic value for determining the risk for developing HCC later in life. (HEPATOLOGY 2012;56:9941003)
  • S. Hagiwara; M. Kudo; T. Nagai; T. Inoue; K. Ueshima; N. Nishida; T. Watanabe; T. Sakurai
    BRITISH JOURNAL OF CANCER 106 12 1997 - 2003 2012年06月 
    BACKGROUND: Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer deaths worldwide. While sorafenib, a multikinase inhibitor targeting the Raf/extracellular signal-regulated protein kinase (ERK) pathway, has been shown recently to provide a survival advantage to patients with advanced HCC, a predictive biomarker has not been developed. We studied whether c-Jun N-terminal kinase (JNK), which promotes liver carcinogenesis in mice, affects therapeutic response to sorafenib in HCC patients. METHODS: We collected pathological specimens from 39 patients with advanced HCC before starting sorafenib treatment, and measured JNK activity in HCCs. RESULTS: In patients treated with sorafenib, the expression of phospho-c-Jun in HCC, as a read out of JNK activity, was significantly higher (P<0.001) in the non-responder group than in the responder group. c-Jun N-terminal kinase activation in HCC was associated with a decreased time to progression and a poor overall survival (P = 0.0028 and P = 0.0008, respectively). CONCLUSION: In addition, JNK activity was significantly correlated with CD133 expression level. Correspondingly, high expression level of CD133 was linked to a poor response to sorafenib. Furthermore, D-JNKi, a specific JNK inhibitor, reduced the growth of xenografted CD133(+) cells in athymic mice. In conclusion, JNK activation was positively correlated with CD133 expression level and inversely correlated with the therapeutic response to sorafenib, suggesting that JNK activity may be considered as a new predictive biomarker for response to sorafenib treatment. British Journal of Cancer (2012) 106, 1997-2003. doi:10.1038/bjc.2012.145 www.bjcancer.com Published online 17 May 2012 (C) 2012 Cancer Research UK
  • 有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    肝臓 53 6 348 - 350 (一社)日本肝臓学会 2012年06月 
    分子標的薬ソラフェニブを投与した進行肝細胞癌患者81例を対象に、mRECIST基準による治療効果判定でCR・PR・SD例を抽出し、SDの持続期間とMedian overall survival(OS)との関係について検討した。mRECISTによる効果判定はCR:2例、PR:16例、SD:36例、PD:27例であった。SDの持続期間の中央値は3.3ヵ月であり、SDの持続期間3ヵ月未満をShort SD群(14例)、3ヵ月以上をLong SD群(22例)に分類し、CR+PR群(18例)とのOSを比較した。3群間では性別のみ有意差を認め、他の因子に有意差はなかった。生存曲線の比較では、OSの中央値はShort SD群6.2ヵ月、Long SD群17.6ヵ月、CR+PR群19.1ヵ月とShort SD群で他2群に比べ有意に短く、Long SD群とCR+PR群の間に有意差はなかった。Short SD群ではソラフェニブと因果関係のある有害事象で投与中止が6例(PS低下、食欲低下各1例、肝機能低下、下痢各2例)あり、他2群では副作用による中止は認めなかった。
  • 有住忠晃; 上嶋 一臣; 萩原 智; 井上 達夫; 北井 聡; 矢田 典久; 櫻井 俊治; 西田 直生志; 工藤 正俊; 竹田治彦; 大﨑往夫
    肝臓 53 6 344 - 347 2012年06月
  • Yasunori Minami; Kinuyo Hatanaka; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    GASTROENTEROLOGY 142 5 S1002 - S1002 2012年05月 [査読有り]
  • Tatsuo Inoue; Tadaaki Arizumi; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Kazuomi Ueshima; Naoshi Nishida; Masatoshi Kudo
    GASTROENTEROLOGY 142 5 S1002 - S1002 2012年05月 [査読有り]
  • Naoshi Nishida; Masatoshi Kudo; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Tatsuo Inoue; Satoru Hagiwara; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Takeshi Nagasaka; Ajay Goel
    GASTROENTEROLOGY 142 5 S910 - S911 2012年05月 [査読有り]
  • Toshiharu Sakurai; Satoru Hagiwara; Tatsuo Inoue; Kazuomi Ueshima; Shigenaga Matsui; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo
    GASTROENTEROLOGY 142 5 S452 - S452 2012年05月 [査読有り]
  • Takafumi Nishimura; Naoshi Nishida
    CANCER RESEARCH 72 2012年04月 [査読有り]
  • Ken Takahashi; Naoshi Nishida; Hiroshi Kawabata; Hironori Haga; Tsutomu Chiba
    INTERNAL MEDICINE 51 19 2745 - 2747 2012年 [査読有り]
     
    Links between hepatitis C virus (HCV) infection and several non-Hodgkin lymphomas have been suggested by epidemiological studies. We herein report the first documented case of a patient with HCV-associated Hodgkin lymphoma who showed a marked regression following interferon-based antiviral therapy. This unique case extends the spectrum of HCV-associated malignant lymphomas, confirms the efficacy of antiviral therapy for this rare extrahepatic manifestation and provides valuable clues for achieving a better understanding of lymphomagenesis in HCV.
  • Naoshi Nishida; Tadaaki Arizumi; Sosuke Hayaishi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Iwao Ikai; Masatoshi Kudo
    DIGESTIVE DISEASES 30 6 547 - 553 2012年 [査読有り]
     
    Objectives: A unique causative aspect of hepatocellular carcinoma (HCC) is a gender difference in its incidence. To determine the specific factors that contribute to a male predominance, we analyzed the clinicopathological factors, and genetic and epigenetic alterations of HCCs in male and female patients. Methods: We retrospectively analyzed three cohorts of patients: the first cohort consisted of 547 patients identified with the first event of HCC, the second cohort included 176 HCC patients, and the third 127 patients with chronic hepatitis C (CHC). Results: Male patients were found to have HCC more frequently than female patients in cases of non-cirrhotic liver (p = 0.0030 by the chi(2) test), especially in hepatitis C-positive cases. However, there were no gender-specific differences in the genetic and epigenetic alterations of cancer-related genes. Deposition of iron was more severe in male CHC patients than in female patients. Conclusions: Male patients with CHC develop HCC more frequently when they have a non-cirrhotic liver than do female patients. This gender difference could be, at least partially, attributed to a different degree of iron deposition, which contributes to the development of HCC in the absence of liver cirrhosis in men with CHC. Copyright (C) 2012 S. Karger AG, Basel
  • Satoru Hagiwara; Toshiharu Sakurai; Shinichi Nishina; Kaoru Tanaka; Masafumi Ikeda; Kazuomi Ueshima; Yasunori Minami; Tatsuo Inoue; Norihisa Yada; Satoshi Kitai; Masahiro Takita; Tomoyuki Nagai; Sousuke Hayaishi; Tadaaki Arizumi; Ah-Mee Park; Hiroshi Munakata; Naoshi Nishida; Masatoshi Kudo
    DIGESTIVE DISEASES 30 6 541 - 546 2012年 [査読有り]
     
    Objective: A number of studies have reported reactivation of hepatitis B during intensive immunosuppressive therapy such as cases of hematological malignancy, whereas little has been reported for characteristics of reactivation triggered by chemotherapy for solid cancer. Methods: A total of 130 patients underwent chemotherapy for treatments of common solid cancer between May 2011 and May 2012 at Kinki University Hospital. Among them, 27 patients were suspected for a past infection of hepatitis B virus (HBV), showing positive for hepatitis B core antibody or surface antibody but negative for hepatitis B surface antigen, and were eligible for this study. Results: Hepatitis B reactivation was observed in 2 of 27 cases (7.4%). The duration between the start of chemotherapy and increase of serum HBV load was 30 days in both cases. Conclusions: We reported the 2 cases of hepatitis B reactivation receiving chemotherapy for solid cancer in terms of patterns and characteristics of reactivation. Accumulation of such cases will help in clarifying the clinical importance of hepatitis B reactivation during treatment of solid malignancies. Copyright (C) 2012 S. Karger AG, Basel
  • Naoshi Nishida; Masatoshi Kudo; Takeshi Nagasaka; Ajay Goel
    HEPATOLOGY 54 462A - 462A 2011年10月 [査読有り]
  • Naoshi Nishida; Takeshi Nagasaka; C. Richard Boland; Tsutomu Chiba; Ajay Goel
    GASTROENTEROLOGY 140 5 S971 - S971 2011年05月 [査読有り]
  • Naoshi Nishida; Ajay Goel
    CURRENT GENOMICS 12 2 130 - 137 2011年04月 [査読有り]
     
    Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide, and the incidence of this fatal disease is still on rise. The majority of HCCs emerge in the background of a chronic liver disease, such as chronic hepatitis and liver cirrhosis. The current understanding is that majority of HCCs evolve as a consequence of chronic inflammation and due to the presence of infection with hepatitis viruses. These underlying pathogenic stimuli subsequently induce a spectrum of genetic and epigenetic alterations in several cancer-related genes, which are involved in cell-cycle regulation, cell growth and adhesion. Such widespread genomic alterations cause disruption of normal cellular signaling and finally lead to the acquisition of a malignant phenotype in HCC. In general, the type of gene alterations, such as point mutations, deletion of chromosomal regions and abnormal methylation of gene promoters differ according to the individual targeted gene. In HCC, incidence of genetic alterations is relatively rare and is limited to a subset of few cancer-specific genes, such as the tumor suppressor p53, RB genes and oncogenes such as the CTNNB1. In contrast, epigenetic changes that involve aberrant methylation of genes and other post-transcriptional histone modifications occur far more frequently, and some of these epigenetic alterations are now being exploited for the development of molecular diagnostic signatures for HCC. In addition, recent findings of unique microRNA expression profiles also provide an evidence for the existence of novel mechanisms for gene expression regulation in HCC. In this review article, we will review the current state of knowledge on the activation of various oncogenic pathways and the inactivation of tumor suppressor pathways in HCC that result in the disruption of cancer-related gene function. In addition, we will specifically emphasize the clinical implication of some of these genetic and epigenetic alterations in the management of hepatocarcinogenesis.
  • Naoshi Nishida
    HISTOLOGY AND HISTOPATHOLOGY 25 5 647 - 654 2010年05月 [査読有り]
     
    Hepatocellular carcinoma (HCC) usually develops on the basis of chronic hepatitis and liver cirrhosis, where inactivation of several tumor suppressor genes (TSGs) takes place via methylation of the promoter. Interestingly, these methylation events are more prevalent in a background liver at high risk of HCC than one at low risk. Abnormal methylation is also observed in precancerous nodules such as dysplastic nodules and adenomas, suggesting that epigenetic alteration is an early event for HCC carcinogenesis. It is possible that infection with the hepatitis virus induces alteration of methylation at promoters of TSGs. Some studies suggested that viral proteins interfere with DNA methyltranferase in chronic hepatitis B. Induction of epigenetic alteration in chronic hepatitis C might, however, might be a consequence of oxidative stress. In addition, we proposed age should be taken into consideration for HCC development via epigenetic pathways. Further investigations are required to understand the mechanism of inducing epigenetic instability during hepatocarcinogenesis.
  • Reiko Akitake; Tomohiro Watanabe; Chikage Zaima; Norimitsu Uza; Hiroshi Ida; Shinsuke Tada; Naoshi Nishida; Tsutomu Chiba
    GUT 59 4 542 - 545 2010年04月 [査読有り]
     
    We report a case of immunoglobulin G4 (IgG4)-related sclerosing disease involving the pancreas, liver and salivary glands. Massive infiltration of IgG4-expressing plasma cells was seen in the liver and submandibular lymph nodes. Interestingly, accumulation of IgG4-expressing plasma cells was also seen in the colon and terminal ileum. Peripheral blood mononuclear cells (PBMCs) isolated from this patient exhibited enhanced production of IgG4 and interleukin-10 upon stimulation with Toll-like receptor (TLR) ligands as compared with those from a healthy control. In contrast, production of tumour necrosis factor alpha and interferon gamma by PBMCs from this patient was markedly reduced. Since colonic mucosa is always exposed to TLR ligands derived from commensal organisms, the results of immunological studies suggest that enhanced T helper type 2 responses to intestinal microflora may underlie the immunopathogenesis in this patient with IgG4-related sclerosing disease.
  • Takeshi Nagasaka; Noriaki Tanaka; Harry M. Cullings; Dong-Sheng Sun; Hiromi Sasamoto; Takuyuki Uchida; Minoru Koi; Naoshi Nishida; Yoshio Naomoto; C. Richard Boland; Nagahide Matsubara; Ajay Goel
    JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 18 1244 - 1258 2009年09月 [査読有り]
     
    The development of noninvasive screening tests is important to reduce mortality from gastrointestinal neoplasia. We sought to develop such a test by analysis of DNA methylation from exfoliated cancer cells in feces. We first analyzed methylation of the RASSF2 and SFRP2 gene promoters from 788 primary gastric and colorectal tissue specimens to determine whether methylation patterns could act as stage-dependent biomarkers of gastrointestinal tumorigenesis. Next, we developed a novel strategy that uses single-step modification of DNA with sodium bisulfite and fluorescence polymerase chain reaction methodology to measure aberrant methylation in fecal DNA. Methylation of the RASSF2 and SFRP2 promoters was analyzed in 296 fecal samples obtained from a variety of patients, including 21 with gastric tumors, 152 with colorectal tumors, and 10 with non-neoplastic or inflammatory lesions in the gastrointestinal lumen. Analysis of DNA from tissues showed presence of extensive methylation in both gene promoters exclusively in advanced gastric and colorectal tumors. The assay successfully identified one or more methylated markers in fecal DNA from 57.1% of patients with gastric cancer, 75.0% of patients with colorectal cancer, and 44.4% of patients with advanced colorectal adenomas, but only 10.6% of subjects without neoplastic or active diseases (difference, gastric cancer vs undiseased = 46.5%, 95% confidence interval (CI) = 24.6% to 68.4%, P < .001; difference, colorectal cancer vs undiseased = 64.4%, 95% CI = 53.5% to 75.2%, P < .001; difference, colorectal adenoma vs undiseased = 33.8%, 95% CI = 14.2% to 53.4%, P < .001). Methylation of the RASSF2 and SFRP2 promoters in fecal DNA is associated with the presence of gastrointestinal tumors relative to non-neoplastic conditions. Our novel fecal DNA methylation assay provides a possible means to noninvasively screen not only for colorectal tumors but also for gastric tumors.
  • Takeshi Nagasaka; Ajay Goel; Kenji Notohara; Takaomi Takahata; Hiromi Sasamoto; Takuyuki Uchida; Naoshi Nishida; Noriaki Tanaka; Clement Richard Boland; Nagahide Matsubara
    INTERNATIONAL JOURNAL OF CANCER 122 11 2429 - 2436 2008年06月 [査読有り]
     
    O-6 -methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene which is frequently methylated in colorectal cancer (CRC). However, it remains controversial whether methylation of specific CpG sequences within MGMT promoter leads to loss of its protein expression, and if MGMT methylation correlates with G to A transition mutations in KRAS. Two methylation sensitive regions (Mp and Eh region) of MGMT promoter were investigated in 593 specimens of colorectal tissue: 233 CRCs, 104 adenomatous polyps (AP), 220 normal colonic mucosa from CRC patients (N-C) and 36 normal colonic mucosa specimens obtained from subjects without colorectal neoplasia (N-N) by combined bisulfite restriction analysis (COBRA). The region-specific methylation data were compared to the MGMT protein expression, spectrum of KRAS mutations and other clinical features. Extensive (including both Mp and Eh) and partial (either Mp or Eh) MGMT methylation were found in 24.5% and 11.6% of CRCs, 3.8% and 27.9% of APs, 0.5% and 7.7% of C-Ns and 2.8% and 2.8% of N-Ns, respectively. Extensive methylation of MGMT promoter was primarily present in CRCs while partial methylation was common in APs. Extensive methylation of MGMT promoter was associated with loss/reduced protein expression (p < 0.0001), as well as with G to A mutations in KRAS (p = 0.0017). We herein provide first evidence that extensive methylation of MGMT promoter region is essential for methylation-induced silencing of this gene. Our data suggest that MGMT methylation may evolve and spread throughout the promoter in a stepwise manner as the colonic epithelial cells progress through the classical-adenoma-cancer multistep cascade. (C) 2008 Wiley-Liss, Inc.
  • Takeshi Nagasaka; Minoru Koi; Matthias Kloor; Johannes Gebert; Alex Vilkin; Naoshi Nishida; Sung Kwan Shin; Hiromi Sasamoto; Noriaki Tanaka; Nagahide Matsubara; C. Richard Boland; Ajay Goel
    GASTROENTEROLOGY 134 7 1950 - 1960 2008年06月 [査読有り]
     
    Background & Aims: Colorectal cancers (CRCs) with the CpG island methylator phenotype (CIMP) often associate with epigenetic silencing of hMLH1 and an activating mutation in the BRAF gene. However, the current CIMP criteria are ambiguous and often result in an underestimation of CIMP frequencies in CRCs. Because BRAF and KRAS belong to same signaling pathway, we hypothesized that not only mutations in BRAF but mutant KRAS may also associate with CIMP in CRC. Methods: We determined the methylation status in a panel of 14 markers (7 canonical CIMP-related loci and 7 new loci), microsatellite instability status, and BRAF/KRAS mutations in a collection of 487 colorectal tissues that included both sporadic and Lynch syndrome patients. Results: Methylation analysis of 7 CIMP-related markers revealed that the mean number of methylated loci was highest in BRAF-mutated CRCs (3.6) vs KRAS-mutated (1.2, P < .0001) or BRAF/KRAS wild-type tumors (0.7, P < .0001). However, analyses with 7 additional markers showed that the mean number of methylated loci in BRAF mutant tumors (4.4) was the same as in KRAS mutant CRCs (4.3, P=.8610). Although sporadic microsatellite instability high tumors had the highest average number of methylated markers (8.4), surprisingly, Lynch syndrome CRCs also demonstrated frequent methylation (5.1). Conclusions: CIMP in CRC may result from activating mutations in either BRAF or KRAS, and the inclusion of additional methylation markers that correlate with mutant KRAS may help clarify CIMP in future studies. Additionally, aberrant DNA methylation is a common event not only in sporadic CRC but also in Lynch syndrome CRCs.
  • Takeshi Nagasaka; Minoru Koi; Naoshi Nishida; Sung Kwan Shin; Nagahide Matsubara; C. R. Boland; Ajay Goel
    GASTROENTEROLOGY 134 4 A615 - A615 2008年04月 [査読有り]
  • Takeshi Nagasaka; Hirorm Sasamoto; Dong Sheng Sun; Tetsuhiro Oka; Keisuke Toda; Nobumasa Taniguchi; Minoru Koi; Naoshi Nishida; C. R. Boland; Ajay Goel; Nagalude Matsubara
    GASTROENTEROLOGY 134 4 A183 - A183 2008年04月 [査読有り]
  • Naoshi Nishida; Takeshi Nagasaka; C. R. Boland; Ajay Goel
    GASTROENTEROLOGY 134 4 A752 - A753 2008年04月 [査読有り]
  • Naoshi Nishida; Takeshi Nagasaka; Takafumi Nishimura; Iwao Lkai; C. Richard Boland; Ajay Goell
    HEPATOLOGY 47 3 908 - 918 2008年03月 [査読有り]
     
    Aberrant DNA methylation is an important epigenetic alteration in hepatocellular carcinoma (HCC). However, the molecular processes underlying the methylator phenotype and the contribution of hepatitis viruses are poorly understood. The current study is a comprehensive methylation analysis of human liver tissue specimens. A total of 176 liver tissues, including 77 pairs of HCCs and matching noncancerous liver and 22 normal livers, were analyzed for methylation. Methylation of 19 epigenetic markers was quantified, and the results were correlated with different disease states and the presence or absence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Based on methylation profiles, the 19 loci were categorized into 3 groups. Normal liver tissues showed methylation primarily in group 1 loci (HIC-1, CASP8, GSTP1, SOCS1, RASSF1A, p16, APC), which was significantly higher than group 2 (CDH1, RUNX3, RIZ1, SFRP2, MINT31) and group 3 markers (COX2, MINT1, CACNA1G, RASSF2, MINT2, Reprimo3, DCC) (P < 0.0001). Noncancerous livers demonstrated increased methylation in both group I and group 2 loci. Methylation was significantly more abundant in HCV-positive livers compared with normal liver tissues. Conversely, HCC showed frequent methylation at each locus investigated in all 3 groups. However, the group 3 loci showed more dense and frequent methylation in HCV-positive cancers compared with both HBV-positive cancers and virus-negative cancers (P < 0.0001). Conclusion: Methylation in HCC is frequent but occurs in a gene-specific and disease-specific manner. Methylation profiling allowed us to determine that aberrant methylation is commonly present in normal aging livers, and sequentially progresses with advancing stages of chronic viral infection. Finally, our data provide evidence that HCV infection may accelerate the methylation process and suggests a continuum of increasing methylation with persistent viral infection and carcinogenesis in the liver.
  • Naoshi Nishida; Takafumi Nishimura; Takeshi Nagasaka; Iwao Ikai; Goel Ajay; C. Richard Boland
    CANCER RESEARCH 67 10 4586 - 4594 2007年05月 [査読有り]
     
    Hepatocellular carcinoma (HCC) with p53 mutations is usually characterized by extensive chromosomal instability (CIN), whereas those with beta-catenin mutations have relatively less CIN and the molecular pathogenesis of these tumors is unknown. Methylation of CpG dinucleotides in the promoters of cancer-related genes is another characteristic feature of HCCs. The aim of this study was to determine the contribution of the methylator phenotype to HCC and its relationship to genomic instability. Fractional allelic loss (FAL) was determined using 400 microsatellite markers in 81 HCCs and 77 corresponding noncancerous livers as a measure of CIN. Methylation of 21 genetic loci was quantitated using combined bisulfite restriction analysis. Using hierarchical clustering analysis based upon the quantification of methylation levels, all HCCs were segregated into two groups characterized by either limited or extensive methylation. Mutations in the beta-catenin and p53 genes were determined by DNA sequencing. We found that the methylation levels were significantly higher in the HCCs than in noncancerous livers in 18 of the 21 loci (P values ranged from 0.035 to <0.0001). Among 18 loci, elevated levels of methylation at nine loci were significantly associated with beta-catenin mutations (P values ranged from 0.02 to <0.0001). In addition, the presence of beta-catenin mutations was associated with HCCs in the extensive methylation group (P < 0.0001), whereas p53 mutations correlated with high FAL scores (P = 0.0036). These data suggest that HCCs can be classified into two distinct categories based upon promoter methylation, CIN, and mutations of cancer-related genes. HCCs with extensive methylation harbor frequent beta-catenin mutations, whereas HCCs with high levels of CIN are associated with p53 mutations, suggesting the presence of two independent pathways for the pathogenesis of HCC.
  • Naoshi Nishida; Takeshi Nagasaka; Kazuhiro Kashiwagi; C. Richard Boland; Ajay Goel
    CANCER BIOLOGY & THERAPY 6 4 525 - 533 2007年04月 [査読有り]
     
    Chromosomal instability (CIN) is a common but not universal feature of colorectal cancer (CRC); however, the molecular basis for CIN is controversial and poorly understood. There are many plausible mechanisms proposed for CIN, including disruption of G(1)/S and G(2)/M checkpoint regulation, and alterations in the spindle checkpoint genes. However, mutations in individual growth regulatory genes are not commonly observed in CRC. Therefore, a more comprehensive analysis of the genes involved in each cell cycle checkpoint regulatory pathway might be required to evaluate a possible role for involvement in CIN. We investigated the presence of high copy amplification of the cyclin E, Aurora-A, Skp2 genes, mutation of ubiquitin ligase CDC4, and promoter methylation of Mad2L1, as well as the expression of the gene products in a panel of 11 human CRC cell lines as well as 48 human CRC specimens. In the cell lines with CIN, we found amplification of the Aurora-A, cyclin E and Skp2 genes, and a mutation in the CDC4 gene, all of which resulted in altered expression of the cognate proteins. In the human CRC tissues, amplification of Aurora-A was frequent (29%), while alterations were rarely observed in cyclin E, Skp2 or CDC4. Aurora-A amplification was strongly associated with a high fractional allelic loss score (p = 0.0001), but not with microsatellite instability, nor with the promoter methylation phenotype in these tumors. Our data confirm involvement in the CDC4-cyclin E pathway of the development of the CIN phenotype in human CRC, and find that amplification of the Aurora-A is a common target for disruption of this pathway.
  • Naoshi Nishida; Takafumi Nishimura; Takeshi Nagasaka; Iwao Ikai; Ajay Goel; C. richard Boland
    GASTROENTEROLOGY 132 4 A730 - A731 2007年04月 [査読有り]
  • Chromosomal instability and epigenetic instability in human hepatocacinogenesis.
    NISHIDA Naoshi
    Current Research in Cancer 2007年 [査読有り][招待有り]
  • T Shibata; T Shibata; Y Maetani; T Kubo; N Nishida; K Itoh
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY 29 3 479 - 481 2006年06月 [査読有り]
     
    Tumor seeding in the chest wall was depicted at follow-up CT obtained 9 months after radiofrequency ablation for hepatocellular carcinoma. Transcatheter arterial embolization was successfully performed, injecting emulsion of 10 mg of epirubicin and 1 ml of iodized oil followed by gelatin sponge particles via the microcatheter placed in the right eleventh intercostal artery. The patient died of tumor growth in the liver one year after the embolization, but no progression of the tumor seeding was noted during the follow-up period. We conclude that transcatheter arterial embolization was effective for the control of tumor seeding after radiofrequency ablation for hepatocellular carcinoma.
  • Takafumi Nishimura; Naoshi Nishida; Toshiki Komeda; Yoshihiro Fukuda; Iwao Ikai; Yoshio Yamaoka; Kazuwa Nakao
    CANCER GENETICS AND CYTOGENETICS 167 1 57 - 65 2006年05月 [査読有り]
     
    Recurrent chromosomal gains at 1q, 6p, 8q, and 17q, or losses at 1p, 4q, 6q, 8p, 9p, 13q, 16q, and 17p are common features of human hepatocellular carcinoma (HCC). For precise determination of the shortest region of overlap (SRO), 49 HCC obtained at the time of surgery or autopsy were subjected to comprehensive microsatellite analysis by using 400 markers distributed at almost equal distances throughout the 22 autosomes and X chromosomes. Each allele showing imbalance was subjected to comparative duplex polymerase chain reaction using a retained allele as an internal control to determine whether the imbalance was the result of chromosomal gain or loss. The following SRO of recurrent chromosomal gains and losses were determined: -1p36.22-p36.33, D1S450-D1S2893, 5.0 mega-base pairs (Mbp), + 1q23.3-q25.3, D1S2878 similar to D1S2619, 16.9 Mbp; -4q21.2 similar to q24, D4S2964-D4S1572, 23.0 Mbp; -6q23.3 similar to qter, D6S292-qter, 34.7 Mb; -8p22 similar to p23.1, M549-MS550, 4.8 Mbp- +8q12.2-q24.13, MS260-MS514, 61.8 Mbp: -13q13.3-q22.1, D13S218-D13S156, 35.6 Mbp: -16q22.1 similar to qter, D16S503-qter, 26.7 Mbp; and -17p12 similar to pter, D17S921-pter, 14.2 Mbp. Contrary to our initial expectations, many HCC showed major deletions or additions of chromosome arms, so that a number of genes were included in the SRO. Although some putative oncogenes or tumor suppressor genes mapped in these SRO may be important, relative copy number changes of numerous other genes may affect pathogenesis of HCC. (c) 2006 Elsevier Inc. All rights reserved.
  • Nishida Naoshi; Ajay Goel; Takeshi Nagasaka; Takafumi Nishimura; C. Richard Boland
    CANCER RESEARCH 66 8 2006年04月
  • N Nishida; Y Komatsu; T Komeda; Y Fukuda
    HEPATOLOGY RESEARCH 34 4 222 - 227 2006年04月 [査読有り]
     
    Background: Interferon (IFN)-beta is known to be involved in the regulation of bone homeostasis. As IFN-alpha and -beta share the same receptor complex and signaling pathway, we speculated that treatment with IFN-a for chronic hepatitis C (CHC) may provide a beneficial effect on bone loss. Methods: Urinary deoxypyridinoline (uDPD) of 41 patients with CHC who had been receiving IFN-alpha for 24 weeks was examined during the period of observation. Among them, eight patients showed a bone mineral density (BMD) of less than 0.850 g/cm(2) before IFN therapy and they were examined a BMD again after completion of IFN administration. Relationships between the percentage difference of uDPD after discontinuation of IFN and various factors related to CHC were also examined. Results: A mean uDPD of 7.1 +/- 3.4 nM/mM creatinine before IFN therapy decreased to 4.5 +/- 2.4 in the 4th week and 4.2 +/- 2.7 in the 24th week of IFN therapy, respectively (p < 0.0001). The reduction in uDPD was more prominent in cases with a lower viral load (P = 0.0266). The BMD of the eight patients, which was less than 0.850g/cm(2) before IFN therapy, showed significant increase after the end of therapy (p = 0.0172). Conclusion: LFN-alpha can improve bone resorption in CHC patients, especially in those with a lower viral load, and increased BMD. These effects are thought to be a result of direct action of IFN on bone homeostasis. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
  • Shunji Nakayama; Yoshihiro Kanbara; Takafumi Nishimura; Naoshi Nishida; Keisuke Hanioka; Mizuho Morita; Masayuki Fujita; Kaoru Sakurai; Yoshitake Hayashi
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY 13 5 416 - 420 2006年 [査読有り]
     
    Allelic imbalance (At), which represents certain chromosomal gains or losses, has been described in hepatocellular carcinoma (HCC), but the significance of At analysis in focal nodular hyperplasia (FNH) has not been fully clarified. We hypothesized, therefore, that comprehensive allelotyping of FNH could be a useful tool for differentiating FNH from HCC. A 27-year-old man was admitted to the hospital because of general fatigue. A computed tomography (CT) scan disclosed a hepatic nodule 8 cm in diameter. No definite diagnosis was made after imaging or by biopsy before surgery. Macroscopically and microscopically, the surgical specimen showed typical features of FNH. Comprehensive microsatellite analysis was carried out with 382 microsatellite markers distributed throughout all chromosomes. To detect At effectively, the cutoff value of the At index was set at 0.70. Among the 382 microsatellite markers, 212 loci were informative, but no At was detected. The absence of gross chromosomal alterations strongly suggested that the large nodule was FNH rather than HCC, in terms of its genetic background. The patient's subsequent clinical course revealed the nodule to be benign. The results suggest that this genome-wide microsatellite analysis is a useful tool for the differential diagnosis of non-neoplastic liver nodules from HCC.
  • T Nishimura; N Nishida; T Komeda; Y Fukuda; K Nakao
    CANCER GENETICS AND CYTOGENETICS 161 2 164 - 169 2005年09月 [査読有り]
     
    It is widely accepted that chromosomal instability is an essential feature of cancer cells including hepatocellular carcinoma (HCC) cells. For an accurate characterization of clonal evolution of HCC cells, we studied chromosomal alterations in various metastatic lesions in an autopsy case of HCC. Tissues from the main tumor, which consisted of 2 macroscopically distinct portions. and from intrahepatic metastasis, portal vein thrombus, epiploic lymph node metastasis, and Pulmonary metastasis as well as from the non-tumorous liver were analyzed with comprehensive microsatellite analysis. Alleles showing imbalance of the main tumor were further subjected to comparative duplex PCR. with use of a retained allele as an internal control, to determine whether the imbalance was the result of chromosomal gain or loss. A striking finding was that allelic imbalances detected in the main tumor and metastatic lesions were almost identical, showing -1p, + 1q, -4q. -7, -8p, + 8q, + 9q, + 10, - 13q, - 17p, + 19p, - 19q, and - X. Additional alterations of + 2q and - 16q were detected in one portion of the main tumor and the portal vein thrombus. In conclusion, clonal evolution of the HCC cells during metastatic progression seems rare, in contrast to many recurrent chromosomal aberrations that may have accumulated before the clinical manifestation. (c) 2005 Elsevier Inc. All rights reserved.
  • T Nishimura; N Nishida; T Itoh; T Komeda; Y Fukuda; Ikai, I; Y Yamaoka; K Nakao
    GENES CHROMOSOMES & CANCER 42 1 34 - 43 2005年01月 [査読有り]
     
    Recurrent chromosomal gain at 1q is one of the most common features of human hepatocellular carcinoma (HCC), but how the gain at 1q contributes to hepatocarcinogenesis is still unclear. To identify the target genes, precise determination of the shortest region of overlap (SRO) and of breakpoints is necessary. Similarly, the role of loss at I p, which is also a major cytogenetic aberration in HCC, needs to be determined. Fifty HCCs were examined with the aid of 59 microsatellite markers distributed throughout both arms of chromosome 1. To detect allelic gain effectively, the cutoff value of the allelic imbalance index was set at 0.70. Alleles showing imbalance were subjected to multiplex PCR, using a retained allele as an internal control, to determine whether the imbalance was the result of chromosomal gain or loss. The SRO of the gains was defined as DIS2878-DIS2619 (1q23-q25.3, 16.9 Mb), which involved 36 cases (72%). Gains in the number of copies of certain oncogenes within this region seemed to be critical for the pathogenesis of HCC. In contrast, the centromeric breakpoints of these gains varied, but they tended to occur mainly in the pericentromeric region (26 of 50 cases, 52%). Rearrangement of specific genes associated with the gains is unlikely. On the other hand, the SRO of deletion was defined as DIS2893-DIS450 (1p36.32-p36.22, 5.1 Mb). Four known putative tumor-suppressor genes (TP73, RIZI, NBLI/DAN, and CDKN2C) were outside the SRO, suggesting the presence of other candidate genes with critical roles in hepatocarcinogenesis. (C) 2004 Wiley-Liss, Inc.
  • Nishida N
    Nihon rinsho. Japanese journal of clinical medicine 62 Suppl 9 131 - 134 2004年09月 [査読有り]
  • T Ito; N Nishida; Y Fukuda; T Nishimura; T Komeda; K Nakao
    JOURNAL OF GASTROENTEROLOGY 39 4 355 - 361 2004年04月 [査読有り]
     
    Background. The INK4a/ARF locus encodes p16(INK4a) and p14(ARF), both of which are crucial for two tumor suppressor pathways, retinoblastoma (RB)/p16(INK4a), and p53/ARF. Inactivation of RB/p16(INK4a), was frequently reported, but alterations of the p14(ARF) gene in hepatocellular carcinoma (HCC) in the Japanese population have been insufficiently analyzed. Methods. To determine the role of p53/ARF alteration in hepatocarcinogenesis, we examined 44 HCCs for mRNA expression, deletion, mutation, and promoter hypermethylation of the p14(ARF) genes alterations of p53 were also analyzed in the same series of HCCs. Results. Homozygous deletion, spanning from exon 1beta to exon 2, was found in 1 HCC mutations within exon 2 were found in 2 HCCs, but no promoter hypermethylation was detected. All 3 HCCs with p14(ARF) alteration were well differentiated. Twelve of the 44 HCCs (27.2%) showed immunohistochemical evidence of p53 alterations however, only 1 of the tumors with p53 alteration was well differentiated. TaqMan polymarase chain reaction (PCR) indicated that the expression of p14(ARF) in HCCs was higher than in that in all but three of the corresponding non-tumorous tissues (P<0.0001), and increased expression of p14(ARF) seemed to be associated with poorly differentiated phenotype. Absence of p14(ARF) expression was seen in only one HCC, with homozygous deletion of the p14(ARF) gene. Conclusions. Compared with p53 alteration, p14(ARF) alteration does not occur frequently, but may play a role in a subset of Japanese HCCs in the early stage of hepatocarcinogenesis. On the other hand, overexpression of p14(ARF) was frequently observed in HCC, especially in poorly differentiated tumors, probably reflecting oncogenic stimuli in these tumors.
  • Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.
    NISHIDA Naoshi
    Cancer Research 2004年 [査読有り]
  • N Nishida; T Nishimura; T Ito; T Komeda; Y Fukuda; K Nakao
    HISTOLOGY AND HISTOPATHOLOGY 18 3 897 - 909 2003年07月 [査読有り]
     
    Recently, many studies have identified losses and gains of several chromosomal loci in human hepatocellular carcinoma (HCC) with fine microsatellite analysis and comparative genomic hybridization. Although distribution of aberrant chromosomal arms differs among HCCs, loss of 1p, 4q, 6q, Sp, 9p, 10q, 13q, 16q and 17p, and gain of 1q, 6p, 8q, 17q and 20q have been recurrently reported, and loss of 4q and 16q seems to occur preferentially in hepatitis B virus-related HCCs. Accumulation of these aberrant chromosomal regions is associated with tumor progression, and some chromosomal aberrations, such as loss of 1p, are frequently identified in well-differentiated HCCs and also detected even in dysplastic nodule and cirrhotic nodule. This evidence suggests that chromosomal instability (CIN) emerges at an early stage during hepatocarcinogenesis and is successively inherent to tumor cells, resulting in acquisition of malignant phenotype. The molecular basis of CIN is beginning to be explored; however, several mechanisms may be involved for CIN of HCC.
  • T Nishimura; N Nishida; T Itoh; M Kuno; M Minata; T Komeda; Y Fukuda; Ikai, I; Y Yamaoka; K Nakao
    GENES CHROMOSOMES & CANCER 35 4 329 - 339 2002年12月 [査読有り]
     
    Allelic imbalance (AI), which represents certain chromosomal gains or losses, has been described in human hepatocellular carcinoma (HCC), but the impact of AI on the early stage of hepatocarcinogenesis has not been fully clarified. Moreover, no previous allelotype studies have identified the difference in chromosomal gain and loss that results in AI. To resolve these problems, we examined 18 well-differentiated HCCs with comprehensive allelotyping by using 400 microsatellite markers with semiquantitative assessment of chromosomal gain or loss. To detect allelic gain effectively, the cutoff value of the allelic imbalance index was set at 0.70. Each allele showing imbalance was subjected to multiplex PCR with use of a retained allele as an internal control to determine whether the imbalance was the result of chromosomal gain or loss. High frequencies of chromosomal gains were detected at 1q (DIS196-DIS2785, 56%), 5q (D5S647-D5S2027, 44%), 6p (6pter-D6S309, 33%), 7 (7pter-D7S657, 22%), and 8q (D8S514-qter, 44%), whereas chromosomal losses were frequently observed at Ip (Ipter-D1S234, 22%), 8p (8pter-D8S549, 44%), and 17p (17pter-D17S921, 28%). The extent of overall chromosomal aberration was closely related to the maximum tumor diameter (P = 0.002) and the presence of hepatitis B surface antigen (P = 0.03). Recurrent chromosomal losses at I p and 8p and gains at 1q and 8q, even in HCCs with a minimal extent of aberrant chromosomes, indicate that these alterations were critical in the early stage of hepatocarcinogenesis. On the other hand, deletions of 13q and 16q were infrequent and were seen only in the most aberrant cases, which suggested that these were late events. (C) 2002 Wiley-Liss, Inc.
  • Y Maetani; K Itoh; H Egawa; H Haga; T Sakurai; N Nishida; F Ametani; T Shibata; T Kubo; K Tanaka; J Konishi
    AMERICAN JOURNAL OF ROENTGENOLOGY 178 4 869 - 875 2002年04月 [査読有り]
     
    OBJECTIVE. The purpose of this study was to determine the imaging features of benign hepatic nodules in patients with Budd-Chiari syndrome and to correlate them with pathologic findings, with special attention placed on the presence of a central scar. MATERIALS AND METHODS. Imaging findings of 59 benign hepatic nodules in four patients with chronic Budd-Chiari syndrome were analyzed retrospectively, and radiologic-pathologic correlation was performed in three patients with 50 hepatic nodules who underwent liver transplantation. All patients underwent multiphasic helical CT. In three patients with 29 lesions, MR imaging, including a multiphasic dynamic study, was performed. The CT and MR imaging findings in these patients were compared with those of 103 small hepatocellular carcinomas in 56 other patients (54 of them displayed chronic hepatitis or liver cirrhosis associated with viral hepatitis but none had Budd-Chiari syndrome). Image analysis was performed by two radiologists with no knowledge of the diagnosis. RESULTS. All patients with Budd-Chiari syndrome exhibited multiple benign nodules up to 3 cm in diameter, and 42 of 59 lesions were hypervascular. Microscopically, 15 of 32 nodules demonstrated a central scar; moreover, some nodules closely resembled focal nodular hyperplasia. Frequencies of hyperintensity on T1-weighted images (14/29 vs 25/103), hypointensity on T2-weighted images (7/29 vs 1/103), and the presence of a central scar (6/59 vs 1/103) were significantly higher in benign nodules than in hepatocellular carcinomas (p < 0.05; Fisher's exact test). Moreover, for lesions larger than I cm, imaging studies revealed a central scar in six of 15 benign lesions. CONCLUSION. Benign hepatic nodules in patients with in Budd-Chiari syndrome are usually small, multiple, and hypervascular. The presence of a central scar is a characteristic feature in those larger than 1 cm in diameter.
  • N Nishida; Y Fukuda; T Komeda; T Ito; T Nishimura; M Minata; M Kuno; H Katsuma; Ikai, I; Y Yamaoka; K Nakao
    ONCOLOGY 62 2 141 - 148 2002年 [査読有り]
     
    Loss of heterozygosity (LOH) on chromosomes 13q, 16q and 17p has been associated with the progression of hepatocellular carcinoma (HCC). To investigate the prognostic impact of such LOH, we examined the metastasisfree survival of curatively resected HCC cases, in whom these LOHs were analyzed. Among the 49 HCC patients examined, the frequency of LOHs was 28% on 13q, 33% on 16q and 40% on 17p. The patients were followed up for metastatic recurrence after surgery and for analysis of the relationship between chromosomal changes and patients' metastasis-free survival. Univariate survival analysis showed the presence of LOH on 16q, 17p and the number of chromosomes with LOH were significantly and negatively associated with metastasis-free survival, indicating that patients with LOH on multiple chromosomes had a poorer prognosis after surgery than those with LOH on a single chromosome or no LOH. Multivariate Cox survival analysis identified the presence of LOH on 16q and the number of chromosomes with LOH as the most significant independent negatively predictive factors for metastasis-free survival. These findings indicate that accumulation of chromosomal changes is associated with metastatic behavior, and that LOH on 16q was the most useful prognostic indicator for metastasis after curative resection of HCC. Copyright (C) 2002 S. Karger AG, Basel.
  • Nishida N; Fukuda Y
    Nihon rinsho. Japanese journal of clinical medicine 59 Suppl 6 134 - 137 2001年10月 [査読有り]
  • M Minata; N Nishida; T Komeda; H Azechi; H Katsuma; T Nishimura; M Kuno; T Ito; Y Yamamoto; Ikai, I; Y Yamaoka; Y Fukuda; K Nakao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 16 4 445 - 451 2001年04月 [査読有り]
     
    Background: We tested for the presence of alpha-fetoprotein (AFP) mRNA by using nested RT-PCR in the peripheral blood of hepatocellular carcinoma (HCC) patients who had undergone curative surgery, and investigated the occurrence of intrahepatic and/or extrahepatic metastasis thereafter, to reveal the optimal timing of blood sampling for the prediction of metastatic recurrence. Methods: Twenty-nine patients with HCC, who had been operated on were analyzed with RT-PCR at several points during the clinical course, and examined for metastatic recurrence for 3-28 months (mean = 18.7 months) after surgery. Results: The presence of AFP mRNA before surgery was significantly correlated with the tumor size (P = 0.017). Metastatic recurrence was associated with the postoperative detection of AFP mRNA (P < 0.001), but not with the preoperative and/or perioperative detection. Furthermore, AFP mRNA was detected in some cases that showed low serum AFP levels at recurrence. The recurrence-free period after the detection of AFP mRNA varied from 1 to 12 months. Conclusions: The postoperative detection of AFP mRNA is useful for the prediction of metastatic recurrence, and long-term follow up with this method should be conducted. (C) 2001 Blackwell Science Asia Pty Ltd.
  • A. Tanaka; R. Takeda; S. Mukaihara; K. Hayakawa; T. Shibata; K. Itoh; N. Nishida; K. Nakao; Y. Fukuda; T. Chiba; Y. Yamaoka
    International Journal of Clinical Oncology 6 6 291 - 295 2001年 [査読有り]
     
    Background. The problem of whether surgical or conservative treatment is indicated for ruptured hepatocellular carcinoma (HCC) has not been analyzed from the viewpoint of long-term development of hepatitis viral infection from liver fibrosis to liver cirrhosis. Although transcatheter arterial embolization (TAE) for hemostasis followed by two-stage hepatectomy has been established as the best treatment for ruptured HCC, there still remain difficulties in the treatment of some patients. Methods. Twelve patients with ruptured HCC who were surgically or conservatively treated were retrospectively analyzed in terms of modality of treatment, liver function, extension of HCC, complications, survival rate, and cause of death. Results. Tumor rupture can occur either in the early phase or in the terminal phase during the development from liver fibrosis to liver cirrhosis, while tumor rupture occurs at the advanced stage in terms of HCC extension. TAE for emergent hemostasis or prevention of re-bleeding was performed in ten patients, while TAE was contraindicated in one patient and emergent laparotomy for hemostasis was performed in one patient. In four patients, elective extended surgical resection was performed, because liver function was evaluated as clinical stage 1 according to the General rules for the clinical and pathological study of primary liver cancer of the Liver Cancer Study Group of Japan. In seven patients, conservative or medical treatment was selected, because liver function was evaluated as poor. The surgically treated group, who could tolerate extensive operation, survived longer than the conservatively treated group. Conclusions. While TAE remains the best method to employ for hemostasis, it still has limitations. Hence, we should be mindful of other possible modalities for hemostasis and their outcomes. Rupture of HCC at an early phase in the development of liver fibrosis is a good indication for elective surgical treatment and should be distinguished from rupture in the terminal phase of liver cirrhosis, which should be treated conservatively. Although elective surgical treatment can be performed in selected patients, tumor size and location of HCC, in addition to liver function, should be taken into consideration.
  • H Azechi; N Nishida; Y Fukuda; T Nishimura; M Minata; H Katsuma; M Kuno; T Ito; T Komeda; R Kita; R Takahashi; K Nakao
    ONCOLOGY 60 4 346 - 354 2001年 [査読有り]
     
    p16, cyclin D1 and retinoblastoma protein (pRB) regulate G(1) to S transition and are commonly targeted in various cancers. However, few studies have simultaneously examined all components of the p16/cyclin D1/pRB pathway (RB pathway) in hepatocellular carcinoma (HCC). To clarify the role of the disruption of the RE pathway in HCC, we analyzed p16, pRB and cyclin D1 in 47 HCCs. Inactivation of p16 was detected in 30 of 47 HCCs (64%) by Western blot analysis and significantly correlated with hypermethylation of the promoter of this gene. pRB expression was found to be absent in 13 of 47 HCCs (28%) by immunohistochemistry. We found that 38 of 47 HCCs (81%) contained at least one inactivation in either PRE or p16. Furthermore, there was a significant inverse correlation between p16 and pRB inactivation (p = 0.041). Overexpression of cyclin D1 was detected in 5 of 47 HCCs (11%) by immunohistochemistry. The cases with cyclin D1 overexpression exhibited an advanced clinicopathological appearance and also contained inactivation of PRE and/or p16. These findings suggest that inactivation of pRB and/or p16 is a major event in human hepatocarcinogenesis, while cyclin D1 overexpression may confer additional growth advantages to the tu mor in addition to PRE and/or p16 inactivation in HCC. Copyright (C) 2001 S. Karger AG, Basel.
  • M Amenomori; T Mori; Y Fukuda; H Sugawa; N Nishida; M Furukawa; R Kita; T Sando; T Komeda; K Nakao
    INTERNAL MEDICINE 37 3 246 - 252 1998年03月 [査読有り]
     
    Thyroid functions were analyzed before, during and after interferon (IFN) therapy in patients with chronic hepatitis C. According to the results of routine thyroid function tests and measurements of the levels of anti-thyroid autoantibody prior to the therapy, patients were divided into 2 groups; Group A (19 patients) had at least one abnormal finding related to the thyroid, and Group B (40 patients) did not show any abnormality. Five patients (26 %) in Group A and 4 (10 %) in Group B showed thyroid dysfunctions which were very clearly reflected by thyrotropin (TSH) measurements. Interestingly, the time of peak TSH elevation in Group A (mean +/- SD, 4.3 +/- 0.8 months) was significantly earlier than that in Group B (6.8 +/- 0.8), Most patients in Group B were diagnosed as having destructive thyroiditis. These findings may suggest that the pathogenesis of IFN-induced thyroid dysfunction consists not only of exacerbation of pre-existing thyroid autoimmunity but also of de novo destructive changes even in the intact thyroid before IFN therapy.
  • N Nishida; Y Fukuda; K Ishizaki; K Nakao
    HISTOLOGY AND HISTOPATHOLOGY 12 4 1019 - 1025 1997年10月 [査読有り]
     
    The mammalian cell cycle is controlled by regulators of the G1 to S transition such as tumor suppressor proteins, p53 and retinoblastoma (RB); cyclin D1 and cyclin-dependent kinase 4; and inhibitor of cyclin dependent kinase, p16(INK4A). Recently, aberrations of these cell cycle-related genes have been reported to contribute to the formation and development of cancer. In human hepatocellular carcinoma (HCC), high frequencies of aberration have been detected in the p53 and RB genes. Loss of heterozygosity (LOH) of chromosome 13q was detected in 35% of HCC and LOH on chromosome 17p was detected in 49%. Mutation of the p53 gene was also detected in 32%. The aberrations of these genes were observed more frequently in poorly differentiated and in advanced HCCs. On the other hand, genetic alterations of the cyclin D1 and p16(INK4A) genes were not so frequent, but appeared to be associated with the aggressive behavior of the tumor, which suggests that disruption of the cell cycle-related genes results in the progression of HCC. Further study with a substantial number of cases is required to determine the actual frequency of the aberrations of the G1 controlling genes in hepatocarcinogenesis.
  • R Kita; N Nishida; Y Fukuda; H Azechi; Y Matsuoka; T Komeda; T Sando; K Nakao; K Ishizaki
    INTERNATIONAL JOURNAL OF CANCER 67 2 176 - 180 1996年07月 [査読有り]
     
    We examined the genomic status of the p16(INK4A) (inhibitor of cyclin-dependent kinase 4 A) and cyclin dependent kinase 4 (CDK4) genes in 62 human hepatocellular carcinomas (HCCs), 5 cholangiocellular carcinomas and 6 cell lines derived from human liver cancers, Although no samples showed the homozygous deletion of the p16(INK4A) gene, we detected intragenic mutations of the p16(INK4A) gene in 3 HCCs and one HCC cell line, which led to an amino-acid substitution or a frameshift. In 2 HCC samples with mis-sense mutations of the p16(INK4A) gene, loss of heterozygosity on 9p22 was also detected, suggesting that the loss of function of p16 was induced during hepatocarcinoegenesis. On the other hand, amplification or rearrangement of the CDK4 gene was not detected in any samples examined in this study. These results indicated that the mutations or deletions of the p16(INK4A) gene are not frequent, but may play a role in a sob-set of human HCC. (C) 1996 Wiley-Liss, Inc.
  • EK Choi; S Uyeno; N Nishida; T Okumoto; S Fujimura; Y Aoki; M Nata; K Sagisaka; Y Fukuda; K Nakao; T Yoshimoto; YS Kim; T Ono
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 354 1 123 - 128 1996年07月 [査読有り]
     
    The state of DNA methylation in the c-fos gene was examined in human livers of different ages, cirrhosis and hepatocellular carcinoma, The degree of methylation in the intron 1 to exon 4 region increased with age, whereas all of the 10 cirrhosis samples revealed a decrease in methylation when compared to normal livers of similar ages. The 11 hepatocellular carcinomas showed varied alterations suggesting that the alteration of the c-Sos gene methylation is related to aging as well as to early-step of hepatocarcinogenesis.
  • T KOMEDA; Y FUKUDA; T SANDO; R KITA; M FURUKAWA; N NISHIDA; M AMENOMORI; K NAKAO
    CANCER 75 9 2214 - 2219 1995年05月 [査読有り]
     
    Background. This study was performed to develop a sensitive method for the detection of circulating hepatocellular carcinoma (HCC) cells in peripheral blood, in advance of the diagnosis of distant metastasis of HCC by conventional means. Methods. Peripheral blood (5 ml) samples were obtained from 64 patients with HCC and from 48 control subjects (31 patients with benign liver disease, 8 with metastatic liver cancer, and 9 with normal liver function). To identify HCC cells in peripheral blood, liver-specific human alpha-fetoprotein (hAFP) mRNA was amplified from total RNA extracted from whole blood by reverse transcriptase-polymerase chain reaction. Results. Human alpha-fetoprotein mRNA was detected in 23 blood samples from the HCC patients (23/64, 36%), in 17 patients in whom there was no clinical evidence of distant metastasis. In contrast, there were no control patients whose samples showed detectable hAFP mRNA in the peripheral blood. The presence of hAFP mRNA in blood seemed to be correlated with the stage (by TNM classification) of HCC, the serum hAFP value, and the presence of intrahepatic metastasis, portal vein thrombosis, and/or distant metastasis. Conclusions. Reverse-transcriptase polymerase chain reaction is a very sensitive method for detecting circulating HCC cells. With this technique, important information for the management of HCC can be acquired, such as the indications for orthotopic liver transplantation in HCC patients. Moreover, use of this detection method may encourage investigation of the mechanism of metastasis in HCC.
  • N NISHIDA; Y FUKUDA; T KOMEDA; R KITA; T SANDO; M FURUKAWA; M AMENOMORI; SHIBAGAKI, I; K NAKAO; M IKENAGA; K ISHIZAKI
    CANCER RESEARCH 54 12 3107 - 3110 1994年06月 [査読有り]
     
    We analyzed the genetic alterations of the cyclin D1 and INT-2 genes in hepatocellular carcinomas (HCCs) from 45 patients. Among these, expression of the cyclin D1 mRNA was also analyzed in 18 of them by Northern blotting. The cyclin D1 gene was amplified 3-16 fold in five HCCs (11%); among these, the INT-2 gene was also amplified 2-10 fold in four HCCs. We analyzed the mRNA of cyclin D1 in four HCCs with gene amplifications, and 6-10 fold overexpressions were detected in all of them. Because the cyclin D1 gene was amplified in patients at an advanced stage of HCC with rapid tumor growth, it appeared to be associated with the aggressive behavior of tumors. Studies on loss of heterozygosity on chromosome 13q, where the retinoblastoma (RB) gene is located, indicated that all HCCs with an amplified cyclin D1 gene retained heterozygosity on chromosome 13q. These results suggest that amplification and overexpression of the cyclin D1 gene result in the rapid growth of a subset of HCC, even though the function of the RB gene is retained.
  • N NISHIDA; Y FUKUDA; K ISHIZAKI
    INTERNATIONAL JOURNAL OF ONCOLOGY 4 3 615 - 622 1994年03月 [査読有り]
     
    The formation and development of cancer is associated with various genetic abnormalities. Recent progress in the study of genetic changes in hepatocellular carcinoma (HCC) have clarified the aberrations of oncogenes and tumor suppressor genes, as well as the role of the hepatitis virus in hepatocarcinogenesis. Overexpression of the c-myc gene, inactivation of the p53 and RB genes, and the loss of heterozygosity (LOH) of some chromosomes where tumor suppressor genes may be located have been reported in association with the progression of HCC. However, genetic abnormalities of HCC at the early stages have yet to be elucidated. On the other hand, the association between HCC and chronic infection with the hepatitis virus also shows the relevance of the oncogenic potential of the hepatitis virus to HCC formation. Some regions of HBV genome, especially the HBV X gene, stimulate the various cellular activities related to tumor promotion and contribute to hepatocarcinogenesis. The knowledge of genetic abnormalities is helpful in the elucidation of pathogenesis and probably in the diagnosis, prognosis and therapy of HCC. Further studies of these genetic changes will apparently promote molecular diagnosis and gene therapy in HCC.
  • Molecular aspects of hepatocarcinogenesis and their clinical implications.
    Nishida, N; Fukuda, Y; Ishizaki, K
    Int. J. Oncol. 4 615 - 622 1994年 [査読有り]
  • N NISHIDA; Y FUKUDA; H KOKURYU; J TOGUCHIDA; DW YANDELL; M IKENEGA; H IMURA; K ISHIZAKI
    CANCER RESEARCH 53 2 368 - 372 1993年01月 [査読有り]
     
    The mutational spectrum of the p53 gene was analyzed in 53 hepatocellular carcinomas. Somatic mutations of the p53 gene were detected in 17 cases (32%). Among these 17 mutations, 9 were missense mutations; the mutations in the other 8 cases were nonsense mutations, deletions, or mutations at the intron-exon junctions. These mutations were found in a wide region stretching from exon 4 to exon 10 without any single mutational hot spot. G:C to T:A transversions were predominant, suggesting the involvement of environmental mutagens in the mutagenesis of the p53 gene in a subset of the hepatocellular carcinoma cases. Mutations of the p53 gene occurred frequently in advanced tumors, although several tumors in the early stages also showed mutations. A deletion map of chromosome 17 was constructed by using 10 polymorphic probes and was compared with the p53 gene mutation in each case. Loss of heterozygosity (LOH) on chromosome 17p was observed in 49% of the cases (24 of 49), and two commonly deleted regions were detected (around the p53 locus and at 17p13.3 to the telomere). Sixteen of the 17 cases with p53 gene mutations showed LOH around the p53 locus, and mutations were rare in hepatocellular carcinomas without LOH. However, no mutations were detected in 8 cases with LOH on 17p, suggesting the possibility that an unidentified tumor suppressor gene(s) located on 17p may have also been involved in hepatocarcinogenesis.
  • N NISHIDA; Y FUKUDA; H KOKURYU; T SADAMOTO; G ISOWA; K HONDA; Y YAMAOKA; M IKENAGA; H IMURA; K ISHIZAKI
    INTERNATIONAL JOURNAL OF CANCER 51 6 862 - 868 1992年07月 [査読有り]
     
    We examined loss of heterozygosity at 13 loci on 5 chromosomes in hepatocellular carcinomas (HCCs) from 56 patients. In 42 of these cases, regenerative nodules of liver cirrhosis were also analyzed. High frequencies of allelic losses were detected on chromosomes 13q (47%), 16q (40%) and 17p (64%), whereas losses on chromosome 4p and 11p were observed in less than 22% of cases in HCCs. In contrast, LOH was not detected on any loci in cirrhotic nodules. On chromosome 13q, the common region of allelic loss was mapped to the region including the retinoblastoma (RB) locus, by using 8 polymorphic probes. Furthermore, one case with 13q loss had an interstitial deletion of the RB gene, indicating the involvement of inactivation of the RB gene in hepatotumorigenesis. Losses were associated with portal-vein thrombosis or intrahepatic metastasis, increased tumor size, a poorly differentiated phenotype and clinical stage. Losses occurring together on 13q, 16q and 17p were significantly higher in patients in clinical stage IV or histologically poorly differentiated tumors, suggesting that the accumulation of allelic loss occurs in advanced tumors and that patients with multiple allelic losses may have a worse prognosis than those with a single loss.
  • 岡 孝和; 前川 高夫; 直木 正雄; 西田 直生志; 西田 真弓; 佐竹 弘; 生田 篤也; 清水 一良; 梶谷 幸夫; 粉川 皓使; 三宅 健夫
    心身医学 30 2 178 - 178 一般社団法人 日本心身医学会 1990年

書籍

  • Naoshi Nishida; Masatoshi Kudo (担当:共編者(共編著者)範囲:)MDPI Books 2023年04月 ISBN: 9783036566917
  • 西田 直生志 (担当:共著範囲:免疫微小環境と免疫チェックポイント阻害剤)アークメディア 2021年09月
  • 西田 直生志 (担当:共著範囲:Chapter 9 今後の課題と展望)オーム社 2021年09月 ISBN: 9784274225765 8,187p
  • 西田, 直生志; 工藤, 正俊 (担当:共著範囲:Chapter 4 超音波画像データベース構築)オーム社 2021年09月 ISBN: 9784274225765 8,187p
  • 西田 直生志 (担当:共著範囲:Chapter 7 超音波画像データベース構築の実際)オーム社 2021年09月 ISBN: 9784274225765 8,187p
  • 西田 直生志 (担当:共著範囲:Chapter 3 超音波画像診断におけるAI診断支援の意義)オーム社 2021年09月 ISBN: 9784274225765 8,187p
  • 日本肝臓学会教育講演会テキスト
    西田 直生志 (担当:分担執筆範囲:肝細胞癌の薬物療法)日本肝臓学会 2019年08月
  • Diagnosis of Liver Disease
    NISHIDA Naoshi (担当:共著範囲:Liver Tumors II: Malignant Tumors of the Liver)Springer Nature 2019年05月
  • 2019 JDDW 教育講演WEB配信
    西田 直生志 (担当:その他範囲:教育講演3)JDDW, URL: https://www.jddw.jp/va_kyouiku.html 2018年12月
  • 消化器内科診察 レジデントマニュアル
    西田 直生志 (担当:共著範囲:)医学書院 2018年11月
  • JDDW2019 教育講演会テキスト
    西田 直生志 (担当:分担執筆範囲:ここまで進んだ肝癌の薬物療法)日本消化器関連学会習慣 2018年11月
  • ESMO HANDBOOK OF IMMUNO-ONCOLOGY
    西田 直生志 (担当:共著範囲:Hepatocellular Carcinoma)European Society of Medical Oncology 2018年10月
  • 【消化器研修ノート】
    西田 直生志 (担当:分担執筆範囲:消化器癌の遺伝子診断・コンパニオン診断)診断と治療社 2016年
  • 【最新内分泌代謝学】
    西田 直生志 (担当:分担執筆範囲:第10章 その他の代謝異常 銅代謝異常(Wilson病))診断と治療社 2013年
  • 【消化器病学の進歩ー原点から未来への情報発信】
    西田 直生志 (担当:分担執筆範囲:III巻-複合領域)医学書院 2009年
  • Current Research in Cancer
    Naoshi Nishida (担当:分担執筆範囲:Chromosomal instability and epigenetic instability)Research Media 2007年
  • 【生活習慣病の科学】
    西田 直生志 (担当:分担執筆範囲:第6章-肝臓病)京都大学学術出版会 2005年
  • 【消化器疾患診療実践ガイド】
    西田 直生志 (担当:分担執筆範囲:第1章-診断編、腹水)文光堂 2005年
  • 消化器疾患診療実践ガイド
    西田 直生志 (担当:分担執筆範囲:第1章-診断編、肝・胆道系疾患における検査値の読み方)文光堂 2005年
  • 免疫学-主要疾患発生のメカニズム
    西田 直生志 (担当:共訳範囲:第14章-肝疾患)ディカル・サイエンス・インターナショナル 1999年
  • 肝癌-診断と治療
    西田 直生志 (担当:分担執筆範囲:遺伝子診断-現状と将来-)日本メディカルセンター 1997年
  • 臨床遺伝学
    石崎寛治; 西田直生志; 和形隆志; 柴垣一夫 (担当:分担執筆範囲:癌と遺伝)診断と治療社 1993年

講演・口頭発表等

  • Naoshi Nishida
    The 33rd Annual Meeting of APASL (Asian Pacific Association for Study of the Liver): Bridging Clinical and Basic Research 2024年03月 口頭発表(招待・特別)
  • 肝がんの集学的治療における血管新生阻害剤と免疫チェックポイント阻害剤の役割  [招待講演]
    西田 直生志
    第6回 中外HCCWEBセミナー 特別講演 2024年03月 公開講演,セミナー,チュートリアル,講習,講義等
  • 西田直生志
    第42回東海超音波研究会 特別講演 2024年01月 口頭発表(招待・特別)
  • 西田直生志; 工藤正俊
    第45回日本肝臓学会西部会:ワークショップ3 予後改善に向けた胆管癌の集学的治療 2023年12月 シンポジウム・ワークショップパネル(公募)
  • 切除不能HCCに対するABC conversion療法とclinical CRの現状  [通常講演]
    青木智子; 西田直生志; 工藤正俊
    第45回日本肝臓学会西部会: ワークショップ1 肝がん局所療法の多様性とその到達点 2023年12月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志; 工藤 正俊
    第59回肝癌研究会 ワークショップ4: 肝腫瘍診療におけるAI/ITの可能性 2023年07月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志; 青木 智子; 盛田 真弘; 千品 寛和; 田北 真弘; 萩原 智; 依田 広; 南 康範; 上嶋 一臣; 工藤 正俊
    第59回肝癌研究会 シンポジウム2: 肝内胆管癌薬物療法の進歩 2023年07月 シンポジウム・ワークショップパネル(公募)
  • 青木智子; 西田直生志; 紅林泰; 坂井和子; 盛田真弘; 千品寛和; 田北雅弘; 萩原智; 依田広; 上嶋一臣; 南康範; 鶴崎正勝; 中居卓也; 坂元亨宇; 西尾和人; 工藤正俊
    第59回日本肝癌研究会 シンポジウム1 肝癌腫瘍微小環境 2023年07月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志
    第23回愛媛消化器超音波カンファレンス 特別講演 2023年07月 公開講演,セミナー,チュートリアル,講習,講義等
  • AIを基盤とした超音波検査の未来像 ー肝腫瘤診断における新たな可能性と展望ー  [招待講演]
    西田 直生志
    第31回がん検診・診断学会総会 シンポジウム-領域横断企画2 AIを用いたがん検診、診断の現状 2023年06月 シンポジウム・ワークショップパネル(指名)
  • 免疫チェックポイント阻害剤投与に伴う HBV 再活性化および抗ウイルス効果についての検討  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    第59回 日本肝臓学会総会 シンポジウム 3: B 型肝炎診療の未来予想図 2023年06月 シンポジウム・ワークショップパネル(公募)
  • 非アルコール性脂肪肝疾患における DNA メチル化に関連する臨床的・病理学的特徴  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    第59回 日本肝臓学会総会 ワークショップ 10: NASH/ASH の病態解明と Transrational Research 2023年06月 シンポジウム・ワークショップパネル(公募)
  • Erythropoietic porphyria(EPP)関連肝障害における瀉血治療の有効性  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    第59 回 日本肝臓学会総会 パネルディスカッション 5:遺伝・代謝性肝疾患の未来予想図 2023年06月 シンポジウム・ワークショップパネル(公募)
  • 高アンモニア血症に対するレボカルニチン自体の効果について  [通常講演]
    萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第59回 日本肝臓学会総会 2023年06月 口頭発表(一般)
  • B型慢性肝炎患者に対するTAFの効果および安全性の検討  [通常講演]
    萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第59回 日本肝臓学会総会 2023年06月 口頭発表(一般)
  • 非硬変肝から発生したFontan術後のHCCの一例  [通常講演]
    有山 武尊; 萩原 智; 西田 直生志; 工藤 正俊
    第59回日本肝臓学会総会 特別企画 研修医・専攻医・医学生セッション 2023年06月 口頭発表(一般)
  • 西田 直生志; 工藤 正俊
    第109回日本消化器病学会総会: シンポジウム3 消化器診療におけるAIの現状と展望 2023年04月 シンポジウム・ワークショップパネル(指名)
  • 免疫複合療法時代における切除不能肝細胞癌へのcancer-free strategy  [通常講演]
    青木 智子; 西田 直生志; 工藤 正俊
    第109回日本消化器病学会総会: シンポジウム14 進行肝癌の治療戦略 2023年04月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志
    私立医科大学臨床検査技師会学術研修会 特別講演 2023年01月 口頭発表(招待・特別)
  • 肝がんの治療 - 薬物治療について -  [招待講演]
    西田 直生志
    神戸市難病団体連絡協議会・肝炎友の会 講演会 2022年12月 公開講演,セミナー,チュートリアル,講習,講義等
  • 西田直生志
    第44回日本肝臓学会東部会 スポンサードセミナー 2022年11月 公開講演,セミナー,チュートリアル,講習,講義等
  • irAE腸炎による消化管穿孔に対してステロイド前のinfliximab先行投与により救命できた一例  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    日本肝臓学会東部会 2022年11月 口頭発表(一般)
  • 発症早期から進行期までを観察し得たirAE胆管炎の一例  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    日本肝臓学会東部会 2022年11月 口頭発表(一般)
  • B型慢性肝炎患者におけるETVとTAFの効果ー安全性の比較ー  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    日本肝臓学会東部会 2022年11月 口頭発表(一般)
  • 萩原智; 西田直生志; 工藤正俊
    日本肝臓学会東部会 2022年11月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志
    JDDW 2022 統合プログラム6 基調講演: AI研究の実装化に向けた課題 2022年10月 口頭発表(基調)
  • 目加田 慶人; 西田直 生志; 工藤 正俊
    JDDW2022 統合プログラム6: AI研究の実装化に向けた課題 2022年10月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志; 上嶋 一臣; 工藤 正俊
    JDDW2022 統合プログラム5 消化肝癌における免疫療法の実際 2022年10月 シンポジウム・ワークショップパネル(公募)
  • 切除不能肝細胞癌におけるhyper progressive diseaseの頻度と有効な後治療  [通常講演]
    青木 智子; 西田 直生志; 工藤 正俊
    JDDW2022 ワークショップ8 進行肝癌薬物療法の課題と展望 2022年10月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志
    第16回肝癌治療ナビゲーション研究会: シンポジウム2 AI 2022年09月 シンポジウム・ワークショップパネル(指名)
  • Masahiro Morita; Naoshi Nishida; Masatoshi Kudo
    The Asian Pacific Association for the Study of the Liver [APASL] 2022, Workshop 15 2022年09月 シンポジウム・ワークショップパネル(指名)
  • Naoshi Nishida
    The Asian Pacific Association for the Study of the Liver [APASL] Oncology 2022, Luncheon Seminar 2 2022年09月 公開講演,セミナー,チュートリアル,講習,講義等
  • Examination of NASH -related Liver Carcinogenesis from Non -developed Fibrosis  [招待講演]
    Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo
    The Asian Pacific Association for the Study of the Liver [APASL] Oncology 2022, Workshop 9 2022年09月 シンポジウム・ワークショップパネル(指名)
  • Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study  [通常講演]
    Thomas Talbo; Antonio D'Alessio; Matthias Pinter; Lorenz Balcar; Bernhard Scheiner; Thomas Marron; Tomi Jun; Sirish Dharmapuri; Celina Ang; Anwaar Saeed; Hannah Hildebrand; Mahvish Muzaffar; Claudia Angela; Maria Fulgenzi; Suneetha Amara; Abdul Rafeh Naqash; Anuhya Gampa; Anjana Pillai; Yinghong Wang; Uqba Khan; Pei-Chang Lee; Yi-Hsiang Huang; Bertram Bengsch; Dominik Bettinger; Yehia Abugabal; Ahmed Kaseb; Tiziana Pressiani; Nicola Personeni; Lorenza Rimassa; Naoshi Nishida; Masatoshi Kudo; Arndt Weinmann; Peter Galle; Ambreen Muhammed; Alessio Cortellini; Arndt Vogel; David J. Pinato
    EASL 2022 2022年07月
  • 免疫チェックポイント阻害剤投与に伴うirAE肝障害、HBV再活性化についての検討  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    第58回日本肝臓学会総会 パネルディスカッション6: 治療起因性肝障害のマネジメント-DILI・HBV再活性化・irAE・IRIS 2022年06月 シンポジウム・ワークショップパネル(公募)
  • Phase 2根治後NIVOLVE試験における奏功症例と特徴  [通常講演]
    青木 智子; 西田 直生志; 工藤 正俊
    第58回肝臓学会総会 シンポジウム2: 肝がんのマネジメント-発がん予防・内科治療・外科治療・再発予防 2022年06月 シンポジウム・ワークショップパネル(公募)
  • Relationship between systemic inflammatory response markers and immune treatment related toxicity (IrAEs) in hepatocellular carcinoma (HCC).  [通常講演]
    Sirish Dharmapuri; Umut Ozbek; Anwaar Saeed; Mahvish Muzaffar; Suneetha Amara; Nicola Personeni; Tiziana Pressiani; Naoshi Nishida; Sonal Paul; Dominik Bettinger; Uqba Khan; Petros Fessas; Yi-Hsiang Huang; Ahmed Omar Kaseb; Anjana Pillai; Lorenza Rimassa; David J. James Pinato; Celina Ang
    ASCO: American Society of Clinical Oncology 2022 2022年06月 ポスター発表
  • Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: Evidence from an observational study.  [通常講演]
    Petros Fessas; Muntaha Naeem; Thomas U. Marron; David Szafron; Elad Sharon; Anwar Saeed; Tomi Jun; Sirish Dharmapuri; Abdul R. Naqash; Thoetchai Peeraphatdi; Anuhya Gampa; Yinghong Wang; Uqba Khan; Mahvish Muzaffar; Musharraf Navaid; ChiehJu Lee; Pei-Chang Lee; Anushi Bulumulle; Bo Yu; Sonal Paul; Neil Nimkar; Dominik Bettinger; Hannah Hildebrand; Yehia I. Abugabal; Tiziana Pressiani; Nicola Personeni; Naoshi Nishida; Masatoshi Kudo; Ahmed Kaseb; Yi-Hsiang Huang; Celina Ang; Anjana Pillai; Lorenza Rimassa; David J. Pinato
    AACR 2022 2022年06月 ポスター発表
  • 西田直生志; 工藤正俊
    第58回肝癌研究会 シンポジウム5: ビッグデータやAI、IoT 活⽤による新たな肝癌診療モデルの構築 2022年05月 シンポジウム・ワークショップパネル(指名)
  • 複合免疫療法時代におけるイメージングバイオマーカーとしてのEOB-MRIの役割  [通常講演]
    青木智子; 西田直生志; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 南康範; 依田広; 祖父江慶太郎; 鶴崎正勝; 工藤正俊
    第58回日本肝癌研究会; パネルディスカッション8 肝癌におけるPrecision Oncology 2022年05月 シンポジウム・ワークショップパネル(公募)
  • 肝グループにおける若手医師の教育は支持されているのか  [通常講演]
    南康範; 盛田真弘; 千品寛和; 青木智子; 田北雅弘; 萩原智; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    第58回日本肝癌研究会; ワークショップ2 肝癌診療における後進の境域 2022年05月 シンポジウム・ワークショップパネル(公募)
  • 複合免疫療法時代におけるhyper progressive disease (HPD)  [通常講演]
    青木智子; 西田直生志; 上嶋一臣; 盛田真弘; 千品寛和; 田北雅弘; 南康範; 萩原智; 依田広; 鶴崎正勝; 工藤正俊
    第58回日本肝癌研究会 パネルディスカッション5; 肝癌免疫療法の治療向上を目指して 2022年05月 シンポジウム・ワークショップパネル(公募)
  • Naoshi Nishida
    The 53th Annual Conference of the Korean Society of Ultrasound In Medicine, Hot Issue 1: AI in abdomen US 2022年05月 口頭発表(招待・特別)
  • 肝疾患の遺伝子異常による病態解明と臨床展開  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    第108回日本消化器病学会総会 ワークショップ10 肝疾患の遺伝子解析による病態解明と臨床展開 2022年04月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌における腫瘍微小免疫環境と免疫チェックポイント阻害剤の効果  [通常講演]
    西田 直生志; 上嶋 一臣; 工藤 正俊
    第108回日本消化器病学会総会 シンポジウム5 消化器癌における免疫治療と分子標的治療の基礎研究と臨床 2022年04月 シンポジウム・ワークショップパネル(公募)
  • Treatment for intermediate-stage HCC beyond up-to-seven criteria  [招待講演]
    Naoshi Nishida
    The 31 Conference of the Asian Pacific Association for the Study of the Liver Disease (APASL) 2022: Meet-the-Experts 11: Tips for Challenging Cases: Thinking Beyond Guidelines 2022年04月 口頭発表(招待・特別)
  • 免疫チェックポイント阻害薬投与に伴うHBV再活性に関する検討  [通常講演]
    盛田真弘; 萩原智; 西田直生志; 工藤正俊
    日本消化器学会近畿地方会 シンポジウム2.肝炎ウイルスコントロール下における課題へのアプローチ 2022年02月 シンポジウム・ワークショップパネル(公募)
  • Final Results of Adjuvant Nivolumab for Hepatocellular Carcinoma (HCC) after Surgical Resection (SR) or Radiofrequency Ablation (RFA) (NIVOLVE): A Phase 2 Prospective Multicenter Single Arm Trial and Exploratory Biomarker Analysis.  [通常講演]
    Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto; Nishio
    ASCO Gastrointestinal Cancers Symposium (ASCO-GI) 2022 2022年01月 ポスター発表
  • Outcomes of beta blockers (BB) in hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs)  [通常講演]
    Linda Wu; Umut Ozbek; Grace Van Hyfte; Pei-Chang Lee; Marlene Reincke; Anuhya Gampa; Yehia Mohamed; Naoshi Nishida; Brooke Wietharn; Suneetha Amara; Lorenz Balcar; Matthias Pinter; A; dt Vogel; Arndt Weinmann; Anwaar Saeed; Lorenza Rimassa; Rafeh Naqash; Mahvish Muzaffar; David Pinato; Celina Ang
    ASCO Gastrointestinal Cancers Symposium (ASCO-GI) 2022 2022年01月 ポスター発表
  • Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis  [通常講演]
    Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio
    2022 ASCO Gastrointestinal Cancers Symposium 2022年01月 ポスター発表
  • 肝細胞がんの治療・薬物治療について  [招待講演]
    西田 直生志
    神戸市難病団体連絡協議会・肝炎友の会 2021年度講演会 2021年12月 公開講演,セミナー,チュートリアル,講習,講義等
  • 西田直生志; 工藤正俊
    日本消化器病週間 JDDW2021 統合プログラム3 (PD) 消化器診療におけるAIの現状と展望 2021年11月 シンポジウム・ワークショップパネル(公募)
  • 盛田真弘; 西田直生志; 工藤正俊
    日本消化器週間 JDDW2021 シンポジウム8 がん微小環境を標的とした消化器がん治療の新展望 2021年11月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志
    日本消化器病週間 JDDW 2021 サテライトシンポジウム72: DX時代の肝疾患診療 2021年11月 公開講演,セミナー,チュートリアル,講習,講義等
  • 免疫チェックポイント阻害剤による肝障害の臨床的、病理学的検討  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    日本消化器病週間 JDDW 2021 ワークショップ3, 薬物性肝障害の実態 2021年11月 シンポジウム・ワークショップパネル(公募)
  • Gd-EOB-DTPA-enhanced MRI肝細胞相で高信号の肝細胞癌は PD-1/PD-L1療法への一次耐性を反映し効果不良である  [通常講演]
    青木 智子; 西田 直生志; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 南 康範; 萩原 智; 依田 広; 祖父江 慶太郎; 鶴崎 正勝; 工藤 正俊
    消化器病学会週間 JDDW 2021 2021年11月 ポスター発表
  • 西田 直生志
    日本超音波医学会第48回関西地方会学術集会 特別企画 「 AI 」 2021年10月 口頭発表(招待・特別)
  • Naoshi Nishida
    JSH International Liver Conference 2021 2021年10月 口頭発表(招待・特別)
  • Deep-learning framework based on a large ultrasound image database to realize computer-aided diagnosis for liver and breast tumors  [通常講演]
    Makoto Yamakawa; Tsuyoshi Shiina; Koichiro Tsugawa; Naoshi Nishida; Masatoshi Kudo
    INTERNATIONAL ULTRASONICS SYMPOSIUM (IEEE IUS 2021) 2021年09月 ポスター発表
  • 西田 直生志; 盛田 真弘; 工藤 正俊
    第58回日本消化器免疫学会総会 シンポジウム2: がん免疫療法の成果と次なる挑戦 2021年07月 シンポジウム・ワークショップパネル(指名)
  • 西田 直生志; 目加田 慶人; 工藤 正俊
    第57回日本肝臓学会総会 ワークショップ11 肝疾患におけるビッグデータとAI(人工知能)の臨床応用 2021年06月 シンポジウム・ワークショップパネル(公募)
  • 池田 裕亮; 目加田 慶人; 西田 直生志
    第57回日本肝臓学会総会 ワークショップ11 肝疾患におけるビッグデータとAI(人工知能)の臨床応用 2021年06月 シンポジウム・ワークショップパネル(公募)
  • Gd-EOB-DTPA-enhanced MRI肝細胞相はPD-1/PD-L1抗体単独療法の非侵襲的なバイオマーカーである
    青木 智子; 西田 直生志; 工藤 正俊
    第57回日本肝臓学会総会 ワークショップ9 肝癌の基礎研究と臨床応用 2021年06月 シンポジウム・ワークショップパネル(公募)
  • US-US overlay fusion ガイドを用いたラジオ波焼灼術の最前線
    南 康範; 西田 直生志; 工藤 正俊
    第57回日本肝臓学会総会 ワークショップ8 肝癌に対する局所療法の最前線 2021年06月 シンポジウム・ワークショップパネル(公募)
  • 盛田 真弘; 西田 直生志; 工藤 正俊
    第57回日本肝臓学会総会 シンポジウム1 進行肝癌に対する薬物療法の新たな展開 2021年06月 シンポジウム・ワークショップパネル(公募)
  • Naoshi Nishida
    The Liver Week 2021, LCSGJ-KLCA Joint Symposium "Updates on Molecular Signature of Hepatocellular Carcinoma" 2021年05月 シンポジウム・ワークショップパネル(指名)
  • Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.  [通常講演]
    Masatoshi Kudo; Kazuomi Ueshima; Shin Nakahira; Naoshi Nishida; Hiroshi Ida; Yasunori Minami; Takuya Nakai; Hiroshi Wada; Shoji Kubo; Kazuyoshi Ohkawa; Asahiro Morishita; Takeo Nomi; Koji Ishida; Shogo Kobayashi; Makoto Umeda; Masakatsu Tsurusaki; Yasutaka Chiba; Kenichi Yoshimura; Kazuko Sakai; Kazuto Nishio
    2021 ASCO Annual Meeting 2021年05月 ポスター発表
  • 西田直生志; 工藤正俊
    第107回日本消化器病学会総会 「シンポジウム1: 消化器領域におけるAI研究の進歩」 2021年04月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志
    【日本内科学会特別シンポジウム】画像関連6学会の診療画像データベース構築とAI開発(AMED研究より)https://www.naika.or.jp/meeting/118-info/amed_202104/ 2021年04月 口頭発表(招待・特別)
  • 西田 直生志
    日本医療研究開発機構臨床ICT事業 令和2年度成果報告 https://www.amed.go.jp/news/event/ict_seika_20210225_report.html 2021年02月 公開講演,セミナー,チュートリアル,講習,講義等
  • Naoshi Nishida
    Asian Pacific Association for the Study of the Liver (APASL) 2021 Symposium 2 "Novel Technology in Hepatology" 2021年02月 口頭発表(招待・特別)
  • 西田直生志; 工藤正俊
    第56回日本肝癌研究会 WS03. 肝細胞癌の亜分類 2020年12月 シンポジウム・ワークショップパネル(公募)
  • 西田 直生志; 山川 誠; 椎名 毅; 目加田 慶人; 工藤 正俊
    日本超音波医学会 第93回学術集会 人工知能応用(工学合同)「総論」 2020年12月 口頭発表(招待・特別)
  • 進行肝癌に対する免疫チェックポイント阻害剤後レンバチニブ療法の画像評価  [通常講演]
    青木智子; 依田広; 盛田真弘; 南知宏; 田北雅弘; 萩原智; 南康範; 上嶋一臣; 西田直生志; 工藤正俊
    日本超音波医学会第93回学術集会 2020年12月 口頭発表(一般)
  • 鑑別診断において造影超音波が有効であった多血性の肝内胆管癌の一例  [通常講演]
    盛田真弘; 南康範; 青木智子; 田北雅弘; 萩原智; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    日本超音波医学会第93回学術集会 2020年12月 口頭発表(一般)
  • 免疫チェックポイント阻害剤登場後のレンバチニブの位置づけ  [通常講演]
    青木智子; 上嶋一巨; 盛田真弘; 田北雅弘; 萩原智; 南康範; 依田広; 西田直生志; 鶴崎正勝; 工藤正俊
    第22回日本肝がん分子標的療法研究会 2020年11月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異  [通常講演]
    西田直生志; 盛田真弘; 工藤正俊
    第28回 日本消化器関連学会週間, シンポジウム3 肝癌診療の現状と未来 2020年11月 シンポジウム・ワークショップパネル(公募)
  • 画像診断における人工知能の応用と超音波AIの開発  [招待講演]
    西田直生志
    日本超音波医学会 第50回北海道地方会学術集会 共催セミナー 2020年10月 口頭発表(招待・特別)
  • 西田 直生志; 工藤 正俊
    第56回日本肝臓学会 ワークショップ: 画像診断の新展開 2020年08月 シンポジウム・ワークショップパネル(公募)
  • B型慢性肝炎患者に対するETVとTAAFの前向き比較観察研究  [通常講演]
    萩原 智; 盛田 真弘; 青木 智子; 田北 真弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第56回日本肝臓学会総会 口頭発表(一般)
  • AFP is elevated more than 10 years before hepatocellular carcinoma development is detected: this observation leads to a practical risk stratification strategy  [通常講演]
    Philip Johnson; Sarah Berhane; Emily de Groo; Hidenori Toyoda; Toshifumi Tada; Takashi Kumada; Shinji Satomura; Yukio Osaki; Masatoshi Kudo; Naoshi Nishida; Toru Kimura; Ruwanthi Kolamunnage-Dona; Thomas Bird; Ruben Amoros; Marta Garcia-Finance; David M. Hughes
    EASL 2020 2020年08月 ポスター発表
  • 椎名 毅; 山川誠; 西田直生志; 工藤正俊
    日本音響学会2020年春季研究発表会、招待講演 口頭発表(招待・特別)
  • NAKASHIMA Takahiro; TSUTSUMI Issei; TAKAMI Hiroki; DOMAN Keisuke; MEKATA Yoshito; NISHIDA Naoshi; KUDO Masatoshi
    Proc. of Joint Int. Workshop on Advanced Image Technology 2020 (IWAIT) 2020年01月 シンポジウム・ワークショップパネル(公募)
  • Naoshi Nishida
    2019 CHA International Gastrointestinal Disease Forum 2019年12月 口頭発表(招待・特別)
  • 肝細胞がんの薬物治療(化学療法)の進歩  [招待講演]
    西田 直生志
    神戸市難病団体連絡協議会・肝炎友の会 講演会 2019年12月 公開講演,セミナー,チュートリアル,講習,講義等
  • 西田 直生志; 工藤 正俊
    JDDW 2019 (統合プログラム5)AIと消化器診療の将来 2019年11月 シンポジウム・ワークショップパネル(公募)
  • DEVELOPMENT OF AI-AIDED US DIAGNOSIS SYSTEM OF LIVER TUMOR USING DEEP NEURAL NETWORK  [通常講演]
    Naoshi Nishida; Makoto Yamakawa; Tsuyoshi Shiina; Masatoshi Kudo
    American Society for the Study of Liver Disease (AASLD) 2019 2019年11月 ポスター発表
  • OBJECTIVE RESPONSE BY MRECIST IS A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL IN UNRESECTABLE HEPATOCELLULAR CARCINOMA TREATED WITH SYSTEMIC THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS  [通常講演]
    Masatoshi Kudo; Kazuomi Ueshima; Naoshi Nishida
    American Society for the Study of Liver Disease (AASLD) 2019 2019年11月 ポスター発表
  • IMPACT OF BASELINE ALBI GRADE ON THE OUTCOMES OF HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB: A MULTICENTER STUDY  [通常講演]
    Masatoshi Kudo; Kazuomi Ueshima; Naoshi Nishida; Satoru Hagiwara; Tomoko Aoki; Tomohiro Minami; Hirokazu Chishina; Masahiro Takita; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Atsushi Hiraoka
    American Society for the Study of Liver Disease (AASLD) 2019 2019年11月 ポスター発表
  • LENVATINIB AS AN INITIAL TREATMENT IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA BEYOND UP-TO-SEVEN CRITERIA AND CHILD-PUGH A LIVER FUNCTION: A MULTICENTER PROPENSITY-SCORE MATCHED STUDY  [通常講演]
    Kazuomi Ueshima; Stephen L. Chan; Tomohiro Minami; Hirokazu Chishina; Tomoko Aoki; Masahiro Takita; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Toshiharu Sakurai; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Naoshi Nishida
    American Society for the Study of Liver Disease (AASLD) 2019 2019年11月 口頭発表(一般)
  • 椎名 毅; 西田 直生志; 工藤 正俊
    日本超音波医学会 関東甲信越地方会学術集会 特別企画【基礎】「超音波診断の標準化について考える」 2019年10月 シンポジウム・ワークショップパネル(指名)
  • Development of computer aided diagnosis system for ultrasound diagnosis of liver lesions using deep learning  [通常講演]
    YAMAKAWA Makoto; SHIINA Tsuyoshi; NISHIDA Naoshi; KUDO Masatoshi
    IEEE International Ultrasonics Symposium 2019 2019年10月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌における薬物療法の展開  [招待講演]
    西田 直生志
    Kansai Liver Forum 2019年09月 口頭発表(招待・特別)
  • 近未来における超音波診断と人工知能の役割 ー診断補助から疾患マネージメントへー  [招待講演]
    西田 直生志
    関西肝疾患カンファレンス 2019年09月 口頭発表(招待・特別)
  • 肝細胞癌の薬物治療  [招待講演]
    西田 直生志
    2019年度 日本肝臓学会教育講演会 2019年08月 公開講演,セミナー,チュートリアル,講習,講義等
  • 深層学習による超音波画像からの肝腫瘍検出に関する初期的検討  [通常講演]
    堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊
    第38回日本医用画像工学会大会(JAMIT) 2019年07月
  • 超音波画像データベース構築の推進と展望  [招待講演]
    西田 直生志; 工藤 正俊
    日本超音波医学会第92回学術集会、Ultrasonic Week 2019: シンポジウム 領域横断3, AI:超音波診断の近未来 2019年05月 口頭発表(招待・特別)
  • 超音波デジタル画像のナショナルデータベース構築基盤整備-人工知能による超音波診断支援に向けて  [招待講演]
    西田 直生志; 工藤 正俊; 日本超音波医学会
    日本医学会総会 2019: 臨床研究等ICT基盤構築・人工知能実装研究事業成果報告会 2019年04月 公開講演,セミナー,チュートリアル,講習,講義等
  • Recent advancement of molecular targeted therapy in hepatocellular carcinoma  [招待講演]
    NISHIDA Naoshi
    The Asian Pacific Association for the Study of the Liver APASL Single Topic Conference “Liver Immunology and Genetics” 2019年04月 口頭発表(招待・特別)
  • Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learning  [通常講演]
    Makoto Yamakawa; Tsuyoshi Shiina; Naoshi Nishida; Masatoshi Kudo
    2019 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM (IUS) 2019年
  • Stem cell feature and immune-suppressive microenvironment in human hepatocellular carcinoma  [通常講演]
    NISHIDA Naoshi; KUDO Masatoshi
    American Association for the Study of Liver Diseases (AASLD) 2018 2018年11月 ポスター発表
  • ここまで進んだ肝癌の薬物療法  [招待講演]
    西田 直生志
    Japan Digestive Disease Week 2018 「教育講演3」 2018年11月 公開講演,セミナー,チュートリアル,講習,講義等
  • 人工知能の利活用を見据えた超音波デジタル画像のビッグデータベース構築基盤整備 ―AI支援型超音波診断システムの開発に向けて―  [招待講演]
    西田 直生志
    第30回日本超音波医学会関東甲信越地方会学術集会 特別シンポジウム 2018年10月 シンポジウム・ワークショップパネル(指名)
  • The Expression of Immune Checkpoint Molecules in HCC Tumor Tissues -Clinicopathological feature of PD-L1-positive HCC-  [招待講演]
    Naoshi NISHIDA
    2018 CHA Liver Center International Symposium Immuno-Oncology for Liver Cancer, Comes of Age! 2018年10月 シンポジウム・ワークショップパネル(指名)
  • 肝炎の最新治療 -新規抗ウイルス剤の使い方-  [招待講演]
    西田 直生志
    近畿大学薬学部生涯教育研修会 2018年09月 公開講演,セミナー,チュートリアル,講習,講義等
  • PD-L1陽性肝癌の特徴と腫瘍免疫環境に関する解析  [通常講演]
    西田 直生志
    第18回日本肝がん分子標的治療研究会 2018年07月 シンポジウム・ワークショップパネル(公募)
  • RFAの効果判定: Hepatic Guideの有用性  [通常講演]
    南知宏; 南康範; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 萩原智; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    第54回肝臓学会総会 2018年06月 口頭発表(一般)
  • 慢性C型肝炎のDAA投与例におけるSVR後のAFP、ALT異常及び肝発癌に関する検討  [通常講演]
    河野匡志; 西田直生志; 千品寛和; 田北雅弘; 萩原智; 依田広; 南康範; 上嶋一臣; 工藤正俊
    第54回肝臓学会総会 ワークショップ11「肝炎ウイルスの制御が肝癌診療に及ぼす影響」 2018年06月 シンポジウム・ワークショップパネル(公募)
  • 遺伝子変化に基づいた肝細胞癌の分子スコアリングと転移再発  [通常講演]
    西田直生志; 工藤正俊
    第54回肝臓学会総会 シンンポジウム1「肝癌治療の新展開」 2018年06月 シンポジウム・ワークショップパネル(公募)
  • Studies on AFP, ALT Abnormalities and Hepatocarcinogenesis after SVR in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals  [通常講演]
    Kono M; Nishida N; Ida H; Minami T; Chishina H; Takita M; Hagiwara S; Minami Y; Ueshima K; Kudo M
    APASL single topic conference on HCC 「hepatitis C」 2018年05月 口頭発表(一般)
  • US-US image overlay fusion を用いたラジオ波焼灼術の早期治療効果判定  [通常講演]
    南康範; 西田直生志; 工藤正俊
    第104回日本消化器病学会総会 シンポジウム6「肝癌診療 up to date」 2018年04月 シンポジウム・ワークショップパネル(公募)
  • PD-L1陽性肝癌の臨床病理学的特徴と免疫環境に関する解析  [通常講演]
    西田 直生志
    第14回肝免疫・ウイルス・フロンティア 2018年04月 口頭発表(招待・特別)
  • 腹壁静脈瘤破裂に対して直接穿刺にて硬化療法を施行した2例  [通常講演]
    半田康平; 萩原智; 福永朋洋; 高田隆太朗; 岡本彩奈; 南知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    第42回肝臓学会西部会 2017年11月 口頭発表(一般)
  • 真性多血症にBudd-Chiari症候群を伴った一例  [通常講演]
    高田隆太朗; 萩原智; 福永朋洋; 半田康平; 岡本彩奈; 南知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    第42回肝臓学会西部会 2017年11月 口頭発表(一般)
  • 胃への遠隔転移を認めた肝細胞癌の一例  [通常講演]
    福永朋洋; 萩原智; 半田康平; 高田隆太朗; 岡本彩奈; 南知宏; 河野匡志; 千品寛和; 有住忠晃; 田北雅弘; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    第42回肝臓学会西部会 2017年11月 口頭発表(一般)
  • DAA投与におけるSVR後のAFP異常値と関連する臨床背景の検討  [通常講演]
    河野匡志; 西田直生志; 千品寛和; 南知宏; 有住忠晃; 田北雅弘; 矢田典久; 萩原智; 南康範; 上嶋一臣; 工藤正俊
    第42回肝臓学会西部会 2017年11月 口頭発表(一般)
  • Clinicopathological characteristics and mutational profile of PD-L1 positive hepatocellular carcinoma  [通常講演]
    Nishida N; Kudo M
    68th Annual meeting of the American Association for the Study of Liver Diseases (AASLD). Parallel Session 22: Hepatocarcinogenesis 2017年10月 シンポジウム・ワークショップパネル(公募)
  • 2nd generation targeted therapy and immune check-point inhibitor for advanced HCC  [招待講演]
    Naoshi Nishida
    The 2nd MYONJI International Liver Symposium 2017年09月 口頭発表(招待・特別)
  • US-US overlay image fusion を用いた肝細胞癌へのラジオ波焼灼術の有用性:従来法との比較  [通常講演]
    南康範; 西田直生志; 工藤正俊
    第53回肝臓学会総会 2017年06月 口頭発表(一般)
  • DAA投与におけるSVR後のAFP及びALT異常値と関連する臨床背景の検討  [通常講演]
    河野匡志; 西田直生志; 南知宏; 千品寛和; 有住忠晃; 田北雅弘; 依田広; 矢田典久; 南康範; 萩原智; 上嶋一臣; 工藤正俊
    第53回肝臓学会総会 2017年06月 口頭発表(一般)
  • US-US image fusion を用いた肝細胞癌へのラジオ波焼灼術の有用性  [通常講演]
    南康範; 西田直生志; 工藤正俊
    第103回日本消化器病学会総会 ワークショップ12「肝画像診断の進歩」 2017年04月 シンポジウム・ワークショップパネル(公募)
  • PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル  [通常講演]
    西田直生志; 工藤正俊
    第103回日本消化器病学会総会 シンポジウム8「肝発癌メカニズムのパラダイムシフトとこれからの展望 2017年04月 シンポジウム・ワークショップパネル(公募)
  • US-US overlay image fusionを用いたラジオ波焼灼術の有用性 従来法との比較  [通常講演]
    南 康範; 西田 直生志; 工藤 正俊
    肝臓 2017年04月
  • DAA投与におけるSVR後のAFP及びALT異常値と関連する臨床背景の検討  [通常講演]
    河野 匡志; 西田 直生志; 南 知宏; 千品 寛和; 有住 忠晃; 田北 雅弘; 依田 広; 矢田 典久; 南 康範; 萩原 智; 上嶋 一臣; 工藤 正俊
    肝臓 2017年04月
  • 肝画像診断の進歩 US-US image fusionを用いた肝細胞癌へのラジオ波焼灼術の有用性  [通常講演]
    南 康範; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2017年03月
  • 肝発癌メカニズムのパラダイムシフトとこれからの展望 PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル  [通常講演]
    西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2017年03月
  • Locked Nucleic Acidsを用いた 血清中マイクロRNA定量と ソラフェニブ治療に対する反応予測  [通常講演]
    西田直生志; 岩西美奈; 南知宏; 千品寛和; 河野匡志; 有住忠晃; 田北雅弘; 矢田典久; 依田広; 萩原智; 南康範; 上嶋一臣; 工藤正俊
    第15回日本肝がん分子標的治療研究会(優秀演題) 2017年01月 シンポジウム・ワークショップパネル(公募)
  • エンテカビルとPEG-IFNα2a/ab 48週併用療法の効果および治療効果予測因子の検討  [通常講演]
    萩原 智; 西田直生志; 工藤正俊
    第24回日本消化器関連学会週間(第20回日本肝臓学会大会) ワークショップ9 B型肝炎治療のアップデート 2016年11月 シンポジウム・ワークショップパネル(公募)
  • Identification of fetal liver-type hepatocellular carcinoma based on a methylome analysis and its association with genetic alterations.  [通常講演]
    Nishida N; Kudo M
    第24回日本消化器関連学会週間(第20回日本肝臓学会大会) International Session, Symposium 1. 「Genetics of hepatocellular carcinoma: Hepatitis virus infection and hepatocarcinogenesis 」. 2016年11月 シンポジウム・ワークショップパネル(公募)
  • Immunotherapy for HCC; hype or hope  [招待講演]
    Naoshi Nishida
    The 1st MYONJI International Liver Symposium 2016年09月 口頭発表(招待・特別)
  • B型肝炎治療のアップデート エンテカビルとPEG-IFNα2a/2b 48週併用療法の効果および治療効果予測因子の検討  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 2016年09月
  • NASH 関連肝発癌における線維化進展と遺伝子変化  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    第52回日本肝癌研究会ワークショップ 2 非ウイルス性肝細胞癌の病態と分類 2016年07月 シンポジウム・ワークショップパネル(公募)
  • ゲノム・エピゲノム・染色体情報に基づいた肝癌の亜分類と転移再発予測  [通常講演]
    西田直生志; 工藤正俊
    第52回日本肝癌研究会 パネルディスカッション 2 肝細胞癌の新たなサブクラス分類と治療ストラテジー 2016年07月 シンポジウム・ワークショップパネル(公募)
  • HCCに対するDEB-TACE時に発生したVascular lakeの検討  [通常講演]
    沼本勲男; 鶴崎正勝; 渡口真史; 日高正二朗; 山川美帆; 任誠雲; 柳生行伸; 村上卓道; 田北雅弘; 萩原智; 南康範; 上嶋一臣; 西田直生志; 工藤正俊; 朝戸信行
    第45回日本IVR学会総会 2016年05月 口頭発表(一般)
  • トルバプタンにおける初期、および遅発性効果予測因子の検討  [通常講演]
    萩原智; 千品寛和; 岩西美奈; 南知宏; 河野匡士; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    第102回日本消化器病学会総会 2016年04月 口頭発表(一般)
  • HCCに対するDEB-TACE時に発生したVascular lakeの検討  [通常講演]
    沼本 勲男; 鶴崎 正勝; 渡口 真史; 日高 正二朗; 山川 美帆; 任 誠雲; 柳生 行伸; 村上 卓道; 田北 雅弘; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊; 朝戸 信行
    IVR: Interventional Radiology 2016年04月
  • NASH関連肝発癌における線維化進展と遺伝子変化  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 2016年04月
  • ダクラタスビル/アスナプレビル併用療法の治療効果と安全性  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    第41回肝臓学会西部会 2015年12月 口頭発表(一般)
  • Classification of tumors based on the integrated profile of genetic and epigenetic alterations and the biological behavior of human hepatocellular carcinoma.  [通常講演]
    Nishida N; Kudo M
    66th Annual meeting of the American Association for the Study of Liver Diseases (AASLD). 2015年11月 口頭発表(一般)
  • ダクラタスビル/アスナプレビル併用療法の治療効果と安全性  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 2015年11月
  • 肝細胞癌に対してUS-US fusion を用いたラジオ波焼灼術  [通常講演]
    南知宏; 南康範; 千品寛和; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 萩原智; 上嶋一臣; 西田直生志; 工藤正俊
    第23回日本消化器関連学会週間(第19回日本肝臓学会大会) 2015年10月 口頭発表(一般)
  • 転移性肝癌に対してUS-US fusion を用いたラジオ波焼灼術  [通常講演]
    南知宏; 南康範; 千品寛和; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 萩原智; 上嶋一臣; 西田直生志; 工藤正俊
    第23回日本消化器関連学会週間(第57回日本消化器病学会大会) 2015年10月 口頭発表(一般)
  • Tumor characteristics and genetic and epigenetic profile of human hepatocellular carcinoma.  [通常講演]
    Nishida N; Kudo M
    第23回日本消化器関連学会週間(第19回日本肝臓学会大会) International Session, Symposium 1. 「Hepatocellular carcinoma: Molecular approaches for diagnosis, prognosis, and therapy」. 2015年10月 シンポジウム・ワークショップパネル(公募)
  • トルバプタンの治療効果における予測因子の検討  [通常講演]
    千品寛和; 萩原智; 岩西美奈; 南知宏; 河野匡士; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 南康範; 上嶋一臣; 西田直生志; 工藤正俊
    第103回日本消化器病学会近畿支部例会 2015年09月 口頭発表(一般)
  • 著明な肝障害を呈した骨髄性ポルフィリン症の一例  [通常講演]
    青山信吾; 萩原智; 岩西美奈; 南知宏; 千品寛和; 河野匡士; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 依田広; 南康範; 上嶋一臣; 桜井俊治; 西田直生志; 工藤正俊
    第103回日本消化器病学会近畿支部例会 2015年09月 口頭発表(一般)
  • 転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2015年09月
  • 肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 2015年09月
  • Epigenetics in HCC pathogenesis  [招待講演]
    Nishida N
    6th Asia-Pathific Primary Liver Cancer Expert Meeeting. Satellite 1. Basics, Genomics, Molecular Biology and Therapy 2015年07月 口頭発表(招待・特別)
  • 転移性肝癌に対してUS-US fusion を用いたラジオ波焼灼術  [通常講演]
    南知宏; 南康範; 千品寛和; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 萩原智; 上嶋一臣; 西田直生志; 工藤正俊
    第51回肝臓学会総会 2015年05月 口頭発表(一般)
  • intermediate stageの肝細胞癌に対してTACE不応後のTACE継続とソラフェニブの検討  [通常講演]
    有住忠晃; 上嶋一臣; 南知宏; 河野拓士; 千品寛和; 田北雅弘; 北井聡; 矢田典久; 萩原智; 南康範; 櫻井俊治; 西田直生志; 工藤正俊
    第51回肝臓学会総会 2015年05月 口頭発表(一般)
  • 変異型HBx遺伝子の肝発癌促進における分子機序の解明  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    第51回肝臓学会総会 ワークショップ4「肝病態を反映する新たなバイオマーカーの探索」 2015年05月 シンポジウム・ワークショップパネル(公募)
  • 血清中マイクロRNAプロファイルとソラフェニブに対する肝細胞癌の反応予測  [通常講演]
    西田直生志; 工藤正俊
    第51回肝臓学会総会 ワークショップ1「肝細胞癌の亜分類と個別化医療」 2015年05月 シンポジウム・ワークショップパネル(公募)
  • 分子生物学的特徴に基づいた肝癌のマネージメント  [通常講演]
    西田直生志; 工藤正俊
    第51回肝臓学会総会 シンンポジウム1「肝発癌研究と臨床への展開」 2015年05月 シンポジウム・ワークショップパネル(公募)
  • NASH関連肝発癌における線維化進展と遺伝子変化  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    第52回肝臓学会総会 2015年05月 口頭発表(一般)
  • トルバプタンの治療効果における予測因子の検討  [通常講演]
    千品寛和; 萩原智; 岩西美奈; 南知宏; 河野匡士; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊
    第101回日本消化器病学会総会 2015年04月 口頭発表(一般)
  • Drug freeを目指したエンテカビルとPEG-IFNα2a/2b 48週併用療法の効果について  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    第101回日本消化器病学会総会 ワークショップ6「HBV感染におけるDrug freeを目指した基礎と臨床のブレークスルー」 2015年04月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌に対してUS-US Fusionを用いたラジオ波焼灼術  [通常講演]
    南康範; 西田直生志; 工藤正俊
    第101回日本消化器病学会総会 ワークショップ7「Navigationに基づいた肝細胞癌IVR治療の最前線 2015年04月 シンポジウム・ワークショップパネル(公募)
  • 肝発癌研究と臨床への展開 分子生物学的特徴に基づいた肝癌のマネージメント  [通常講演]
    西田 直生志; 海道 利実; 工藤 正俊
    肝臓 2015年04月
  • intermediate stageの肝細胞癌に対してTACE不応後のTACE継続とソラフェニブの検討  [通常講演]
    有住 忠晃; 上嶋 一臣; 南 知宏; 千品 寛和; 河野 匡志; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    肝臓 2015年04月
  • 転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 2015年04月
  • 肝病態を反映する新たなバイオマーカーの探索 変異型HBx遺伝子の肝発癌促進における分子機序の解明  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    肝臓 2015年04月
  • 肝細胞癌の亜分類と個別化医療 血清中マイクロRNAプロファイルとソラフェニブに対する肝細胞癌の反応性予測  [通常講演]
    西田 直生志; 工藤 正俊
    肝臓 2015年04月
  • トルバプタンの治療効果における予測因子の検討  [通常講演]
    千品 寛和; 井上 達夫; 南 知宏; 河野 匡志; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2015年03月
  • Navigationに基づいた肝細胞癌IVR治療の最前線 肝細胞癌に対してUS-US Fusionを用いたラジオ波焼灼術  [通常講演]
    南 康範; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2015年03月
  • Pathological feature, oxidative DNA damage and epigenetic alteration of tumor suppressor genes in non-alcoholic fatty liver disease.  [通常講演]
    Nishida N; Yada N; Arizumi T; Takita M; Kitai S; Inoue T; Hagiwara S; Minami Y; Sakurai T; Ueshima K; Kudo M
    65th Annual meeting of the American Association for the Study of Liver Diseases (AASLD). 2014年11月 口頭発表(一般)
  • B-modeで描出困難な肝癌に対するFusion imaging+造影USガイドでのラジオ波焼灼術  [通常講演]
    南知宏; 南康範; 千品寛和; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 井上達夫; 萩原智; 上嶋一臣; 西田直生志; 工藤正俊
    第22回日本消化器関連学会週間(第18回日本肝臓学会大会) シンポジウム14「NBNC肝がんの諸問題」 2014年10月 口頭発表(一般)
  • NBNC肝癌の背景肝におけるメチル化プロファイルと加齢および糖尿病の影響  [通常講演]
    西田直生志; 工藤正俊
    第22回日本消化器関連学会週間(第18回日本肝臓学会大会) シンポジウム14「NBNC肝がんの諸問題」 2014年10月 シンポジウム・ワークショップパネル(公募)
  • Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer  [通常講演]
    櫻井俊治; 工藤正俊; 西田直生志; 藤田潤; 樫田博史
    第73回日本癌学会総会 English Oral Session: Understanding the mechanism that causes the malignant potential of colorectal cancer 2014年09月 口頭発表(一般)
  • 炎症からの大腸発癌におけるストレス応答蛋白Cirpの役割(Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer)  [通常講演]
    櫻井 俊治; 工藤 正俊; 西田 直生志; 藤田 潤; 樫田 博史
    日本癌学会総会記事 2014年09月
  • B-modeで描出困難な肝癌に対するFusion imaging+造影USガイドでのラジオ波焼灼術  [通常講演]
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 2014年09月
  • NBNC肝がんの諸問題 NBNC肝癌の背景肝におけるメチル化プロファイルと加齢および糖尿病の影響  [通常講演]
    西田 直生志; 工藤 正俊
    肝臓 2014年09月
  • ソラフェニブ投与にてPD 判定であった進行肝細胞癌患者の検討  [通常講演]
    有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田直生志; 工藤 正俊
    第10回日本肝がん分子標的治療研究会 2014年06月 口頭発表(一般)
  • Oxidative stress and epigenetic instability in human hepatocarcinogenesis  [招待講演]
    Nishida N; Yada N; Arizumi T; Takita M; Kitai S; Inoue T; Hagiwara S; Minami Y; Sakurai T; Ueshima K; Kudo M
    4th International Kyoto Liver Cancer Symposium. Eraly Morning Breakfast Workshop 3:Carcinogenesis, Genomics, Pathways and Targets 2014年06月 口頭発表(招待・特別)
  • Interventional radiology における支援画像「FlightPlan」の有用性  [通常講演]
    南康範; 南知宏; 千品 寛和; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 萩原智; 井上達夫; 上嶋一臣; 西田直生志; 工藤正俊; 柳生行伸; 鶴崎正勝; 村上卓道
    第50回日本肝癌研究会 2014年06月 口頭発表(一般)
  • B-modeで描出困難な肝癌に対するFusion image+造影USガイドでのラジオ波焼灼術の有用性  [通常講演]
    南知宏; 千品寛和; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 萩原智; 井上達夫; 南康範; 上嶋一臣; 西田直生志; 工藤正俊
    第50回日本肝癌研究会 ビデオセッション6「ラジオ波治療の技術の進歩 2014年06月 口頭発表(一般)
  • 肝細胞癌におけるサイトケラチン19の発現とメチル化の意義  [通常講演]
    横道直佑; 永坂岳司; 西田直生志; 久保田暢人; 吉田一博; 藤原裕子; 藤智和; 河合毅; 谷口文崇; 八木孝仁; 藤原俊儀
    第50回日本肝癌研究会 パネルディスカッッション2「ゲノム•エピゲノム解析に基づく肝癌診療の将来展望」 2014年06月 シンポジウム・ワークショップパネル(公募)
  • ヒト肝発癌における酸化ストレスとエピゲノム変異の関連  [通常講演]
    萩原智; 西田直生志; 工藤正俊
    第50回日本肝癌研究会 パネルディスカッッション2「ゲノム•エピゲノム解析に基づく肝癌診療の将来展望」 2014年06月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌(HCC)合併の非代償性肝硬変患者に対する局所治療の有用性についての検討  [通常講演]
    北井聡; 工藤正俊; 西田直生志; 泉並木; 坂元亨宇; 松山裕; 市田隆文; 中島収; 松井修; 具英成; 國土典宏; 幕内雅敏
    第50回日本肝癌研究会 ワークショップ1「Child-Pugh C肝癌に対する治療」 2014年06月 シンポジウム・ワークショップパネル(公募)
  • TACE不応の進行肝細胞癌患者に対するソラフェニブの開始時期の検討  [通常講演]
    有住 忠晃; 上嶋 一臣; 千品 寛和; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    The Liver Cancer Journal 2014年06月
  • 高齢者genotype1b高ウイルス量のC型肝炎患者における治療効果と安全性:ReGIT-J試験の層別解析  [通常講演]
    西川浩樹; 榎本平之; 斎藤正樹; 会澤信弘; 津田泰宏; 樋口和秀; 岡崎和一; 関寿人; 金守良; 本合泰; 城村尚登; 西田直生志; 工藤正俊; 大崎征夫; 西口修平
    第50回日本肝臓学会総会 2014年05月 口頭発表(一般)
  • 肝外再発例の肝癌DNAメチル化プロファイルを用いた治癒切除後の早期再発予測  [通常講演]
    西田直生志; 中居卓也; 工藤 正俊
    第50回日本肝臓学会総会 2014年05月 口頭発表(一般)
  • plain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測  [通常講演]
    南康範; 南知宏; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 井上達夫; 萩原智; 上嶋一臣; 西田直生志; 工藤正俊; 柳生行伸; 村上卓道
    第100回日本消化器病学会総会 2014年04月 口頭発表(一般)
  • NASH/NAFLDモデルマウスの発癌過程における酸化的DNA損傷とエピゲノム変異の誘導  [通常講演]
    西田直生志; 工藤正俊
    第100回日本消化器病学会総会 ワークショップ9: NAFLD/NASHにおける新知見と治療法の進歩 2014年04月 シンポジウム・ワークショップパネル(公募)
  • Serum microRNAs as diagnostic biomarkers for early colorectal neoplasms.  [通常講演]
    Yamada A; Horimatsu T; Okugawa Y; Nishida N; Kou T; Kusaka T; Honjo H; Amanuma Y; Kikuchi O; Muto M; Goel A; Boland CR
    Annual meeting of the American Association for cancer research (AACR) 2014 2014年04月 口頭発表(一般)
  • 高齢者Genotype 1b高ウイルス量のC型慢性肝炎患者における治療効果と安全性 ReGIT-J試験の層別解析  [通常講演]
    西川 浩樹; 榎本 平之; 斎藤 正紀; 会澤 信弘; 津田 泰宏; 樋口 和秀; 岡崎 和一; 関 寿人; 金 守良; 本合 泰; 城村 尚登; 西田 直生志; 工藤 正俊; 大崎 往夫; 西口 修平
    肝臓 2014年04月
  • 肝外再発例の肝癌DNAメチル化プロファイルを用いた治癒切除後の早期再発予測  [通常講演]
    西田 直生志; 中居 卓也; 工藤 正俊
    肝臓 2014年04月
  • plain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測  [通常講演]
    南 康範; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊; 柳生 行伸; 村上 卓道
    日本消化器病学会雑誌 2014年03月
  • NAFLD/NASHにおける新知見と治療法の進歩 NASH/NAFLDモデルマウスの発癌過程におけるDNA酸化損傷とエピゲノム変異の誘導  [通常講演]
    西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2014年03月
  • TACE不応の進行肝癌に対するソラフェニブ開始時期の検討  [通常講演]
    有住忠晃; 上嶋一臣; 千品寛和; 田北雅弘; 北井聡; 井上達夫; 矢田典久; 萩原智; 南康範; 櫻井俊治; 西田直生志; 工藤正俊
    第9回日本肝がん分子標的治療研究会 2014年01月 口頭発表(一般)
  • TACE不応の進行肝細胞癌に対するソラフェニブ開始時期の検討.  [通常講演]
    有住 忠晃; 上嶋 一臣; 千品 寛和; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第9回日本肝がん分子標的治療研究会 2014年01月 海運クラブ, 東京 第9回日本肝がん分子標的治療研究会
  • 変異型HBxの肝発癌促進における分子機序の解明  [通常講演]
    萩原智; 櫻井俊治; 西田直生志; 工藤正俊
    第21回浜名湖シンポジウム 2013年12月 口頭発表(一般)
  • Role of oxidative stress and epigenetic alteration on chronic hepatitis C-related human hepatocarcinogenesis  [通常講演]
    Nishida N; Kudo M; Arizumi T; Takita M; Kitai S; Yada N; Inoue T; Hagiwara S; Minami Y; Sakurai T; Ueshima K; Nagasaka T; Goel A
    The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) 2013年11月 口頭発表(一般) Washington D.C. The 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD)
  • HBs抗原消失を目指したエンテカビルとPEG-IFN48週併用療法の効果について  [通常講演]
    萩原 智; 西田 直生志; 工藤 正俊
    第15回葵肝臓研究会 2013年11月 メルパルク京都 第15回葵肝臓研究会
  • 便中メチル化CpG検出による消化器癌診断  [通常講演]
    永坂岳司; 吉田一博; 森川達也; 母里淑子; 横道直佑; 久保田暢人; 竹原裕子; 稲田涼; 楳田祐三; 西崎正彦; 香川俊輔; 西田直生志; 貞森裕; 八木孝仁; 藤原俊儀
    第51回日本癌治療学会学術集会 2013年10月 口頭発表(一般)
  • 肝嚢胞に対するオレイン酸モノエタノールアミン注入療法の検討  [通常講演]
    田北雅弘; 有住忠晃; 北井聡; 井上達夫; 矢田典久; 萩原智; 南康範; 上嶋一臣; 西田直生志; 工藤正俊
    第21回日本消化器関連学会週間(第17回日本肝臓学会大会) 2013年10月 口頭発表(一般)
  • サイトケラチン19 は肝細胞癌の新規予後予測マーカーである  [通常講演]
    横道直佑; 永坂岳司; 西田直生志; 楳田祐三; 森川達也; 久保田暢人; 吉田一博; 竹原裕子; 母里淑子; 貞森裕; 八 木孝仁; 藤原俊儀; Goel Ajay
    第72回日本癌学会学術総会 2013年10月 口頭発表(一般)
  • サイトケラチン19は肝細胞癌の新規予後予測マーカーである(Cytokeratin 19 Staining is a Nobel Prognostic Biomarker for Hepatocellular Carcinoma)  [通常講演]
    横道 直佑; 永坂 岳司; 西田 直生志; 楳田 祐三; 森川 達也; 久保田 暢人; 吉田 一博; 竹原 裕子; 母里 淑子; 貞森 裕; 八木 孝仁; 藤原 俊儀; Ajay Goel
    日本癌学会総会記事 2013年10月
  • 肝のう胞に対するオレイン酸モノエタノールアミン注入療法の検討  [通常講演]
    田北 雅弘; 有住 忠晃; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第17回日本肝臓学会大会(第21回日本消化器関連学会週間JDDW2013) 2013年10月 グランドプリンスホテル新高輪, 東京 第17回日本肝臓学会大会(第21回日本消化器関連学会週間JDDW2013)
  • Sorafenib treatment for non-hypervascular hepatocellular carcinoma  [通常講演]
    Arizumi T; Ueshima K; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 口頭発表(一般) Washington D.C. Seventh Annual Conference International Liver Cancer Association (ILCA)
  • The factors related to the vascularization of border line lesions detected as low intensity on hepatobiliary phase image of GD-EOB-DTPA MRI  [通常講演]
    Inoue T; Arizumi T; Ueshima K; Nishida N; Kudo M
    Seventh Annual Conference International Liver Cancer Association (ILCA) 2013年09月 口頭発表(一般) Washington D.C. Seventh Annual Conference International Liver Cancer Association (ILCA)
  • Unique association between global dna hypomethylation and chromosomal alterations in human hepatocellular carcinoma.  [通常講演]
    Nishida N; Kudo M; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Hagiwara S; Inoue T; Minami Y; Ueshima K; Sakurai T; Yokomichi N; Nagasaka T; Goel A
    Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA) 2013年09月 口頭発表(一般) Washington D.C., USA Seventh Annual Conference International Liver Cancer Asso-ciation(ILCA)
  • がんリスクの評価と予防 便中メチル化CpG検出による消化器癌診断  [通常講演]
    永坂 岳司; 吉田 一博; 森川 達也; 母里 淑子; 横道 直祐; 久保田 暢人; 竹原 祐子; 稲田 涼; 楳田 祐三; 西崎 正彦; 香川 俊輔; 西田 直生志; 貞森 裕; 八木 孝仁; 藤原 俊義
    日本癌治療学会誌 2013年09月
  • 肝のう胞に対するオレイン酸モノエタノールアミン注入療法の検討  [通常講演]
    田北 雅弘; 有住 忠晃; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 2013年09月
  • 慢性C型肝炎に対するテラプレビル3剤併用療法中に結核性リンパ節炎を発症した1例  [通常講演]
    千品 寛和; 井上 達夫; 南 知宏; 岡元 寿樹; 山田 光成; 田中 梨絵; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 口頭発表(一般) 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • 急性発症型自己免疫性肝炎の一例  [通常講演]
    岩西 美奈; 萩原 智; 鍵岡 賛典; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 南 康範; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第99回例会 2013年09月 口頭発表(一般) 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第99回例会
  • サイトケラチン19は肝細胞癌の肝外転移や術後再発を予測する  [通常講演]
    横道 直佑; 永坂 岳司; 西田 直生志; 楳田 祐三; 母里 淑子; 森川 達也; 吉田 一博; 貞森 裕; 八木 孝仁; 藤原 俊義
    日本消化器外科学会総会 2013年07月 口頭発表(一般)
  • Viral Hepatitis and HCC  [招待講演]
    Naoshi Nishida
    The 4th Primary Liver Cancer Expart Meetind (APPLE) 2013 : Early Morning Breakfast Workshop 2 2013年07月 口頭発表(招待・特別)
  • 経皮的ラジオ波焼灼術後の穿刺経路焼灼は必要か?: 後出血予防の検討  [通常講演]
    南 康範; 早石 宗右; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊; 鄭 浩柄
    第49回日本肝癌研究会 2013年07月 口頭発表(一般) 京王プラザホテル, 東京 第49回日本肝癌研究会
  • エピゲノム変異からみたヒト肝発癌における喫煙の影響とGST遺伝子多型に関する研究  [通常講演]
    西田 直生志; 工藤 正俊
    第28回喫煙科学研究財団助成研究発表会 2013年07月 京王プラザホテル 第28回喫煙科学研究財団助成研究発表会
  • 進行肝細胞癌のソラフェニブ治療における腫瘍血流と治療効果との関連  [通常講演]
    有住忠晃; 上嶋一臣; 田北雅弘; 北井聡; 井上達夫; 矢田典久; 萩原智; 南康範; 櫻井俊治; 西田直生志; 工藤正俊
    第8回日本肝がん分子標的治療研究会 ワークショップ1「分子標的薬の効果予後予測因子から治療法対象を考える」 2013年06月 シンポジウム・ワークショップパネル(公募)
  • PEG-IFNα2a少量長期投与における発癌リスク因子の検討-IL28B遺伝子多型との関連性も含めて-  [通常講演]
    萩原智; 櫻井俊治; 上嶋一臣; 南康範; 井上達夫; 矢田典久; 北井聡; 田北雅弘; 永井知行; 有住忠晃; 田中梨絵; 西田直生志; 工藤正俊
    第49回日本肝臓学会総会 2013年06月 口頭発表(一般)
  • 乏血性進行肝細胞患者に対するソラフェニブの治療成績  [通常講演]
    有住忠晃; 上嶋一臣; 田北雅弘; 北井聡; 井上達夫; 矢田典久; 萩原智; 南康範; 櫻井俊治; 西田直生志; 工藤正俊
    第49回日本肝臓学会総会 2013年06月 口頭発表(一般)
  • ヒト肝癌に認められるゲノムワイドな脱メチル化と染色体不安定性の関連  [通常講演]
    西田直生志; 有住忠晃; 田北雅弘; 北井聡; 矢田典久; 井上達夫; 萩原智; 南康範; 櫻井俊治; 上嶋一臣; 工藤正俊
    第49回日本肝臓学会総会 2013年06月 口頭発表(一般)
  • 非定型的な様相を呈する限局性結節性過形成についての検討  [通常講演]
    喜多竜一; 西田直生志; 那須章弘; 西島規浩; 若狭明子; 佐々木素子; 木村達; 大崎征夫; 中島収; 工藤正俊; 中沼安二
    第49回日本肝臓学会総会 ワークショップ2:良性肝細胞結節の諸問題:肝細胞腺腫、限局性結節性過形成を含む過形成結節の基礎と臨床 2013年06月 シンポジウム・ワークショップパネル(公募)
  • 進行肝細胞癌のソラフェニブ治療における腫瘍血流と治療効果との関連. ワークショップ1「分子標的薬の効果予後予測因子から治療法対象を考える」  [通常講演]
    有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第8回日本肝がん分子標的治療研究会 2013年06月 和倉温泉「加賀屋」, 石川 第8回日本肝がん分子標的治療研究会
  • Loss at long arm of chromosome 4 as a predictive factor for recurrence of human hepatocellular carcinoma after orthotopic living-donor liver transplantation  [通常講演]
    Nishimura T; Mori Y; Uemoto S; Nishida N
    49th Annual meeting of the American Society of Clinical Oncology (ASCO) 2013年05月 口頭発表(一般)
  • 肝血管脂肪腫の3例  [通常講演]
    田中梨絵; 南康範; 田北雅弘; 北井聡; 井上達夫; 矢田典久; 萩原智; 上嶋一臣; 西田直生志; 工藤正俊
    日本超音波医学会 第86回 学術集会 2013年05月 口頭発表(一般)
  • 超音波を施行した0歳児の嘔吐症例の検討  [通常講演]
    前野 知子; 横川 美加; 辻 裕美子; 塩見香織; 前川 清; 井上 達夫; 南 康範; 西田 直生志; 八木 誠; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 口頭発表(一般) 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • Genetic and Epigenetic Alterations in the Netrin-1 Receptors, Unc5c and DCC, Constitutes a Previously Unrecognized Pathway in Gastric Cancer Progression  [通常講演]
    Kubota N; Nagasaka T; Toda K; Mori Y; Morikawa T; Umeda Y; Yokomichi N; Yoshida K; Takehara Y; Takehara K; Nyuya A; Shiwaku R; Shigeyasu K; Suno M; Nishida N; Fujiwara T; Goel A
    83th Digestive Disease Week (DDW) 2013年05月 口頭発表(一般)
  • Fecal DNA Methylation Assay for the Identification of a Multiple Gastrointestinal Cancers Including Pancreatic Caner  [通常講演]
    Morikawa T; Nagasaka T; Yoshida K; Mori Y; Kubota N; Takehara Y; Yokomichi N; Nishida N; Takehara K; Shigeyasu K; Nyuya A; Shiwaku R; Suno M; Fujiwara T; Goel A
    83th Digestive Disease Week (DDW) 2013年05月 口頭発表(一般)
  • Cytokeratin 19 Staining Is a Novel, Predictive Biomarker for Extra-Hepatic Metastasis in Hepatocellular Carcinoma  [通常講演]
    Yokomichi N; Nagasaka T; Nishida N; Umeda Y; Mori Y; Morikawa T; Kubota N; Yoshida K; Takehara Y; Takehara K; Shigeyasu K; Nyuya A; Shiwaku A; Suno M; Fujiwara T; Goel A
    83th Digestive Disease Week (DDW) 2013年05月 口頭発表(一般)
  • Heat Shock Protein 27 Expression Is Inversely Correlated With Intraepithelial Neoplasia and Positively Correlated With Poor Differentiation of Gastric Cancer  [通常講演]
    Nagata Y; Sakurai T; Takayama M; Nagai T; Kawasaki M; Asakuma Y; Hagiwara S; Nishida N; Matsui S; Kashida H; Kudo M
    83th Digestive Disease Week (DDW) 2013年05月 口頭発表(一般)
  • MGMT Methylation As a Novel Biomarker for the Identification of Stage III Colorectal Cancers At High-Risk of Disease Recurrence Following Curative Surgery  [通常講演]
    Mori Y; Nagasaka T; Tazawa H; Umeda Y; Morikawa T; Kubota N; Yoshida K; Takehara Y; Yokomichi N; Takehara K; Shigeyasu K; Nyuya A; Shiwaku R; Suno M; Nishida N; Fujiwara T; Goel A
    83th Digestive Disease Week (DDW):AGA Research Foum: Biomarker in Cancer (1) 2013年05月 シンポジウム・ワークショップパネル(公募)
  • Accumulation of Epigenetic Alteration Could Predict Malignant Formation in Intraductal Papillary Mucinous Neoplasm (IPMN)  [通常講演]
    Yoshida K; Nagasaka T; Umeda Y; Nyokomichi N; Mori Y; Kubota N; Morikawa T; Takehara Y; Takehara K; Shigeyasu K; Nyuya A; Shiwaku R; Suno M; Nishida N; Fujiwara T; Goel A
    83th Digestive Disease Week (DDW):AGA Research Foum:Biology of Pancreatic Cancer and HCC 2013年05月 口頭発表(一般)
  • Heat shock protein 27 expression is inversely correlated with intraepithelial neoplasia and positively correlated with poor differentiation of gastris cancer.  [通常講演]
    Nagata Y; Sakurai T; Takayama M; Nagai T; Kawasaki M; Asakuma Y; Hagiwara S; Nishida N; Matsui S; Kashida H; Kudo M
    83th Digestive Disease Week (DDW) 2013年05月 口頭発表(一般) Orlando, USA Digestive Disease Week(DDW) 2013
  • Noninvasive assessment of liver fibrosis by measurement of LF index in patients with chronic viral hepatitis.  [通常講演]
    Yada M; Hagiwara S; Arizumi T; Takita M; Kitai S; Inoue T; Minami Y; Ueshima K; Nishida N; Kudo M
    Digestive Disease Week(DDW) 2013 2013年05月 口頭発表(一般) Orlando, USA Digestive Disease Week(DDW) 2013
  • 肝血管筋脂肪腫の3例  [通常講演]
    田中 梨絵; 南 康範; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本超音波医学会第86回学術集会 2013年05月 大阪国際会議場, 大阪 日本超音波医学会第86回学術集会
  • Landscape of DNA methylation status of human hepatocellular carcinoma revealed by Human Methylation BeadChip 450K  [通常講演]
    Nishimura N; Mori M; Nishida N
    104th American Association of Cancer Research (AACR) Annual Meetin 2013年04月 口頭発表(一般)
  • 肝血管筋脂肪腫の3例  [通常講演]
    田中 梨絵; 南 康範; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    超音波医学 2013年04月
  • 超音波を施行した0歳児の嘔吐症例の検討  [通常講演]
    前野 知子; 横川 美加; 辻 裕美子; 塩見 香織; 前川 清; 井上 達夫; 南 康範; 西田 直生志; 八木 誠; 工藤 正俊
    超音波医学 2013年04月
  • PEG-IFNα2a少量長期療法における発癌リスク因子の検討 IL28B遺伝子多型との関連も含めて  [通常講演]
    萩原 智; 櫻井 俊治; 上嶋 一臣; 南 康範; 井上 達夫; 矢田 典久; 北井 聡; 田北 雅弘; 永井 知行; 有住 忠晃; 田中 梨絵; 西田 直生志; 工藤 正俊
    肝臓 2013年04月
  • 乏血性進行肝細胞癌患者に対してソラフェニブ治療の成績  [通常講演]
    有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    肝臓 2013年04月
  • ヒト肝癌に認められるゲノムワイドな脱メチル化と染色体不安定性の関連  [通常講演]
    西田 直生志; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 工藤 正俊
    肝臓 2013年04月
  • 良性肝細胞性結節の諸問題 肝細胞腺腫、限局性結節性過形成を含む過形成結節の基礎と臨床 非定型的な様相を呈する限局性結節性過形成についての検討  [通常講演]
    喜多 竜一; 西田 直生志; 那須 章弘; 西島 規浩; 若狭 朋子; 佐々木 素子; 木村 達; 大崎 征夫; 中島 収; 工藤 正俊; 中沼 安二
    肝臓 2013年04月
  • 肝血管脂肪腫の3例  [通常講演]
    田中梨絵; 上嶋一臣; 千品寛和; 有住忠晃; 田北雅弘; 北井聡; 井上達夫; 矢田典久; 萩原智; 南康範; 西田直生志; 工藤正俊
    第99回日本消化器病学会総会 2013年03月 口頭発表(一般)
  • サイトケラチン19発現は肝細胞癌の上皮間葉移行と肝外転移を予測する  [通常講演]
    横道 直佑; 永坂 岳司; 西田 直生志; 楳田 祐三; 母里 淑子; 森川 達也; 久保田 暢人; 吉田 一博; 貞森 裕; 八木 孝仁; 藤原 俊義
    日本外科学会雑誌 2013年03月
  • 肝血管筋脂肪腫の3例  [通常講演]
    田中 梨絵; 上嶋 一臣; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊
    第99回日本消化器病学会総会 2013年03月 かごしま県民交流センター, 鹿児島 第99回日本消化器病学会総会
  • 肝血管筋脂肪腫の3例  [通常講演]
    田中 梨絵; 上嶋 一臣; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2013年02月
  • 腫瘍内出血を呈した肉腫様肝癌の1例  [通常講演]
    千品 寛和; 井上 達夫; 田中 梨絵; 山田 光成; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第98回例会 2013年02月 口頭発表(一般) 神戸ポートピアホテル, 兵庫 日本消化器病学会近畿支部第98回例会
  • ソラフェニブ治療におけるJNK活性の重要性-CD133との関連も含めて  [通常講演]
    萩原智; 櫻井俊治; 上嶋一臣; 永井知行; 西田直生志; 工藤正俊
    日本肝がん分子標的治療研究会 2013年01月 口頭発表(一般)
  • ソラフェニブ治療におけるJNK活性の重要性-CD133との関連も含めて  [通常講演]
    萩原智; 櫻井俊治; 西田直生志; 工藤正俊
    第20回浜名湖シンポジウム 2012年12月 口頭発表(一般)
  • 肝発癌のDriverとなり得るエピゲノム変異の同定と発癌予測  [通常講演]
    西田直生志; 永井知行; 萩原智; 櫻井俊治; 工藤正俊
    第20回浜名湖シンポジウム シンポジウム-ゲノム情報の臨床応用 2012年12月 シンポジウム・ワークショップパネル(公募)
  • The retrospective study of novel anticancer agent, miriplatin in TACE and TAI for unresectable hepatocellular carcinoma in Japan.  [通常講演]
    Nagai Y; Ueshima K; Hayaishi S; Takita M; Kitai S; Yada N; Inoue T; Hagiwara S; Minami Y; Nishida N; Kudo M
    Asian Pacific Digestive Week (APDW) 2012 2012年12月 口頭発表(一般) Bangkok, Thailand Asian Pacific Digestive Week (APDW) 2012
  • Tumor resonse assessment of sorafenib in patients with hepatocellular carcinoma: Comparision of RECIST, MRECIST and RECICL.  [通常講演]
    Arizumi T; Ueshima K; Takeda H; OsakiY; Hayaishi S; Takita M; Inoue T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    20th United European Gastroenterology Week (EUGW) 2012年10月 口頭発表(一般)
  • 転移性肝癌に対する肝動脈塞栓術とラジオ波焼灼術の併用療法の有用性  [通常講演]
    南康範; 有住忠晃; 早石右宗; 田北雅弘; 北井聡; 矢田典久; 井上達夫; 萩原智; 上嶋一臣; 西田直生志; 工藤正俊
    第19回日本消化器関連学会週間(第54回日本消化器病学会大会) 2012年10月 口頭発表(一般)
  • 肝癌の遺伝子変化および背景肝組織の男女差に関する検討  [通常講演]
    西田直生志; 工藤正俊
    第20回日本消化器関連学会週間(第16回日本肝臓学会大会) ワークショップ7:消化器疾患と性差 2012年10月 シンポジウム・ワークショップパネル(公募)
  • 肝発癌における酸化ストレスとエピゲノム変異  [通常講演]
    西田直生志; 工藤正俊
    第20回日本消化器関連学会週間(第16回日本肝臓学会大会) パネルディスカッション5:消化器癌と酸化ストレス 2012年10月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性の検討~造影CTとの比較~  [通常講演]
    井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012 2012年10月 口頭発表(一般) 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012
  • 肝嚢胞に対するオレイン酸モノエタノールアミン注入療法の検討  [通常講演]
    田北 雅弘; 井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012 2012年10月 口頭発表(一般) 神戸国際展示場, 兵庫 第20回日本消化器関連学会週間JDDW2012
  • 肝癌の遺伝子変化および背景肝組織の男女差に関する検討. ワークショップ7「消化器疾患と性差」  [通常講演]
    西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 神戸国際会議場, 兵庫 第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • 肝発癌における酸化ストレスとエピゲノム変異. パネルディスカッション5「消化器癌と酸化ストレス」  [通常講演]
    西田 直生志; 工藤 正俊
    第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会 2012年10月 ポートピアホテル, 兵庫 第20回日本消化器関連学会週間JDDW2012(第16回日本肝臓学会大会・第54回日本消化器病学会大会・第84回日本消化器内視鏡学会総会・第10回日本消化器外科学会大会・第50回日本消化器がん検診学会
  • Cytokeratin 19 predicts extrahepatic metastasis for hepatocellular carcinoma with epitherial-mesenchimal transition.  [通常講演]
    Yokomichi N; Nagasaka T; Nishida N; Kubota N; Morikawa T; Miri Y; Umeda Y; Sadamori H; Yagi T; Fujiwara T
    第71回日本癌学会学術総会 2012年09月 口頭発表(一般)
  • Genome-wide methylation profiling of human hepatocellular carcinoma by using BeadChip 450K.  [通常講演]
    Nishimura T; Nishida N
    第71回日本癌学会学術総会: English Oral Session (Epigenetics: DNA methylome) 2012年09月 口頭発表(一般)
  • Impact of DNA methylation alterations in chronic hepatitis C on emergence of human hepatocellular carcinoma  [通常講演]
    Nishida N; Nagasaka T; Nishimura T; Kudo M
    第71回日本癌学会学術総会: English Oral Session (DNA methylation and Biomarker) 2012年09月 口頭発表(一般)
  • 転移性肝癌に対する肝動脈塞栓術とラジオ波焼灼術の併用療法の有用性  [通常講演]
    南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2012年09月
  • 肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性の検討 造影CTとの比較  [通常講演]
    井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 2012年09月
  • 肝嚢胞に対するオレイン酸モノエタノールアミン注入療法の検討  [通常講演]
    田北 雅弘; 井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    肝臓 2012年09月
  • 消化器疾患と性差 肝癌の遺伝子変化および背景肝組織の男女差に関する検討  [通常講演]
    西田 直生志; 工藤 正俊
    肝臓 2012年09月
  • 消化器癌と酸化ストレス 肝発癌における酸化ストレスとエピゲノム変異  [通常講演]
    西田 直生志; 工藤 正俊
    肝臓 2012年09月
  • サイトケラチン19発現はEMT変化と肝細胞癌の肝外転移を予測する(Cytokeratin 19 predicts extrahepatic metastasis for hepatocellular carcinoma with epithelial-mesenchymal transition)  [通常講演]
    横道 直佑; 永坂 岳司; 西田 直生志; 久保田 暢人; 森川 達也; 母里 淑子; 楳田 祐三; 貞森 裕; 八木 孝仁; 藤原 俊義
    日本癌学会総会記事 2012年08月
  • BeadChip450Kを用いた肝細胞癌のゲノムワイドメチル化解析(Genome-wide methylation profiling of human hepatocellular carcinoma by using BeadChip 450K)  [通常講演]
    西村 貴文; 西田 直生志
    日本癌学会総会記事 2012年08月
  • C型慢性肝炎組織におけるDNAメチル化の出現と肝発癌におけるインパクト(Impact of DNA methylation alterations in chronic hepatitis C on emergence of human hepatocellular carcinoma)  [通常講演]
    西田 直生志; 永坂 岳司; 西村 貴文; 工藤 正俊
    日本癌学会総会記事 2012年08月
  • 多発性の限局性結節性過形成(FNH)およびFNH様結節に関する検討  [通常講演]
    喜多竜一; 工藤正俊; 西田直生志; 那須章洋; 木村達; 大﨑往夫; 依田広; 恵荘裕嗣; 千葉勉
    第48回日本肝癌研究会 ワークショップ2「肝癌類似病変診断の新しい展開: 肝細胞腺腫とFNHを中心に」 2012年07月 シンポジウム・ワークショップパネル(公募)
  • 転移性肝癌に対する肝動脈塞栓術とラジオ波焼灼術の併用療法の有用性  [通常講演]
    南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第48回日本肝癌研究会 2012年07月 口頭発表(一般) 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 進行肝細胞癌に対するソラフェニブ投与における投与後の腫瘍濃染の低下の有無と生存期間の検討  [通常講演]
    有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第48回日本肝癌研究会 2012年07月 口頭発表(一般) 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性~造影CTとの比較~  [通常講演]
    井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第48回日本肝癌研究会 2012年07月 口頭発表(一般) 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • Risk Assessment of Hepatocellular Carcinoma Using Epigenetic Alterations in Chronic Hepatitis  [招待講演]
    NISHIDA Naoshi
    The 9th Korea-Japan Liver Symposium: Management of Hepatocellular Carcinoma; An Update in 2012 2012年07月 口頭発表(招待・特別)
  • 多発性の限局性結節性過形成(FNH)およびFNH様結節に関する検討. ワークショップ2「肝癌類似病変診断の新しい展開: 肝細胞腺腫とFNHを中心に」  [通常講演]
    喜多 竜一; 工藤 正俊; 西田 直生志; 那須 章洋; 木村; 達; 大﨑; 往夫; 依田 広; 恵荘; 裕嗣; 千葉 勉
    第48回日本肝癌研究会 2012年07月 石川県立音楽堂, ANAクラウンプラザホテル金沢, 石川 第48回日本肝癌研究会
  • 当院における肝細胞癌分子標的治療の現状  [通常講演]
    上嶋一臣; 有住忠晃; 早石宗右; 田北雅弘; 北井聡; 矢田典久; 井上達夫; 萩原智; 南康範; 櫻井俊治; 西田直生志; 工藤正俊
    第6回日本肝がん分子標的治療研究会 パネルディスカッション「ソラフェニブ治療の実践-多数症例の使用経験を踏まえた治療の実践と問題点の解決を示す―」 2012年06月 シンポジウム・ワークショップパネル(公募)
  • IL28BとPEG-IFN/RBV併用療法をうけたHCVジェノタイプ1型高ウイルス量患者の効果との関連について  [通常講演]
    田北 雅弘; 萩原 智; 有住 忠晃; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊; 鄭 浩柄
    第48回日本肝臓学会総会 2012年06月 口頭発表(一般) JR金沢駅前もてなしドーム, 金沢 第48回日本肝臓学会総会
  • Novel Association between global DNA hypomethylation and chromosomal instability phenotype in human hepatocellular carcinoma (AASLD Basic Plenary)  [通常講演]
    Nishida N; Kudo M
    82th Digestive Disease Week (DDW):AASLD Basic Plenary 2012年06月 シンポジウム・ワークショップパネル(指名)
  • 当院における肝細胞癌分子標的治療の現状. パネルディスカッション「ソラフェニブ治療の実践-多数症例の使用経験を踏まえた治療の実践と問題点の解決を示す―」  [通常講演]
    上嶋 一臣; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊
    第6回日本肝がん分子標的治療研究会 2012年06月 ザ・プリンス箱根, 神奈川 第6回日本肝がん分子標的治療研究会
  • Usefullness of contrast-enhanced ultrasonography to evaluate a post treatment effect of Radiofrequentry ablation about Hepatocellular carcinoma; Comparion with Contrast-enhanced CT  [通常講演]
    Inoue T; Arizumi T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai Y; Ueshima K; Nishida N; Kudo M
    82th Digestive Disease Week (DDW) 2012年05月 口頭発表(一般)
  • Usefulness of contrast-enhanced ultrasonography to evaluate a post treatment effect of radiofrequentry ablation about hepatocellular carcinoma: comparison with contrast-enhanced CT  [通常講演]
    Inoue T; Arizumi T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai Y; Ueshima K; Nishida N; Kudo M
    82th Digestive Disease Week (DDW) 2012年05月 口頭発表(一般) San Diego, USA Digestive Disease Week(DDW) 2012
  • The gross classification of hepatocellular carcinoma: usefulness of contrast-enhanced sonography using perfluorocarbon microbubbles (sonazoid)  [通常講演]
    Minani Y; Hatanaka K; Arizumi T; Hayaishi S; Takita M; Kitai S; Yada N; Inoue T; Hgiwara S; Ueshima K; Nishida N; Kudo M
    Digestive Disease Week(DDW) 2012 2012年05月 口頭発表(一般) San Diego, USA Digestive Disease Week(DDW) 2012
  • Activation of JNK in the Non-cancerous liver tissue predicts a high risk of recurrence after hepatic resection for hepatocellular carcinoma  [通常講演]
    Sakurai T; Hagiwara S; Inoue T; Ueshima K; Matsui S; Nishida N; Kashida H; Kudo M
    Digestive Disease Week(DDW) 2012 2012年05月 口頭発表(一般) San Diego, USA Digestive Disease Week(DDW) 2012
  • Novel association between global DNA hypomethylation and chromosomal instability phenotype in human hepatocellular carcinoma  [通常講演]
    Nishida N; Kudo M; Arizumi T; Hayaish S; Takita M; Kitai S; Yada N; Inoue T; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Nagasaka T; Goel A
    Digestive Disease Week(DDW) 2012 Basic Plenary 2012年05月 口頭発表(一般) San Diego, USA Digestive Disease Week(DDW) 2012
  • 非上皮性肝悪性腫瘍の3例.  [通常講演]
    足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第98回日本消化器病学会総会 2012年04月 口頭発表(一般) 京王プラザ 第98回日本消化器病学会総会
  • IL28BとPEG-IFN/RBV併用療法をうけたHCVジェノタイプ1型高ウイルス量患者の効果との関連について  [通常講演]
    田北 雅弘; 萩原 智; 有住 忠晃; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊
    肝臓 2012年04月
  • Comprehensive DNA methylation profiling of human hepatocellular carcinoma.  [通常講演]
    Nishimura T; Nishida N
    103th American Association of Cancer Research (AACR) annual meeting 2012年03月 口頭発表(一般)
  • 非上皮性肝悪性腫瘍の3例  [通常講演]
    足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊
    日本消化器病学会雑誌 2012年03月
  • 進行肝細胞癌患者に対する分子標的薬(ソラフェニブ)投与における治療効果判定基準の比較.  [通常講演]
    有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊; 竹田 治彦; 大﨑
    第18回肝血流動態イメージ研究会 2012年01月 口頭発表(一般) 神戸ポートピアホテル, 兵庫 第18回肝血流動態イメージ研究会
  • 造影エコーによる肝癌肉眼分類の有用性について.  [通常講演]
    早石 宗右; 南 康範; 畑中 絹世; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 西田 直生志; 工藤 正俊
    日本消化器病学会近畿支部第96回例会 2012年01月 口頭発表(一般) 大阪国際交流センター, 大阪 日本消化器病学会近畿支部第96回例会
  • Impact on aberrant methylation of a unique subset of tumor suppressor genes on the initial steps of human hepatocarcinogenesis  [通常講演]
    Nishida N; Kudo M; Nagasaka T; Goel A
    62th Annual meeting of the American Association for the Study of Liver Diseases (AASLD). Parallel Session 31: Mechanism of hepatic carcinogenesis 2011年11月 シンポジウム・ワークショップパネル(公募)
  • Impact on aberrant methylation of an unique subset of tumor suppressor genes on the initial steps of human hepatocarcinogenesis.  [通常講演]
    Nishida N; Kudo M; Nagasaka T; Goel A
    The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2011年11月 シンポジウム・ワークショップパネル(公募) San Francisco, USA The 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
  • 超音波エラストグラフィーは、肝生検の代替になりうるか.  [通常講演]
    矢田 典久; 萩原 智; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊
    第53回大阪肝穿刺生検治療研究会 2011年11月 口頭発表(一般) ホテルグランヴィア大阪, 大阪 第53回大阪肝穿刺生検治療研究会
  • C型慢性肝炎組織における癌抑制遺伝子メチル化と肝発癌  [通常講演]
    西田直生志
    第19回日本消化器関連学会週間(第15回日本肝臓学会大会) ワークショップ14:エピジェネティックスと消化器癌 2011年10月 シンポジウム・ワークショップパネル(公募)
  • Genetic and epigenetic analysis for the prediction of recurrent hepatocellular carcinoma after liver transplantation.  [通常講演]
    Takafumi Nishimura; Naoshi Nishida; Shinji Uemoto; Yoshihiro Fukuda
    第70回日本癌学会学術総会 2011年10月 口頭発表(一般)
  • 肝細胞がんに対する生体肝移植後の転移再発予測因子探索のための統合的ゲノム・エピゲノム解析(Genetic and epigenetic analysis for the prediction of recurrent hepatocellular carcinoma after liver transplantation)  [通常講演]
    西村 タカフミ; 西田 直生志; 上本 伸二; 福田 善弘
    日本癌学会総会記事 2011年09月
  • エピジェネティクスと消化器癌 C型慢性肝炎組織における癌抑制遺伝子メチル化と肝発癌  [通常講演]
    西田 直生志
    肝臓 2011年09月
  • HCVの自然排除群の関連遺伝子の検討ーIL-28B遺伝子とHLA抗原の多様性の検討を中心に  [通常講演]
    井本勉; 金守良; 田中靖人; 金啓二; 谷口美幸; 福田善弘; 西田直生志; 国立裕之; 畦地英全; 米田俊貴; 勝島慎二; 竹内孝男; 山東剛裕; 河原啓; 菅野雅彦
    第47回日本肝臓学会総会 プレナリーセッション3 2011年06月 シンポジウム・ワークショップパネル(公募)
  • C型肝炎関連発癌の初期段階における癌抑制遺伝子の異常メチル化の役割  [通常講演]
    西田直生志; 福田善弘; 千葉勉
    第47回日本肝臓学会総会 シンポジウム1:ウイルス肝炎•肝癌制圧の分子基盤 2011年06月 シンポジウム・ワークショップパネル(公募)
  • Characterization of step-wise accumulation of DNA methylation alterations during human hepatocarcinogenesis. (DDW Poster of Distinction).  [通常講演]
    Nishida N; Nagasaka T; Boland CR; Chiba T; Goel A
    81th Digestive Disease Week (DDW) 2011年05月
  • HCVの自然排除群の関連遺伝子の検討 IL 28B遺伝子とHLA抗原の多型性の検索を中心に  [通常講演]
    井本 勉; 金 守良; 田中 靖人; 金 啓二; 谷口 美幸; 福田 善弘; 西田 直生志; 国立 裕之; 畦地 英全; 米田 俊貴; 勝島 慎二; 竹内 孝男; 山東 剛裕; 河原 啓; 菅野 雅彦
    肝臓 2011年04月
  • ウイルス肝炎・肝癌制圧の分子基盤 C型肝炎関連発癌の初期段階における癌抑制遺伝子の異常メチル化の役割  [通常講演]
    西田 直生志; 福田 善弘; 千葉 勉
    肝臓 2011年04月
  • 短期間の内に増大傾向を示した多発性肝限局性結節性過形成の一例  [通常講演]
    荒澤 壮一; 西田 直生志; 依田 広; 秦 浩一郎; 影山 詔一; 福山 宏樹; 村田 充子; 磯田 裕義; 波多野 悦朗; 千葉 勉
    超音波医学 2011年03月
  • 短期間の内に増大傾向を示した多発性肝限局性結節性過形成の一例  [通常講演]
    荒澤 壮一; 西田 直生志; 依田 広; 秦 浩一郎; 影山 詔一; 福山 宏樹; 村田 充子; 磯田 裕義; 波多野 悦朗; 千葉 勉
    第37回超音波医学会 関西地方会学術集会 2010年10月 口頭発表(一般)
  • 血清中の肝癌由来DNAの定量化と治療マーカーへの応用  [通常講演]
    西田直生志; 福田善弘
    第18回日本消化器関連学会週間 (第14回日本肝臓学会大会) ワークショップ7: 肝細胞癌に対する新たな診断•治療マーカーの確立 2010年10月 シンポジウム・ワークショップパネル(公募)
  • ヒト肝発癌過程におけるゲノム•エピゲノムの包括的解析  [通常講演]
    西田直生志; 福田善弘
    第18回日本消化器関連学会週間 (第14回日本肝臓学会大会) シンポジウム17:肝癌のメカニズムと治療戦略 2010年10月 シンポジウム・ワークショップパネル(公募)
  • 膵臓仮性嚢胞が穿破したと考えられる腎皮膜下嚢胞に対し超音波内視鏡(EUS)ガイド下ドレナージが著効した一例  [通常講演]
    木村典世; 本澤有介; 澤井勇吾; 宇座徳光; 児玉裕三; 西田直生志; 千葉勉
    第85回日本消化器内視鏡学会近畿地方会 2010年10月 口頭発表(一般)
  • Impact of gene sliencing on the recurrence of hepatocellular carcinoma after living-donor liver transplantation  [通常講演]
    Takafumi Nishimura; Naoshi Nishida; Shinji Uemoto; Yoshihiro Fukuda
    第69回日本癌学会総会 2010年09月 口頭発表(一般)
  • 肝細胞癌に対する新たな診断・治療マーカーの確立(基礎から臨床へ) 血清中の肝癌由来DNAの定量化と治療マーカーへの応用  [通常講演]
    西田 直生志; 福田 善弘
    肝臓 2010年09月
  • 肝がんのメカニズムと治療戦略 ヒト肝発癌過程におけるゲノム、エピゲノム変化の包括的解析  [通常講演]
    西田 直生志; 福田 善弘
    肝臓 2010年09月
  • 肝細胞癌に対する生体肝移植治療後の転移再発予測因子としての遺伝子メチル化の検討(Impact of gene silencing on the recurrence of hepatocellular carcinoma after living-donor liver transplantation)  [通常講演]
    西村 貴文; 西田 直生志; 上本 伸二; 福田 善弘
    日本癌学会総会記事 2010年08月
  • Epigenetic Alterations during HCV-related human hepatocarcinogenesis and its clinical implication  [招待講演]
    Nishida N
    World Congress of Virus and Infections 2010, Hepatitis C Symposium 2010年07月 口頭発表(招待・特別)
  • 肝癌症例における血中メチル化DNAを用いた腫瘍ダイナミクスの推定  [通常講演]
    西田直生志; 福田善弘
    第46回日本肝臓学会総会 2010年05月 口頭発表(一般)
  • 肝癌症例における血清中メチル化DNAの量的変化を用いた腫瘍ダイナミクスの推定  [通常講演]
    西田 直生志; 福田 善弘
    肝臓 2010年04月
  • 肝発癌過程における遺伝子メチル化の変化  [通常講演]
    西田直生志; 福田善弘; 千葉勉
    第17回日本消化器関連学会週間 (第13回日本肝臓学会大会) シンポジウム6:消化器癌におけるエピジェネティクス 2009年10月 シンポジウム・ワークショップパネル(公募)
  • C型肝炎ウイルスによる肝発癌とDNAメチル化の不安定性  [招待講演]
    西田 直生志
    第9回肝疾患フォーラム学術集会 2009年10月 口頭発表(招待・特別)
  • 消化器癌におけるエピジェネティクス 肝発癌過程における遺伝子メチル化の変化  [通常講演]
    西田 直生志; 福田 善弘; 千葉 勉
    肝臓 2009年09月
  • 肝臓癌の発生と遺伝子異常-エピジェネティクスの面からみた肝癌診療への応用-  [招待講演]
    西田 直生志
    日本消化器病学会近畿支部例会 第30回教育公演会 2009年06月 口頭発表(招待・特別)
  • 肝発癌過程における遺伝子メチル化の変化と肝癌診断への応用 (第45回日本肝臓学会優秀演題: 同 会長奨励賞受賞演題)  [通常講演]
    西田直生志; 福田善弘; 千葉勉
    第45回日本肝臓学会総会 ワークショップ7:肝癌発生•進展の分子機構と臨床への還元 2009年06月 シンポジウム・ワークショップパネル(公募)
  • 肝癌発生・進展の分子機構と臨床への還元 肝発癌過程における遺伝子メチル化の変化と肝癌診断への応用  [通常講演]
    西田 直生志; 千葉 勉; 福田 善弘
    肝臓 2009年04月
  • 食道粘膜下血腫の一例  [通常講演]
    川口直; 西島規浩; 宇座徳光; 西田直生志
    第82回日本消化器内視鏡学会近畿地方会 2009年03月 口頭発表(一般)
  • 肝発癌における染色体不安定性とメチル化不安定性の関わり  [招待講演]
    西田 直生志
    第21回肝臓フォーラム 2009年03月 口頭発表(招待・特別)
  • Aberrant methylation of multiple tumor suppressor genes in hepatocellular carcinoma.  [招待講演]
    Nishida N
    APASL Meeting, 2008 Asian Hepatitis Forum: Basic Research 2008年12月 口頭発表(招待・特別)
  • Clonal relationship of multi-nodular hepatocellular carcinoma in patietns undergoing living-donar liver transplantation  [通常講演]
    Takafumi Nishimura; Naoshi Nishida; Noriko Deguchi; Rie Kinoshita; Mikiko Ueda; Taiji Takada; Shinji Uemoto; Yoshihiro Fukuda
    第67回日本癌学会総会 2008年10月 口頭発表(一般)
  • Analysis of DNA methylation for detecting gastrointestinal neoplasia  [通常講演]
    Yakeshi Nagasaka; Nagahide Matsubara; Naoshi Nishida; Noriki Tanaka
    第67回日本癌学会総会 2008年10月 口頭発表(一般)
  • Progression of aberrant methylation in multiple cancer-related genes in HCV-related hepatocarcinogenesis.  [通常講演]
    Nishida N; Nishimura T; Chiba T; Fukuda Y
    第67回日本癌学会総会 English Workshops 3: Hepatocellular carcinoma 2008年10月 シンポジウム・ワークショップパネル(公募)
  • DNAメチル化検出による糞便からの消化器腫瘍の診断(Analysis of fecal DNA methylation for detecting gastrointestinal neoplasia)  [通常講演]
    永坂 岳司; 松原 長秀; 西田 直生志; 田中 紀章
    日本癌学会総会記事 2008年09月
  • HCV関連肝癌の発癌過程における癌関連遺伝子の異常メチル化の進展(Progression of aberrant methylation in multiple cancer-related genes in HCV-related hepatocarcinogenesis)  [通常講演]
    西田 直生志; 西村 貴文; 千葉 勉; 福田 善弘
    日本癌学会総会記事 2008年09月
  • 肝移植治療を受けた多発性肝細胞癌症例におけるクローン関連性の検討(Clonal relationship of multi-nodular hepatocellular carcinoma in patients undergoing living-donor liver transplantation)  [通常講演]
    西村 貴文; 西田 直生志; 出口 法子; 木下 絵理; 上田 幹子; 高田 泰次; 上本 伸二; 福田 善弘
    日本癌学会総会記事 2008年09月
  • C型肝炎からの発癌における遺伝子メチル化の不安定性  [通常講演]
    西田直生志; 福田善弘; 千葉勉
    第44回日本肝臓学会総会 ワークショップ3:肝の発癌と進展における分子代謝学的研究 2008年06月 シンポジウム・ワークショップパネル(公募)
  • 肝疾患に認められる遺伝子メチル化の進行とHCVの関与  [通常講演]
    西田直生志; 福田善弘; 千葉勉
    第94回日本消化器病学会総会 パネルディスカッション1:消化器領域におけるゲノム解析の現状と展望 2008年05月 シンポジウム・ワークショップパネル(公募)
  • Mutation in both KRAS and BRAF contribute to the methylator phenotype in colon cancer  [通常講演]
    Nagasaka, T; Koi M; Nishida N; Shin SK; Matsubara N; Boland CR; Goel A
    78th Digestive Disease Week (DDW) 2008年05月 口頭発表(一般)
  • Detection of colorectal neoplasia through analysis of fecal DNA methylation.  [通常講演]
    Nagasaka, T; Sasamoto H; Sun DS; Oka T; Toda K; Taniguchi N; Koi M; Nishida N; Boland CR; Goel A; Matsubara N
    78th Digestive Disease Week (DDW) 2008年05月 口頭発表(一般)
  • Sequential progression of aberrant methylation in cancer-related genes in various stages of human hepatocarcinogenesis: Presidential Plenary  [通常講演]
    Nishida N; Nagasaka T; Boland CR; Goel A
    78th Digestive Disease Week (DDW):AASLD Presidential Plenary 2008年05月 シンポジウム・ワークショップパネル(公募)
  • C型肝炎からの発癌における遺伝子メチル化の不安定性  [通常講演]
    西田 直生志; 福田 善弘; 千葉 勉
    肝臓 2008年04月
  • 消化器領域におけるゲノム解析の現状と展望 肝疾患に認められる遺伝子メチル化の進行とHCVの関与  [通常講演]
    西田 直生志; 福田 善弘; 千葉 勉
    日本消化器病学会雑誌 2008年03月
  • 肝組織における癌関連遺伝子プロモーターメチル化の定量的解析  [通常講演]
    西田直生志; 福田善弘
    第16回浜名湖シンポジウム シンポジウム-消化器疾患におけるtranslational Research 2007年12月 シンポジウム・ワークショップパネル(公募)
  • 大腸癌におけるCDC4-サイクリンE経路の破綻と染色体不安定性  [通常講演]
    西田直生志; 永坂岳司; 柏木和宏; Ajay Goel; 福田善弘; 千葉勉
    第15回日本消化器関連学会週間(第49回日本消化器病学会大会) 2007年10月 口頭発表(一般)
  • ヒト肝細胞癌における染色体不安定性、メチル化不安定性と癌関連遺伝子変異の相関  [通常講演]
    西田直生志; 西村貴文; 永坂岳司; 福田善弘; 千葉勉
    第66回日本癌学会総会 ワークショップ9:Epigenetics 2007年10月 シンポジウム・ワークショップパネル(公募)
  • 大腸癌におけるCDC4-サイクリンE経路の破綻と染色体不安定性  [通常講演]
    西田 直生志; 永坂 岳司; 柏木 一宏; Goel Ajay; 福田 善弘; 千葉 勉
    日本消化器病学会雑誌 2007年09月
  • ヒト肝細胞癌における染色体不安定性、メチル化不安定性と癌関連遺伝子変異の相関(Chromosomal instability, Epigenetic instability and mutations of cancer-related gene in human hepaticellular carcinoma)  [通常講演]
    西田 直生志; 西村 貴文; 永坂 岳司; 福田 善弘; 千葉 勉
    日本癌学会総会記事 2007年08月
  • 肝発癌における染色体不安定性とメチル化不安定性の関わり  [通常講演]
    西田直生志; 西村貴文; 福田善弘
    第43回日本肝臓学会総会 ワークショップ5:肝発癌の分子機序 2007年05月 シンポジウム・ワークショップパネル(公募)
  • Genetic instability and epigenetic instability in human hepatocarcinogenesis.  [通常講演]
    Nishida N; Nishimura T; Nagasaka T; Ikai, I; Goel A; Boland CR
    77th Digestive Disease Week (DDW): AASLD Topic Forum 2007年05月 シンポジウム・ワークショップパネル(公募)
  • 肝発癌における染色体不安定性とメチル化不安定性  [通常講演]
    西田 直生志; 西村 貴文; 福田 善弘
    肝臓 2007年04月
  • Methylation profiling of human hepatocellular carcinoma  [通常講演]
    Nishida N; Goel A; Nagasaka T; Nishimura T; Boland CR
    97th American Association of Cancer Research (AACR) annual meeting 2006年04月 口頭発表(一般)
  • 包括的マイクロサテライト解析を用いた肝細胞癌のクローン不均一性の検討  [通常講演]
    西村 貴文; 米田 俊貴; 福田 善弘; 西田 直生志; 中尾 一和
    日本癌学会総会記事 2005年09月 口頭発表(一般)
  • Alterations of hCDC4 and accumulation of phosphorylated cyclin E in human cancer cell lines: A possible mechanism for chromosomal instability  [通常講演]
    Nishida N; Goel A; Kashiwagi K; Boland CR
    96th American Association of Cancer Research (AACR) annual meeting 2005年04月 口頭発表(一般)
  • 抗セントロメア抗体が単独陽性で他の染色型の抗核抗体が陰性の1型自己免疫性肝炎の検討  [通常講演]
    井本勉; 金守良; 福田善弘; 西田直生志; 大曲勝久; 二宮俊明; 前川陽子; 金啓二
    第40回日本肝臓学会総会 2004年06月 口頭発表(一般)
  • Integrity of acquired chromosomal alterations during the metastatic progression of human hepatocellular carcinoma detected by high-density comprehensive allelotype analysis  [通常講演]
    Nishimura T; Nishida N; Komeda T; Fukuda Y; Nakao K
    40th Annual meeting of the American Society of Clinical Oncology (ASCO) 2004年06月 口頭発表(一般)
  • 難治性C型肝炎に対するBDDの有効性の検証  [通常講演]
    福田善弘; 西田直生志; 米田俊貴
    第90回日本消化器病学会総会 2004年04月 口頭発表(一般)
  • 抗セントロメア抗体が単独陽性で他の染色型の抗核抗体が陰性のI型自己免疫性肝炎例の検討  [通常講演]
    井本 勉; 金 守良; 福田 善弘; 西田 直生志; 大曲 勝久; 二宮 俊明; 前川 陽子; 金 啓二
    肝臓 2004年04月
  • 抵GAD抗体陽性の糖尿病を伴ったヘモクロマトーシスの一例  [通常講演]
    田中智洋; 安立英矢; 井上元; 益崎裕章; 海老原健; 中所英樹; 米田俊貴; 林達也; 西田直生志; 細田公則; 福田善弘; 中尾一和
    第14回臨床内分泌代謝Update 2004年03月 口頭発表(一般)
  • Shortest region of overlap of recurrent chromosomal gains or losses in human hepatocellular carcinoma detected by semiquantitative comprehensive allelotype analysis.  [通常講演]
    Nishimura T; Nishida N; Komeda T; Fukuda Y; Ikai I; Nakao K
    95th American Association of Cancer Research (AACR) annual meeting. 2004年03月 口頭発表(一般)
  • 難治性C型肝炎に対するBDD(Biphenyl Dimethyl Dicarboxylate)の有効性の検証  [通常講演]
    福田 善弘; 西田 直生志; 米田 俊貴
    日本消化器病学会雑誌 2004年03月
  • 抗GAD抗体陽性の糖尿病を伴ったヘモクロマトーシスの一例  [通常講演]
    田中 智洋; 安立 英矢; 井上 元; 益崎 裕章; 海老原 健; 中所 英樹; 米田 俊貴; 林 達也; 西田 直生志; 細田 公則; 福田 善弘; 中尾 一和
    日本内分泌学会雑誌 2003年12月
  • 原発性胆汁性肝硬変の母娘例  [通常講演]
    米田俊貴; 伊藤照明; 久野雅人; 西村貴文; 西田直生志; 中尾一和; 池原幸辰; 足立正彦; 与芝真彰; 福田善弘
    第35回日本肝臓学会西部会 2003年11月 口頭発表(一般)
  • IVRが奏功したBudd-Chiari症候群の3例  [通常講演]
    西田直生志; 岩村伸一; 米田俊貴; 西村貴文; 伊藤照明; 前谷洋爾; 伊藤亨; 中尾一和; 千葉勉; 福田善弘
    第35回日本肝臓学会西部会 2003年11月 口頭発表(一般)
  • 発癌過程における酸化ストレスの役割 チオレドキシンの面から  [通常講演]
    皆田睦子; 西田直生志; 福田善弘
    第35回日本肝臓学会西部会 パネルディスカッション2:酸化ストレスと肝障害 2003年11月 シンポジウム・ワークショップパネル(公募)
  • 慢性C型肝炎のインターフェロン治療に伴う骨吸収の改善効果と骨量増加  [通常講演]
    西田直生志; 米田俊貴; 西村貴文; 伊藤照明; 久野雅人; 小松弥郷; 中尾一和; 福田善弘
    第11回日本消化器関連学会週間(第7回日本肝臓学会大会) 2003年10月 口頭発表(一般)
  • 原発性胆汁性肝硬変の母娘例  [通常講演]
    米田 俊貴; 伊藤 照明; 久野 雅人; 西村 貴文; 西田 直生志; 中尾 一和; 池原 幸辰; 足立 正彦; 与芝 真彰; 福田 善弘
    肝臓 2003年10月
  • IVRが奏効したBudd-Chiari症候群の3症例  [通常講演]
    西田 直生志; 岩村 伸一; 米田 俊貴; 西村 貴文; 伊藤 照明; 前谷 洋爾; 伊藤 亨; 中尾 一和; 千葉 勉; 福田 善弘
    肝臓 2003年10月
  • 酸化ストレスと肝障害 肝発癌過程における酸化ストレスの役割 チオレドキシンの面から  [通常講演]
    皆田 睦子; 西田 直生志; 福田 善弘
    肝臓 2003年10月
  • 半定量マイクロサテライト解析を用いた肝細胞癌の包括的染色体解析  [通常講演]
    西村貴文; 西田直生志; 米田俊貴; 猪飼伊和夫; 福田善弘; 中尾一和
    第62回日本癌学会総会 2003年09月 口頭発表(一般)
  • 慢性C型肝炎のインターフェロン治療に伴う骨吸収の改善効果と骨量増加  [通常講演]
    西田 直生志; 米田 俊貴; 西村 貴文; 伊藤 照明; 久野 雅人; 小松 弥郷; 中尾 一和; 福田 善弘
    肝臓 2003年09月
  • 半定量マイクロサテライト解析を用いた肝細胞癌の包括的染色体解析  [通常講演]
    西村 貴文; 西田 直生志; 米田 俊貴; 猪飼 伊和夫; 福田 善弘; 中尾 一和
    日本癌学会総会記事 2003年08月
  • Discrete breakpoint and the shortest region of overlap of chromosome arm 1q again in human hepatocellular carcinoma detected by semiquantitative microsatellite andlasis.  [通常講演]
    Nishimura T; Nishida N; Fukuda Y; Yamaoka Y; Nakao K
    94th American Association of Cancer Research (AACR) annual meeting. 2003年07月 口頭発表(一般)
  • 半定量マイクロサテライト解析を用いた肝細胞癌における第1染色体長腕重複領域の検討  [通常講演]
    西村貴文; 西田直生志; 伊藤照明; 米田俊貴; 福田善弘; 山岡義生; 中尾一和
    第39回日本肝臓学会総会 2003年05月 口頭発表(一般)
  • Extension of abnormal chromosome region predicts the metastasis of human hepatocellular carcinomas  [通常講演]
    Nishida N; Nishimura T; Fukuda Y; Nakao K
    73th Digestive Disease Week (DDW) 2003年05月 口頭発表(一般)
  • 半定量マイクロサテライト解析を用いた肝細胞癌における第1染色体長腕重複領域の検討  [通常講演]
    西村 貴文; 西田 直生志; 伊藤 照明; 米田 俊貴; 福田 善弘; 山岡 義生; 中尾 一和
    肝臓 2003年04月
  • 染色体不安定性による肝癌の転移再発予測  [通常講演]
    西田直生志; 西村貴文; 福田善弘
    第10回日本消化器関連学会週間 (第44回日本消化器病学会大会 2002年10月 口頭発表(一般)
  • マイクロサテライトを用いた肝細胞癌における第1染色体長腕重複領域の決定  [通常講演]
    西村 貴文; 西田 直生志; 福田 善弘; 中尾 一和
    日本癌学会総会記事 2002年10月 シンポジウム・ワークショップパネル(公募)
  • ヒト肝細胞癌におけるKiSS-1およびhOT7T175発現の検討  [通常講演]
    伊藤照明; 西田直生志; 久野雅人; 西村貴文; 米田俊貴; 福田善弘; 中尾一和
    第38回日本肝臓学会総会 2002年06月 口頭発表(一般)
  • B型肝硬変症例に対するラミブジンの投与戦略  [通常講演]
    米田俊貴; 西田直生志; 福田善弘
    第38回日本肝臓学会総会 2002年06月 口頭発表(一般)
  • ヒト肝細胞癌におけるKiSS-1及びhOT7T175発現の検討  [通常講演]
    伊藤 照明; 西田 直生志; 久野 雅人; 西村 貴文; 米田 俊貴; 福田 善弘; 中尾 一和
    肝臓 2002年05月
  • B型肝硬変症例に対するラミブジンの投与戦略  [通常講演]
    米田 俊貴; 西田 直生志; 福田 善弘
    肝臓 2002年05月
  • 染色体不安定性にもとづく肝癌の転移再発予測  [通常講演]
    西田直生志; 西村貴文; 福田善弘
    第76回日本消化器病学会 近畿支部例会 シンポジウム1:消化器癌の転移に対する治療戦略 2002年02月 シンポジウム・ワークショップパネル(公募)
  • 関節痛、関節炎を初発症状としたB型急性肝炎例でのHBV genotyp分子系統樹解析  [通常講演]
    福田善弘; 菅内文中; 溝上雅史; 伊藤照明; 久野雅人; 西村貴文; 米田俊貴; 西田直生志; 中尾一和
    第34回日本肝臓学会西部会 2001年12月 口頭発表(一般)
  • 乳癌術後5-FU及びTamoxifen内服中に肝障害を認めた2例  [通常講演]
    伊藤照明; 西田直生志; 久野雅人; 西村貴文; 米田俊貴; 中尾一和; 児玉宏; 福田善弘
    第34回日本肝臓学会西部会 2001年12月 口頭発表(一般)
  • 当科において生体肝移植を検討した肝細胞癌合併ウイルス性肝硬変の2症例  [通常講演]
    米田俊貴; 伊藤照明; 久野雅人; 西村貴文; 西田直生志; 中尾一和; 福田善弘; 上本伸二; 田中紘一
    第34回日本肝臓学会西部会 ワークショップ1:肝細胞癌の発癌予防と治療の最前線 2001年12月 シンポジウム・ワークショップパネル(公募)
  • 京滋地区医療施設における肝移植に関するアンケート調査  [通常講演]
    米田俊貴; 西田直生志; 福田善弘
    第34回日本肝臓学会西部会 主題示説1:近未来医療—移植から再生医療 2001年12月 シンポジウム・ワークショップパネル(公募)
  • 乳癌術後5-FU及びTamoxifen内服中に肝障害を認めた2例  [通常講演]
    伊藤 照明; 西田 直生志; 久野 雅人; 西村 貴文; 米田 俊貴; 中尾 一和; 児玉 宏; 福田 善弘
    肝臓 2001年11月
  • 近未来医療 移植から再生医療 京滋地区医療施設における肝移植に関するアンケート調査  [通常講演]
    米田 俊貴; 西田 直生志; 福田 善弘
    肝臓 2001年11月
  • 肝細胞癌の発癌予防と治療の最前線 当科において生体肝移植を検討した,肝細胞癌合併ウイルス性肝硬変の2症例  [通常講演]
    米田 俊貴; 伊藤 照明; 久野 雅人; 西村 貴文; 西田 直生志; 中尾 一和; 福田 善弘; 上本 伸二; 田中 紘一
    肝臓 2001年11月
  • 関節痛,関節炎を初発症状としたB型急性肝炎例でのHBV genotype,分子系統樹解析  [通常講演]
    福田 善弘; 菅内 文中; 溝上 雅史; 伊藤 照明; 久野 雅人; 西村 貴文; 米田 俊貴; 西田 直生志; 中尾 一和
    肝臓 2001年11月
  • ヒト肝細胞癌におけるp14ARF異常の解析及びp53異常との関連  [通常講演]
    伊藤照明; 西田直生志; 畦地英全; 久野雅人; 西村貴文; 米田俊貴; 福田善弘; 中尾一和
    第9回日本消化器関連学会週間 (第5回日本肝臓学会大会) 2001年10月 口頭発表(一般)
  • 切除肝細胞癌における転移再発•予後予測因子としてのVGEF, Cyclin D1, E-Cadherinの検討  [通常講演]
    皆田睦子; 伊藤照明; 久野雅人; 西村貴文; 米田俊貴; 西田直生志; 中尾一和; 猪飼伊和夫; 山岡義生; 福田善弘; 中尾一和
    第9回日本消化器関連学会週間 (第5回日本肝臓学会大会) 2001年10月 口頭発表(一般)
  • ヒト肝発癌過程における遺伝子染色体異常の意義  [通常講演]
    西田 直生志
    第1回肝疾患フォーラム学術集会 2001年09月 口頭発表(招待・特別)
  • 多発性関節痛で発症したB型肝炎の1例  [通常講演]
    船越生吾; 西田直生志; 伊藤照明; 久野雅人; 西村貴文; 米田俊貴; 中尾一和; 村上雅朗; 福田善弘
    第165回日本内科学会近畿会地方会 2001年09月 口頭発表(一般)
  • インド旅行後に発症した急性E型肝炎の1例  [通常講演]
    髭 英樹; 伊藤照明; 久野雅人; 西村貴文; 米田俊貴; 西田直生志; 中尾一和; 福田善弘; 加藤重延
    第75回日本消化器病学会近畿支部例会 2001年09月 口頭発表(一般)
  • 急性B型肝炎初感染後にHBVキャリア化した1成人例  [通常講演]
    久野雅人; 伊藤照明; 西村貴文; 米田俊貴; 西田直生志; 中尾一和; 福田善弘
    第75回日本消化器病学会近畿支部例会 2001年09月 口頭発表(一般)
  • マイクロサテライト解析による染色体欠失と重複の判定  [通常講演]
    西村貴文; 西田直生志; 米田俊貴; 福田善弘; 中尾一和
    第60回日本癌学会総会 2001年09月 口頭発表(一般)
  • マイクロサテライト解析における染色体欠失と重複の判定  [通常講演]
    西村 貴文; 西田 直生志; 米田 俊貴; 福田 善弘; 中尾 一和
    日本癌学会総会記事 2001年09月
  • 切除肝細胞癌における転移再発・予後予測因子としてのVEGF,Cyclin D1,E-cadherinの検討  [通常講演]
    皆田 睦子; 伊藤 照明; 久野 雅人; 西村 貴文; 米田 俊貴; 西田 直生志; 中尾 一和; 猪飼 伊和夫; 山岡 義生; 福田 善弘
    肝臓 2001年09月
  • ヒト肝細胞癌におけるp14ARF異常の解析及びp53異常との関連  [通常講演]
    伊藤 照明; 西田 直生志; 畦地 英全; 久野 雅人; 西村 貴文; 米田 俊貴; 福田 善弘; 中尾 一和
    肝臓 2001年09月
  • Comprehensive allelotyping of well differentiated human hepatocellular carcinoma. Evaluation of chromosomal gain or loss with multiplex PCR.  [通常講演]
    Nishimura T; Nishida N; Azechi H; Itoh T; Kuno M; Minata M; Fukuda Y; Nakao K
    37th Annual meeting of the American Society of Clinical Oncology (ASCO) 2001年05月 口頭発表(一般)
  • Prognostic impact of multiple allelic losses for metastatic recurrence in hepatocellular carcinoma after curative resection. (DDW Poster of Distinction).  [通常講演]
    Nishida N; Nishimura T; Fukuda Y; Nakao K
    71th Digestive Disease Week (DDW). 2001年05月 口頭発表(一般)
  • 高分化肝細胞癌における包括的アレロタイプ解析  [通常講演]
    西村貴文; 西田直生志; 福田義弘
    第87回日本消化器病学会総会 2001年04月 口頭発表(一般)
  • 切除肝細胞癌におけるE-Cadherinの発現と予後  [通常講演]
    皆田睦子; 西田直生志; 福田善弘; 西村貴文; 米田俊貴; 猪飼伊和夫
    第59回日本癌学会総会 2000年10月 口頭発表(一般)
  • 高分化肝細胞癌における包括的アレロタイプ解析  [通常講演]
    西村貴文; 西田直生志; 福田善弘; 皆田睦子; 米田俊貴; 猪飼伊和夫; 中尾一和
    第59回日本癌学会総会 2000年10月 口頭発表(一般)
  • Discrete breakpoint and the shortest region of overlap of chromosome arm 1q again in human hepatocellular carcinoma detected by semiquantitative microsatellite andlasis.  [通常講演]
    Nishimura T; Nishida N; Fukuda Y; Yamaoka Y; Nakao K
    51th American Association for Study of Liver Diseases (AASLD). 2000年10月 口頭発表(一般)
  • 肺炎後に発見されたC型慢性肝炎に合併した肝 inflammatory pseudotumor の1例  [通常講演]
    朴 貴典; 西村貴文; 伊藤照明; 久野雅人; 畦地英全; 皆田睦子; 西田直生志; 中尾一和; 福田善弘
    第73回日本消化器学会近畿支部例会 2000年09月 口頭発表(一般)
  • 高分化肝細胞癌における包括的アレロタイプ解析  [通常講演]
    西村 貴文; 西田 直生志; 福田 善弘; 皆田 睦子; 米田 俊貴; 猪飼 伊和夫; 中尾 一和
    日本癌学会総会記事 2000年09月
  • Aberrations of cell cycle-related genes of HCC in Japan  [通常講演]
    Nishida, N; Fukuda Y; Azechi H; Nishimura T; Minata M; Kuno M; Nakao K
    IASL-APASL JOINT MEETING. 2000年06月 口頭発表(一般)
  • Vascular endotherial growth factor / vascular permeability factor (VEGF/VPF) in ascites from patients with liver disease.  [通常講演]
    Minata M; Nishida N; Nakao K; Komeda T; Fukuda Y
    70th Digestive Disease Week (DDW) 2000年05月 口頭発表(一般)
  • 特発性細菌性腹膜炎症例における腹水中VGEFの検討  [通常講演]
    皆田睦子; 久野雅人; 西村貴文; 松岡陽子; 西田直生志; 中尾一和; 福田善弘; 米田俊貴
    第97回内科学会総会 2000年04月 口頭発表(一般)
  • 肝細胞癌の遺伝子異常とその臨床的意義  [通常講演]
    西田直生志; 畦地英全; 西村貴文; 皆田睦子; 久野雅人; 猪飼伊和夫; 山岡善生; 中尾一和; 福田善弘
    第86回日本消化器病学会 2000年04月 口頭発表(一般)
  • 肝細胞癌の遺伝子異常とその臨床的意義  [通常講演]
    西田 直生志; 畦地 英全; 西村 貴文; 皆田 睦子; 久野 雅人; 猪飼 伊和夫; 山岡 義生; 中尾 一和; 福田 善弘
    日本消化器病学会雑誌 2000年03月
  • 硬化性胆管炎を合併したと考えられる自己免疫性膵炎1例  [通常講演]
    小池雄太; 荒牧 陽; 西田直生志; 畦地英全; 久野雅人; 西村貴文; 皆田睦子; 中尾一和; 瀧上雅博; 福田善弘
    第72回日本消化器学会近畿支部例会 2000年02月 口頭発表(一般)
  • 特発性細菌性腹膜炎症例における腹水中VEGFの検討  [通常講演]
    皆田 睦子; 久野 雅人; 西村 貴文; 畦地 英全; 松岡 陽子; 西田 直生志; 中尾 一和; 福田 善弘; 米田 俊貴
    日本内科学会雑誌 2000年02月
  • 特発性細菌性腹膜炎症例における腹水中VGEFの検討  [通常講演]
    皆田睦子; 西村貴文; 勝間寛和; 井上基; 畦地英全; 松岡陽子; 西田直生志; 中尾一和; 米田俊貴; 福田善弘
    第33回日本肝臓学会西部会 1999年12月 口頭発表(一般)
  • C型慢性肝炎に対するインターフェロンβ、α併用療法  [通常講演]
    勝間寛和; 西村貴文; 畦地英全; 井上基; 皆田睦子; 松岡陽子; 西田直生志; 中尾一和; 米田俊貴; 福田善弘
    第33回日本肝臓学会西部会 1999年12月 口頭発表(一般)
  • 脂肪肝を基盤に発生した肝細胞癌の3症例  [通常講演]
    西村貴文; 勝間寛和; 井上基; 畦地英全; 皆田睦子; 松岡陽子; 西田直生志; 中尾一和; 米田俊貴; 伊藤亨; 福田善弘
    第33回日本肝臓学会西部会 1999年12月 口頭発表(一般)
  • 肝細胞癌におけるp16INK4A遺伝子プロモーター領域のメチル化とp16、RB蛋白発現の検討  [通常講演]
    畦地英全; 西田直生志; 西村貴文; 勝間寛和; 皆田睦子; 松岡陽子; 中尾一和; 福田善弘
    第3回日本肝臓学会大会 1999年10月 口頭発表(一般)
  • 特発性細菌性腹膜炎症例における腹水中VEGFの検討  [通常講演]
    皆田 睦子; 西村 貴文; 勝間 寛和; 井上 基; 畦地 英全; 松岡 陽子; 西田 直生志; 中尾 一和; 米田 俊貴; 福田 善弘
    肝臓 1999年10月
  • 脂肪肝を基盤に発生した肝細胞癌の3症例  [通常講演]
    西村 貴文; 勝間 寛和; 井上 基; 畦地 英全; 皆田 睦子; 松岡 陽子; 西田 直生志; 中尾 一和; 米田 俊貴; 伊藤 亨
    肝臓 1999年10月
  • C型慢性肝炎に対するインターフェロンβ,α併用療法  [通常講演]
    勝間 寛和; 西村 貴文; 畦地 英全; 井上 基; 皆田 睦子; 松岡 陽子; 西田 直生志; 中尾 一和; 米田 俊貴; 福田 善弘
    肝臓 1999年10月
  • ヒト肝細胞癌におけるRB経路分子異常と臨床像  [通常講演]
    西田直生志; 畦地英全; 高橋怜; 西村貴文; 中尾一和; 福田善弘
    第58回日本癌学会総会 1999年09月 口頭発表(一般)
  • 肝細胞癌におけるp16INK4A遺伝子プロモーター領域のメチル化とp16,RBタンパク発現の検討  [通常講演]
    畦地 英全; 西田 直生志; 西村 貴文; 勝間 寛和; 皆田 睦子; 松岡 陽子; 中尾 一和; 福田 善弘
    肝臓 1999年09月
  • ヒト肝細胞癌におけるRB経路分子異常と臨床像  [通常講演]
    西田 直生志; 畦地 英全; 高橋 玲; 西村 貴文; 中尾 一和; 福田 善弘
    日本癌学会総会記事 1999年08月
  • 肝細胞癌におけるp15INK4B、p16INK4A伊遺伝子プロモーター領域のメチル化の検討  [通常講演]
    畦地英全; 西田直生志; 西村貴文; 勝間寛和; 井上基; 皆田睦子; 松岡陽子; 中尾一和; 福田善弘
    第35回日本肝臓学会総会 1999年06月 口頭発表(一般)
  • 肝細胞癌における血中AFPmRNAの検出と転移再発の関係  [通常講演]
    皆田睦子; 米田俊貴; 勝間寛和; 畦地英全; 西田直生志; 猪飼伊和夫; 中尾一和; 福田善弘
    第35回日本肝癌研究会 1999年06月 口頭発表(一般)
  • ヒト肝細胞癌におけるp53およびRB経路分子異常の意義  [通常講演]
    西田直生志; 畦地英全; 西村貴文; 勝間寛和; 皆田睦子; 中尾一和; 福田善弘
    第35回日本肝癌研究会 ワークショップ:肝癌に対する分子生物学的アプローチ 1999年06月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌におけるp15INK4B,p16INK4A遺伝子プロモーター領域のメチル化の検討  [通常講演]
    畦地 英全; 西田 直生志; 西村 貴文; 勝間 寛和; 井上 基; 皆田 睦子; 松岡 陽子; 中尾 一和; 福田 善弘
    肝臓 1999年05月
  • Molecular basis of HCC carcinogenesis.  [招待講演]
    Nishida N
    The 5th Congress of East-Asian CICD: Symposium 1: Recent advances in Hepatocellular Carcinoma 1999年04月 口頭発表(招待・特別)
  • 肝細胞癌の治療中に非ホジキンリンパ腫の発生をみたC型肝硬変の1症例  [通常講演]
    畦地英全; 勝間寛和; 皆田睦子; 井上 基; 松岡陽子; 西村貴文; 西田直生志; 中尾一和; 福田善弘
    第70回日本消化器学会近畿支部例会 1999年02月 口頭発表(一般)
  • 血中癌細胞の検出からみた肝細胞癌の転移再発とその予後に関する検討  [通常講演]
    皆田睦子; 米田俊貴; 西田直生志; 福田善弘
    第34回日本肝癌研究会 1998年10月 口頭発表(一般)
  • Hypomethylation of c-myc and c-fos genes in chronic hepatitis/liver cirrhosis and hepatocellular carcinoma  [通常講演]
    Nishida N; Fukuda Y; Kokuryu H; Nakao K
    11th World Congresses of Gastroenterology 1998年09月 口頭発表(一般)
  • 肝癌と遺伝子 遺伝子治療を含めて 肝細胞癌の遺伝子異常  [通常講演]
    西田 直生志; 福田 善弘
    肝臓 1998年07月
  • 慢性肝疾患における癌遺伝子の低メチル化  [通常講演]
    西田直生志; 西村貴文; 勝間寛和; 井上基; 畦地英全; 皆田睦子; 松岡陽子; 中尾一和; 福田善弘
    第95回日本内科学会総会 1998年04月 口頭発表(一般)
  • 慢性肝疾患における癌遺伝子の低メチル化  [通常講演]
    西田 直生志
    日本内科学会雑誌 1998年02月
  • 肝細胞癌の遺伝子異常  [招待講演]
    西田 直生志
    第7回臨床医のための肝臓分子病理セミナー 1998年01月 口頭発表(招待・特別)
  • 再生不良性貧血を合併した非A,非B,非C,非G型急性肝炎の一例  [通常講演]
    畦地英全; 西村貴文; 勝間寛和; 井上基; 皆田睦子; 松岡陽子; 米田俊貴; 佐々木豊; 西田直生志; 中尾一和; 福田善弘
    第32回日本肝臓学会西部会 1997年12月 口頭発表(一般)
  • 長期間経過観察しえたC型慢性肝疾患にBenign Monoclonal Gammopathyを合併した3症例  [通常講演]
    井上基; 勝間寛和; 畦地英全; 皆田睦子; 松岡陽子; 西村貴文; 米田俊貴; 西田直生志; 奥野芳章; 中尾一和; 福田善弘; 長町大志; 高橋玲; 寺尾秀一
    第32回日本肝臓学会西部会 1997年12月 口頭発表(一般)
  • 慢性肝疾患、肝細胞癌における血中Vascular Endothelial Growth Factor (VEGF)の測定とその意義  [通常講演]
    皆田睦子; 西村貴文; 井上基; 勝間寛和; 畦地英全; 松岡陽子; 西田直生志; 中尾一和; 福田善弘
    第32回日本肝臓学会西部会 1997年12月 口頭発表(一般)
  • Vascular endotherial growth factor / vascular permeability factor (VEGF/VPF) in ascites from patients with Hepatocellular carcinoma.  [通常講演]
    Minata M; Fukuda Y; Nishimura T; Katsuma H; Inoue M; Azechi H; Matsuoka Y; Komeda T; Nishida N; Ikemoto M; Nakao K
    48th American Association for the Study of Liver Diseases (AASLD) 1997年11月 口頭発表(一般)
  • Alteration of cell cycle related genes in human hepatocellular carcinom  [通常講演]
    Nishida N; Fukuda Y; Kita R; Nishimura T; Katsuma H; Inoue M; Azechi H; Minata, M; Matsuoka Y; Komeda T; Nakao K
    48th American Association for the Study of Liver Diseases (AASLD) 1997年11月 口頭発表(一般)
  • 肝硬変、肝細胞癌における胸、腹水中Vascular Endothelial Growth Factor (VEGF)/Vascular Permeability factor (VPF)の測定とその意義  [通常講演]
    皆田睦子; 米田俊貴; 西村貴文; 井上基; 勝間寛和; 畦地英全; 松岡陽子; 西田直生志; 中尾一和; 福田善弘
    第1回日本肝臓学会大会 1997年10月 口頭発表(一般)
  • 肝細胞癌の遺伝子異常  [通常講演]
    西田直生志; 福田善弘
    第1回日本肝臓学会大会 シンポジウム1:肝細胞癌と遺伝子 1997年10月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌における細胞周期制御遺伝子異常の相互関係  [通常講演]
    西田直生志; 勝間寛和; 井上基; 畦地英全; 皆田睦子; 松岡陽子; 米田俊貴; 喜多竜一; 中尾一和; 福田善弘
    第33回日本肝臓学会総会 1997年09月 口頭発表(一般)
  • 肝細胞癌の遺伝子異常  [通常講演]
    西田 直生志
    肝臓 1997年09月
  • 肝細胞癌における細胞周期制御遺伝子異常の相互関係  [通常講演]
    西田 直生志
    肝臓 1997年03月
  • 肝細胞癌の発生・進展に関わる遺伝子異常  [通常講演]
    西田直生志; 喜多竜一; 福田善弘; 中尾一和
    第66回日本消化器病学会近畿支部例会 シンポジウム1:消化器癌の病態と診断に対する分子生物学的アプローチ 1997年02月 シンポジウム・ワークショップパネル(公募)
  • IFN治療にて著効を得た後に肝細胞癌の発生をみた2例  [通常講演]
    米田俊貴; 勝間寛和; 井上基; 畦地英全; 皆田睦子; 吉永孝之; 松岡陽子; 西田直生志; 中尾一和; 福田善弘
    第31回日本肝臓学会西部会 1996年11月 口頭発表(一般)
  • 肝細胞癌と多臓器重複癌の検討、特に膵臓癌との同時重複の二症例  [通常講演]
    畦地英全; 勝間寛和; 井上基; 皆田睦子; 吉永孝之; 松岡陽子; 米田俊貴; 喜多竜一; 山東剛裕; 西田直生志; 中尾一和; 福田善弘
    第31回日本肝臓学会西部会 1996年11月 口頭発表(一般)
  • Intravenous Spreading of Hepatocellular Carcinoma Cells and Its Clinical Significance  [通常講演]
    Komeda T; Fukuda Y; Minata M; Azechi H; Yoshinaga T; Matsuoka Y; Nishida N; Nakao K
    47th American Association for the Study of Liver Disease (AASLD). 1996年10月 口頭発表(一般)
  • 肝発癌における細胞周期関連遺伝子変化の意義  [通常講演]
    西田直生志; 喜多竜一
    第37回日本消化器病学会大会 ワークショップ1:消化器癌と分子生物学 1995年11月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌患者血中におけるhAFPmRNA検出と臨床予後に関する検討  [通常講演]
    米田俊貴; 福田善弘; 松岡陽子; 喜多竜一; 山東剛裕; 西田直生志; 雨森正洋; 中尾一和
    第54回日本癌学会総会 1995年10月 口頭発表(一般)
  • 肝癌における細胞周期制御遺伝子(CDK4, p16, Cyclin D1) の異常についての検討  [通常講演]
    喜多竜一; 福田善弘; 西田直生志; 松岡陽子; 米田俊貴; 山東剛裕; 雨森正洋; 中尾一和; 石崎寛治
    第54回日本癌学会総会 1995年10月 口頭発表(一般)
  • 肝細胞癌の進展と細胞周期関連遺伝子の異常  [通常講演]
    西田直生志; 福田善弘; 喜多竜一; 山東剛裕; 米田俊貴; 松岡陽子; 雨森正洋; 中尾一和; 石崎寛治
    第54回日本癌学会総会 1995年10月 口頭発表(一般)
  • 肝細胞癌の進展と細胞周期関連遺伝子の異常  [通常講演]
    西田 直生志
    日本癌学会総会記事 1995年09月
  • 肝発癌における細胞周期関連遺伝子変化の意義  [通常講演]
    西田 直生志
    日本消化器病学会雑誌 1995年09月
  • 肝細胞癌•胆管癌におけるp16およびcyclin Eの遺伝子変化についての検討  [通常講演]
    喜多竜一; 西田直生志; 松岡陽子; 米田俊貴; 山東剛裕; 古川元庸; 雨森正洋; 福田善弘; 中尾一和; 石崎寛治
    第31回日本肝臓学会総会 1995年07月 口頭発表(一般)
  • B型肝炎の経過におけるHBVDNA及びPre-core mutant virus量測定の意義  [通常講演]
    喜多竜一; 福田善弘; 松岡陽子; 米田俊貴; 山東剛裕; 古川元庸; 西田直生志; 雨森正洋; 中尾一和; 申貞均
    第29回日本肝臓学会西部会 1994年12月 口頭発表(一般)
  • 針生検後の静脈血肝細胞遊離に関する検討:RT-PCR法を用いた研究  [通常講演]
    米田俊貴; 福田善弘; 松岡陽子; 喜多竜一; 山東剛裕; 古川元庸; 西田直生志; 雨森正洋; 中尾一和
    第29回日本肝臓学会西部会 1994年12月 口頭発表(一般)
  • 肝細胞癌におけるCDK,CDK4 inhibitor遺伝子の変化  [通常講演]
    喜多竜一; 西田直生志; 松岡陽子; 米田俊貴; 山東剛裕; 古川元庸; 福田善弘; 石崎寛治; 中尾一和
    第29回日本肝臓学会西部会 1994年12月 口頭発表(一般)
  • RT-PCR法におけるヒト末消血中AFP転写産物検出  [通常講演]
    米田俊貴; 福田善弘; 喜多竜一; 山東剛裕; 古川元庸; 西田直生志; 雨森正洋; 中尾一和
    第53回日本癌学会総会 1994年10月 口頭発表(一般)
  • ヒト肝細胞癌におけるサイクリンD1遺伝子の増幅と過剰発現  [通常講演]
    西田 直生志
    肝臓 1994年06月 口頭発表(一般)
  • Aberration of the p53 gene in human hepatocellular carcinoma in Japan  [通常講演]
    Nishida N; Fukuda Y; Komeda T; Sando T; Kita R; Furukawa M; Amenomori M; Nakao K
    International Association of Study of Liver Disease (IASL) CANCUN MEETING, 1994年05月 口頭発表(一般)
  • Sensitive detection of hepatoma-derived transcripts from human peripheral blood by reverse transcription-polymerase chain reaction  [通常講演]
    Komeda T; Fukuda Y; Sando T; Kita R; Furukawa M; Nishida N; Amenomori M; Nakao K
    International Association of Study of Liver Disease (IASL) CANCUN MEETING 1994年05月 口頭発表(一般)
  • ヒト肝細胞癌の遺伝子異常、悪性度、予後推定における遺伝子診断の可能性の検討  [通常講演]
    西田直生志; 福田善弘; 中尾一和
    第91回日本内科学会総会 1994年04月 口頭発表(一般)
  • 肝細胞癌の遺伝子異常と臨床像  [通常講演]
    西田直生志; 福田善弘
    第2回日本消化器関連学会週間(第80回日本消化器病学会総会) リサーチフォーラム7:分子生物学から見た肝発癌機構 1994年04月 シンポジウム・ワークショップパネル(公募)
  • ヒト肝細胞癌の遺伝子異常と臨床像  [通常講演]
    西田 直生志
    日本消化器病学会雑誌 1994年03月
  • Role and mutational heterogeneity of the p53 gene in hepatocellular  [通常講演]
    Nishida N; Fukuda Y; Ishizaki K; Nakao K
    Keystone Symposium: Tumor suppressor gene 1994年02月 口頭発表(一般)
  • ヒト肝細胞癌の癌遺伝子異常 悪性度,予後推定における遺伝子診断の可能性の検討  [通常講演]
    西田 直生志
    日本内科学会雑誌 1994年02月
  • 肝細胞癌の悪性度評価としての癌抑制遺伝子の検討  [通常講演]
    西田直生志; 福田善弘; 中尾一和
    第1回浜名湖シンポジウム シンポジウム1:遺伝子診断 1993年12月 シンポジウム・ワークショップパネル(公募)
  • 末消血中からの肝細胞癌の検出に関する検討  [通常講演]
    米田俊貴; 喜多竜一; 山東剛裕; 古川元庸; 西田直生志; 雨森正洋; 国立裕之; 福田善弘; 中尾一和
    第28回日本肝臓学会西部会 1993年11月 口頭発表(一般)
  • 急速な進行を示したSCC抗原産生肝癌の一症例とその樹立細胞株の性状  [通常講演]
    喜多竜一; 雨森正洋; 西田直生志; 古川元庸; 山東剛裕; 米田俊貴; 国立裕之; 福田善弘; 中尾一和
    第28回日本肝臓学会西部会 1993年11月 口頭発表(一般)
  • 肝細胞癌におけるp53遺伝子の異常  [通常講演]
    西田 直生志
    日本癌学会総会記事 1993年10月 口頭発表(一般)
  • Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human Hepatocellular carcinoma  [通常講演]
    Nishida N; Fukuda Y; Kokuryu H; Sadamoto T; Isowa G; Honda K; Yamaoka Y; Ikenaga M; Imura H; Ishizaki K
    International Association of Study of Liver Disease (IASL) Brighton MEETING 1993年06月 口頭発表(一般)
  • 肝細胞癌におけるp53遺伝子の異常  [通常講演]
    西田 直生志
    肝臓 1993年06月
  • C型慢性活動性肝炎に対するインターフェロン(IFN)治療における甲状腺機能異常について  [通常講演]
    雨森正洋; 森徹; 福田善弘; 須川秀夫; 西田直生志; 古川元庸; 喜多竜一; 山東剛裕; 米田俊貴; 中尾一和
    第29回日本肝臓学会総会 1993年05月 口頭発表(一般)
  • 肝細胞癌におけるp53遺伝子の異常  [通常講演]
    西田直生志; 石崎寛治; 福田善弘; 国立裕之; 井村裕夫
    第29回日本肝臓学会総会 1993年05月 口頭発表(一般)
  • 肝組織における糖輸送担体遺伝子発現の検討  [通常講演]
    雨森正洋; 米田俊貴; 山東剛裕; 喜多竜一; 古川元庸; 西田直生志; 藤本栄司; 国立裕之; 福田善弘; 福本学; 清野裕
    第79回日本消化器病学会総会 1993年03月 口頭発表(一般)
  • 肝細胞癌に膵癌を重複した一例  [通常講演]
    喜多竜一; 山東剛裕; 古川元庸; 西田直生志; 藤本栄司; 雨森正洋; 国立裕之; 福田善弘; 井村裕夫; 長谷川浩二; 嶋田俊秀
    第56回日本消化器病学会近畿支部例会 1993年01月 口頭発表(一般)
  • 良性肝疾患におけるAFP高値例の検討  [通常講演]
    山東剛裕; 喜多竜一; 古川元庸; 西田直生志; 藤本栄司; 雨森正洋; 国立裕之; 福田善弘; 井村裕夫
    第56回日本消化器病学会近畿支部例会 1993年01月 口頭発表(一般)
  • 慢性肝疾患患者における血中エリスロポイエチン濃度とその臨床的意義  [通常講演]
    喜多竜一; 山東剛裕; 古川元庸; 西田直生志; 雨森正洋; 藤本栄司; 米田俊貴; 国立裕之; 平井素子; 福田善弘; 井村裕夫
    第27回日本肝臓学会西部会 1992年11月 口頭発表(一般)
  • 慢性肝疾患における可溶性IL-2レセプター(IL-2Rα,FcεR2)の動態  [通常講演]
    古川元庸; 山東剛裕; 喜多竜一; 西田直生志; 雨森正洋; 藤本栄司; 米田俊貴; 平井素子; 国立裕之; 福田善弘; 井村裕夫; 内山卓
    第27回日本肝臓学会西部会 1992年11月 口頭発表(一般)
  • C型慢性肝炎にBenign Monoclonal Gammopathyを合併した3症例  [通常講演]
    藤本栄司; 米田俊貴; 山東剛裕; 喜多竜一; 古川元庸; 西田直生志; 雨森正洋; 国立裕之; 福田善弘; 井村裕夫
    第27回日本肝臓学会西部会 1992年11月 口頭発表(一般)
  • 肝細胞癌のヘテロ接合性の消失と癌抑制遺伝子の異常  [通常講演]
    西田 直生志
    日本癌学会総会記事 1992年09月 口頭発表(一般)
  • 肝細胞癌の進展における癌抑制遺伝子の異常  [通常講演]
    西田直生志; 石崎寛治; 福田善弘; 国立裕之; 井村裕夫
    第28回日本肝臓学会総会 要請演題1:肝疾患のゲノム診断 1992年06月 シンポジウム・ワークショップパネル(公募)
  • 肝細胞癌の進展における癌抑制遺伝子の異常  [通常講演]
    西田 直生志
    肝臓 1992年05月
  • 肝細胞癌におけるp53遺伝子突然変異と17p染色体欠失の解析  [通常講演]
    西田直生志; 福田善弘; 国立裕之; 雨森正洋; 藤本栄司; 古川元庸; 山東剛裕; 喜多竜一; 井村裕夫
    第78回日本消化器病学会総会 1992年04月 口頭発表(一般)
  • 多臓器不全を伴ったB型劇症肝炎の一救命例  [通常講演]
    古川元庸; 西田直生志; 露岡清隆; 藤本栄司; 国立裕之; 福田善弘; 井村裕夫
    第55回日本消化器病学会近畿支部例会 1992年03月 口頭発表(一般)
  • 肝細胞癌におけるp53遺伝子突然変異と17p染色体欠失の解析  [通常講演]
    西田 直生志
    日本消化器病学会雑誌 1992年02月
  • S-Adenosyl-L-Methionin(SAME)投与による肝炎、肝癌自然発症ラット肝腫瘍発生抑制の検討  [通常講演]
    国立裕之; 福田善弘; 西田直生志; 藤本栄司; 露岡清隆; 古川元庸; 喜多竜一; 山東剛裕; 井村裕夫
    第26回日本肝臓学会西部会 1991年11月 口頭発表(一般)
  • 肝細胞癌のRFLPによる染色体欠失の解析  [通常講演]
    西田直生志; 福田善弘; 国立裕之; 藤本栄司; 露岡清隆; 古川元庸; 喜多竜一; 山東剛裕; 井村裕夫
    第26回日本肝臓学会西部会 1991年11月 口頭発表(一般)
  • C型慢性肝炎に対するインターフェロン治療の経験  [通常講演]
    西田直生志; 福田善弘; 国立裕之; 雨森正洋; 藤本栄司; 露岡清隆; 古川元庸; 井村裕夫
    第53回日本消化会病学会西部会近畿支部例会 1991年09月 口頭発表(一般)
  • 肝細胞癌のRFLPによる染色体欠失の解析  [通常講演]
    西田 直生志
    肝臓 1991年09月
  • C型慢性肝炎に対するインターフェロン治療の経験  [通常講演]
    西田 直生志
    日本消化器病学会雑誌 1991年08月
  • 慢性肝炎の肝組織におけるIL-2α産生に関する免疫組織学的検討  [通常講演]
    古川元庸; 福田善弘; 福本学; 平井素子; 国立裕之; 雨森正洋; 藤本栄司; 西田直生志; 露岡清隆; 井村裕夫
    第27回日本肝臓学会総会 1991年05月 口頭発表(一般)
  • 胃5点生検からみた健常群、胃潰瘍群、十二指腸潰瘍群、胃十二指腸潰瘍合併群の粘膜状態の比較  [通常講演]
    小林久隆; 梶谷幸生; 前川高天; 金岡正樹; 西田直生志; 直木正雄; 佐竹弘; 清水一良; 粉川晧仲
    第77回日本消化器病学会総会 1991年03月 口頭発表(一般)
  • 肝細胞癌のRFLPによる染色体欠失の解析  [通常講演]
    西田直生志; 石崎寛治; 国立裕之; 福田善弘; 雨森正洋; 藤本栄司; 露岡清隆; 古川元庸; 井村裕夫
    第77回日本消化器病学会総会 1991年03月 口頭発表(一般)
  • 肝細胞癌のRFLPによる染色体欠失の解析  [通常講演]
    西田 直生志
    日本消化器病学会雑誌 1991年02月
  • 肝炎ウイルスの重感染:特にC型肝炎ウイルスに関連して  [通常講演]
    福田善弘; 国立裕之; 雨森正洋; 藤本栄司; 平井素子; 西田直生志; 露岡清隆; 古川元庸; 井村裕夫
    第25回日本肝臓学会西部会 1990年11月 口頭発表(一般)
  • 肝外症状を伴った非A非B型急性肝炎  [通常講演]
    雨森正洋; 福田善弘; 国立裕之; 藤本栄司; 平井素子; 西田直生志; 露岡清隆; 井村裕夫
    第25回日本肝臓学会西部会 1990年11月 口頭発表(一般)
  • 慢性肝疾患における血中ヒトインスリン様成長因子およびIGF結合蛋白の検討  [通常講演]
    西田直生志; 福田善弘; 露岡清隆; 雨森正洋; 藤本栄司; 平井素子; 国立裕之; 長谷寛二; 島津章; 井村裕夫
    第76回日本消化器病学会総会 1990年03月 口頭発表(一般)
  • 慢性肝疾患における血中ヒトインスリン様成長因子およびIGF結合蛋白の検討  [通常講演]
    西田 直生志
    日本消化器病学会雑誌 1990年02月
  • 胃5点生検からみた高齢者十二指腸潰瘍の胃炎について  [通常講演]
    西田直生志; 梶谷幸生; 前川高天; 金岡正樹; 直木正雄; 佐竹弘; 清水一良; 粉川晧仲
    第43回国立病院療養所総合医学会 1988年11月 口頭発表(一般)
  • 高コレステロール血症を呈しLp-TAEにより改善をみた肝細胞癌の1症例  [通常講演]
    西田直生志; 福田善弘; 瀬古修二; 平岩望; 長谷寛二; 井村裕夫
    第21回日本肝臓学会西部会 1987年12月 口頭発表(一般)
  • 高コレステロール血症を呈しLp-TAEにより改善をみた肝細胞癌の1症例  [通常講演]
    西田 直生志
    肝臓 1987年07月

MISC

  • 西田 直生志 日本がん検診・診断学会誌 31 (1) 98 -98 2023年06月
  • B型肝炎診療の未来予想図(現状と課題) 免疫チェックポイント阻害剤投与に伴うHBV再活性化および抗ウイルス効果についての検討
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 64 (Suppl.1) A51 -A51 2023年04月
  • 遺伝・代謝性肝疾患の未来予想図(現状と課題) Erythropoietic porphyria(EPP)関連肝障害における瀉血治療の有効性
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 64 (Suppl.1) A111 -A111 2023年04月
  • NASH/ASHの病態解明とTransrational Research 非アルコール性脂肪肝疾患におけるDNAメチル化に関連する臨床的・病理学的特徴
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 64 (Suppl.1) A208 -A208 2023年04月
  • 非硬変肝から発生したFontan術後HCCの1例
    有山 武尊; 萩原 智; 西田 直生志; 工藤 正俊 肝臓 64 (Suppl.1) A324 -A324 2023年04月
  • B型慢性肝炎患者に対するTAFの効果および安全性の検討
    萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 64 (Suppl.1) A425 -A425 2023年04月
  • 高アンモニア血症に対するレボカルニチン自体の効果について
    萩原 智; 盛田 真弘; 千品 寛和; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 64 (Suppl.1) A432 -A432 2023年04月
  • 切除不能HCCに対するABC conversion療法と造影超音波によるclinical CRの補助診断
    青木 智子; 南 康範; 依田 広; 千品 寛和; 田北 雅弘; 萩原 智; 上嶋 一臣; 鶴崎 正勝; 西田 直生志; 工藤 正俊 超音波医学 50 (Suppl.) S598 -S598 2023年04月
  • 【US Today 2023 超音波検査・診断最前線 腹部領域の最新動向を中心に】腹部領域の技術と臨床の最新動向 AI超音波診断の最新動向と今後の展望
    西田 直生志; 工藤 正俊 INNERVISION 38 (5) 40 -43 2023年04月
  • 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 120 (臨増総会) A36 -A36 2023年03月
  • 青木 智子; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 120 (臨増総会) A85 -A85 2023年03月
  • 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 120 (臨増総会) A36 -A36 2023年03月
  • 青木 智子; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 120 (臨増総会) A85 -A85 2023年03月
  • 【肝胆膵診療のDX(デジタルトランスフォーメーション)新時代】肝胆膵診療のデジタル化の現状 肝疾患診療における医用画像のデジタライゼーションと人工知能
    西田 直生志 肝胆膵 86 (2) 183 -189 2023年02月
  • 西田 直生志 Medical Technology 50 (12) 1266 -1269 2022年12月
  • 西田 直生志 近畿大学医学雑誌 47 (3-4) 53 -63 2022年12月
  • 西田 直生志 近畿大学医学雑誌 47 (3-4) 53 -63 2022年12月
  • 西田 直生志 Medical Technology 50 (12) 1266 -1269 2022年12月
  • 西田 直生志; 工藤 正俊 臨床消化器内科 37 (13) 1653 -1661 2022年11月
  • 西田 直生志; 工藤 正俊 臨床消化器内科 37 (13) 1653 -1661 2022年11月
  • 代謝性肝疾患の標準治療確立のためのエビデンス構築 NAFLD関連肝癌における背景肝のエピゲノム変異の蓄積
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.3) A654 -A654 2022年10月
  • B型慢性肝炎患者におけるETVとTAFの効果・安全性の比較
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.3) A768 -A768 2022年10月
  • 発症早期から進行期までを観察しえたirAE胆管炎の1例
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.3) A793 -A793 2022年10月
  • irAE腸炎による消化管穿孔に対してステロイド前のinfliximab先行投与により救命できた1例
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.3) A794 -A794 2022年10月
  • 超音波診断支援AIの開発と実装化における課題
    西田 直生志 Gastroenterological Endoscopy 64 (Suppl.2) 1870 -1870 2022年10月
  • 西田 直生志 日本消化器病学会雑誌 119 (臨増大会) A452 -A452 2022年10月
  • 西田 直生志 日本消化器病学会雑誌 119 (臨増大会) A452 -A452 2022年10月
  • 超音波診断支援AIの開発と実装化における課題
    西田 直生志 日本消化器がん検診学会雑誌 60 (Suppl大会) 916 -916 2022年10月
  • 超音波診断支援AIの開発と実装化における課題
    西田 直生志 日本消化器がん検診学会雑誌 60 (Suppl大会) 916 -916 2022年10月
  • 超音波診断支援AIの開発と実装化における課題
    西田 直生志 Gastroenterological Endoscopy 64 (Suppl.2) 1870 -1870 2022年10月
  • 肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果
    西田 直生志; 上嶋 一臣; 工藤 正俊 肝臓 63 (Suppl.2) A465 -A465 2022年09月
  • 超音波診断支援AIの開発と実装化における課題
    西田 直生志 肝臓 63 (Suppl.2) A467 -A467 2022年09月
  • 腹部超音波動画からの肝腫瘍検出AIシステムの開発
    目加田 慶人; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.2) A467 -A467 2022年09月
  • 進行肝癌の薬物治療の課題と展望 切除不能肝細胞癌におけるhyper progressive disease(HPD)の頻度と有効な後治療
    青木 智子; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.2) A537 -A537 2022年09月
  • 【肝の画像診断最前線】肝腫瘤診断における超音波AIの開発と社会実装
    西田 直生志 消化器・肝臓内科 12 (3) 352 -358 2022年09月
  • 肝細胞癌の微小環境と再発予防における免疫チェックポイント阻害剤の効果
    西田 直生志; 上嶋 一臣; 工藤 正俊 肝臓 63 (Suppl.2) A465 -A465 2022年09月
  • 超音波診断支援AIの開発と実装化における課題
    西田 直生志 肝臓 63 (Suppl.2) A467 -A467 2022年09月
  • 腹部超音波動画からの肝腫瘍検出AIシステムの開発
    目加田 慶人; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.2) A467 -A467 2022年09月
  • 進行肝癌の薬物治療の課題と展望 切除不能肝細胞癌におけるhyper progressive disease(HPD)の頻度と有効な後治療
    青木 智子; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.2) A537 -A537 2022年09月
  • 【肝の画像診断最前線】肝腫瘤診断における超音波AIの開発と社会実装
    西田 直生志 消化器・肝臓内科 12 (3) 352 -358 2022年09月
  • 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 肝細胞癌の新たな免疫クラス分類
    盛田 真弘; 西田 直生志; 工藤 正俊 肝胆膵 85 (3) 345 -353 2022年09月
  • 【進化する肝細胞癌の薬物療法:2022 update】免疫療法の基礎と臨床 Wnt/β-catenin変異を有するHCCの二面性(Inflamed and non-inflamed)
    青木 智子; 西田 直生志; 工藤 正俊 肝胆膵 85 (3) 369 -374 2022年09月
  • 【肝疾患における画像診断の進歩-腹部超音波、CT、MRI-】人工知能を応用した超音波画像診断
    西田 直生志; 工藤 正俊 消化器内科 4 (8) 36 -43 2022年08月
  • 【肝疾患における画像診断の進歩-腹部超音波、CT、MRI-】人工知能を応用した超音波画像診断
    西田 直生志; 工藤 正俊 消化器内科 4 (8) 36 -43 2022年08月
  • アノテーションが不完全な教師データを用いた腹部超音波画像からの肝腫瘍検出
    池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊 日本医用画像工学会大会予稿集 41回 192 -193 2022年07月
  • 西田 直生志 日本消化器病学会雑誌 119 (7) 626 -641 2022年07月
  • 西田 直生志 日本消化器病学会雑誌 119 (7) 626 -641 2022年07月
  • アノテーションが不完全な教師データを用いた腹部超音波画像からの肝腫瘍検出
    池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊 日本医用画像工学会大会予稿集 41回 192 -193 2022年07月
  • 非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例
    加藤 弘樹; 松井 繁長; 田北 雅弘; 上中 大地; 今村 瑞貴; 原 茜; 野村 健司; 瀬海 郁衣; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 本庶 元; 米田 頼晃; 上嶋 一臣; 渡邉 智裕; 西田 直生志; 辻 直子; 樫田 博史; 工藤 正俊 日本消化器内視鏡学会近畿支部例会プログラム・抄録集 108回 89 -89 2022年06月
  • 非代償性肝硬変による直腸静脈瘤出血に対して内視鏡的組織接着剤注入術を施行した1例
    加藤 弘樹; 松井 繁長; 田北 雅弘; 上中 大地; 今村 瑞貴; 原 茜; 野村 健司; 瀬海 郁衣; 高田 隆太郎; 河野 匡志; 正木 翔; 永井 知行; 本庶 元; 米田 頼晃; 上嶋 一臣; 渡邉 智裕; 西田 直生志; 辻 直子; 樫田 博史; 工藤 正俊 日本消化器内視鏡学会近畿支部例会プログラム・抄録集 108回 89 -89 2022年06月
  • 肝がんのマネジメント-発がん予防・内科治療・外科治療・再発予防 Phase 2根治後NIVOLVE試験における奏効症例の特徴
    青木 智子; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.1) A35 -A35 2022年04月
  • 治療起因性肝障害のマネジメント-DILI・HBV再活性化・irAE・IRIS 免疫チェックポイント阻害剤投与に伴うirAE肝障害・HBV再活性化についての検討
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.1) A95 -A95 2022年04月
  • 【革新的技術が変える肝疾患診療】AIによる超音波診断
    西田 直生志; 工藤 正俊 消化器・肝臓内科 11 (4) 465 -474 2022年04月
  • 肝がんのマネジメント-発がん予防・内科治療・外科治療・再発予防 Phase 2根治後NIVOLVE試験における奏効症例の特徴
    青木 智子; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.1) A35 -A35 2022年04月
  • 治療起因性肝障害のマネジメント-DILI・HBV再活性化・irAE・IRIS 免疫チェックポイント阻害剤投与に伴うirAE肝障害・HBV再活性化についての検討
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 63 (Suppl.1) A95 -A95 2022年04月
  • 西田 直生志; 上嶋 一臣; 工藤 正俊 日本消化器病学会雑誌 119 (臨増総会) A41 -A41 2022年03月
  • 萩原 智; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 119 (臨増総会) A214 -A214 2022年03月
  • 西田 直生志; 上嶋 一臣; 工藤 正俊 日本消化器病学会雑誌 119 (臨増総会) A41 -A41 2022年03月
  • 萩原 智; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 119 (臨増総会) A214 -A214 2022年03月
  • 肝炎ウイルスコントロール下における課題へのアプローチ ICI投与とHBVフォローにおける問題点
    盛田 真弘; 萩原 智; 西田 直生志; 工藤 正俊 日本消化器病学会近畿支部例会プログラム・抄録集 116回 73 -73 2022年02月
  • 免疫チェックポイント阻害剤をめぐる諸問題 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討
    萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会近畿支部例会プログラム・抄録集 116回 79 -79 2022年02月
  • 上・下腸間膜動静脈奇形に伴う門脈圧亢進からの難治性腹水及び循環血液量低下に伴う血圧低下に対し血管内治療(IVR)にて改善しえた1例
    上原 広樹; 田北 雅弘; 杉森 啓伸; 岡井 夏輝; 野村 健司; 盛田 真弘; 千品 寛和; 青木 智子; 萩原 智; 依田 広; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会近畿支部例会プログラム・抄録集 116回 88 -88 2022年02月
  • 大丸直哉; 田北雅弘; 浦瀬篤史; 千品寛和; 青木智子; 萩原智; 依田広; 上嶋一臣; 鶴崎正勝; 鶴崎正勝; 西田直生志; 工藤正俊 リザーバー&ポート研究会プログラム・抄録集 46th 2022年
  • 【AIの足音は肝胆膵診療に聞こえてきたか!】肝臓学とAI 超音波画像でのAIを用いた肝腫瘤検出と鑑別診断
    西田 直生志; 山川 誠; 目加田 慶人; 椎名 毅; 工藤 正俊 肝胆膵 84 (1) 37 -45 2022年01月
  • 【AIの足音は肝胆膵診療に聞こえてきたか!】肝臓学とAI AIを用いたHCCに対するTKIの効果予測
    池田 裕亮; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊 肝胆膵 84 (1) 63 -68 2022年01月
  • ATP-binding cassette transporter G2(ABCG2)の発現低下はerythropoietic porphyria(EPP)における肝障害の重症化と関連する
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 62 (Suppl.3) A737 -A737 2021年11月
  • Segmental arterial mediolysis(SAM)に伴う肝動脈瘤破裂に対して肝動脈塞栓術を施行した1例
    加藤 弘樹; 千品 寛和; 瀬海 郁衣; 盛田 真弘; 青木 智子; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 62 (Suppl.3) A824 -A824 2021年11月
  • 超音波画像ナショナルデータベース構築とAI支援による次世代超音波診断システムの実用化
    工藤 正俊; 西田 直生志; 椎名 毅 医療情報学連合大会論文集 41回 176 -180 2021年11月
  • 超音波画像ビッグデータベース構築とAIによる超音波診断支援 超音波AIの社会実装に向けて
    西田 直生志 日本超音波医学会関西地方会学術集会 48回 42 -42 2021年10月
  • 超音波画像ビッグデータベース構築とAIによる超音波診断支援 超音波AIの社会実装に向けて
    西田 直生志 日本超音波医学会関西地方会学術集会 48回 42 -42 2021年10月
  • 腹部超音波スクリーニング支援のための深層学習による撮影断面推定に関する初期検討
    目加田 慶人; 道満 恵介; 小川 眞広; 西田 直生志; 工藤 正俊 日本医用画像工学会大会予稿集 40回 301 -303 2021年10月
  • 盛田 真弘; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 118 (臨増大会) A535 -A535 2021年10月
  • 盛田 真弘; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 118 (臨増大会) A535 -A535 2021年10月
  • 腹部超音波スクリーニング支援のための深層学習による撮影断面推定に関する初期検討
    目加田 慶人; 道満 恵介; 小川 眞広; 西田 直生志; 工藤 正俊 日本医用画像工学会大会予稿集 40回 301 -303 2021年10月
  • B-mode超音波検査による肝腫瘍検出・診断を支援するAIモデルの開発
    西田 直生志; 工藤 正俊 肝臓 62 (Suppl.2) A457 -A457 2021年09月
  • 薬物性肝障害の実態 免疫チェックポイント阻害剤投与後に発現した肝障害の臨床的、病理学的検討
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 62 (Suppl.2) A515 -A515 2021年09月
  • Gd-EOB-DTPA-enhanced MRI肝細胞相で高信号の肝細胞癌は、PD-1/PD-L1療法への一次耐性を反映し予後不良である
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊 肝臓 62 (Suppl.2) A552 -A552 2021年09月
  • 工藤 正俊; 青木 智子; 上嶋 一臣; 西田 直生志 肝胆膵 83 (3) 475 -483 2021年09月
  • 青木 智子; 西田 直生志; 上嶋 一臣; 祖父江 慶太郎; 鶴崎 正勝; 工藤 正俊 肝胆膵 83 (2) 209 -218 2021年08月
  • 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 WNT/β-catenin経路の活性化と免疫療法の効果
    盛田 真弘; 西田 直生志; 工藤 正俊 肝胆膵 83 (2) 197 -207 2021年08月
  • 【ここまできた肝細胞癌の薬物療法:2021 update】免疫療法の動向 WNT/β-catenin変異のimaging biomarkerとしてのEOB-MRI
    青木 智子; 西田 直生志; 上嶋 一臣; 祖父江 慶太郎; 鶴崎 正勝; 工藤 正俊 肝胆膵 83 (2) 209 -218 2021年08月
  • 進行肝癌に対する薬物治療法の新たな展開 肝細胞癌における腫瘍免疫環境と抗PD-1抗体有効群の選別
    盛田 真弘; 西田 直生志; 工藤 正俊 肝臓 62 (Suppl.1) A20 -A20 2021年04月
  • 肝癌に対する局所療法(肝切除、アブレーション、TACE、他)の最前線 US-US overlay fusionガイドを用いたラジオ波焼灼術の最前線
    南 康範; 西田 直生志; 工藤 正俊 肝臓 62 (Suppl.1) A179 -A179 2021年04月
  • 肝癌の基礎研究と臨床応用 Gd-EOB-DTPA-enhanced MRI肝細胞相はPD-1/PD-L1抗体単独療法の非侵襲的なバイオマーカーである
    青木 智子; 西田 直生志; 工藤 正俊 肝臓 62 (Suppl.1) A187 -A187 2021年04月
  • 肝疾患におけるビックデータとAI(人工知能)の臨床応用 機械学習を用いた進行肝癌に対するチロシンキナーゼ阻害剤の効果予測の試み
    池田 裕亮; 目加田 慶人; 西田 直生志 肝臓 62 (Suppl.1) A202 -A202 2021年04月
  • 肝疾患におけるビックデータとAI(人工知能)の臨床応用 超音波画像ビッグデータベース構築と腹部超音波B-mode検査における肝腫瘍検出のAI支援
    西田 直生志; 目加田 慶人; 工藤 正俊 肝臓 62 (Suppl.1) A203 -A203 2021年04月
  • 消化器領域におけるAI研究の進歩 腹部超音波B-modeでの肝腫瘤検出・診断支援システムの開発
    西田 直生志; 工藤 正俊 日本消化器病学会雑誌 118 (臨増総会) A28 -A28 2021年03月
  • 消化器領域におけるAI研究の進歩 腹部超音波B-modeでの肝腫瘤検出・診断支援システムの開発
    西田 直生志; 工藤 正俊 日本消化器病学会雑誌 118 (臨増総会) A28 -A28 2021年03月
  • 青木 智子; 西田 直生志 日本臨床 別冊 (肝・胆道系症候群II) 292 -294 2021年02月
  • 西田 直生志; 工藤 正俊 肝臓 61 (12) 623 -636 2020年12月 [査読有り][招待有り]
  • 進歩する化学療法時代に注意すべき肝細胞癌の遠隔転移
    吉田 早希; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊 肝臓 61 (Suppl.3) A924 -A924 2020年11月
  • 難治性腹水に対するデンバーシャント術の試み
    家村 郁衣; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊 肝臓 61 (Suppl.3) A946 -A946 2020年11月
  • 進行肝癌に対する免疫チェックポイント阻害薬後レンバチニブ療法の画像評価
    青木 智子; 依田 広; 盛田 真弘; 南 知宏; 田北 雅弘; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊 超音波医学 47 (Suppl.) S167 -S167 2020年11月
  • 鑑別診断において造影超音波が有用であった多血性の肝内胆管癌の1例
    盛田 真弘; 南 康範; 青木 智子; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 超音波医学 47 (Suppl.) S275 -S275 2020年11月
  • 超音波画像ビッグデータベース構築とAI支援肝腫瘍検出・診断システムの開発 AMED臨床研究等ICT基盤構築・人工知能実装研究事業での取り組み
    西田 直生志; 山川 誠; 椎名 毅; 目加田 慶人; 工藤 正俊 超音波医学 47 (Suppl.) S544 -S544 2020年11月
  • 青木 智子; 南 康範; 鶴崎 正勝; 盛田 真弘; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 松井 繁長; 西田 直生志; 樫田 博史; 工藤 正俊 日本門脈圧亢進症学会雑誌 26 (4) 244 -248 2020年11月
  • 進歩する化学療法時代に注意すべき肝細胞癌の遠隔転移
    吉田 早希; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊 肝臓 61 (Suppl.3) A924 -A924 2020年11月
  • 難治性腹水に対するデンバーシャント術の試み
    家村 郁衣; 青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 鶴崎 正勝; 西田 直生志; 工藤 正俊 肝臓 61 (Suppl.3) A946 -A946 2020年11月
  • 食道・胃静脈瘤治療の現状と今後の展望 B-RTOにおける奏効率向上の工夫と肝予備能の温存
    青木 智子; 鶴崎 正勝; 小田 晃義; 沼本 勲男; 柳生 行伸; 田北 雅弘; 萩原 智; 南 康範; 上嶋 一臣; 依田 広; 西田 直生志; 松井 繁長; 樫田 博史; 工藤 正俊 日本門脈圧亢進症学会雑誌 26 (3) 69 -69 2020年10月
  • 西田 直生志; 盛田 真弘; 工藤 正俊 日本消化器病学会雑誌 117 (臨増大会) A513 -A513 2020年10月
  • 鑑別診断に造影超音波が有用であった多血性の肝内胆管癌の1例
    吉田 早希; 南 康範; 盛田 真弘; 青木 智子; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会近畿支部例会プログラム・抄録集 113回 103 -103 2020年10月
  • 【肝細胞癌治療のパラダイムチェンジ-進化する薬物療法2020 Update Part I-(免疫療法)】免疫療法の基礎 肝細胞癌における微小免疫環境と免疫チェックポイント阻害剤
    西田 直生志; 工藤 正俊 肝・胆・膵 81 (4) 643 -650 2020年10月
  • 鑑別診断に造影超音波が有用であった多血性の肝内胆管癌の1例
    吉田 早希; 南 康範; 盛田 真弘; 青木 智子; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会近畿支部例会プログラム・抄録集 113回 103 -103 2020年10月
  • 肝癌診療の現状と未来 肝細胞癌における腫瘍免疫環境と癌関連分子の遺伝子変異
    西田 直生志; 盛田 真弘; 工藤 正俊 日本消化器病学会雑誌 117 (臨増大会) A513 -A513 2020年10月
  • 全身化学療法により生存利益を得られる切除不能C型肝細胞癌の特徴
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊 肝臓 61 (Suppl.2) A647 -A647 2020年09月
  • 切除不能肝細胞癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ二次療法
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊 肝臓 61 (Suppl.2) A654 -A654 2020年09月
  • 全身化学療法により生存利益を得られる切除不能C型肝細胞癌の特徴
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊 肝臓 61 (Suppl.2) A647 -A647 2020年09月
  • 切除不能肝細胞癌に対する免疫チェックポイント阻害薬不応後のレンバチニブ二次療法
    青木 智子; 上嶋 一臣; 盛田 真弘; 千品 寛和; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 西田 直生志; 鶴崎 正勝; 工藤 正俊 肝臓 61 (Suppl.2) A654 -A654 2020年09月
  • 山川 誠; 椎名 毅; 西田 直生志; 工藤 正俊 日本音響学会誌 76 (12) 706 -711 2020年09月 [招待有り]
  • 西田 直生志; 山川 誠; 椎名 毅; 工藤 正俊 臨床消化器内科 35 (9) 1166 -1174 2020年08月
  • AIによる肝腫瘤検出・判別支援システムの開発-超音波とAI
    西田 直生志; 山川 誠; 椎名 毅; 工藤 正俊 臨床消化器内科 増刊号-これ一冊でわかる消化器超音波検査 35 (9) 278 -286 2020年08月 [招待有り]
  • 西田 直生志; 工藤 正俊 臨床検査 64 (8) 850 -857 2020年08月 [招待有り]
  • 大塚 康生; 青木 智子; 南 知宏; 田北 雅弘; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 117 (臨増総会) A291 -A291 2020年07月
  • B型慢性肝炎患者(CH-B)に対する,ETVとTAFの前向き比較観察研究
    萩原 智; 盛田 真弘; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 61 (Suppl.1) A423 -A423 2020年04月
  • 画像診断の新展開 人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援
    西田 直生志; 工藤 正俊 肝臓 61 (Suppl.1) A203 -A203 2020年04月
  • 画像診断の新展開 人工知能を用いた腹部超音波からのリアルタイム肝腫瘤検出支援
    西田 直生志; 工藤 正俊 肝臓 61 (Suppl.1) A203 -A203 2020年04月
  • B型慢性肝炎患者(CH-B)に対する,ETVとTAFの前向き比較観察研究
    萩原 智; 盛田 真弘; 青木 智子; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 61 (Suppl.1) A423 -A423 2020年04月
  • 盛田 真弘; 西田 直生志 肝胆膵 80 (4) 617 -627 2020年04月
  • Masatoshi Kudo; Kazuomi Ueshima; Stephen Lam Chan; Tomoko Aoki; Satoru Hagiwara; Yasunori Minami; Hiroshi Ida; Mamoru Takenaka; Tomohiro Watanabe; Masahiro Morita; Chikara Ogawa; Yoshiyuki Wada; Masafumi Ikeda; Hiroshi Ishii; Namiki Izumi; Atsushi Hiraoka; Hiroshi Aikata; Naoshi Nishida JOURNAL OF CLINICAL ONCOLOGY 38 (4) 2020年02月
  • 青木智子; 依田広; 盛田真弘; 南知宏; 田北雅弘; 萩原智; 南康範; 上嶋一臣; 西田直生志; 工藤正俊 超音波医学 Supplement 47 2020年
  • 大塚康生; 青木智子; 南知宏; 田北雅弘; 萩原智; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊 日本消化器病学会雑誌(Web) 117 2020年
  • 椎名毅; 山川誠; 西田直生志; 工藤正俊 日本音響学会研究発表会講演論文集(CD-ROM) 2020 2020年
  • 【肝胆膵領域のゲノム医療新時代-遺伝子パネルがやってきた!-】肝臓 肝癌のゲノム多様性と個別化医療
    盛田 真弘; 西田 直生志 肝・胆・膵 79 (6) 1061 -1067 2019年12月 [招待有り]
  • 鑑別診断において造影超音波が有用であった多血性の肝内胆管癌(腫瘤形成型)の1例
    友岡 瑞樹; 盛田 真弘; 南 康範; 依田 広; 南 知宏; 青木 智子; 田北 雅弘; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 60 (Suppl.3) A926 -A926 2019年11月
  • 鑑別診断において造影超音波が有用であった多血性の肝内胆管癌(腫瘤形成型)の1例
    友岡 瑞樹; 盛田 真弘; 南 康範; 依田 広; 南 知宏; 青木 智子; 田北 雅弘; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 60 (Suppl.3) A926 -A926 2019年11月
  • Naoshi Nishida; Makoto Yamakawa; Tsuyoshi Shiina; Masatoshi Kudo HEPATOLOGY 70 1211A -1212A 2019年10月
  • Deep neural networkを用いた超音波デジタル画像における肝腫瘍病名判別の試み
    西田 直生志; 工藤 正俊 肝臓 60 (Suppl.2) A566 -A566 2019年10月
  • Deep neural networkを用いた超音波デジタル画像における肝腫瘍病名判別の試み
    西田 直生志; 工藤 正俊 肝臓 60 (Suppl.2) A566 -A566 2019年10月 [招待有り]
  • 西田 直生志 消化器・肝臓内科 6 (4) 346 -354 2019年10月 [招待有り]
  • 難治性腹水に対して行われたデンバーシャント術の報告
    青木 智子; 田北 雅弘; 大塚 康生; 南 知宏; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 鶴崎 正勝; 工藤 正俊 日本門脈圧亢進症学会雑誌 25 (3) 146 -146 2019年09月
  • 難治性腹水に対して行われたデンバーシャント術の報告
    青木 智子; 田北 雅弘; 大塚 康生; 南 知宏; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 鶴崎 正勝; 工藤 正俊 日本門脈圧亢進症学会雑誌 25 (3) 146 -146 2019年09月
  • 深層学習による超音波画像からの肝腫瘍検出に関する初期的検討
    堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊 日本医用画像工学会大会予稿集 38回 48 -48 2019年07月
  • 深層学習による超音波画像からの肝腫瘍検出に関する初期検討
    堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正敏 日本医用画像工学会大会予稿集 38回 391 -394 2019年07月
  • 深層学習による超音波画像からの肝腫瘍検出に関する初期的検討
    堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正俊 日本医用画像工学会大会予稿集 38回 48 -48 2019年07月
  • 深層学習による超音波画像からの肝腫瘍検出に関する初期検討
    堤 一晴; 中島 崇博; 道満 恵介; 目加田 慶人; 西田 直生志; 工藤 正敏 日本医用画像工学会大会予稿集 38回 391 -394 2019年07月
  • 南 康範; 南 知宏; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓クリニカルアップデート 5 (1) 39 -42 2019年05月
  • 南 康範; 南 知宏; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓クリニカルアップデート 5 (1) 39 -42 2019年05月
  • AI:超音波診断の近未来 超音波画像データベース構築の推進と展望
    西田 直生志; 工藤 正俊 超音波医学 46 (Suppl.) S187 -S187 2019年04月
  • 鎌田 研; 千葉 康敬; 渡邉 智裕; 櫻井 俊治; 西田 直生志; 筑後 考章; 松本 逸平; 竹山 宜典; 北野 雅之; 工藤 正俊; 竹中 完; 三長 孝輔; 大本 俊介; 宮田 剛; 山雄 健太郎; 今井 元; 中井 敦史; 田中 秀和 日本消化器内視鏡学会雑誌 61 (4) 417 -426 2019年
  • 鎌田 研; 竹中 完; 石川 嶺; 吉川 智恵; 岡本 彩那; 山崎 友裕; 中井 敦史; 大本 俊介; 三長 孝輔; 山雄 健太郎; 櫻井 俊治; 松井 繁長; 渡邉 智裕; 西田 直生志; 樫田 博史; 工藤 正俊 胃と腸 53 (13) 1795 -1799 2018年12月
  • 南 康範; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝胆膵 77 (6) 1139 -1144 2018年12月
  • PD-L1陽性肝癌の臨床病理学的特徴と免疫環境に関する解析
    西田 直生志; 工藤 正俊 The Liver Cancer Journal 10 (Suppl.2) 31 -33 2018年12月
  • 【慢性炎症から肝胆膵癌にいたるランドスケープ】 慢性炎症と肝胆膵癌への展望
    正宗 淳; 坂本 直哉; 古川 徹; 西田 直生志 肝・胆・膵 77 (3) 695 -705 2018年09月 [招待有り]
  • 正宗 淳; 坂本 直哉; 古川 徹; 西田 直生志 肝胆膵 77 (3) 695 -705 2018年09月 [招待有り]
  • 田北 雅弘; 南 知宏; 千品 寛和; 河野 匡志; 萩原 智; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 消化器内視鏡 30 (8) 1086 -1089 2018年08月
  • 全 陽; 西田 直生志; 千葉 哲博; 田中 真二 肝胆膵 76 (5) 953 -964 2018年05月 [招待有り]
  • 肝臓 治療 安全かつ確実なRFA治療を目指した超音波技術の工夫 US-US image overlay fusionを用いたラジオ波焼灼術の有用性 従来治療との比較
    南 康範; 南 知宏; 千品 寛和; 田北 雅弘; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 超音波医学 45 (Suppl.) S327 -S327 2018年04月
  • 肝癌治療の新展開 遺伝子変化に基づいた肝細胞癌の分子スコアリングと転移再発
    西田 直生志; 海道 利実; 工藤 正俊 肝臓 59 (Suppl.1) A73 -A73 2018年04月
  • 肝炎ウイルスの制御が肝癌診療に及ぼす影響 慢性C型肝炎のDAA投与例におけるSVR後のAFP、ALT異常及び肝発癌に関する検討
    河野 匡志; 西田 直生志; 工藤 正俊 肝臓 59 (Suppl.1) A259 -A259 2018年04月
  • 肝癌診療up to date US-US image overlay fusionを用いたラジオ波焼灼術の早期治療効果判定
    南 康範; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 115 (臨増総会) A46 -A46 2018年03月
  • C型肝炎に対する初回インターフェロンフリー治療不成功例の臨床的特徴
    吉田 晃浩; 萩原 智; 南 知宏; 千品 寛和; 河野 匡; 田北 雅弘; 依田 広; 上嶋 一臣; 南 康範; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 115 (臨増総会) A308 -A308 2018年03月
  • C型肝炎に対するダクラタスビル・アスナプレビル治療奏功後肝発癌についての臨床的特徴
    田中 秀和; 萩原 智; 南 知宏; 千品 寛和; 河野 匡志; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 115 (臨増総会) A312 -A312 2018年03月
  • 南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 矢田 典久; 萩原 智; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 59 (2) 142 -144 2018年02月
  • 吉田晃浩; 萩原智; 南知宏; 千品寛和; 河野匡; 田北雅弘; 依田広; 上嶋一臣; 南康範; 西田直生志; 工藤正俊 日本消化器病学会雑誌(Web) 115 2018年
  • 田中秀和; 萩原智; 南知宏; 千品寛和; 河野匡志; 田北雅弘; 南康範; 依田広; 上嶋一臣; 西田直生志; 工藤正俊 日本消化器病学会雑誌(Web) 115 2018年
  • DAA投与におけるSVR後のAFP異常値と関連する臨床背景の検討
    河野 匡志; 西田 直生志; 千品 寛和; 南 知宏; 有住 忠晃; 田北 雅弘; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 工藤 正俊 肝臓 58 (Suppl.3) A801 -A801 2017年11月
  • 胃への遠隔転移を認めた肝細胞癌の一例
    福永 朋洋; 萩原 智; 半田 康平; 高田 隆太郎; 岡本 彩那; 南 知宏; 河野 匡志; 千品 寛和; 有住 忠晃; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 58 (Suppl.3) A934 -A934 2017年11月
  • 真性多血症にBudd-Chiari症候群を伴った1例
    高田 隆太郎; 萩原 智; 福永 朋洋; 半田 康平; 岡本 彩那; 南 知宏; 河野 匡志; 千品 寛和; 有住 忠晃; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 58 (Suppl.3) A940 -A940 2017年11月
  • 腹壁静脈瘤破裂に対し直接穿刺にて硬化療法を施行した2例
    半田 康平; 萩原 智; 福永 明洋; 高田 隆太郎; 岡本 彩那; 南 知宏; 河野 匡志; 千品 寛和; 有住 忠晃; 田北 雅弘; 南 康範; 依田 広; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 58 (Suppl.3) A943 -A943 2017年11月
  • Naoshi Nishida; Masatoshi Kudo HEPATOLOGY 66 87A -87A 2017年10月
  • 肝細胞癌治療における免疫チェックポイント阻害剤
    西田 直生志 Medical Science Digest 43 (7) 328 -330 2017年06月
  • US-US overlay image fusionを用いたラジオ波焼灼術の有用性 従来法との比較
    南 康範; 西田 直生志; 工藤 正俊 肝臓 58 (Suppl.1) A348 -A348 2017年04月
  • DAA投与におけるSVR後のAFP及びALT異常値と関連する臨床背景の検討
    河野 匡志; 西田 直生志; 南 知宏; 千品 寛和; 有住 忠晃; 田北 雅弘; 依田 広; 矢田 典久; 南 康範; 萩原 智; 上嶋 一臣; 工藤 正俊 肝臓 58 (Suppl.1) A314 -A314 2017年04月
  • 肝発癌メカニズムのパラダイムシフトとこれからの展望 PD-L1陽性肝癌の臨床病理学的特徴と遺伝子変異プロファイル
    西田 直生志; 工藤 正俊 日本消化器病学会雑誌 114 (臨増総会) A64 -A64 2017年03月
  • 肝画像診断の進歩 US-US image fusionを用いた肝細胞癌へのラジオ波焼灼術の有用性
    南 康範; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 114 (臨増総会) A202 -A202 2017年03月
  • T. Arizumi; K. Ueshima; M. Iwanishi; H. Chishina; M. Kono; M. Takita; S. Kitai; T. Inoue; N. Yada; S. Hagiwara; H. Ida; Y. Minami; T. Sakurai; N. Nishida; M. Kitano; M. Kudo DIGESTIVE DISEASES 35 (6) 625 -626 2017年
  • B型肝炎治療のアップデート エンテカビルとPEG-IFNα2a/2b 48週併用療法の効果および治療効果予測因子の検討
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 57 (Suppl.2) A509 -A509 2016年09月
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo Hepatology 64 (1) 306 2016年07月
  • Satoru Hagiwara; Naoshi Nishida; Masatoshi Kudo Hepatology 63 (5) 1744 -1745 2016年05月
  • 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 113 (5) 775 -784 2016年05月
  • NASH関連肝発癌における線維化進展と遺伝子変化
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 57 (Suppl.1) A309 -A309 2016年04月
  • HCCに対するDEB-TACE時に発生したVascular lakeの検討
    沼本 勲男; 鶴崎 正勝; 渡口 真史; 日高 正二朗; 山川 美帆; 任 誠雲; 柳生 行伸; 村上 卓道; 田北 雅弘; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊; 朝戸 信行 IVR: Interventional Radiology 31 (Suppl.) 156 -156 2016年04月
  • ダクラタスビル/アスナプレビル併用療法の治療効果と安全性
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 56 (Suppl.3) A935 -A935 2015年11月
  • 肝細胞癌に対してUS-US fusionを用いたラジオ波焼灼術
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 56 (Suppl.2) A739 -A739 2015年09月
  • 転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 112 (臨増大会) A871 -A871 2015年09月
  • 肝発癌研究と臨床への展開 分子生物学的特徴に基づいた肝癌のマネージメント
    西田 直生志; 海道 利実; 工藤 正俊 肝臓 56 (Suppl.1) A18 -A18 2015年04月
  • 肝細胞癌の亜分類と個別化医療 血清中マイクロRNAプロファイルとソラフェニブに対する肝細胞癌の反応性予測
    西田 直生志; 工藤 正俊 肝臓 56 (Suppl.1) A102 -A102 2015年04月
  • 肝病態を反映する新たなバイオマーカーの探索 変異型HBx遺伝子の肝発癌促進における分子機序の解明
    萩原 智; 西田 直生志; 工藤 正俊 肝臓 56 (Suppl.1) A126 -A126 2015年04月
  • intermediate stageの肝細胞癌に対してTACE不応後のTACE継続とソラフェニブの検討
    有住 忠晃; 上嶋 一臣; 南 知宏; 千品 寛和; 河野 匡志; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊 肝臓 56 (Suppl.1) A524 -A524 2015年04月
  • 転移性肝癌に対してUS-US fusionを用いたラジオ波焼灼術
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 56 (Suppl.1) A326 -A326 2015年04月
  • Navigationに基づいた肝細胞癌IVR治療の最前線 肝細胞癌に対してUS-US Fusionを用いたラジオ波焼灼術
    南 康範; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 112 (臨増総会) A222 -A222 2015年03月
  • トルバプタンの治療効果における予測因子の検討
    千品 寛和; 井上 達夫; 南 知宏; 河野 匡志; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 112 (臨増総会) A364 -A364 2015年03月
  • 西田 直生志; 工藤 正俊 日本臨床 73 (増刊1 最新肝癌学) 164 -169 2015年01月
  • NBNC肝がんの諸問題 NBNC肝癌の背景肝におけるメチル化プロファイルと加齢および糖尿病の影響
    西田 直生志; 工藤 正俊 肝臓 55 (Suppl.2) A528 -A528 2014年09月
  • B-modeで描出困難な肝癌に対するFusion imaging+造影USガイドでのラジオ波焼灼術
    南 知宏; 南 康範; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 55 (Suppl.2) A605 -A605 2014年09月
  • 炎症からの大腸発癌におけるストレス応答蛋白Cirpの役割(Stress response protein Cirp links inflammation and tumorigenesis in colitis-associated cancer)
    櫻井 俊治; 工藤 正俊; 西田 直生志; 藤田 潤; 樫田 博史 日本癌学会総会記事 73回 E -3021 2014年09月
  • TACE不応の進行肝細胞癌患者に対するソラフェニブの開始時期の検討
    有住 忠晃; 上嶋 一臣; 千品 寛和; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊 The Liver Cancer Journal 6 (2) 122 -123 2014年06月
  • T. Arizumi; K. Ueshima; H. Chishina; M. Takita; S. Kitai; T. Inoue; N. Yada; S. Hagiwara; Y. Minami; T. Sakurai; N. Nishida; M. Kudo JOURNAL OF HEPATOLOGY 60 (1) S253 -S253 2014年04月
  • 肝外再発例の肝癌DNAメチル化プロファイルを用いた治癒切除後の早期再発予測
    西田 直生志; 中居 卓也; 工藤 正俊 肝臓 55 (Suppl.1) A210 -A210 2014年04月
  • 高齢者Genotype 1b高ウイルス量のC型慢性肝炎患者における治療効果と安全性 ReGIT-J試験の層別解析
    西川 浩樹; 榎本 平之; 斎藤 正紀; 会澤 信弘; 津田 泰宏; 樋口 和秀; 岡崎 和一; 関 寿人; 金 守良; 本合 泰; 城村 尚登; 西田 直生志; 工藤 正俊; 大崎 往夫; 西口 修平 肝臓 55 (Suppl.1) A233 -A233 2014年04月
  • NAFLD/NASHにおける新知見と治療法の進歩 NASH/NAFLDモデルマウスの発癌過程におけるDNA酸化損傷とエピゲノム変異の誘導
    西田 直生志; 工藤 正俊 日本消化器病学会雑誌 111 (臨増総会) A194 -A194 2014年03月
  • plain cone-beam CTによる肝動脈塞栓術の定量的治療効果予測
    南 康範; 南 知宏; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊; 柳生 行伸; 村上 卓道 日本消化器病学会雑誌 111 (臨増総会) A275 -A275 2014年03月
  • サイトケラチン19は肝細胞癌の新規予後予測マーカーである(Cytokeratin 19 Staining is a Nobel Prognostic Biomarker for Hepatocellular Carcinoma)
    横道 直佑; 永坂 岳司; 西田 直生志; 楳田 祐三; 森川 達也; 久保田 暢人; 吉田 一博; 竹原 裕子; 母里 淑子; 貞森 裕; 八木 孝仁; 藤原 俊儀; Ajay Goel 日本癌学会総会記事 72回 445 -445 2013年10月
  • 肝のう胞に対するオレイン酸モノエタノールアミン注入療法の検討
    田北 雅弘; 有住 忠晃; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 54 (Suppl.2) A614 -A614 2013年09月
  • がんリスクの評価と予防 便中メチル化CpG検出による消化器癌診断
    永坂 岳司; 吉田 一博; 森川 達也; 母里 淑子; 横道 直祐; 久保田 暢人; 竹原 祐子; 稲田 涼; 楳田 祐三; 西崎 正彦; 香川 俊輔; 西田 直生志; 貞森 裕; 八木 孝仁; 藤原 俊義 日本癌治療学会誌 48 (3) 590 -590 2013年09月
  • サイトケラチン19は肝細胞癌の肝外転移や術後再発を予測する
    横道 直佑; 永坂 岳司; 西田 直生志; 楳田 祐三; 母里 淑子; 森川 達也; 吉田 一博; 貞森 裕; 八木 孝仁; 藤原 俊義 日本消化器外科学会総会 68回 O -4 2013年07月
  • 萩原 智; 櫻井 俊治; 上嶋 一臣; 永井 知行; 西田 直生志; 工藤 正俊 The Liver Cancer Journal 5 (2) 130 -131 2013年06月
  • 西田 直生志 癌と人 (40) 36 -37 2013年05月
  • 良性肝細胞性結節の諸問題 肝細胞腺腫、限局性結節性過形成を含む過形成結節の基礎と臨床 非定型的な様相を呈する限局性結節性過形成についての検討
    喜多 竜一; 西田 直生志; 那須 章弘; 西島 規浩; 若狭 朋子; 佐々木 素子; 木村 達; 大崎 征夫; 中島 収; 工藤 正俊; 中沼 安二 肝臓 54 (Suppl.1) A80 -A80 2013年04月
  • ヒト肝癌に認められるゲノムワイドな脱メチル化と染色体不安定性の関連
    西田 直生志; 有住 忠晃; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 工藤 正俊 肝臓 54 (Suppl.1) A149 -A149 2013年04月
  • 乏血性進行肝細胞癌患者に対してソラフェニブ治療の成績
    有住 忠晃; 上嶋 一臣; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊 肝臓 54 (Suppl.1) A284 -A284 2013年04月
  • PEG-IFNα2a少量長期療法における発癌リスク因子の検討 IL28B遺伝子多型との関連も含めて
    萩原 智; 櫻井 俊治; 上嶋 一臣; 南 康範; 井上 達夫; 矢田 典久; 北井 聡; 田北 雅弘; 永井 知行; 有住 忠晃; 田中 梨絵; 西田 直生志; 工藤 正俊 肝臓 54 (Suppl.1) A372 -A372 2013年04月
  • 超音波を施行した0歳児の嘔吐症例の検討
    前野 知子; 横川 美加; 辻 裕美子; 塩見 香織; 前川 清; 井上 達夫; 南 康範; 西田 直生志; 八木 誠; 工藤 正俊 超音波医学 40 (Suppl.) S547 -S547 2013年04月
  • 肝血管筋脂肪腫の3例
    田中 梨絵; 南 康範; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 超音波医学 40 (Suppl.) S573 -S573 2013年04月
  • 横道 直佑; 永坂 岳司; 西田 直生志; 楳田 祐三; 母里 淑子; 森川 達也; 久保田 暢人; 吉田 一博; 貞森 裕; 八木 孝仁; 藤原 俊義 日本外科学会雑誌 114 (2) 644 -644 2013年03月
  • 横道 直佑; 永坂 岳司; 西田 直生志; 楳田 祐三; 母里 淑子; 森川 達也; 久保田 暢人; 吉田 一博; 貞森 裕; 八木 孝仁; 藤原 俊義 日本外科学会雑誌 114 (臨増2) 644 -644 2013年03月
  • 肝血管筋脂肪腫の3例
    田中 梨絵; 上嶋 一臣; 千品 寛和; 有住 忠晃; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 110 (臨増総会) A342 -A342 2013年02月
  • 消化器癌と酸化ストレス 肝発癌における酸化ストレスとエピゲノム変異
    西田 直生志; 工藤 正俊 肝臓 53 (Suppl.2) A604 -A604 2012年09月
  • 消化器疾患と性差 肝癌の遺伝子変化および背景肝組織の男女差に関する検討
    西田 直生志; 工藤 正俊 肝臓 53 (Suppl.2) A654 -A654 2012年09月
  • 肝嚢胞に対するオレイン酸モノエタノールアミン注入療法の検討
    田北 雅弘; 井上 達夫; 有住 忠晃; 早石 宗右; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 53 (Suppl.2) A697 -A697 2012年09月
  • 肝細胞癌に対するラジオ波焼灼療法の治療効果判定における造影超音波検査の有用性の検討 造影CTとの比較
    井上 達夫; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 萩原 智; 南 康範; 上嶋 一臣; 西田 直生志; 工藤 正俊 肝臓 53 (Suppl.2) A724 -A724 2012年09月
  • 転移性肝癌に対する肝動脈塞栓術とラジオ波焼灼術の併用療法の有用性
    南 康範; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 109 (臨増大会) A713 -A713 2012年09月
  • C型慢性肝炎組織におけるDNAメチル化の出現と肝発癌におけるインパクト(Impact of DNA methylation alterations in chronic hepatitis C on emergence of human hepatocellular carcinoma)
    西田 直生志; 永坂 岳司; 西村 貴文; 工藤 正俊 日本癌学会総会記事 71回 255 -255 2012年08月
  • BeadChip450Kを用いた肝細胞癌のゲノムワイドメチル化解析(Genome-wide methylation profiling of human hepatocellular carcinoma by using BeadChip 450K)
    西村 貴文; 西田 直生志 日本癌学会総会記事 71回 257 -257 2012年08月
  • サイトケラチン19発現はEMT変化と肝細胞癌の肝外転移を予測する(Cytokeratin 19 predicts extrahepatic metastasis for hepatocellular carcinoma with epithelial-mesenchymal transition)
    横道 直佑; 永坂 岳司; 西田 直生志; 久保田 暢人; 森川 達也; 母里 淑子; 楳田 祐三; 貞森 裕; 八木 孝仁; 藤原 俊義 日本癌学会総会記事 71回 353 -353 2012年08月
  • 有住 忠晃; 上嶋 一臣; 早石 宗右; 田北 雅弘; 北井 聡; 井上 達夫; 矢田 典久; 萩原 智; 南 康範; 櫻井 俊治; 西田 直生志; 工藤 正俊 The Liver Cancer Journal 4 (2) 138 -139 2012年06月
  • 有住 忠晃; 上嶋 一臣; 竹田 治彦; 大崎 往夫; 萩原 智; 井上 達夫; 北井 聡; 矢田 典久; 櫻井 俊治; 西田 直生志; 工藤 正俊 肝臓 53 (6) 344 -347 2012年06月
  • IL28BとPEG-IFN/RBV併用療法をうけたHCVジェノタイプ1型高ウイルス量患者の効果との関連について
    田北 雅弘; 萩原 智; 有住 忠晃; 早石 宗右; 上田 泰輔; 北井 聡; 矢田 典久; 井上 達夫; 南 康範; 鄭 浩柄; 上嶋 一臣; 櫻井 俊治; 西田 直生志; 工藤 正俊 肝臓 53 (Suppl.1) A538 -A538 2012年04月
  • 非上皮性肝悪性腫瘍の3例
    足立 哲平; 有住 忠晃; 早石 宗右; 田北 雅弘; 北井 聡; 矢田 典久; 井上 達夫; 萩原 智; 南 康範; 櫻井 俊治; 上嶋 一臣; 西田 直生志; 工藤 正俊 日本消化器病学会雑誌 109 (臨増総会) A294 -A294 2012年03月
  • エピジェネティクスと消化器癌 C型慢性肝炎組織における癌抑制遺伝子メチル化と肝発癌
    西田 直生志 肝臓 52 (Suppl.2) A571 -A571 2011年09月
  • 肝細胞がんに対する生体肝移植後の転移再発予測因子探索のための統合的ゲノム・エピゲノム解析(Genetic and epigenetic analysis for the prediction of recurrent hepatocellular carcinoma after liver transplantation)
    西村 タカフミ; 西田 直生志; 上本 伸二; 福田 善弘 日本癌学会総会記事 70回 368 -368 2011年09月
  • ウイルス肝炎・肝癌制圧の分子基盤 C型肝炎関連発癌の初期段階における癌抑制遺伝子の異常メチル化の役割
    西田 直生志; 福田 善弘; 千葉 勉 肝臓 52 (Suppl.1) A23 -A23 2011年04月
  • HCVの自然排除群の関連遺伝子の検討 IL 28B遺伝子とHLA抗原の多型性の検索を中心に
    井本 勉; 金 守良; 田中 靖人; 金 啓二; 谷口 美幸; 福田 善弘; 西田 直生志; 国立 裕之; 畦地 英全; 米田 俊貴; 勝島 慎二; 竹内 孝男; 山東 剛裕; 河原 啓; 菅野 雅彦 肝臓 52 (Suppl.1) A146 -A146 2011年04月
  • 短期間の内に増大傾向を示した多発性肝限局性結節性過形成の一例
    荒澤 壮一; 西田 直生志; 依田 広; 秦 浩一郎; 影山 詔一; 福山 宏樹; 村田 充子; 磯田 裕義; 波多野 悦朗; 千葉 勉 超音波医学 38 (2) 176 -176 2011年03月
  • 肝がんのメカニズムと治療戦略 ヒト肝発癌過程におけるゲノム、エピゲノム変化の包括的解析
    西田 直生志; 福田 善弘 肝臓 51 (Suppl.2) A446 -A446 2010年09月
  • 肝細胞癌に対する新たな診断・治療マーカーの確立(基礎から臨床へ) 血清中の肝癌由来DNAの定量化と治療マーカーへの応用
    西田 直生志; 福田 善弘 肝臓 51 (Suppl.2) A469 -A469 2010年09月
  • 肝細胞癌に対する生体肝移植治療後の転移再発予測因子としての遺伝子メチル化の検討(Impact of gene silencing on the recurrence of hepatocellular carcinoma after living-donor liver transplantation)
    西村 貴文; 西田 直生志; 上本 伸二; 福田 善弘 日本癌学会総会記事 69回 342 -342 2010年08月
  • 肝癌症例における血清中メチル化DNAの量的変化を用いた腫瘍ダイナミクスの推定
    西田 直生志; 福田 善弘 肝臓 51 (Suppl.1) A254 -A254 2010年04月
  • 肝発癌における染色体不安定性とメチル化不安定性の関わり
    西田 直生志 肝臓フォーラム記録集 2009 196 -210 2010年02月
  • 消化器癌におけるエピジェネティクス 肝発癌過程における遺伝子メチル化の変化
    西田 直生志; 福田 善弘; 千葉 勉 肝臓 50 (Suppl.2) A433 -A433 2009年09月
  • 肝癌発生・進展の分子機構と臨床への還元 肝発癌過程における遺伝子メチル化の変化と肝癌診断への応用
    西田 直生志; 千葉 勉; 福田 善弘 肝臓 50 (Suppl.1) A95 -A95 2009年04月
  • HCV関連肝癌の発癌過程における癌関連遺伝子の異常メチル化の進展(Progression of aberrant methylation in multiple cancer-related genes in HCV-related hepatocarcinogenesis)
    西田 直生志; 西村 貴文; 千葉 勉; 福田 善弘 日本癌学会総会記事 67回 107 -107 2008年09月
  • 肝移植治療を受けた多発性肝細胞癌症例におけるクローン関連性の検討(Clonal relationship of multi-nodular hepatocellular carcinoma in patients undergoing living-donor liver transplantation)
    西村 貴文; 西田 直生志; 出口 法子; 木下 絵理; 上田 幹子; 高田 泰次; 上本 伸二; 福田 善弘 日本癌学会総会記事 67回 164 -164 2008年09月
  • DNAメチル化検出による糞便からの消化器腫瘍の診断(Analysis of fecal DNA methylation for detecting gastrointestinal neoplasia)
    永坂 岳司; 松原 長秀; 西田 直生志; 田中 紀章 日本癌学会総会記事 67回 333 -333 2008年09月
  • C型肝炎からの発癌における遺伝子メチル化の不安定性
    西田 直生志; 福田 善弘; 千葉 勉 肝臓 49 (Suppl.1) A358 -A358 2008年04月
  • 消化器領域におけるゲノム解析の現状と展望 肝疾患に認められる遺伝子メチル化の進行とHCVの関与
    西田 直生志; 福田 善弘; 千葉 勉 日本消化器病学会雑誌 105 (臨増総会) A86 -A86 2008年03月
  • 出口 法子; 西村 貴文; 西田 直生志; 柳田 敦子; 波多野 悦郎; 羽賀 博典; 福田 善弘 健康科学: 京都大学医学部保健学科紀要 (4) 19 -23 2008年03月
  • 大腸癌におけるCDC4-サイクリンE経路の破綻と染色体不安定性
    西田 直生志; 永坂 岳司; 柏木 一宏; Goel Ajay; 福田 善弘; 千葉 勉 日本消化器病学会雑誌 104 (臨増大会) A661 -A661 2007年09月
  • ヒト肝細胞癌における染色体不安定性、メチル化不安定性と癌関連遺伝子変異の相関(Chromosomal instability, Epigenetic instability and mutations of cancer-related gene in human hepaticellular carcinoma)
    西田 直生志; 西村 貴文; 永坂 岳司; 福田 善弘; 千葉 勉 日本癌学会総会記事 66回 268 -268 2007年08月
  • 肝発癌における染色体不安定性とメチル化不安定性
    西田 直生志; 西村 貴文; 福田 善弘 肝臓 48 (Suppl.1) A69 -A69 2007年04月
  • 包括的マイクロサテライト解析を用いた肝細胞癌のクローン不均一性の検討
    西村 貴文; 米田 俊貴; 福田 善弘; 西田 直生志; 中尾 一和 日本癌学会総会記事 64回 468 -468 2005年09月
  • 小松 弥郷; 西田 直生志; 八十田 明宏; 佐久間 陽子; 小笹 亜美; 中津留 有子; 米田 俊貴; 西村 貴文; 伊藤 照明; 荒井 宏司; 中尾 一和; 福田 善弘 Osteoporosis Japan 12 (3) 375 -378 2004年08月
  • T Nishimura; N Nishida; T Komeda; Y Fukuda; K Nakao JOURNAL OF CLINICAL ONCOLOGY 22 (14) 847S -847S 2004年07月
  • 抗セントロメア抗体が単独陽性で他の染色型の抗核抗体が陰性のI型自己免疫性肝炎例の検討
    井本 勉; 金 守良; 福田 善弘; 西田 直生志; 大曲 勝久; 二宮 俊明; 前川 陽子; 金 啓二 肝臓 45 (Suppl.1) A332 -A332 2004年04月
  • 難治性C型肝炎に対するBDD(Biphenyl Dimethyl Dicarboxylate)の有効性の検証
    福田 善弘; 西田 直生志; 米田 俊貴 日本消化器病学会雑誌 101 (臨増総会) A364 -A364 2004年03月
  • 田中 智洋; 安立 英矢; 井上 元; 益崎 裕章; 海老原 健; 中所 英樹; 米田 俊貴; 林 達也; 西田 直生志; 細田 公則; 福田 善弘; 中尾 一和 日本内分泌学会雑誌 79 94 -94 2003年12月
  • 酸化ストレスと肝障害 肝発癌過程における酸化ストレスの役割 チオレドキシンの面から
    皆田 睦子; 西田 直生志; 福田 善弘 肝臓 44 (Suppl.3) A496 -A496 2003年10月
  • IVRが奏効したBudd-Chiari症候群の3症例
    西田 直生志; 岩村 伸一; 米田 俊貴; 西村 貴文; 伊藤 照明; 前谷 洋爾; 伊藤 亨; 中尾 一和; 千葉 勉; 福田 善弘 肝臓 44 (Suppl.3) A553 -A553 2003年10月
  • 原発性胆汁性肝硬変の母娘例
    米田 俊貴; 伊藤 照明; 久野 雅人; 西村 貴文; 西田 直生志; 中尾 一和; 池原 幸辰; 足立 正彦; 与芝 真彰; 福田 善弘 肝臓 44 (Suppl.3) A589 -A589 2003年10月
  • 慢性C型肝炎のインターフェロン治療に伴う骨吸収の改善効果と骨量増加
    西田 直生志; 米田 俊貴; 西村 貴文; 伊藤 照明; 久野 雅人; 小松 弥郷; 中尾 一和; 福田 善弘 肝臓 44 (Suppl.2) A436 -A436 2003年09月
  • 半定量マイクロサテライト解析を用いた肝細胞癌の包括的染色体解析
    西村 貴文; 西田 直生志; 米田 俊貴; 猪飼 伊和夫; 福田 善弘; 中尾 一和 日本癌学会総会記事 62回 228 -228 2003年08月
  • N Nishida; T Nishimura; Y Fukuda; K Nakao GASTROENTEROLOGY 124 (4) A774 -A774 2003年04月
  • 半定量マイクロサテライト解析を用いた肝細胞癌における第1染色体長腕重複領域の検討
    西村 貴文; 西田 直生志; 伊藤 照明; 米田 俊貴; 福田 善弘; 山岡 義生; 中尾 一和 肝臓 44 (Suppl.1) A262 -A262 2003年04月
  • N Nishida; T Nishimura; T Komeda; Y Fukuda; K Nakao HEPATOLOGY 36 (4) 699A -699A 2002年10月
  • マイクロサテライトを用いた肝細胞癌における第1染色体長腕重複領域の決定
    西村 貴文; 西田 直生志; 福田 善弘; 中尾 一和 日本癌学会総会記事 61回 99 -99 2002年10月
  • B型肝硬変症例に対するラミブジンの投与戦略
    米田 俊貴; 西田 直生志; 福田 善弘 肝臓 43 (Suppl.1) A159 -A159 2002年05月
  • ヒト肝細胞癌におけるKiSS-1及びhOT7T175発現の検討
    伊藤 照明; 西田 直生志; 久野 雅人; 西村 貴文; 米田 俊貴; 福田 善弘; 中尾 一和 肝臓 43 (Suppl.1) A232 -A232 2002年05月
  • 姫野 泰雄; 畦地 英全; 西田 直生志; 福田 善弘 逓信医学 53 (6) 373 -375 2001年12月
  • 関節痛,関節炎を初発症状としたB型急性肝炎例でのHBV genotype,分子系統樹解析
    福田 善弘; 菅内 文中; 溝上 雅史; 伊藤 照明; 久野 雅人; 西村 貴文; 米田 俊貴; 西田 直生志; 中尾 一和 肝臓 42 (Suppl.3) A504 -A504 2001年11月
  • 肝細胞癌の発癌予防と治療の最前線 当科において生体肝移植を検討した,肝細胞癌合併ウイルス性肝硬変の2症例
    米田 俊貴; 伊藤 照明; 久野 雅人; 西村 貴文; 西田 直生志; 中尾 一和; 福田 善弘; 上本 伸二; 田中 紘一 肝臓 42 (Suppl.3) A465 -A465 2001年11月
  • 近未来医療 移植から再生医療 京滋地区医療施設における肝移植に関するアンケート調査
    米田 俊貴; 西田 直生志; 福田 善弘 肝臓 42 (Suppl.3) A476 -A476 2001年11月
  • 乳癌術後5-FU及びTamoxifen内服中に肝障害を認めた2例
    伊藤 照明; 西田 直生志; 久野 雅人; 西村 貴文; 米田 俊貴; 中尾 一和; 児玉 宏; 福田 善弘 肝臓 42 (Suppl.3) A577 -A577 2001年11月
  • 西田 直生志; 福田 善弘 日本臨床 59 (増刊6 肝癌の診断と治療) 134 -137 2001年10月
  • ヒト肝細胞癌におけるp14ARF異常の解析及びp53異常との関連
    伊藤 照明; 西田 直生志; 畦地 英全; 久野 雅人; 西村 貴文; 米田 俊貴; 福田 善弘; 中尾 一和 肝臓 42 (Suppl.2) A365 -A365 2001年09月
  • 切除肝細胞癌における転移再発・予後予測因子としてのVEGF,Cyclin D1,E-cadherinの検討
    皆田 睦子; 伊藤 照明; 久野 雅人; 西村 貴文; 米田 俊貴; 西田 直生志; 中尾 一和; 猪飼 伊和夫; 山岡 義生; 福田 善弘 肝臓 42 (Suppl.2) A367 -A367 2001年09月
  • マイクロサテライト解析における染色体欠失と重複の判定
    西村 貴文; 西田 直生志; 米田 俊貴; 福田 善弘; 中尾 一和 日本癌学会総会記事 60回 104 -104 2001年09月
  • 福田 善弘; 西村 貴文; 畦地 英全; 西田 直生志 現代医療 33 (9) 2339 -2346 2001年09月
  • N Nishida; Y Fukuda; T Ito; T Nishimura; M Kuno; T Komeda; Ikai, I; Y Yamaoka; K Nakao GASTROENTEROLOGY 120 (5) A556 -A556 2001年04月
  • T Nishimura; N Nishida; H Azechi; M Minata; M Kuno; K Nakao; Y Fukuda HEPATOLOGY 32 (4) 236A -236A 2000年10月
  • 高分化肝細胞癌における包括的アレロタイプ解析
    西村 貴文; 西田 直生志; 福田 善弘; 皆田 睦子; 米田 俊貴; 猪飼 伊和夫; 中尾 一和 日本癌学会総会記事 59回 308 -308 2000年09月
  • 肝性脳症患者に対するラグノスゼリーの使用経験 服用性に関する患者アンケート調査
    福田 善弘; 西田 直生志 医薬ジャーナル 36 (8) 2300 -2303 2000年08月
  • M Minata; N Nishida; K Nakao; T Komeda; Y Fukuda GASTROENTEROLOGY 118 (4) A1470 -A1470 2000年04月
  • 肝細胞癌の遺伝子異常とその臨床的意義
    西田 直生志; 畦地 英全; 西村 貴文; 皆田 睦子; 久野 雅人; 猪飼 伊和夫; 山岡 義生; 中尾 一和; 福田 善弘 日本消化器病学会雑誌 97 (臨増総会) A205 -A205 2000年03月
  • 特発性細菌性腹膜炎症例における腹水中VEGFの検討
    皆田 睦子; 久野 雅人; 西村 貴文; 畦地 英全; 松岡 陽子; 西田 直生志; 中尾 一和; 福田 善弘; 米田 俊貴 日本内科学会雑誌 89 (臨増) 107 -107 2000年02月
  • 【高度医療研究】C型肝炎による肝発癌機構の解明,及び遺伝子診断への応用に関する研究
    姫野 泰雄; 畦地 英全; 西田 直生志; 福田 善弘 逓信医学 52 (1) 19 -22 2000年01月
  • C型慢性肝炎に対するインターフェロンβ,α併用療法
    勝間 寛和; 西村 貴文; 畦地 英全; 井上 基; 皆田 睦子; 松岡 陽子; 西田 直生志; 中尾 一和; 米田 俊貴; 福田 善弘 肝臓 40 (Suppl.3) 136 -136 1999年10月
  • 脂肪肝を基盤に発生した肝細胞癌の3症例
    西村 貴文; 勝間 寛和; 井上 基; 畦地 英全; 皆田 睦子; 松岡 陽子; 西田 直生志; 中尾 一和; 米田 俊貴; 伊藤 亨 肝臓 40 (Suppl.3) 146 -146 1999年10月
  • 特発性細菌性腹膜炎症例における腹水中VEGFの検討
    皆田 睦子; 西村 貴文; 勝間 寛和; 井上 基; 畦地 英全; 松岡 陽子; 西田 直生志; 中尾 一和; 米田 俊貴; 福田 善弘 肝臓 40 (Suppl.3) 118 -118 1999年10月
  • 肝細胞癌におけるp16INK4A遺伝子プロモーター領域のメチル化とp16,RBタンパク発現の検討
    畦地 英全; 西田 直生志; 西村 貴文; 勝間 寛和; 皆田 睦子; 松岡 陽子; 中尾 一和; 福田 善弘 肝臓 40 (Suppl.2) 214 -214 1999年09月
  • ヒト肝細胞癌におけるRB経路分子異常と臨床像
    西田 直生志; 畦地 英全; 高橋 玲; 西村 貴文; 中尾 一和; 福田 善弘 日本癌学会総会記事 58回 125 -125 1999年08月
  • 肝細胞癌におけるp15INK4B,p16INK4A遺伝子プロモーター領域のメチル化の検討
    畦地 英全; 西田 直生志; 西村 貴文; 勝間 寛和; 井上 基; 皆田 睦子; 松岡 陽子; 中尾 一和; 福田 善弘 肝臓 40 (Suppl.1) 336 -336 1999年05月
  • 勝間 寛和; 西田 直生志; 福田 善弘 治療学 33 (3) 263 -267 1999年03月
  • 【症候・病態の分子メカニズム】消化器 主要疾患・症候群 肝癌
    福田 善弘; 西田 直生志 Molecular Medicine 35 (臨増) 169 -171 1998年12月
  • 西田 直生志 最新医学 53 (8) 1857 -1862 1998年08月
  • 西田 直生志; 福田 善弘 肝臓 39 (7) 483 -485 1998年07月
  • 西田 直生志; 福田 善弘 肝臓 39 (7) 483 -485 1998年07月
  • 西田 直生志 Medical Practice 15 (7) 1206 -1207 1998年07月
  • 慢性肝疾患における癌遺伝子の低メチル化
    西田 直生志 日本内科学会雑誌 87 (臨増) 209 -209 1998年02月
  • N Nishida; Y Fukuda; R Kita; T Nishimura; H Katsuma; M Inoue; H Azechi; M Minata; Y Matsuoka; T Komeda; K Nakao HEPATOLOGY 26 (4) 1299 -1299 1997年10月
  • M Minata; Y Fukuda; T Nishimura; H Katsuma; M Inoue; H Azechi; Y Matsuoka; T Komeda; N Nishida; M Ikemoto; K Nakao HEPATOLOGY 26 (4) 1736 -1736 1997年10月
  • 肝癌-診断と治療の進歩 肝癌発生の病態 肝癌に蓄積する遺伝子異常
    西田 直生志; 畦地 英全; 勝間 寛和 内科 80 (4) 628 -632 1997年10月
  • 肝細胞癌の遺伝子異常
    西田 直生志 肝臓 38 (Suppl.2) 57 -57 1997年09月
  • 肝細胞癌における細胞周期制御遺伝子異常の相互関係
    西田 直生志 肝臓 38 (Suppl.1) 156 -156 1997年03月
  • 喜多 竜一; 西田 直生志; 福田 善弘 最新医学 52 (増刊) 515 -522 1997年03月
  • T Komeda; Y Fukuda; M Minata; H Azechi; T Yoshinaga; Y Matsuoka; R Kita; N Nishida; K Nakao HEPATOLOGY 24 (4) 1383 -1383 1996年10月
  • 肝癌の分子遺伝学的解析
    福田 善弘; 喜多 竜一; 西田 直生志 臨床医 22 (4) 497 -500 1996年04月
  • T KOMEDA; Y FUKUDA; Y MATSUOKA; R KITA; T SANDO; N NISHIDA; K NAKAO HEPATOLOGY 22 (4) 1330 -1330 1995年10月
  • 消化器癌の悪性度評価 消化器癌と増殖因子
    西田 直生志; 福田 善弘 臨床消化器内科 10 (12) 1759 -1764 1995年10月
  • 肝発癌における細胞周期関連遺伝子変化の意義
    西田 直生志 日本消化器病学会雑誌 92 (臨増) 1445 -1445 1995年09月
  • 肝細胞癌の進展と細胞周期関連遺伝子の異常
    西田 直生志 日本癌学会総会記事 54回 261 -261 1995年09月
  • 西田 直生志; 福田 善弘 医学のあゆみ 171 (14) 1115 -1120 1994年12月
  • 肝癌発生の分子生物学 分子病理学的見地から
    西田 直生志; 喜多 竜一; 福田 善弘 肝胆膵 29 (2) 227 -234 1994年08月
  • ヒト肝細胞癌におけるサイクリンD1遺伝子の増幅と過剰発現
    西田 直生志 肝臓 35 (Suppl.1) 116 -116 1994年06月
  • N NISHIDA; Y FUKUDA; T KOMEDA; T SANDO; R KITA; M FURUKAWA; AK NAKAO HEPATOLOGY 19 (4) I109 -I109 1994年04月
  • ヒト肝細胞癌の遺伝子異常と臨床像
    西田 直生志 日本消化器病学会雑誌 91 (臨増) 537 -537 1994年03月
  • N NISHIDA; Y FUKUDA; K NAKAO; K ISHIZAKI JOURNAL OF CELLULAR BIOCHEMISTRY 201 -201 1994年02月
  • ヒト肝細胞癌の癌遺伝子異常 悪性度,予後推定における遺伝子診断の可能性の検討
    西田 直生志 日本内科学会雑誌 83 (臨増) 265 -265 1994年02月
  • 肝細胞癌におけるp53遺伝子の異常
    西田 直生志 日本癌学会総会記事 52回 245 -245 1993年10月
  • 肝細胞癌におけるp53遺伝子の異常
    西田 直生志 肝臓 34 (Suppl.1) 98 -98 1993年06月
  • 肝細胞癌のヘテロ接合性の消失と癌抑制遺伝子の異常
    西田 直生志 日本癌学会総会記事 51回 110 -110 1992年09月
  • N NISHIDA; K ISHIZAKI; Y FUKUDA; H KOKURYU; H IMURA HEPATOLOGY 16 (2) 577 -577 1992年08月
  • 内科医のための分子生物学的アプローチ 肝癌
    西田 直生志; 福田 善弘; 姫野 泰雄 Modern Physician 12 (8) 1173 -1177 1992年08月
  • 肝細胞癌の進展における癌抑制遺伝子の異常
    西田 直生志 肝臓 33 (Suppl.1) 50 -50 1992年05月
  • 肝細胞癌におけるp53遺伝子突然変異と17p染色体欠失の解析
    西田 直生志 日本消化器病学会雑誌 89 (臨増) 266 -266 1992年02月
  • 肝細胞癌のRFLPによる染色体欠失の解析
    西田 直生志 肝臓 32 (Suppl.2) 85 -85 1991年09月
  • C型慢性肝炎に対するインターフェロン治療の経験
    西田 直生志 日本消化器病学会雑誌 88 (臨増) 2457 -2457 1991年08月
  • HBV-HCVの重感染
    福田 善弘; 西田 直生志; 国立 裕之 消化器科 14 (5) 393 -401 1991年05月
  • 肝細胞癌のRFLPによる染色体欠失の解析
    西田 直生志 日本消化器病学会雑誌 88 (臨増) 542 -542 1991年02月
  • 佐竹 弘; 西田 真弓; 西田 直生志 Progress in Medicine 10 (3) 639 -649 1990年03月
  • 慢性肝疾患における血中ヒトインスリン様成長因子およびIGF結合蛋白の検討
    西田 直生志 日本消化器病学会雑誌 87 (臨増) 555 -555 1990年02月
  • 清水 一良; 西田 直生志; 直木 正雄 臨牀と研究 66 (12) 4027 -4032 1989年12月
  • 清水 一良; 西田 直生志; 直木 正雄 Therapeutic Research 10 (7) 2794 -2801 1989年07月
  • 岡 孝和; 前川 高天; 直木 正雄; 西田 直生志; 西田 真弓; 佐竹 弘; 生田 篤也; 清水 一良; 梶谷 幸夫; 粉川 皓仲; 三宅 健夫 心身医学 29 (抄録) 86 -86 1989年05月
  • 岡 孝和; 前川 高天; 直木 正雄; 西田 直生志; 西田 真弓; 佐竹 弘; 生田 篤也; 清水 一良; 梶谷 幸夫; 粉川 皓仲; 三宅 健夫 心身医学 29 (抄録) 87 -87 1989年05月
  • 佐竹 弘; 西田 直生志; 直木 正雄 医療 43 (4) 456 -461 1989年04月
  • 胃5点生検法から見た高齢者十二指腸潰瘍の胃炎について
    西田 直生志 Geriatric Medicine 26 (11) 1736 -1736 1988年11月
  • 胃5点生検からみた高齢者十二指腸潰瘍の胃炎について
    西田 直生志 医療 42 (増刊1) 192 -192 1988年10月
  • 高コレステロール血症を呈しLp-TAEにより改善をみた肝細胞癌の1症例
    西田 直生志 肝臓 28 (7) 995 -995 1987年07月

受賞

  • 2022年06月 一般社団法人 日本肝臓学会 Hepatology Research Citation Award:
     Immune checkpoint blockade for the treatment of human hepatocellular carcinoma 
    受賞者: 西田 直生志
  • 2021年04月 公益財団法人喫煙科学財団 一般研究助成「がん」
     肝癌のオーダーメイド治療を見据えた腫瘍免疫環境の解析と喫煙の影響に関する研究 
    受賞者: 西田 直生志
  • 2020年04月 国立情報学研究所 公募型共同研究戦略研究公募型
     画像データの機械学習を用いた肝癌化学療法の治療効果予測に関する研究 
    受賞者: 西田 直生志
  • 2017年04月 公益財団法人喫煙科学研究財団 一般研究助成
     
    受賞者: 西田 直生志
  • 2012年06月 財団法人ひと・健康・未来研究財団 研究助成(医学分野)
     
    受賞者: 西田 直生志
  • 2012年05月 82th Digestive Disease Week (DDW) Basic Plenary 2012
     Novel Association between global DNA hypomethylation and chromosomal instability phenotype in human hepatocellular carcinoma 
    受賞者: Naoshi Nishida
  • 2012年04月 公益財団法人喫煙科学研究財団 研究助成金
     
    受賞者: 西田 直生志
  • 2011年11月 公益財団法人大阪癌研究会 一般学術研究助成金
     
    受賞者: 西田 直生志
  • 2011年05月 81th Digestive Disease Week (DDW) DDW Poster of Distinction
     Characterization of step-wise accumulation of DNA methylation alterations during human hepatocarcinogenesis. 
    受賞者: Naoshi Nishida
  • 2009年09月 日本肝臓学会 日本肝臓学会総会 会長奨励賞
     
    受賞者: 西田 直生志
  • 2008年10月 CHUGAI Award 日本肝臓学会冠アワード (CHUGAI Award)
     JPN 
    受賞者: 西田直生志
  • 2008年05月 78th Digestive Disease Week (DDW) Presidential Plenary 2008
     Sequential progression of aberrant methylation in cancer-related genes in various stages of human hepatocarcinogenesis. 
    受賞者: Naoshi Nishida
  • 2008年 財団法人京都がん協会 がん研究助成金 がん研究助成金
     
    受賞者: 西田 直生志
  • 2007年04月 難波照男記念健康づくり研究所研究助成金 研究助成金
     
    受賞者: 西田 直生志
  • 2003年11月 京都成人病科学カンファレンス 第7回成人病臨床科学賞
     
    受賞者: 西田 直生志
  • 2001年05月 71th Digestive Disease Week (DDW) DDW Poster of Distinction
     Prognostic impact of multiple allelic losses for metastatic recurrence in hepatocellular carcinoma after curative resection. 
    受賞者: Naoshi Nishida
  • 1999年04月 日本郵政逓信病院 高度医療研究助成金
     
    受賞者: 西田 直生志
  • 1994年04月 浜名湖シンポジウム「分子消化器病研究会」 研究奨励賞
     
    受賞者: NISHIDA Naoshi
  • 1993年07月 日本肝臓学会 日本肝臓学会研究奨励賞
     
    受賞者: 西田 直生志

共同研究・競争的資金等の研究課題

  • 胆道癌のドライバー変異に着目した腫瘍免疫微小環境の再構築と治療最適化
    日本学術振興会:科学研究費助成事業
    研究期間 : 2024年04月 -2027年03月 
    代表者 : 西田 直生志, 目加田 慶人
  • 日本学術振興会:科学研究費助成事業
    研究期間 : 2022年04月 -2025年03月 
    代表者 : 萩原 智; 工藤 正俊; 西田 直生志
  • 公益財団法人 喫煙科学財団:一般研究
    研究期間 : 2021年04月 -2024年03月 
    代表者 : 西田 直生志
  • 国立研究開発法人日本医療研究開発機構:令和3年度革新的がん医療実用化研究事業
    研究期間 : 2021年04月 -2024年03月 
    代表者 : 工藤 正俊; 西田 直生志
  • 日本学術振興会:科学研究費助成事業
    研究期間 : 2021年04月 -2024年03月 
    代表者 : 工藤 正俊; 西田 直生志
     
    肝細胞癌(肝癌)根治療法後に再発予防目的で免疫チェックポイント阻害剤(ICI)が投与された例を用い、根治療法後の血中のcirculating tumor DNA(ctDNA)が腫瘍再発の予測因子となりうるかを検討した。 ICIをアジュバントで投与された31例を用いた。根治術後血漿よりCAPP-sequenceにてctDNAを検討し、valiantが10 copy/ml以上をminimum residual disease (MRD)陽性とした。さらに、根治術時の腫瘍免疫状態(tumor microenvironment: TME)を解析するため、免疫染色にて腫瘍のCD8、PD-1、PD-L1、Foxp3、β-catenin、glutamine synthetase (GS)陽性細胞を検討した。加えて、Tumor Mutation Load Assayにて肝癌のゲノム解析を行い、遺伝子変異は10 copy以上のvaliant出現を陽性、copy number gain (CNG)は3 copy以上を陽性とした。β-cateninとGSの染色結果より2群(β-catenin経路活性化、非活性化)、TMEの状態により4群(CD8、PD-1、PD-L1とFoxp3染色により、hot型、exhausted型、cold型、Treg型)に分類した。ICI投与による術後無再発生存期間(RFS)はβ-catenin経路非活性化群で活性化群より有意に長く、またhot/exhausted型はcold/Treg型に比較して有意に長かった。β-catenin経路関連遺伝子のCNG陰性例では陽性例と比較し、有意にRFSが延長していた。一方、MRD陰性例は陽性例に比較してRFSが長い傾向にあったが有意ではなかった。MRDの肝癌根治療法後に再発に対する効果の解析にはさらなる検討が必要である。
  • 日本学術振興会:科学研究費助成事業
    研究期間 : 2021年04月 -2024年03月 
    代表者 : 西田 直生志; 目加田 慶人
     
    肝細胞癌(肝癌)治療に用いられる分子標的治療薬には、効果予測のバイオマーカーがない。本年度は96症例のCT画像から抽出した画像特徴と付帯データを用いて、ニューラルネットワーク(NN)にて分子標的治療薬であるレンバチニブ治療開始後の病勢制御を予測した。治療開始後1-3ヶ月目、及び4-6ヶ月目の造影CTを解析し、いずれかでprogressive diseaseであったものを病勢制御失敗、4-6ヶ月目の造影CTでstable disease、partial response, complete responseと判定されたものを病勢制御成功と判断した。門脈相CTから特徴数を減らすために肝臓部位のRadiomics特徴を算出し,107個のRadiomics特徴を入力した。病勢制御予測にはニューラルネットワーク(NN)を用い、学習データ数が少ないこともあり,Radiomics特徴や付帯データを入力とする多層パーセプトロン型のNNを利用した.モデルの精度評価のため勾配ブースティングを用いたモデルと比較した。各モデルの分子標的治療薬の予測結果を評価するためにLeave one out法を100回行った結果を用いた。NNとLightGBMでは平均正解率はどちらも同じ0.58となったが, LightGBMでは平均感度が非常に高く,特異度は非常に低い結果となった。これに対してNNの予測結果は平均感度と特異度はどちらも大きく離れていないため本研究においてNNはLightGBMよりも適していることが示唆された。96例を用いた学習を複数回行った結果,NNの平均正解率0.58,最大正解率0.66,平均感度0.61,平均特異度が0.53となった。今後は,データ拡張や画像データから特徴の抽出など検討する必要がある。
  • 日本学術振興会:科学研究費助成事業 基盤研究(C)
    研究期間 : 2018年04月 -2021年03月 
    代表者 : 工藤 正俊; 西田 直生志
     
    昨年に解析に用いた154例の肝癌およびその非癌部肝を用い、(1)PD-L1, PD-1, LAG-3, TIM-3の腫瘍細胞、CD8+腫瘍浸潤リンパ球(TIL)での発現、3種の幹細胞マーカー発現を、免疫染色にて解析した。409種の癌関連遺伝子とTERT promoterの変異を検討し、TILでの局在確認のため、PD-1, LAG-3, TIM-3 とCD8の2重染色を行った。(2)TCGAデータベースから得た377例の肝癌のデータセットを用い、結果を確認した。 (1)肝癌細胞のPD-L1発現はCK19及びSALL4発現と相関した。PD-L1陽性肝癌はCD8+TIL量が有意に多く、TILには複数の抑制型受容体が発現していた。一方、PI3K-Akt経路に活性型変異を持つ肝癌はPD-L1陽性肝癌に多く、しかしPI3K-Akt変異陰性のPD-L1陽性例と比べ、CD8+TIL量は少ない。他方、βカテニン経路の活性型変異を持つ肝癌はPD-L1陰性 かつCD8+TILに乏しかった。(2) TCGAコホートでも腫瘍のPD-L1発現はPI3K-Akt経路活性型変異と正の関連 (OR=2.7447, 1.0212-7.3766)、及びβカテニン経路活性型変異と負の関連 (OR=0.0083, 0.0011-0.6306)を示した。すなわち、PD-L1陽性肝癌は幹細胞マーカー陽性が多く、TILが多い"immune hot-type"を示した。TIL由来IFN-γ等がPD-L1発現を誘導したと解釈でき、TILには複数の抑制型受容体が発現している。しかし、PI3K-Akt変異を持つPD-L1陽性肝癌ではTILが比較的少なく、CD8+TILからの刺激なくPD-L1が誘導される可能性がある。一方、βカテニン経路活性型変異を持つ肝癌はPD-L1陰性かつ"immune clod-type"を示した。
  • 日本学術振興会:科学研究費助成事業 基盤研究(B)
    研究期間 : 2018年04月 -2021年03月 
    代表者 : 永坂 岳司; 山口 佳之; 楳田 祐三; 堅田 洋佑; 西田 直生志; 堀田 勝幸; 母里 淑子
     
    肺癌や消化器癌などの固形癌は、早期癌の状態で発見できれば外科的切除にて十分根治が見込め、また、根治切除後の補助化学療法により死亡率が減少することも示されている。これら事実は、画像上で診断可能となる前の微小癌状態 (発症前期) ならば、少なくとも一定の割合の肺癌・消化器癌は化学予防 (Chemoprevention) にて治癒できる可能性があることを示唆する。本研究では、研究代表者らが開発したメチル化DNA検出技術を用い、(1) 喀痰を用いた肺癌・便を用いた消化器癌の非侵襲的がんスクリーニングの精確性の検証、 (2) 発症前期での微小癌検出を行うための診断アルゴリズムの開発、を行う。これら研究と並行して、(3) 新規の前向き臨床試験を計画遂行し、検体収集および臨床データ収集を行い、(1)、(2) にて開発を行った診断アルゴリズムを含む検出システムの検証を行うことで、非侵襲的メチル化DNA検出を新機軸とした発症前期における肺癌/消化器癌を診断/予測し、Chemopreventionを可能にする革新的先制医療 (Preemptive Medicine)への「橋渡し」を行う。すでに収集されている便・喀痰便検体を用い、(1)肺癌・消化器癌全体の非侵襲的がんスクリーニングの精確性の検証を行い、発表できるところまで仕上げる予定である。(2) メチル化DNA解析結果と臨床データを照合することによる診断アルゴリズムの開発は、プログラム言語をpython3に統一しシュミレーションを開始している。(3) 前向き臨床試験を計画し臨床試験として開始する予定である。
  • 大学共同利用機関法人 情報・システム研究機構 国立情報学研究所: